A cross-national comparison of public expenditures on drug treatment : context is key by Vander Laenen, Freya & Lievens, Delfine
IS
S
N
 2
3
1
4
-9
2
6
4
INSIGHTS
24
Drug treatment 
expenditure: 
a methodological 
overview 
D
R
U
G
 T
R
E
A
T
M
E
N
T
 E
X
P
E
N
D
IT
U
R
E
 | A
 m
e
th
o
d
o
lo
g
ica
l o
ve
rvie
w

Drug treatment 
expenditure: 
a methodological 
overview
24
I Legal notice
This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. 
Neither the EMCDDA not any person acting on behalf of the EMCDDA is responsible for the use that might be made 
of the following information.
More information on the European Union is available on the internet (http://europa.eu)
Luxembourg, Publications Office of the European Union, 2017
Print ISBN 978-92-9497-213-2 ISSN 1606 1683 doi:10.2810/812985 TD-XD-17-001-EN-C 
PDF ISBN 978-92-9497-214-9 ISSN 2314-9264 doi:10.2810/052028 TD-XD-17-001-EN-N
© European Monitoring Centre for Drugs and Drug Addiction, 2017 
Reproduction is authorised provided the source is acknowledged.
This publication should be referenced as: 
European Monitoring Centre for Drugs and Drug Addiction (2017), Drug treatment expenditure: a methodological 
overview, EMCDDA Insights 24, Publications Office of the European Union, Luxembourg.
Printed by Bietlot in Belgium
PRINTED ON ELEMENTAL CHLORINE-FREE BLEACHED PAPER (ECF)
Europe Direct is a service to help you find answers to your questions about the European Union
Freephone number* : 00 800 67 89 10 11
* Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 I info@emcdda.europa.eu 
emcdda.europa.eu I twitter.com/emcdda I facebook.com/emcdda
 5  Foreword
 7  Executive summary
 11  Acknowledgements
 13  INTRODUCTION
Drug treatment expenditure: a methodological overview
Cláudia Costa Storti
SECTION I
Towards an overall estimate of public expenditure on drug treatment
 25  CHAPTER 1
A methodology for estimating health expenditure on drug treatment: the Australian 
experience
Alison Ritter, Jenny Chalmers and Lynda Berends
SECTION II
Focusing on labelled expenditure
 41  CHAPTER 2
Estimating labelled public expenditure on drug treatment in Croatia
Sanja Mikulić
 47  CHAPTER 3
Expenditure on drug treatment in the Czech Republic
Jiri Vopravil
 53  CHAPTER 4
Bottom-up versus top-down methods of cost estimation: the case of medical drug 
treatment and rehabilitation in Hungary
György Hajnal and Iga Kender-Jeziorska
SECTION III
Focus on unlabelled expenditure
 63  CHAPTER 5
A methodological inventory for the assessment of selected, unlabelled direct public 
expenditure in the field of drug demand reduction
Alain Origer
 75  CHAPTER 6
Estimating the costs of treating drug-related health problems in the United Kingdom
Charlotte Davies
 83  CHAPTER 7
Public expenditure on drug treatment and associated comorbidities: a case study of 
Bergamo 
Sabrina Molinaro, Michela Franchini, Stefania Pieroni, Roberta Potente, Elisa Benedetti, Marco 
Riglietta, Elvira Beato and Carla Rossi
  I Contents
INSIGHTS I Drug treatment expenditure: a methodological overview
4
 97  CHAPTER 8
Public expenditure on opioid substitution treatment in Italy
Bruno Genetti, Elisabetta Simeoni, Cláudia Costa Storti, Alessandra Andreotti and 
Daniele Fassinato
 111  CHAPTER 9
A methodology for an EU cross-country comparison? Public expenditure 
on drug treatment in hospitals
Delfine Lievens and Freya Vander Laenen
SECTION IV
Other tools to measure the costs of drug- 
related harm
 123  CHAPTER 10
The cost calculator: a tool for estimating public spending on 
drug treatment in England
Virginia Musto
 129  CHAPTER 11
Empirical estimation of drug treatment costs in Portugal
Ricardo Gonçalves, Domingos Duran, Sofia Nogueira da Silva and Fátima 
Trigueiros
SECTION V
Contextualising costs
 143  CHAPTER 12
Estimating the costs of substitution therapy for heroin and opioid 
addiction in the United States: insights and challenges
Ervant Maksabedian, Rosalie Liccardo Pacula and Bradley Stein
 159  CHAPTER 13
A cross-national comparison of public expenditures on drug treatment: 
context is key
Freya Vander Laenen and Delfine Lievens
 167  CHAPTER 14
Social cost of illicit drugs in France: what’s new in estimating the value for 
lives lost and illness?
Pierre Kopp and Marysia Ogrodnik
SECTION VI
Insights and implications
 179  CHAPTER 15
Estimating drug treatment expenditure: discussion and concluding 
remarks
Cláudia Costa Storti and Charlotte Davies
 191  Abbreviations
5I Foreword
It is estimated that around 1.2 million people receive treatment for drug-related problems 
in the European Union (EU) per year. This is a result of the expansion in the provision of 
drug abuse treatment across Europe since the mid-1990s, which has helped to increase 
the availability of and access to treatment. While treatment systems are under increasing 
pressure to respond in a timely, effective and flexible manner to clients’ needs, the change 
in the drugs used, the higher prevalence of polydrug use and the provision of ongoing care 
for chronic cases have increased pressure on health providers. However, simultaneously, 
budgets have tended to shrink in many European countries as a consequence of austerity 
measures implemented in the health sector following the 2008 recession. In this economic 
climate, more than ever, policymakers and service planners require data and information 
on the capacity, performance and costs of national treatment systems in order to support 
investment decisions and to make sound policy choices.
Evaluating drug policy has been an EU priority since the publication of the EU drugs 
strategy (2000-04). Subsequently, implementing cost-effective actions in drug policy was 
addressed both in the EU drugs strategy (2005-12) and in the EU drugs action plan (2009-
12). More recently, the EU drugs strategy for 2013-20 confirms the objective of contributing 
to better dissemination of evaluation results, and the EU action plan on drugs (2017-20) 
identifies developments in national evaluations and public expenditure estimates of 
Member States as an overarching indicator for measuring the EU action plan achievements.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has been given 
the objective of developing analytical instruments to better assess the effectiveness and 
impact of drug policy using a number of tools including the analysis of public expenditure. 
Therefore, the EMCDDA aims to contribute to developing estimates of public expenditure 
in EU Member States. The need to develop means of estimating public expenditure reflects 
the importance of making data and models available, as a first step in the economic 
evaluation of policies and interventions. In fact, the resolute political will to address the 
drugs problem in Europe lies not only in the development of appropriate policies, but also 
in the amount of public funds assigned to implement cost-effective policies. Limited data 
and/or insufficient comprehension of the financing of drug treatment will inevitably hinder 
the efficient allocation of resources.
Data collection and research on treatment activity and outcomes are well established in 
Europe, but there is limited information available on the costs of, and expenditure on, drug 
treatment. Analysing public expenditure on drug treatment is still difficult. Information and 
data are sparse and national estimates tend to use neither comparable definitions nor 
agreed methodologies. In the absence of systematic discussion of these issues, there has 
been little opportunity for policymakers, practitioners and researchers to take advantage of 
existing knowledge and experience.
As a first step in addressing this gap, this EMCDDA Insights report has brought together 
a set of diverse studies, encompassing much of the recent work on drug treatment 
expenditure in different parts of the world, thereby providing a unique overview of the 
methodologies used. The very existence of these studies is testament to the growing 
importance of this field of enquiry. Despite an increase in the number of studies over the 
past decade, there is still much to be done in terms of methodological development. The 
topic remains in its infancy. Issues that act as barriers to the rapid development of this 
field include the absence of commonly agreed definitions and approaches; the lack of 
harmonised or complete datasets on drug-related public spending and/or on the activity 
of drug-related health providers; and uncertainty about the most appropriate economic 
models to use.
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The analysis contained within this report will be of interest to both those commissioning — 
or thinking of commissioning — expenditure/cost studies and those carrying out the 
studies, including accounting authorities; entities seeking funds to finance their service 
provision; researchers; officials looking to evaluate drug policy priorities and develop drug 
policy strategies and action plans; and those involved in the economic evaluation of drug 
policy.
Although this edition of the EMCDDA Insights series does not intend to be definitive, I am 
pleased to present what I hope will be seen as an important marker in the development of 
better estimates for public expenditure on drug treatment and a contribution to defining 
good practice in drug policy evaluation, leading, ultimately, to a more cost-effective 
allocation of resources in future.
Alexis Goosdeel 
Director, EMCDDA
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Each year, around 1.2 million people in the European Union (EU) undergo treatment for 
problems related to drug abuse. There are associated requirements for policymakers 
and planners to determine the capacity and performance of national treatment systems 
and evaluate their costs. Responses are required to central policy questions such as 
‘What treatments are offered?’, ‘Are they effective?’ and ‘How much does treatment 
cost?’. However, despite the collection of data on treatment activity being relatively well 
established in Europe, there has been limited focus on the costs of, and expenditure on, 
drug treatment. Limited data and/or insufficient insight into the financing of drug treatment 
will inevitably hinder the efficient allocation of resources.
This European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Insights report 
gathers together studies from a wide range of experts, providing a unique overview of the 
methodologies currently used for estimating drug treatment expenditure. In the absence of 
a systematic discussion of these issues, there has been little opportunity for policymakers, 
practitioners and researchers to take advantage of existing knowledge and experience. With 
the goal of taking the first step towards closing this gap, this report brings together a set of 
diverse studies encompassing much of the recent work on drug treatment expenditure in 
different parts of the world. It therefore reflects the current state of the art in this field and, 
by focusing on methods, it will facilitate analysis of the main methodological commonalities 
and considerations arising from these estimates.
Section I describes a step-by-step approach to the estimate of costs, applied to the 
Australian health system, where the objective was to estimate public expenditure on 
drug treatment, analysing the potential use of international datasets and attempting to 
apply international standards for health expenditure accounting. This analysis shows 
the difficulties faced at the different stages of the estimation process and presents the 
solutions adopted. Starting with discussing an adequate definition of drug treatment, it 
stresses the importance of establishing clear definitions and boundaries for the types 
of treatment included; mapping the corresponding funding systems concerned; and 
suggesting suitable methods for estimates. Additionally, the authors discuss the feasibility 
of using international datasets and the adequacy of considering national databases. Last 
but not least, the transparency of the models used is analysed and consistency across 
various estimates investigated. The study concludes by stressing the need to discuss the 
limitations of estimates, and by highlighting that estimates for the costs of drug treatment 
still require a series of compromises, because the datasets require further improvement.
Section II comprises a set of studies focusing primarily on data on public expenditure on 
drug treatment that is identified as drug-related either in public accountancy documents 
or by experts, i.e. this section focuses on ‘labelled expenditure’ on drug treatment. These 
studies exemplify and discuss how to collect and use these data. Chapter 2 concerns 
the costs of drug treatment in Croatia. The authors systematically describe the data 
collection exercise, which aimed to identify and estimate labelled public expenditure on 
drug treatment. Chapter 3 concerns the routine data collection exercise that takes place in 
the Czech Republic annually, and the data for labelled expenditure on drug treatment are 
contextualised as a proportion of the total public expenditure on drug treatment. Finally, 
in Chapter 4, an example from Hungary describes a sporadic data collection exercise, 
in which interviews with experts were used as a complementary method to collect data. 
These studies show that in most cases ‘labelled expenditure’ does not account for total 
expenditure on drug treatment and, therefore, that additional methods are required to 
estimate public expenditure on drug treatment.
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Section III puts the spotlight on methods applied to estimate the public expenditure on 
drug treatment that is not identified as drug related in public accountancy documents, i.e. 
‘unlabelled expenditure’. Chapter 5 describes the method that has been used annually in 
Luxembourg since 2002 to estimate public expenditure on drug-related hospital episodes, 
inpatient drug treatment episodes, opioid substitution treatment, and treatment of HIV 
(human immunodeficiency virus) infections and AIDS (acquired immune deficiency 
syndrome) associated with drug use. Chapter 6 describes the method used to estimate 
public spending on drug treatment and on associated comorbidities in hospitals in the 
United Kingdom, accounting for inpatient stays, which covers both emergency services for 
acute problems (overdoses and psychosis) and planned treatment for chronic associated 
infectious diseases. Chapter 7 presents a method applied in an Italian region to estimate 
public expenditure on drug treatment, taking into account drug-related pathologies and 
associated comorbidities, that was provided in hospital and outpatient specialist care. In 
this study, spending on pharmaceutical prescriptions and specialised services provided 
by addiction treatment services was also included. In Chapter 8, a different approach was 
adopted for estimating the costs of Italy’s provision of opioid substitution treatment. This 
study disentangles spending on drug treatment from spending on treating other addictions. 
Chapter 9 presents a methodology to estimate public expenditure on drug treatment in 
hospitals, for most European countries, based on international datasets.
While the objective of the studies described in Sections I, II and III is to estimate spending 
either on a specific type of drug treatment or on several types, depending on the data 
available and methods, the studies presented in Section IV provide tools to account for 
costs with different aims. Chapter 10 presents a tool — a calculator — developed by Public 
Health England to support local authorities in estimating their spending on drug-related 
specific interventions. This tool may be used by treatment providers to make their own 
estimates of costs and will increase drug treatment providers’ capacity to evaluate costs 
and analyse cost-effectiveness. Chapter 11 describes a method to estimate changes in 
spending caused by changes in the level of services provided, according to the different 
types of drug services available (such as treatment, harm reduction, prevention and social 
reintegration). From a policy point of view, these results may support future decision-
making when planning drug-related health budgets.
The studies comprising Section V highlight the fact that public spending is only part of the 
picture, and they also raise new questions. Do the methods used to estimate spending on 
drug treatment vary if the private sector pays a significant part of the bill? What are the 
socioeconomic factors required to contextualise the size and meaning of public spending 
on drug-related health? What other costs does society bear besides the drug-related health 
bill?
Chapter 12 shows how the costs of drug treatment varies in the United States, according 
to the payer (public versus private payers), type of treatment (inpatient and outpatient 
providers) and type of pharmacological treatment adopted (pharmacological versus 
behavioural therapies). Since treatment options for any given client vary based on a whole 
host of factors, including the setting in which treatment is offered, the credentials or 
certification of the provider, geographic variation in access to therapies, and differences 
in what is covered by health insurers, these complicating factors, coupled with the lack of 
price transparency for most services, make calculation of the average cost of treatment 
a challenging task. In this framework, this study exemplifies how these factors impact 
the costs of pharmaceuticals and, therefore, sharply modify the costs of drug treatment 
for opioid use in outpatient settings. Chapter 13 describes a methodological framework 
to explain and contextualise the size of spending on drug treatment. The main factors 
influencing drug treatment expenditure are analysed. Here, three classes of factors explain 
public spending: type of healthcare policy, type of drug treatment policy and socioeconomic 
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context. By tackling these factors, this report moves the discussion forward from a pure 
analysis of public expenditure methods to a broader framework, more useful in a complete 
evaluation of drug policy. Chapter 14 presents a method to compute the social costs of 
illicit drugs. The authors show that drug-related public expenditure accounts for only part 
of the total costs incurred by society as a result of the illicit drug phenomenon, using the 
example of estimates for social costs of illicit drugs France in 2010.
This EMCDDA Insights report concludes by identifying a set of desirable first steps that 
may be taken to develop estimates of spending on drug treatment. While recognising 
the limitations imposed by currently available datasets, the report sheds light on current 
practice and, in doing so, suggests areas for future methodological development. In 
addition, it may also help users of these estimates to better understand their meaning and 
to contextualise results. This way, the EMCDDA hopes that the evaluation of drug policy and 
the methods used to estimate public expenditure on drug treatment in Europe will become 
more scientific, widely accepted and integrated with good practice.
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I Preamble
According to the most recent European Drug Report 
(EMCDDA, 2016), each year approximately 1.2 million 
people in the European Union (EU) are treated for drug 
abuse-related problems. This can be attributed to the 
increased provision of drug treatment that has taken place 
across Europe since the mid-1990s, as the involvement 
of a more diverse range of treatment providers has helped 
to increase the availability of and access to treatment. 
Treatment systems are increasingly required to be 
sufficiently flexible and responsive to meet clients’ needs 
resulting from changing drug use patterns and polydrug 
use, and to provide ongoing care for chronic cases. 
However, many European countries have in recent years 
seen health budgets cut in real terms (EMCDDA, 2014). As 
a result, it is more important than ever for policymakers and 
service planners to have access to data and information 
on the capacity and performance of national treatment 
systems to justify investment decisions and to make robust 
policy choices.
Data collection and research on treatment activity and 
outcomes are well established in Europe, but there has 
been limited information on the costs of, and expenditure 
on, drug treatment. Limited data and/or insufficient insight 
into the financing of drug treatment will inevitably hinder 
the efficient allocation of resources. Service providers 
need accurate information on the costs in order to plan 
the allocation of resources. Decision-makers and funders 
can use such information as a means of cost control, for 
example, by comparing costs of similar services or those of 
alternative providers of similar services. Finally, as analysis 
of cost-effectiveness involves analysing the costs of 
alternative treatments and their outcomes as part of a fuller 
economic analysis (Gold et al., 1996), other information 
on service costs and public expenditure on drug 
treatment is needed to determine the cost-effectiveness 
of interventions, treatment programmes and the wider 
treatment and drug policy.
National estimates of drug treatment expenditure 
differ (EMCDDA, 2017), and the methods employed by 
researchers have varied and have not always been fully 
explicated. This not only affects the ability to assess the 
comparability of study results, but also limits further 
methodological development. This European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) Insights 
report seeks to address this information gap by gathering 
together a wide range of papers describing the methods 
used to estimate drug treatment expenditure in existing 
studies, as well as other associated costs. It draws on the 
experiences of a diverse group of contributors from Europe 
and beyond, including economists, policy advisers and 
scholars. The breadth of focus and approach across the 
papers provides a rich source of information on estimating 
drug treatment expenditure, including information on data 
sources, their uses and limitations. In turn, this allows the 
identification of common conceptual and methodological 
topics for discussion. By bringing together examples 
from diverse European countries, the United States and 
Australia, this publication also provides a unique insight 
into the role of contextual factors, such as national health 
systems, drug treatment provision and data availability, on 
the interpretation of results.
Furthermore, this publication provides examples of how 
public expenditure data can be used and which tools may 
be useful and further developed to carry out analysis. This 
may support commissioners and policymakers in their 
resource allocation and policy decision-making. Moreover, 
as some countries have had to face severe levels of 
austerity in the health sector recently (EMCDDA, 2014), 
it becomes more relevant to evaluate, for instance, if the 
savings in healthcare more than offset their implementation 
costs or if, conversely, they have generated a net increase in 
government expenditure over time. Finally, this publication 
aims to provide a better understanding of how studies can 
be used and interpreted. The last section discusses the 
type of information that helps to contextualise estimates of 
expenditure on drug treatment.
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In the absence of a systematic discussion of these 
issues, there has been little opportunity for policymakers, 
practitioners and researchers to take advantage of existing 
knowledge and experience. As a first step in addressing 
this gap, this EMCDDA Insights report aims to bring 
together a set of very diverse studies, encompassing 
much of the recent work on drug treatment expenditure 
in different parts of the world. While acknowledging the 
heterogeneity of the studies, it also offers a rich source of 
information that represents to a large extent the current 
state of the art in this field. By focusing on methodology, 
it particularly aims to stimulate discussion about the 
main methodological commonalities and considerations, 
building up a knowledge base on which methods and data 
are appropriate in different circumstances.
This analysis will be of interest to both those 
commissioning — or thinking of commissioning — 
expenditure/cost studies and those carrying out the 
studies, including accounting authorities; entities seeking 
funds to finance their service provision; researchers; 
officials looking to evaluate drug policy priorities and 
develop drug policy strategies and action plans; and those 
involved in the economic evaluation of drug policy.
I Background
The EU drugs strategy (2000-04) established evaluation 
of drug policy as an EU priority. Subsequently, the 
implementation of cost-effective actions in drug policy was 
addressed both in the EU drugs strategy (2005-12) and 
in the EU action plan on drugs (2009-12), specifically in 
objectives 23 and 24. In the years that followed, both the 
EU drugs strategy (2013-20) and the EU action plans on 
drugs (2013-16 and 2017-20) restated these principles. 
The EMCDDA was tasked with developing analytical 
instruments to better assess the effectiveness and impact 
of drug policy using a number of tools including analysis 
of public expenditure. Following on from this, in the EU 
action plans the EMCDDA was given responsibility for 
promoting scientific evaluation of policies and interventions 
at national, EU and international levels. It was also tasked 
with contributing to the development of estimates of public 
expenditure in EU Member States. The need to develop 
means of estimating public expenditure reflects the 
importance of making these data available, as a first step in 
the economic evaluation of policies and interventions.
In 2007, a first attempt was made to estimate drug-related 
public expenditure, including drug treatment, across 
European countries. The EMCDDA gathered national 
estimates of government funds spent on drug-related 
initiatives. However, the methods and coverage of 
estimates differed substantially across countries, making 
comparisons impossible (EMCDDA, 2008). In 2010, the 
EMCDDA invited Reitox (1) focal points to focus specifically 
on drug treatment costs within their national reports. 
Again, the topic was both politically and methodologically 
challenging, and the varying availability of information, as 
well as the complexity of funding arrangements, meant 
that, at best, only incomplete estimates could be made of 
the costs of (or expenditure on) drug treatment in Europe 
(EMCDDA, 2011). Consequently, with the support of 
Reitox focal points and using other additional datasets, 
the EMCDDA analysed trends in national spending on 
drug-related health (EMCDDA, 2014). Nevertheless, that 
study also found that difficulties in evaluating expenditure 
on health policy constrained the analysis. Various attempts 
to estimate drug treatment and related health expenditure 
have repeatedly been confronted with a common issue, 
namely that definitions and methods used to measure 
spending on treatment differed across estimations.
Taking these experiences into account and the repeated 
requests for guidance from some of the national advisers 
to policymakers, in 2013, the EMCDDA commissioned 
a literature review on the methods used to estimate 
public expenditure on illicit drug treatment. This resulted 
in a study that provided a short summary of the main 
approaches that had been applied in scientific studies and 
some grey literature (Vander Laenen and Lievens, 2013). 
From this study, the results clearly show that there are still 
methodological and data issues that require identification, 
discussion and development. First, there is a lack of 
a commonly accepted agreement on which costs should 
be included. Second, different definitions are used even 
when similar types of costs are analysed. Third, the data 
used vary markedly. Last but not least, the methods used 
to estimate the same type of costs are neither harmonised 
nor fully comparable.
This EMCDDA Insights report aims to address these 
challenges by focusing on the methodologies behind 
recent estimates rather than the results. Throughout the 
publication, authors have focused on different aspects of 
estimates, highlighting specific methods that have been 
used in practice either to collect data or to model the 
available data that produced the best possible estimates. 
These examples will help us to understand the diversity of 
approaches used, identify the underlying methodological 
and data issues and support an open and frank discussion 
of practice in the field and the strengths and limitations of 
different approaches. In doing so, the intention is to help 
(1) Reitox is the European information network on drugs and drug addiction.
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to drive innovation and improve practice, which provides 
a solid foundation for the future development of the field.
I  Financing schemes, costs of health and funding drug treatment
In Europe and Australia, the public sector is the main 
source of finance for healthcare. Overall, health insurance 
coverage is universal or almost universal in all EU Member 
States through compulsory health insurance or national 
or local health service provision. In 2015, for instance, 
public expenditure represented 79 % of the total health 
expenditure in the 28 EU Member States (EU-28) and 
67 % in Australia. In the United States, 49 % of total health 
expenditure was publicly funded in 2015. Furthermore, 
the proportion of national resources allocated to health is 
important to note. In Australia, public spending on health 
represented 8 % of gross domestic product (GDP), while in 
the EU national figures varied between 3 % and 9 %, and in 
the United States it was 8 % (OECD, 2016).
While the proportion of national resources spent on drug 
treatment policy is much smaller than the total public 
expenditure on health (EMCDDA, 2014), it still represents 
a significant component.
In addition to public expenditure on drug treatment, there 
are also important private sources of funding. The private 
sector (private entities) allocates resources that could be 
allocated elsewhere if illicit drugs did not exist. Examples of 
private expenditure are payments for health services using 
private health insurance or out-of-pocket payments made 
by individuals during drug treatment (Kopp and Fenoglio, 
2000). Furthermore, economists also consider external 
Public expenditure defined
Public expenditure of the general government is the 
value of goods and services purchased or utilised 
by the general government in order to perform each 
of its functions. The general government consists of 
a central government, sub-national governments and 
social security. Sub-national governments comprise 
the regional and local governments and municipalities 
(according to country) that usually manage budgets 
of varying size and nature, according to the political 
configuration of the country concerned.
costs, i.e. the costs of decisions taken by agents that have 
a relevant impact on others. A common example of an 
external cost is loss of productivity associated with the 
use of drugs: as a result of illness, a person may be less 
productive because of increased absenteeism or lower 
output during working time. The social costs of illicit drugs 
are the sum of public, private and external costs (Kopp and 
Fenoglio, 2000; Single et al., 2003; Vander Laenen et al., 
2011). Social costs include both tangible, i.e. costs that 
can easily be measured in monetary terms, and intangible 
costs. Intangible costs such as the human pain caused by 
the premature drug-related death of a relative cannot be 
easily quantified, although there have been attempts to 
do so. Examples of methods used to measure intangible 
costs are, for example, the use of ‘the willingness to pay 
approach’.
Although the focus of this publication is on public 
expenditure and the costs borne by public entities, in order 
to frame public expenditure on drug treatment in a wider 
context landscape, this collection of studies includes an 
estimate of the costs of treatment from both public and 
private perspectives and also the costs to society. This 
shows how estimates of public expenditure contribute to 
wider cost studies and provides insight into the potential 
impact of differences in the structure of health financing 
on treatment costs. Indeed, changes in the financing of 
healthcare, for example more private sector funding, are 
likely to have an impact on public expenditure on drug 
treatment (Reuter, 2006). This publication broadens 
the perspective further and discusses how other 
socioeconomic factors such as the epidemic situation 
in a country or its overall economic situation may have 
an impact on the volume and characteristics of public 
spending.
I  Reporting health and drug-related public expenditure
Eurostat publishes annual data on total general 
government public expenditure. Total expenditure is broken 
down into 10 main socioeconomic functions of government 
if the Classification of the Functions of Government 
(COFOG) is used. Health is one of the functional groups 
defined. Furthermore, spending on health is broken down 
into sub-categories such as medical products; appliances 
and equipment; outpatient services;  public health services; 
and research and development (R&D) related to health 
(Eurostat, 2011). Eurostat has been reporting these data 
for the EU-28 countries since 2002 (Eurostat, 2017).
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In addition, a system of accountancy geared to classifying 
and producing data on health spending has been created 
by a group of international organisations — the World 
Health Organization (WHO), the Organisation for Economic 
Cooperation and Development (OECD) and Eurostat 
(Lequiller and Blades, 2014): the System of Health 
Accounts (SHA). The SHA aims, among other objectives, 
to provide a framework for the main aggregates relevant 
to international comparisons of health expenditure and 
health systems analysis and to provide a tool, expandable 
by country, to produce data to monitor the health system. 
The SHA has been used to develop common indicators 
on health and long-term care expenditure, to monitor 
various policy objectives, and to evaluate healthcare 
systems’ performance. Annual data have been published 
by specific diseases for 12 countries since 2002. It 
includes data on total current spending for the public and 
private sectors and data for spending on the sub-groups 
such as inpatient/hospitals, outpatient/ambulatory and 
medical goods. Furthermore, spending data are published 
according to the International Statistical Classification 
of Diseases and Related Health Problems, 10th revision 
(ICD-10 codes), in which the class ‘Mental and behavioural 
disorders’ includes data on drug-related spending 
(OECD, 2017).
There are important differences between the SHA and 
COFOG. The SHA publishes data on public and private 
expenditure, while COFOG is restricted to governmental 
administrative spending. The purpose of the SHA is to 
provide a complete overview of all expenditure related to 
healthcare, while COFOG intends to classify transactions in 
government-funded healthcare.
Neither COFOG nor the SHA approach to public health 
spending provides data specifically on spending on drug 
treatment.
Studies on expenditure on drug treatment remain scarce. 
In the last 10 years, 18 EU countries have reported 
comprehensive estimates for drug-related expenditure 
incurred by general government, which includes spending 
on drug treatment. These have estimated total drug-related 
public expenditure at between 0.01 % and 0.5 % of GDP, 
with health expenditure representing between 15 % and 
53 % of total drug-related expenditure (EMCDDA, 2017).
However, caution is required when interpreting these 
data. Comparisons between countries are not possible, 
as these studies do not always apply the same definition 
of drug treatment, they include different types of 
treatment provision services, they are not always equally 
comprehensive, they do not apply the same classification 
of expenditure, or they do not use comparable methods. 
Therefore, it is still not possible to provide a reliable and 
complete European picture of public expenditure on drug 
treatment (EMCDDA, 2014).
I  Core concepts associated with drug-related estimates
While a number of attempts to estimate public expenditure 
on initiatives to reduce drug demand have been made, the 
sub-categories used to classify activities vary considerably. 
One of the key issues in the design of an expenditure study 
on drug treatment is the definition of drug treatment itself. 
International definitions of treatment such the WHO’s are 
broad, often encompassing a wide range of treatments:
The term ‘treatment’ is used to define the process 
that begins when psychoactive substance users 
come into contact with a health provider or other 
community service, and may continue through 
a succession of specific interventions until the 
highest attainable level of health and well-being is 
reached. Treatment and rehabilitation are defined 
as a comprehensive approach to identification, 
assistance, health care, and social integration with 
regard to persons presenting problems caused by 
the use of any psychoactive substance.
(WHO, 1998, p. 3)
The EMCDDA’s Treatment Demand Indicator (TDI) 
Standard Protocol, which guides EU countries in the 
harmonised reporting of treatment activity data at 
a European level, contains a definition that is similarly 
broad. Treatment is defined as ‘any activity that directly 
targets individuals who have problems with their drug use 
and which aims to improve the psychological, medical 
or social state of those who seek help for their drug 
problems’ (EMCDDA, 2012). It is therefore important that 
an operational definition of treatment is developed. A major 
consideration is how expansive the definition of treatment 
should be. A broader definition of treatment leads to the 
inclusion of different types of drug treatment services and, 
therefore, has a large impact on cost estimates, methods 
and data.
In addition, the fluid boundaries between the conventional 
categorisation of drug-related interventions — treatment, 
harm reduction and prevention — can make it difficult to 
adhere to a narrow definition of drug treatment. Some 
researchers utilise the sub-categories of prevention, 
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17
treatment and harm reduction, while others categorise 
most activities in these areas under the broad heading 
of health. Some researchers also include expenditure on 
social protection, i.e. spending on programmes designed to 
reduce poverty and vulnerability, or reintegration initiatives. 
The papers within this publication, therefore, use a wide 
range of classifications, and authors have been asked to 
describe the methods they have used in ‘real-life’ projects. 
In Chapter 1, the authors stress the importance of starting 
empirical studies on costs by clearly defining which drug 
treatments are included in estimates.
One classification of drug-related public expenditure 
frequently used by authors is labelled drug-related 
expenditure versus unlabelled expenditure. Labelled drug-
related expenditure is the ex ante planned expenditure that 
reflects, among other factors, the voluntary commitment 
of governments in the field of drugs. Labelled expenditure 
can be traced back by a detailed review of budgets and/or 
fiscal year-end accountancy reports for an implemented or 
executed budget. Concrete examples of the use of this type 
of data are provided in Chapters 2, 3 and 4.
Ideally, all public expenditure on drug-related matters 
should feature as labelled expenditure in government 
budgetary documents, with budget documentation 
covering all implemented drug-related activities. However, 
in practice this situation is confounded by three important 
issues that characterise drug treatment provision: (1) drug-
related programmes and activities can be found at many 
different government levels; (2) drug-related programmes 
are frequently provided as part of programmes with 
broader goals; and (3) the reactive nature of some drug-
related expenditure means that these costs depend upon 
the number of clients presenting for treatment, which 
cannot be known at the beginning of the financial year. 
Therefore, not all drug-related expenditure is identified 
as such in national budgets or year-end reports. Often, 
it is embedded in broader budgets, accounting for the 
‘unlabelled drug-related expenditure’, and needs to be 
estimated using modelling approaches. Two main types 
of modelling approaches are commonly used: the top-
down approach and the bottom-up approach (EMCDDA, 
2008). The top-down modelling approach is mainly used 
when the data available on drug-related expenditure are 
embedded in programmes with broader goals and the 
fraction attributable to drugs is possible to disentangle with 
clear and measurable criteria. Criteria are frequently based 
on activity data, such as the proportion of drug-related 
clients or services in the total. The bottom-up modelling 
approach starts by estimating the cost of providing a unit 
of treatment, taking into account all possible productive 
factors, and then estimates the costs of providing all 
types of treatment to all clients. Ideally, the top-down 
and the bottom-up approaches should give comparable 
results. Chapters 5, 6, 7, 8 and 9 present examples of 
diverse methods used to estimate different types of drug 
treatments based on unlabelled expenditure data.
I The structure of this publication
This publication is divided into six sections. Section I 
provides an introduction and overview of the topic by 
describing the methods used to carry out a comprehensive 
public expenditure study, helpfully setting out the key 
steps required. Section II explores how drug budgets can 
be interrogated to identify drug treatment expenditure. 
The authors use a variety of methods to do this, including 
using administrative documents and expert assessment. 
In Section III, the authors focus on the methods used 
to identify drug treatment expenditure within broader 
health budgets. The role of attributable fractions, the use 
of healthcare activity data, the identification of cost data, 
the choice of top-down or bottom-up methodology, and 
conceptual differences in the definition of drug treatment 
are all key issues here. In Section IV, the focus changes 
slightly and the tools described aim to support a different 
type of cost estimates. In Chapter 10, the authors suggest 
a method to help drug-related health providers to estimate 
costs themselves, while Chapter 11 describes a method 
to estimate the impact that variations in service provision 
have on spending. Furthermore, Section V broadens 
the focus and looks at contextual factors that help to 
understand how estimates of public expenditure can 
be used. Chapters 12 and 13 put the emphasis on the 
importance of the structure of the schemes financing 
health and on contextual (such as the epidemic situation 
of a country) or macroeconomic factors as determinants 
of costs. Chapter 14 presents an example of how studies 
of drug-related expenditure may contribute to the broader 
evaluation of societal costs. Finally, Chapter 15 covers the 
commonalities and main methodological considerations 
across the studies reported in this edition in our Insights 
series.
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SECTION I
Towards an overall estimate of public 
expenditure on drug treatment
CHAPTER 1
A methodology for estimating health expenditure 
on drug treatment: the Australian experience
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I Overview
In Chapter 1, Alison Ritter and colleagues provide a complete description 
of the method used to estimate total public expenditure on drug-related 
health, in a step-by-step approach. The method used to define treatment, 
choose data and model costs is detailed and the main challenges 
discussed. The authors, first, emphasise the need to establish clear 
definitions and boundaries for the types of health provision for which costs 
are going to be included; second, identify the types and categories of 
existing funding; and, third, suggest the most suitable method to estimate 
it, depending on the category, type of treatment and data available. In every 
case, consistency across the various estimates is valuable, and a clear 
description of the methods applied is required to permit other researchers 
to replicate the estimates. Last but not least, the limitations of estimates 
need to be clearly specified. Finally, the authors conclude that no method 
is perfect. Indeed, they conclude that any estimate of the costs of drug 
abuse treatment will require a series of compromises, with assumptions 
to be discussed and datasets that could be further improved. In their case, 
the authors could not isolate expenditure on treatment for alcohol misuse 
from the spending on drug treatment.
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I Introduction
Estimating the expenditure associated with drug abuse 
treatment (1) is an important exercise. Conducted at 
a single point in time, it can inform the current investment 
in drug treatment for any one state or nation. Conducted 
over time, it can be used to monitor changes in 
expenditure. Furthermore, the investment in drug treatment 
relative to other areas of health (and overall government 
expenditure) can be an important performance indicator. 
It is also a useful tool for cross-national comparisons, for 
which the methodology needs to be standardised. Drug 
treatment expenditure can provide an evidence base 
for policy decisions about resource allocation, and can 
encourage policy reform such that better health outcomes 
are achieved from treatment.
In this study, we provide the details of one approach 
to estimating health expenditure in drug treatment, 
informed by an international framework, which draws 
on our experience in Australia (Ritter et al., 2015). We 
outline the steps and approach, highlighting lessons 
learned and potential pitfalls for other investigators. It is 
hoped this chapter can be used to inform drug treatment 
expenditure estimates in other locations and the evolution 
of methodologies.
It should be noted that, in Australia, treatment for alcohol 
use disorders is provided by and integrated with treatment 
for drug use disorders. Hence we cannot separate alcohol 
from other drug treatment, and the expenditure estimates 
in this study cover all substances (Ritter et al., 2015). It was 
not possible for us to separate alcohol expenditure from 
drugs expenditure. Indeed, we would argue that, given the 
(1) Although we use the generic term ‘drug treatment’, this is inclusive of 
alcohol, licit drugs used illicitly and illicit drugs.
very high rates of polydrug use (presentations to treatment 
for misuse of both alcohol and illicit drugs together), it 
makes little sense to even try and separate them.
International standards for health expenditure accounting 
specify the framework for health expenditure estimates 
(OECD et al., 2011). These are referred to as the SHA and 
have been developed with cooperation from the OECD, 
Eurostat and the WHO. The SHA ‘proposes a framework 
for the systematic description of the financial flows related 
to health’ (p. 3) such that reliable and timely data are 
developed that are comparable both across countries 
and over time (2). Our starting premise was that drug 
treatment expenditure estimates should be consistent 
with these international standards, and hence consistent 
with the ways in which health expenditure is analysed at 
a global level. There is little point in introducing novel or 
unique approaches when estimating costs within drug 
treatment that cannot then be compared with other health 
expenditure, because the allocation of resources across 
(and beyond) health portfolios occurs within a policy 
environment of competing priorities. As will be seen 
below, wherever possible we follow the SHA (OECD et al., 
2011), but the particularities and peculiarities of both drug 
treatment and any one country’s health system also need 
to be taken into account.
By way of background, Australian healthcare is funded 
through a number of complex arrangements (Duckett and 
Willcox, 2011; Hall, 2015). While Australia purports to 
have universal healthcare coverage, the reality is that most 
patients pay some form of co-payment and/or are privately 
insured. That notwithstanding, two levels of government 
(2) Within each country, an institute or research body is usually responsible 
for filing that country’s SHA return. The Australian Institute of Health and 
Welfare (AIHW) is responsible for the annual health expenditure estimates 
in Australia (Australian Institute of Health and Welfare, 2014). 
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fund healthcare in Australia — the federal (Commonwealth) 
government and the states/territories (the latter largely 
via tax transfers from the federal government to the 
states). Acute healthcare — hospitals and emergency 
departments — is funded by both levels of government, 
whereas primary healthcare (through general medical 
practitioners (GPs) in community settings) is funded 
solely by the federal government. The federal government 
also funds medications (through the Pharmaceutical 
Benefits Scheme). The more specific funding flows for 
drug treatment in Australia represent a complex set of 
arrangements from three levels of government — federal, 
state and local — along with numerous intermediary 
bodies. The full details of the Australian funding flows for 
drug treatment can be found in Chalmers et al. (2016).
The perspective taken for this study, as detailed below, is 
public expenditure funding only. We exclude all private and 
patient/client funding for healthcare. The focus is also only 
on funding from designated health departments. This is 
a limitation of applying the SHA to drug treatment where 
some drug treatment is not funded by government and it is 
not possible to differentiate, or it is funded by government 
departments other than health. These issues are discussed 
next.
I  First step: defining the scope of estimates and identifying the financing agents
The SHA (OECD et al., 2011) provides the following four 
criteria for establishing the bounds of the goods and 
services (activities) covered by health expenditure (pp. 
55-56): (1) the primary purpose of the activity is health 
(improving or maintaining health, or preventing ill health); 
(2) the activity is provided on the basis of qualified medical 
or healthcare knowledge and skills; (3) the consumption 
is for the final use of healthcare goods and services of 
residents; and (4) some entity, not necessarily the recipient, 
pays for the healthcare activities (there is a transaction). 
The SHA identifies the range of health-related activities 
and services and it includes health promotion and 
prevention, treatment and rehabilitation, and ongoing or 
palliative care (p. 52). Australia’s official estimate of health 
expenditure (Australian Institute of Health and Welfare, 
2014) conforms to the international framework for health 
accounts (OECD et al., 2011) and creates a boundary for 
health interventions provided within healthcare settings, 
by health practitioners and funded by health departments. 
Already we see a potential issue for drug treatment — not 
all drug treatment is necessarily provided by healthcare 
practitioners (criterion 2), nor is it necessarily a transaction 
funded by health departments (criterion 4). For example, 
in the case of drug treatment in Australia, correctional 
services (such as prison and parole) provide considerable 
drug treatment. Non-healthcare practitioners, such as 
welfare officers, employment officers and correctional staff 
can provide drug treatment. Funding that sits outside the 
health department is not included within the SHA. Thus, 
in the work we present in this chapter, and consistent 
with the international framework of health expenditure, 
we do not include services funded by departments other 
than health or by non-government-funded sources of 
care (such as philanthropy). The extent to which this may 
underestimate the total health expenditure is an important 
consideration for each country. In the case of Australia, we 
suspect that most drug treatment is funded through public 
health departments and provided by healthcare services, 
and, as such, it is preferable to follow the boundaries given 
in international standards. This may not be true for other 
countries, notably developing nations.
Aside from defining the boundary around the health 
expenditure, a definition of drug treatment is required. In 
the work we completed in Australia, alcohol and other drug 
treatment was defined as ‘that which is directed towards 
an individual regarding changing his/her alcohol or other 
drug use’ (UNODC, 2006). This would include detoxification 
services, medication-assisted treatments, rehabilitation 
and counselling services. Under this definition, the authors 
excluded harm reduction interventions (such as needle 
syringe programmes) because they focus on reducing the 
harmful consequences of drug use, rather than the drug 
use itself (3).
Establishing the definition of drug treatment, and 
documenting the various treatment types, is an important 
step. The UNODC definition above is widely accepted. 
A useful reference may also be the WHO Atlas on 
substance use (WHO, 2010), which contains multiple 
descriptions of drug treatment types. The EMCDDA 
Treatment Demand Indicator (TDI) Standard Protocol 
(http://www.emcdda.europa.eu/html.cfm/index65315EN.
html July 2000) defines treatment as ‘any activity that 
directly targets individuals who have problems with their 
drug use and which aims to improve the psychological, 
medical or social state of those who seek help for their 
(3) Note that the EMCDDA TDI Protocol also excludes needle syringe services 
(Standard Protocol, July 2000, p. 18), unless they are provided as part of 
a treatment centre’s activities. 
Chapter 1 I A methodology for estimating health expenditure on drug treatment: the Australian experience
27
drug problems’ (p. 16). This definition is consistent with the 
UNODC definition (4).
We approached the exercise by developing a list of all the 
drug treatment interventions that could be included within 
the health expenditure accounts, and then deliberating 
on the inclusion/exclusion of each one in relation to its 
consistency with the SHA (OECD et al., 2011) criteria. Each 
country may come up with its own definition, and list of 
drug treatment types. In our Australian study, the following 
interventions were included: detoxification/withdrawal; 
counselling; therapeutic communities and residential 
rehabilitation; outreach support; assessment and case 
management; and pharmacotherapy — short-term 
medication prescribing or maintenance medications. This 
is consistent with the SHA (OECD et al., 2011) definition of 
health.
Having defined the boundary around health expenditure 
and drug treatment, it is also helpful in this preparatory 
stage to fully understand the various funding sources. 
This can be achieved through a systematic collation 
of information about drug treatment funding sources. 
Three strategies can be used: the first is a literature 
search (including grey literature), which identifies drug 
treatment funding sources in the country. This may 
include government reports and documents, along with 
research studies. The WHO Atlas may also be helpful in 
this regard (WHO, 2010). A second strategy is to take the 
list of treatment types (see above) and identify the funding 
sources for each of these. In our experience it is likely that 
there will be at least two or three different funding sources 
for each treatment type. Third, there is value in interviewing 
a number of treatment providers and asking them to 
describe their funding sources. This can sometimes reveal 
sources that are otherwise not identified. Understanding 
the funding sources for drug treatment is essential before 
beginning to assess the extent of expenditure. This 
preliminary step in documenting funding sources will reveal 
the different types of funds and the different ‘buckets of 
money’ from which drug treatment expenditure is drawn.
We appreciate that this is a challenging exercise. In our 
work, we identified more than 20 different funding sources 
in Australia and a complex array of funding flows, with 
many intermediaries between the funding source and the 
treatment provider (Chalmers et al., 2016). Nonetheless 
we argue that time spent in this preparatory phase, 
(4) It should be noted, however, that the TDI Protocol does not define inclu-
sion based on this definition of treatment, but rather it defines inclusion 
based on the identification of the treatment centres, which are of five 
basic types: outpatient services; inpatient/residential services; low-thresh-
olds service; treatment offered by GPs; treatment units in prison (TDI 
Standard Protocol, 2000). It is solely these units that are included in the 
identification of cases for treatment in the TDI. 
to understand the funding sources for the treatment 
types, is time well spent, as it will assist when the actual 
expenditure estimates (the amounts of money) are 
undertaken. The lists of drug treatment types and funding 
sources may also be useful as a stand-alone exercise for 
countries where expenditure estimates cannot be provided.
I Next step: categorisation
The SHA (OECD et al., 2011) provides three ‘axes’ for 
categorising health accounts:
1. healthcare functions;
2. healthcare providers;
3. financing schemes.
These axes provide three different dimensions or ways 
of structuring health accounts. Each axis has a specific 
classificatory structure. While there is not such a precise 
match made clear in the SHA (OECD et al., 2011), if we 
take the first axis, referring to healthcare functions, i.e. 
in the accounting process, all the resources involved in 
the process of satisfying health needs are identified. The 
second axis refers to the type of healthcare provider, i.e. 
the accounting process captures all the organisations and 
actors involved in the provision of healthcare; and the third 
axis refers to the financing schemes (such as national 
health service, social health insurance and voluntary 
insurance). The SHA (OECD et al., 2011) notes that the first 
axis, healthcare by function, is the preferred axis on which 
to build expenditure estimates because it is seen to be the 
most inclusive (healthcare which has been ‘consumed’ 
needs to also have been ‘produced’ and ‘financed’) and 
the most consistent with the main aim of this study, i.e. to 
estimate health expenditure with the purpose of treating 
drug dependence. The ‘healthcare function’ axis also 
aligns well with the four criteria referred to earlier (the 
primary purpose of the activity is health; the activity is 
provided on the basis of qualified medical or healthcare 
knowledge and skills; the consumption is for the final use 
of healthcare goods and services of residents; and some 
entity, not necessarily the recipient, pays for the healthcare 
activities). However, as noted earlier, drug treatment sits at 
the boundary of these criteria and is not always provided 
by qualified medical personnel, and so on. For that reason, 
a single axis of the SHA may not suffice.
In our study, we explored each of the three axes in 
relation to the structure of drug treatment provision 
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and expenditure in Australia before selecting the most 
appropriate and most simple SHA classificatory system 
to use. Thus, for the purposes of estimating drug 
treatment health expenditure, selecting and categorising 
the expenditure can be done according to healthcare 
functions (axis 1), healthcare providers (axis 2) or 
healthcare financing schemes (axis 3). Categorisation of 
health expenditure by healthcare functions could follow 
the types of drug treatment provision, i.e. withdrawal, 
rehabilitation, pharmacotherapy maintenance, and so 
on. Thus, expenditure in each of these categories would 
be calculated. Alternatively, health expenditure can be 
calculated in terms of providers. In the SHA (OECD et al., 
2011) the categories of providers include organisations 
such as hospitals, ambulatory care providers, and so 
on. This second axis (healthcare providers) is consistent 
with the current EMCDDA TDI Standard Protocol, which 
identifies the drug treatment centre types (e.g. inpatient, 
outpatient). For estimating drug treatment expenditure, 
however, it may be more relevant to conceptualise provider 
types by practitioners (such as medical doctors, including 
addiction medicine specialists, psychologists, social 
workers, drug workers/counsellors and pharmacists), 
rather than by type of treatment centre. Categorisation by 
practitioner type is helpful for thinking through the types 
of expenditure data because in many instances the type 
of expenditure data is linked to the type of practitioner. For 
example, in Australia GPs are funded through Medicare 
(which reimburses practitioners for each unit of service 
they provide), whereas drug treatment workers are funded 
through block grants provided to non-governmental 
organisations (NGOs). However, the problem with using 
only provider type (axis 2) is that it becomes unnecessarily 
complicated because most of the practitioners work 
together (in clinical teams) at any one site (or organisation). 
The third categorisation option is financing scheme. Here, 
the different financing schemes can be categorised: for 
example, government block grants, activity-based funding 
(ABF), public healthcare (e.g. Medicaid, Medicare).
In our study, we considered all three category types 
(functions, providers and financing schemes), which assists 
in ensuring that all types of health expenditure have been 
identified. Understanding the different types of expenditure 
across functions, providers and financing systems is, in 
our opinion, the only way to establish a clear approach 
to estimation of health expenditure. Then, in an ideal 
world, one of the category systems from the SHA would 
be selected and applied. In our study; however, it became 
apparent that not one of the three axes or categorisation 
systems alone would be suitably straightforward and 
simple, accommodate the variety of data sources available 
and ensure no overlap. For example, if hospitals (a provider) 
are all funded through a particular mechanism, it is 
sensible to choose the hospital category (and hence axis 2, 
providers) as the system to use. However, many treatment 
types are provided by multiple and different providers. 
In another example, if pharmacotherapy treatment (a 
function) is funded through a singular mechanism (whether 
provided in a hospital or in a community setting), then 
that categorisation system (function) may make the most 
sense. But this may not apply to other functions, such as 
withdrawal treatment, which can be provided in hospital 
or a community setting and by multiple practitioners 
(resulting in multiple expenditure data sources for those 
other functions). The target is to find a systematic way of 
categorising the types of expenditure that is pragmatic, 
is suitable for the data available, and does not entail 
unnecessarily complicated accounting work in order to use 
the categorisation. It is essential that the categories chosen 
are mutually exclusive — so that expenditure is not double 
counted.
Taking into account the difficulty in directly applying the 
classification suggested by the SHA, this study used the 
following mutually exclusive categories to classify health 
expenditure on drug treatment in Australia:
1.  NGOs funded by government: national (federal) funding 
and state funding;
2.  hospitals: public and private hospitals receiving funding 
from government;
3.  primary care (community-based) services provided by 
GPs and allied health professionals;
4.  pharmaceutical medication (Pharmaceutical Benefits 
Scheme).
In our pragmatically oriented approach, we did not confine 
ourselves to only one SHA axis (function, provider or 
financing), but we used a blended approach that made 
sense in terms of the separate ‘buckets of money’ spent 
on drug treatment in Australia. In the main, however, the 
categorisation largely follows the second axis approach, 
in which health accountancy is organised by provider type 
(NGOs, hospitals, GPs and allied health professionals) (5), 
with the exception of the pharmaceutical medications, 
which is a function, not a provider type (6). The four 
categories above are also largely distinguishable by 
financing mechanism: government funding to non-
governmental treatment providers is via block grants; 
hospital funding is largely ABF in Australia (Eagar, 2010; 
Health Policy Solutions et al., 2011); pharmaceuticals are 
(5) And aligns with the SHA sub-accounts of, respectively HP.3.3 and HP.3.4; 
HP.1.1 and HP.1.2; HP.3.1.1 and HP.3.3. 
(6) And aligns with HC.5.1.1.
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funded by the federal government at a unit cost per drug; 
and primary care services are funded through government 
reimbursement to the practitioner on a fee-for-service 
basis (7).
As noted previously, ensuring that there is no double 
counting is important. For example, in the case of 
hospitals, medications are provided for inpatients but 
are funded through the hospital funding system, not the 
pharmaceutical medications systems (which is confined 
to ambulatory care). Thus there is no double counting of 
medication expenditure between the two categories in our 
study. Each category needs to be reviewed for possible 
overlap with other categories.
In summary, categorisation for the Australian case example 
was largely by provider type, which usefully aligned with 
the different financing systems. This categorisation was 
the most appropriate for Australia, but it may not be as 
applicable in another country. Again, laying out all the 
functions, providers and financing systems will assist in 
identifying the most pragmatic categorisation for the health 
expenditure estimate in a country.
I  Third step: collating and counting the expenditure 
Having established mutually exclusive categories of health 
expenditure on drug treatment, the next step is to calculate 
the expenditure for each of these items. Methods may 
vary depending on what data are available and the extent 
to which individual client versus total budget costs are 
available. Here we provide the detailed methods for the four 
categories used to assess Australian health expenditure 
on drug treatment. It is more complicated than it seems at 
first sight and, while each country will be unique in terms 
of its categories, systems, data availability and accounting 
records, it is hoped that, by providing a worked example, 
insights for other countries will be possible. The full details 
of the expenditure estimates and the results can be 
found in Ritter et al. (2015), including the supplementary 
information associated with the paper.
(7) These financing schemes align with SHA sub-account HF.1.1 but describe 
the mechanism of payment.
I Non-governmental organisations 
Drug treatment is largely provided by NGOs in Australia. 
The funding may be sourced from different levels of 
government: federal, state or local. In Australia, both federal 
and state governments provide funds to NGOs to deliver 
drug treatment. These funds are provided as block grants, 
specifically for drug treatment, and hence the expenditure 
estimate here is relatively straightforward: the total value 
of all grants awarded to NGOs to provide drug treatment. 
The expenditure estimates are generally labelled as public 
expenditure for drug-related initiatives, but one needs to 
know the programme name (in order to find it in budget 
papers (8)) and also to extract any non-treatment activities 
from those accounts.
In an ideal world, each government would be able to 
provide a publicly available account of its expenditure 
(grants provided) to NGOs for drug treatment. In reality, 
there may be concerns about confidentiality, and data may 
be aggregated at such a level that drug treatment may not 
be distinguishable from other grants provided to NGOs. 
Furthermore, the opportunity to identify expenditure by 
type of drug treatment, such as withdrawal compared with 
pharmacotherapy maintenance, would be ideal in terms 
of analysing trends within drug treatment budgets and 
assessing efficiency, but achieving this level of detail was 
not possible in this study.
For the federal government estimate, two specific grant 
schemes covered federal expenditure in relation to drug 
treatment (see Ritter et al., 2015). In Australia, the details 
of these schemes and the grant amounts can be found in 
a number of different sources: notably published public 
records and direct from the federal government. Where 
possible, it is helpful to use two or more different sources 
as a check on the reliability of the figures. We found that 
our sources did not match perfectly (Ritter et al., 2015), and 
we took a middle point (9).
For state governments (of which there are eight in 
Australia), a different approach was taken. Public records 
are not available at state level, so we conducted interviews 
with senior health officials in each state and requested 
their expenditure estimates. The key challenge with 
this approach is that each state records expenditure in 
a slightly different way, and at different levels of detail. For 
example, in some cases, the data provided were highly 
detailed, down to individual programmes and organisations 
that were funded. In other cases, total spending figures 
(8) In our case the two programmes were the Non-Government Organisation 
Treatment Grant Program (NGOTGP) and the Substance Misuse Service 
Delivery Grant Fund (SMSDGF).
(9) The size of the difference was AUD 18 000 (the total federal government 
estimate was AUD 130 281 000 — see Ritter et al., 2015).
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were provided. While we requested only expenditure on 
treatment, as per the definition given earlier, we were aware 
that in some cases the state governments were unable 
to provide a single figure for drug treatment, and their 
estimates included some prevention and/or harm reduction 
activities. In some cases this was readily identifiable (such 
as needle and syringe programmes), while in other cases 
the prevention and harm reduction activities could not be 
identified and excluded. This introduced some uncertainty 
into the estimation and it highlights one challenge of using 
a boundary between drug treatment and harm reduction 
services.
The year of the estimate needs to be consistent within this 
single category and between all categories. The choice 
of a reference year is somewhat arbitrary but should 
reflect the year for which most data are available. Data 
that pertain to years other than the reference year require 
adjustment with a price index, such as the consumer 
price index, so that expenditure is presented in constant 
terms. Furthermore, where data are from different years, 
a qualitative assessment of any major shifts in demand for 
treatment or shifts in government policy may be required. 
If there have not been major shifts in treatment demand 
or government policy since the year of the estimate, data 
from years other than the reference year can more reliably 
be interpreted as consistent with the reference year. It is 
important to document the likelihood of these impacts.
I Hospitals 
Hospitals provide a variety of drug treatments to admitted 
clients; in Australia, they are largely focused on withdrawal 
(detoxification) and counselling services. The approach 
to estimating hospital expenditure will vary depending 
again on available data and the financing system in use. In 
Australia, hospitals are funded through a combination of 
block grants and ABF. These two different systems need 
to be taken into account when estimating expenditure. 
The detailed calculations, including those for private 
hospitals (10) compared with public hospitals, can be found 
in Ritter et al. (2015).
For the ABF component of hospitals (which represents 
most of the funding), the number of hospital 
separations (11) by diagnostic code is available, along with 
the costs attached to those diagnostic codes, as derived 
from the ABF approach. The ABF approach for hospitals 
is internationally recognised (Eagar, 2010; O’Reilly et al., 
(10) In Australia, the federal government subsidies a proportion of private hos-
pitals. Only federal government funding for private hospitals was included. 
(11) ‘Separations’ is the term used in Australia to refer to a single episode of 
care in a hospital.
2012). The basis of ABF (also called case-mix or episode of 
care funding) is the grouping of care for similar conditions 
with similar costs (that is, the activity is defined and 
classified into a discrete number of groups based on data 
about costs). The Australian ABF (12) has an elaborate 
classification system of several hundred diagnostic-related 
groups (DRGs) (13). Each care episode is allocated a DRG 
code by computer software based on clinical coding in 
medical records, which forms the basis of the payment.
A price is assigned to each DRG. There is a difference 
between the ‘price’ — which is the payment amount — 
and the ‘costs’, which is the total cost of providing the 
services for that specified DRG. While cost data are used to 
determine the DRG categories, the setting of the price paid 
is a different exercise. The agreed price paid may be set 
low to encourage technical efficiency or it may be set high 
to encourage certain types of practices/care (allocative 
efficiency). In Australia, the prices for public hospital 
services (activities) are set by an independent body, the 
Independent Hospital Pricing Authority (IHPA), in order to 
minimise political influence on price setting. Setting the 
price can occur either for each DRG (segmented approach) 
or by using a standard price (national efficient price) 
and then each DRG is weighted against that price. The 
latter system is used in Australia. The IHPA sets a single 
benchmark efficient price for all hospital services, called 
the national efficient price (NEP), and payments for specific 
activities (separations) are then calculated using payment 
weights, or national weighted activity units (Independent 
Hospital Pricing Authority, n.d.).
The exercise of estimating expenditure on drug treatment 
through hospitals, then, it is the multiplication of the 
number of diagnostically relevant separations by the 
appropriate unit cost, as specified under ABF. While that 
sounds relatively straightforward, there are a number of 
intricacies involved. Here we use the example of which 
diagnostic codes to use. First, one must decide between 
only using the primary diagnosis or including secondary 
diagnosis. The rationale for primary diagnosis only is that 
we are interested in drug treatment expenditure (not 
expenditure associated with hospitalisations and medical 
care for other conditions that may be compounded by 
alcohol or drug disorders). Hence the primary diagnosis 
alone was used. Second, one needs to choose which 
diagnostic system, as there is more than one. In Australia, 
hospitals code separations use two different codes: 
(12) Australian public hospital services’ ABF is reputed to be one of the most 
sophisticated ABF systems in the world and has been sold to a number of 
other countries.
(13) The DRG is determined by computer software using information from 
a number of variables including principal diagnosis (i.e. the ICD code), 
secondary diagnoses (complications and comorbidities), significant 
operating room and/or non-operating room procedures, age, sex, length 
of stay (same day/multi-day), and discharge status.
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diagnostic codes (ICD-AM diagnosis of abuse and 
dependence — Australian modification) and DRGs (major 
diagnostic groups, classed together because of similarity 
in treatment approach) (O’Reilly et al., 2012). Neither of 
these codes (ICD-AM diagnosis or DRG) is a perfect match 
with the definition of drug treatment. In the main, drug 
researchers have tended to use the ICD codes to identify 
admissions related to alcohol and other drugs (Australian 
Institute of Health and Welfare, 2013) but these clearly 
overestimate hospital admissions for treatment and can 
be more correctly labelled ‘hospitalisations associated 
with drug use’ (Australian Institute of Health and Welfare, 
2013, p. 86). The way in which hospitals are funded 
through ABF uses the DRG (rather than ICD) and for this 
reason — because it is more likely to reflect treatment 
received — the DRGs were used for Australia (14) (see 
also Ritter et al., 2015, for more details). This is merely 
by way of demonstrating that the decisions made during 
the analytical procedure, such as which diagnostic 
system to use to code hospital separations, will impact 
on the expenditure estimate, and they should be fully 
documented. To summarise, for our Australian estimates of 
hospital-based drug treatment, we established the number 
of treatment episodes that were provided in Australian 
hospitals (called ‘separations’) using the DRG codes in 
our reference year, using primary diagnosis only (because 
we wanted to count drug treatment, not other healthcare 
treatment). We then applied the weighted NEP to these, to 
give us the expenditure by government (the amount they 
paid the hospitals for the care provided).
A central issue here is the use of an activity-based costing 
approach, conforming to a more bottom-up method than 
largely top-down methods (which divide total budgets 
by the amount of drug treatment activity). While there 
is no definitive definition of top-down versus bottom-up 
estimation methods, we consider top-down to be an 
estimate that derives from a total budget, which may then 
be divided by the amount of activity under interest. Bottom-
up is when individual activities are costed (usually at the 
client level) and then summed. In our work, the hospital 
ABF approach is nearer to bottom-up (the multiplication of 
numbers of clients by a unit cost), whereas the estimates 
of the government spending on NGOs are more like top-
down to the extent that they are total expenditure figures 
from government; and the pharmaceutical cost estimates 
(14) The relevant International statistical classification of diseases and related 
health problems, 10th revision, Australian modification (ICD-10-AM). Sev-
enth edition codes for principal diagnoses were F10 (alcohol), F11 (illicit 
opioids), F12 (cannabinoids), F13 (benzodiazepines), F14 (cocaine), F15 
(stimulants, including amphetamines, pseudoephedrine, volatile nitrates 
and caffeine), F16 (hallucinogens, including LSD and ecstasy), F18 (vol-
atile solvents), and F19 (multiple drug use and use of other psychoactive 
substances). We included separations where the Australian national 
DRGs (AN-DRGs) were intoxication and withdrawal or alcohol and other 
drugs disorder and dependence (V60A, V60B, V61Z, V62B, V63Z, V64Z). 
are definitely top-down inasmuch as they involve taking 
a labelled budget expenditure item (pharmaceuticals 
budget in Australia) and dividing by the amount of drug 
treatment prescribing. In an ideal world there would be 
complete consistency across all the estimates: that is, 
either an activity-based or bottom-up costing approach 
would be used for all expenditure categories, or a top-
down approach would be used consistently. Top-down 
approaches can produce higher estimates (Chapko et 
al., 2009; Mercier and Naro, 2014). Therefore, where the 
methods vary, it is prudent to conduct some kind of cross-
check of the figures. We did this for the Australian hospital 
data: comparing the ABF approach with a top-down 
accounting approach. We found that a total of AUD 53.5 
billion was spent on Australian hospitals in 2011/2012 
(Australian Institute of Health and Welfare, 2014), of which 
70 % was spent on admitted clients. The percentage 
of drug treatment separations can be calculated from 
the total number of separations for admitted clients 
(Australian Institute of Health and Welfare, 2014) — in our 
case it was 0.71 % (Ritter et al., 2015), resulting in a top-
down expenditure estimate of AUD 264 699 445. This is 
lower than the estimate obtained with the main method 
(AUD 313 169 372).
I  Primary care (community-based) services provided by GPs and allied health practitioners
As with all the other categories, a thorough understanding 
of how primary care works and the ways in which 
practitioners and services are funded is essential. In 
Australia, primary care is funded by the federal government 
through a universal healthcare scheme (Medicare). 
Where such a scheme exists, and specific details of drug 
treatment are recorded and published (such as ‘item 
numbers’, as they are called in Australia), the calculation 
can be relatively straightforward. Unfortunately drug 
treatment does not have its own item number in the 
Australian coding scheme (and we suspect in many other 
countries as well). This then requires sampled data about 
the extent of drug treatment activity within primary care 
settings.
In Australia, an annual survey is conducted (known as 
BEACH), which collects data from a sample of around 
1 000 GPs, who each record details of about 100 
consecutive consultations. The database contains details 
of approximately 100 000 consultations per year, including 
the problems managed and how they are managed, for 
each patient for whom a clinical service is provided by the 
participating GP (Britt et al., 2010). It also includes details 
of prescribing, which we used for the pharmaceutical 
medications estimate (see below). The extrapolation 
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method we used to get from sample to national estimates 
is fully described in Britt et al. (2010, 2014) (15). This 
provides the basis for an Australian expenditure estimate 
for drug treatment in primary care settings. If there 
is no ongoing survey of primary care services within 
the country, an alternative approach may be to use 
published research studies regarding sampled primary 
care services. The representativeness of any sampling is 
crucial in deciding whether the data are suitable for use 
in developing a national estimate. In the BEACH data, the 
representativeness of the final weighted age-sex patient 
sample of encounters is compared with that of patients at 
all encounters claimed (excluding those with Department 
of Veterans’ Affairs (DVA) patients) as GP consultation 
service items through Medicare in the 2013-14 study 
period (data provided by the Department of Health). In each 
year, there is an excellent fit in the age-sex distribution of 
patients at the weighted BEACH encounters with that of 
the Medicare Benefits Schedule (MBS) claims distribution, 
with most precision ratios within the range 0.91-1.09 (Britt 
et al., 2014) (16).
Sampled data identifying the number of drug treatment 
services provided can then be multiplied by the unit cost 
per treatment (or occasion of service). In our case we 
used the price paid by the government to the providers 
(MBS (17)) (refer to Ritter et al., 2015, for details). As with 
the hospital estimates, the amount therefore reflects the 
price the government pays for the service, not the cost of 
delivering the service. The MBS of fees is set by the federal 
government and is the amount the government considers 
appropriate and fair for each service type. The schedule 
fee for an item is determined at the time of listing and 
calculated in consultation with the medical profession. It 
takes into account the direct and indirect costs of providing 
the service (e.g. the length and complexity of the service, 
any consumables used, administrative costs and rent for 
premises). The schedule fees for MBS items are generally 
indexed yearly by a combination of a wage index (the safety 
net adjustment) and the consumer price index. However, 
(15) The annual rate per 100 encounters is extrapolated to national estimates 
based on the number of Medicare GP consultation items claimed in 
that year. For example, in 2013-14, 133.4 million GP service items were 
claimed. Depression was managed at a rate of 4.3 per 100 GP encounters 
in 2013-14. Hence the Australia-wide estimate was (4.3/100) × 133.4 
million = 5.7 million times (Britt et al., 2014).
(16) Occasionally, where participants in a particular age or sex group are 
over-represented or under-represented, GP age-sex weights need to be 
applied to the datasets in post-stratification weighting to achieve compa-
rable estimates and precision. Because there are always marginal (even 
if not statistically significant) differences, even in years where the BEACH 
participants are representative in all age and sex categories, post-stratifi-
cation weighting is applied for consistency over recording years. In addi-
tion, because each GP provides data on 100 consecutive encounters, the 
data are assigned another weight directly proportional to the activity level 
of the reporting GP (where GP activity level is measured by the number of 
MBS general practice service items claimed by the GP in the previous 12 
months). 
(17) MBS online: http://www.mbsonline.gov.au/internet/mbsonline/publish-
ing.nsf/Content/Home accessed 20 June 2017.
some MBS items, for example pathology and diagnostic 
services, have not been routinely indexed since 1998 (18).
We compared the primary method we used here (more 
bottom-up) with a top-down approach (dividing the total 
primary care budget by the proportion of occasions of 
service represented by drug treatment). In our work, 
the top-down calculations resulted in a higher estimate 
(AUD 70 million) than the main calculation (AUD 53 million) 
(Ritter et al., 2015).
The boundary around primary care services, and the extent 
to which other drug treatment is provided by practitioners 
other than those whose services are recorded in the 
data, is of concern. In the Australian example, only GPs 
were included in the BEACH data, but we are aware that 
psychiatrists and physicians also provide drug treatment in 
primary care settings. These were not able to be included 
in the Australian estimates. Specification of the limitations 
and exclusions in any estimation is essential.
Another important expenditure item is the allied health 
services provided in primary care settings. The extent 
to which national administrative data (such as ‘item 
numbers’) or national regular survey sampled data (such as 
BEACH data) are available varies. In Australia, expenditure 
on allied health services is not available from either of 
these sources. As a result, we turned to research studies 
of allied health services to ascertain expenditure. The use 
of research studies or published evaluations is a valuable 
approach when systematic administrative data are 
unavailable, but this approach is limited by concerns about 
generalisability and representativeness.
In Australia we identified two specific schemes (‘Better 
Access’ and ‘ATAPS’) that are programmes aimed at 
improving access to allied health services for people with 
mental health problems, inclusive of alcohol and other drug 
use disorders. Both programmes provide treatment for 
alcohol and drug use disorders, so they meet the definition 
of treatment used across the study. But directly labelled 
expenditure items for the programmes were not available. 
As a consequence, we turned to published evaluations 
that included budget data (details can be found in Ritter 
et al., 2015). This small example highlights the inherent 
limitations of any expenditure estimate — it is driven by 
knowledge of programmes and services and/or funding 
schemes as well as available data. We were able to 
include some allied health expenditure estimates for drug 
treatment in Australia. This may not be the case in other 
countries, where services cannot be readily identified or 
(18) MBS Online: http://www.mbsonline.gov.au/internet/mbsonline/publish-
ing.nsf/Content/Home accessed 20 June 2017.
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where services have not been subject to evaluations from 
which data can be drawn.
I  Pharmaceutical medications (Pharmaceutical Benefits Scheme)
In the first instance, understanding the kinds of 
pharmaceutical medications used in the treatment of 
alcohol or other drug use disorders and how they are 
provided and funded is important. For example, as noted 
earlier, hospitals provide medications, but this cost is 
included within the above expenditure estimate. So, for 
Australia, we need to estimate only medications provided 
as part of ambulatory care (in general medical practice 
settings). Ideally one would have data concerned with 
the extent of prescribing for drug treatment, the specific 
types of medications and the number of prescriptions, so 
that government expenditure on those medications can 
be apportioned. The extent to which all these data are 
available in any one country will vary. In Australia, we do 
not have data on all prescribing for drug treatment (there 
are data on all prescribing, but they are not distinguishable 
by the condition for which the prescription is made). In this 
circumstance, we have to return to the use of sampled data 
and assume that the sample is representative of the whole 
country.
In Australia, medications are funded through the 
Pharmaceutical Benefits Scheme (PBS). There are readily 
available data sources for the expenditure on the PBS in 
Australia (for example Australian Statistics on Medicines: 
http://www.pbs.gov.au/info/browse/statistics). It is 
hoped that other countries also have government reports 
detailing total expenditure on prescription medications. 
In a top-down approach, these total spending figures can 
then be divided by the amount of GP prescribing that is 
drug treatment specific (from the BEACH sampled data 
described earlier). The key assumption here is that the 
medications used in drug treatment cost the same, on 
average, as all other medications. This top-down method, 
as discussed earlier, would ideally be compared with 
a more bottom-up estimate. Unfortunately we had no way 
of doing this, given the data limitations in Australia.
One specific type of medication used in drug treatment is 
opioid agonist medication (methadone and buprenorphine). 
In Australia these two medications have a separate funding 
stream and hence are readily identifiable in government 
reports (i.e. labelled expenditure). It is important, therefore, 
to account for these separately (and remove them from 
the top-down estimate to avoid double counting). These 
calculations can be seen in Ritter et al. (2015). There may 
be other special medications in other countries that are 
confined to drug treatment that also require such special 
treatment.
There are other costs within this category of 
pharmaceutical medications, such as diagnostic testing 
and pathology, that are very difficult to estimate accurately 
(see Ritter et al., 2015). All such exclusions should be noted 
in the analysis.
I Concluding comments
As we have demonstrated in this paper, there are four key 
stages that are essential when estimating drug treatment 
health expenditure:
1.  Understand the system, the providers, the financing 
approaches and the treatment types. Each country and 
health system is different; detailed understanding of the 
system will be invaluable in dealing with the micro-
issues around the expenditure.
2.  Be pragmatic in making decisions about the approach: 
there will always be uncertainties, and having 
a completely standardised method for every number 
generated is unlikely to be feasible.
3.  ‘The devil is in the detail’. In other words, as one 
burrows into the actual estimation, there will be many 
decisions to be made, assumptions to be dealt with and 
uncertainties to manage.
4.  The documentation of all decisions made, no matter 
how trivial, is essential for research transparency and 
replication.
Beyond the development of the health expenditure 
estimate, there are further important analyses — such as 
reporting the results in terms of confidence intervals and 
conducting sensitivity analyses. These are the next steps 
once the drug treatment health expenditure has been 
estimated (19).
No method is perfect — any expenditure estimate for 
drug treatment will be a series of compromises. There 
will always remain assumptions and unknowns in these 
analyses. Each time such an analysis is undertaken, there 
(19) Note that capital expenditure has not been explicitly covered, except 
where capital expenditure forms part of the expenditure estimate, which 
is the case for the Australian hospital estimate, where the NEP is inclusive 
of capital expenditure. The SHA manual (OECD et al., 2011) provides 
some details regarding capital items and the approach taken in the inter-
national health accounts system.
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is opportunity for improvements in the estimation and the 
associated methods. The use of the SHA (OECD et al., 
2011) is encouraged because it provides the potential for 
an internationally consistent approach.
The purpose of these health expenditure estimates is to 
enable analysis of trends over time within any one country 
(including changing trends in funding sources as well as 
amounts and distribution between functions) as well as 
cross-country comparisons. This is not an end in itself, but 
rather contributes to the possibilities for policy reform, 
improvements in treatment service systems and hence 
improvements in health outcomes.
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I Overview
Chapters 2, 3 and 4 present different methods used to estimate drug-
related public expenditure based mostly, but not only, on data identified as 
drug-related expenditure, i.e. labelled expenditure. Data sources used to 
compile labelled expenditure were mostly public accountancy documents 
or key experts’ advice. Sanja Mikulić, in Chapter 2, shows the method 
applied to make a systematic data collection of labelled public expenditure 
on drug abuse treatment in Croatia. The author made a systematic 
review of public accountancy documents from the state and local and 
regional self-government units, and consulted the financial plans of public 
bodies and the budgets of institutions treating drug misuse. To assess 
the data collected, a questionnaire was sent to the entities responsible 
for implementing the national drug strategy. Despite the success in 
developing comprehensive estimates, this study describes the difficulties 
of identifying all sources of public expenditure on drug treatment in 
Croatia.
In Chapter 3, Jiri Vopravil describes the data collection exercise developed 
in the Czech Republic, a country where data on drug-related labelled 
public expenditure on treatment are compiled annually. One important 
data source for Vopravil was the executed budgets of ministries with 
drug programmes. Data either are collected from budgetary documents 
or are provided by representatives of individual ministries, governmental 
institutions and regional drug policy coordinators. In this country, despite 
the public accountancy system providing annually available data on 
labelled drug-related expenditure, it is not possible to differentiate between 
spending on harm reduction and drug treatment.
In Chapter 4, among other topics, György Hajnal and Iga Kender-
Jeziorska describe the use of interviews of experts as a method of 
compiling information on data sources, and methods for estimating or 
contextualising the results of estimates in Hungary. The authors discuss 
the usefulness and the validity of this method, especially for countries 
hampered by scarce data and poor-quality data or exposed to high-risk 
biased data. There was the concern that data reported would be biased, 
as the financing of the data providers can depend, at least partly, on their 
reporting. In this context, the authors discuss how to achieve the best 
possible estimates in the face of limited data availability.
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I Introduction
For many years, there were no available data on public 
expenditure on drug abuse treatment in Croatia, as there 
were no data encompassing all types of labelled and 
unlabelled public expenditure. Therefore, in cooperation 
with the Institute of Economics, the Office for Combating 
Drug Abuse conducted a research project, ‘The study of 
public expenditure and the establishment of performance 
indicators in the field of combating drug abuse in the 
Republic of Croatia’, in 2012 (Budak et al., 2013). The 
objective of the project was to analyse public expenditure in 
the area of combating drug abuse and to propose a system 
of performance indicators for systematic monitoring of 
the results and the use of public funds for combating drug 
abuse in the Republic of Croatia. The research involved 
major stakeholders in the area of combating drug abuse, 
ministries and public institutions at the state level, counties 
and institutions at the country level, and civil society 
organisations active in the areas of addiction prevention, 
law enforcement, treatment, harm reduction and social 
reintegration of drug users.
This study describes the method used to compile the 
data on labelled drug-related public expenditure on drug 
treatment.
I Institutional framework 
In Croatia, there are several types of treatment provided to 
drug users: inpatient and outpatient treatment provided 
by medical facilities and hospitals; and treatment and 
psychosocial rehabilitation, carried out in therapeutic 
communities.
Outpatient treatment is the main form of treatment 
for drug-dependent persons not only for opiate users, 
but also for users of other types of substances. It is 
carried out in services responsible for implementing 
prevention initiatives and for the outpatient treatment of 
drug dependence within the county institutes for public 
health. The most common form of treatment carried 
out in the services is opioid substitution therapy (OST), 
with the support of methadone or buprenorphine. The 
same treatment units providing OST also provide other 
types of health services to drug users: psychosocial 
treatment; screening of urine for the presence of drugs 
and their metabolites; testing of capillary blood for human 
immunodeficiency virus (HIV), hepatitis C virus (HCV), 
hepatitis B virus (HBV) and syphilis; somatic reviews; and 
a number of preventive and educational activities, as well 
as other specific methods and procedures in accordance 
with the needs of the users. In 2013, the prevalence of 
opiate users in the total number of persons treated was 
similar to previous years and amounted to 80 %. In terms 
of the main substance used by opiate users, the most 
frequently used was heroin, while the most commonly 
used substance among non-opiate users was cannabis. 
Most opiate users are on some form of substitution 
therapy. Within the Croatian health system, inpatient 
treatment is provided in hospitals. This is available in 
different types of hospitals. Treatment is provided at 
psychiatric hospitals, at addiction departments in general, 
county and university hospitals, and at the prison hospital 
in Zagreb. As addiction requires long-term care and 
follow-up after hospital treatment, outpatient treatment 
is provided by the mental health and addiction prevention 
service and/or in one of the therapeutic communities in 
Croatia.
There are eight therapeutic communities providing 
treatment and psychosocial rehabilitation to drug users, as 
well as provision from NGOs and religious communities. 
By fulfilling certain conditions, therapeutic communities 
can get a contract on a permanent base with the Ministry 
of Social Policy and Youth. In these cases, the costs of the 
services are funded as ongoing activity by the Ministry.
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According to the Law on Combating Drug Abuse (1), the 
responsibility for financing drug treatment programmes lies 
with the Ministry of Health, whereas the delivery of drug 
treatment programmes is the responsibility of the services 
for addiction prevention and hospital institutions. They are 
financed by the Ministry of Health for the implementation 
of their work programmes, while the Croatian Institute for 
Health Insurance (social security) and local government 
are responsible for the administrative and basic operational 
costs (staff and utilities costs). All programmes to treat 
drug misuse are funded by public funds.
I Methods of estimates
As defined by the EMCDDA, drug-related labelled 
expenditure comprises those funds allocated by 
governments to spend on programmes to tackle the illicit 
drug phenomenon, which are identified as such in the 
budget (‘labelled’) (2). Therefore, in this study, drug-related 
labelled expenditure includes all expenditure referenced 
as drug related and found in public accountancy with the 
keywords ‘combating drug abuse and drug addiction’, 
‘social reintegration’ and ‘addiction treatment’ as part of 
their description, and similar activities listed as special 
programmes, activities or projects in the state budget, 
budgets of local and regional self-government units, 
financial plans of public bodies and budgets of other 
institutions active in different aspects of combating drug 
abuse.
The data gathered and used to estimate labelled drug-
related public expenditure in Croatia were based on the 
analysis of documents and data (3), on the findings of 
a questionnaire sent to all entities, and on interviews 
with key stakeholders in this field. Each ministry and 
other central and local government units and institutions 
responsible for the implementation of the national drug 
(1) Law on Combating Drug Abuse (OG 107/01, 87/02, 163/03, 141/04, 
40/07, 149/09, 84/11, 80/13). 
(2) See http://www.emcdda.europa.eu/topics/drug-related-public-expendi-
ture
(3) Strategy and related documents: National Strategy on Combating Nar-
cotic Drugs Abuse in the Republic of Croatia 2006-2012, Action Plan on 
Combating Narcotic Drugs Abuse for the period 2009-2012, Annual Im-
plementing Plan of the Action Plan on Combating Narcotic Drugs Abuse, 
County Action Plans on Combating Narcotic Drugs Abuse 2009-2012, 
reports on the implementation of the National Strategy on Combating 
Narcotic Drugs Abuse in the Republic of Croatia, Strategic Plan of the 
Office for Combating Narcotic Drugs Abuse (2012-2014), budgetary 
statistics of the Ministry of Finance (Implementation of the State Budget 
of the Republic of Croatia for the period 2009-2011, implementation of 
the budgets of local and regional self-government units for the period 
2009-2011).
strategic documents (4) were asked to specify labelled 
expenditure from 2009 to 2012. In the questionnaire 
that was specifically created by an expert team from 
the Institute of Economics for the purpose of the study 
(available in Budak et al., 2013), all surveyed institutions 
had to enter drug-related public expenditure in the national 
currency as specified in their annual budgets.
In addition to the data on labelled expenditure collected 
through the questionnaire, the state budget data available 
from the Ministry of Finance were also consulted (Švaljek 
and Budak, 2014).
I Classifying drug-related expenditure
In order to identify the different elements of drug-related 
expenditure, the activities conducted by public bodies to 
combat drug abuse and financed from state or county 
budgets were grouped in accordance with the division 
provided by Reuter (2006). The classification was extended 
to include social reintegration, resulting in five groups 
of activities: addiction prevention, treatment, social 
reintegration, harm reduction programmes and the penal 
system. Total public expenditure in the area of combating 
drug abuse was also broken down by the five relevant 
international COFOG categories: general public services, 
public order and safety, health, education and social 
protection.
Table 2.1 gives an overview of the relevant public 
expenditure groups used by public institutions involved in 
activities aimed at combating drug abuse in Croatia, broken 
down by the main public functions using the COFOG 
system.
(4) Office for Combating Drug Abuse, Ministry of Health, Ministry of Social 
Policy and Youth, Ministry of Defence, Ministry of Science, Education and 
Sport, Ministry of the Interior, Ministry of Finance — Customs Administra-
tion, Ministry of Justice, Croatian Institute for Health Insurance, Croatian 
National Institute of Public Health, Croatian Employment Service, coun-
ties, NGOs.
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TABLE 2.1
Public expenditure according to the classification of 
public functions
Public functions Sub-categories of public functions
01 General public services 014 Basic research
03 Public order and safety 031 Police services
033 Law courts
034 Prisons
07 Health 071 Medical products, appliances 
and equipment
072 Outpatient services
073 Hospital services
074 Public health services
075 R&D
09 Education 091 Pre-primary and primary 
education
092 Secondary education
094 Tertiary education
095 Education non-definable by level
096 Subsidiary services to education
10 Social protection 105 Unemployment
106 Housing
107 Social exclusion
Source: Institute of Economics, Zagreb, 2013.
For the identification of treatment costs, the relevant 
budget expenditure was public function 07 Health 
(COFOG definitions) and its sub-categories and treatment 
programmes (Reuter’s definition).
In the questionnaire, the institutions responsible for 
drug treatment (i.e. the Ministry of Health, the Ministry 
of Social Policy and Youth, the Croatian Employment 
Service, the Croatian Public Health Institute, the Croatian 
Health Insurance Agency, the Office for Combating Drug 
Abuse and all Croatian counties) were asked to classify 
budget expenditure by public functions and by the type 
of programme using the COFOG categories and Reuter’s 
categories (Reuter, 2006).
Direct participation of relevant ministries and other public 
bodies was necessary, to provide help to classify labelled 
public expenditure according to activities, based both 
on the Reuter categories and on the COFOG categories. 
Experts were, therefore, invited to interviews and were 
selected upon recommendation and their track record of 
cooperation with the Office for Combating Drug Abuse of 
the Government of the Republic of Croatia. The refined 
selection criteria aimed to create a representative pool 
of experts representing each institution, comprising at 
least one budgetary/financing expert, one drug-related 
programme expert and one ‘hands-on’ implementation 
expert.
The interviews were also used to help classify labelled 
expenditure and identify unlabelled expenditure. Certain 
public bodies responsible for drug policy do not have 
a special allocation for drug-related initiatives in their 
budgets. Instead, financing is carried out in the framework 
of regular activities. Institutions were expected to assess 
part of the funds for their regular activities, aimed at drug 
policy activities.
Prior to the interviews, the invited experts were provided 
with the previously collected data on labelled expenses 
reported in their institutions’ budgets for 2009-12. For 
each institution, the preliminary indicators to estimate 
unlabelled expenditure were listed (Budak et al., 2013). 
The questions developed in the interview guides were: 
‘Please describe your institution’s activities that might be 
related to drug control’; ‘Which activity do you consider 
to fall into prevention, treatment, harm reduction, law 
enforcement and social integration?’; and ‘What portion 
of your institution’s regular activity could be attributed 
to each programme, and why?’ In the course of the 
interview, questions were directed towards exploration 
of topics related to assessing and allocation of activities 
to a particular programme. There were two interviewers 
present at each interview. One asked questions, while the 
other one made notes, and their roles were reversed in 
consecutive interviews. Afterwards, notes were transcribed 
and sent to interviewees for verification and amendments. 
Verified notes were used for estimating the structure of 
unlabelled public expenditure by the type of programme. 
All interviews were conducted face to face. The average 
duration of the interview was 90 minutes. In total, 88 
persons were consulted during the whole process, among 
them 27 in the direct semi-structured interviews held in 
November 2012. The list of participants, their positions and 
dates of interviews are available in Budak et al. (2013, pp. 
77-80) and Švaljek and Budak (2014, p. 418).
I Findings
Labelled expenditure by activity groups amounted to 
between HRK 70 and 88 million per year, between 2011 
and 2013. Annual labelled expenditure on treatment 
(close to HRK 50 million per year) was rather stable. The 
largest element was the cost of methadone therapy for the 
treatment of opiate drug users (HRK 40 million in 2011), 
financed by the Croatian Health Insurance Agency (the 
social security).
Labelled expenditure on drug-related health, classified in 
accordance with the COFOG system, was, for the most 
INSIGHTS I Drug treatment expenditure: a methodological overview
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part, directed to financing public health services and 
medical products, appliances and equipment. By type of 
treatment provider, the largest proportion of expenditure 
was allocated to public health services, followed by hospital 
services and outpatient services (Table 2.2).
Figure 2.1 provides an overview of the structure of the 
financing of labelled drug-related public expenditure in 
Croatia grouped by ministries and public bodies at state 
level and counties and county public bodies at regional 
level, as well as civil society organisations in the following 
activity groups: (1) addiction prevention, (2) treatment, 
(3) social reintegration, (4) harm reduction programmes 
and (5) penal system (Budak et al., 2013, p. 18). Treatment 
programmes were funded mostly by health insurance funds 
and central government and in small part by counties.
FIGURE 2.1
Labelled drug-related public expenditure by activity 
groups, 2011-2013
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Source: Institute of Economics, Zagreb, 2013, and Office for Combating Drug 
Abuse, Zagreb.
Furthermore, it is estimated that the major part of drug-
related unlabelled health expenditure is assigned to 
treatment (80 %). The unlabelled expenditure relates to 
the out-of-hospital medical treatment of opioid-dependent 
clients, such as visits to the primary healthcare doctor’s 
office in order to receive prescribed methadone therapy. 
It also includes the unlabelled costs of hospital treatment 
of addicted clients. Distribution of clean needles, free HIV 
testing and other harm reduction programmes also make 
up part of the unlabelled health public expenditure, at an 
estimated 20 %. As external healthcare staff also provide 
such treatment services in the prison system for all drug-
addicted prisoners, this expenditure is evidenced under the 
health sector expenditure as treatment.
Within health services, unlabelled public expenditure 
associated with preventing drug abuse in primary care 
and hospital healthcare are estimated. An appropriate 
indicator is the ratio of the total number of hospital beds to 
the number of hospital beds for the treatment of disorders 
caused by drugs. The calculated value of this indicator 
was 0.46 %, and this is then multiplied by the percentage 
of total expenditure that the Croatian Health Insurance 
Institute focused on primary and hospital care in order to 
assess unspecified expenses in healthcare. Unlabelled 
public expenditure on drug treatment amounted to 
between HRK 52 and 49 million per year between 2011 
and 2012.
Total public expenditure for treatment (labelled and 
unlabelled) in 2012 amounted to HRK 123 564 311.98, of 
which HRK 74 236 386.63 was for labelled expenditure 
(close to 60 % of total drug-related public expenditure 
on treatment) and HRK 49 327 925.35 for unlabelled 
expenditure. Labelled drug-related public expenditure 
was mostly intended to finance healthcare (spending 
on treatment amounted to an average of 82.3 % of total 
labelled public expenditure).
TABLE 2.2
Estimation of labelled public expenditure on drug treatment by COFOG classification, 2009-2012, in kunas
COFOG classification 2009 2010 2011 2012
07 Health 60 781 706.79 65 943 523.81 71 237 249.41 60 838 823.51
071 Medical products, 
appliances and equipment
26 742 655.31 37 580 189.52 39 621 972.25 28 886 968.88
072 Outpatient services 110 000.00 110 000.00 0.00 0.00
073 Hospital services 600 000.00 840 000.00 1 040 000.00 520 000.00
074 Public health services 33 271 446.85 27 355 729.66 30 517 672.53 31 374 250.00
075 R&D 57 604.63 57 604.63 57 604.63 57 604.63
Source: Institute of Economics, Zagreb, 2013.
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I Conclusions
The drug-related labelled public expenditure on treatments 
does not capture all drug treatment-related public 
expenditure. Some parts of particular programmes can be 
identified in the budget, but some activities are ‘hidden’ 
in other budgetary items. Most public bodies do not have 
in their budgets labelled public expenditure intended for 
combating drug abuse and drug addiction, i.e. there are 
no special-purpose programmes, activities and projects or 
a plan for allocation of appropriate resources to activities 
aimed at combating drug abuse and drug addiction, but 
they are financed within regular activities. To assess the 
total drug treatment-related public expenditure, one has to 
identify both the labelled and unlabelled expenditure.
Assessment of drug treatment-related expenditure requires 
many assumptions to identify to which type of programme 
expenditure belongs. Estimation of this cost was 
constrained by the data available and the lack of evidence 
from the budget programmes of central government units.
The government spending intended for drug treatment 
mentioned in the national drug strategy is not complete 
and refers only to labelled expenditure, and it is highly 
likely that the unlabelled expenditure exceeds this amount 
(Švaljek and Budak, 2014, p. 409).
The study demonstrates the difficulties in developing 
precise estimates and helps to identify the main sources 
of data for expenditure on drug treatment and drug policy. 
Besides the issue of public finance information, there 
is a general lack of the data needed to estimate drug 
treatment costs. For example, detailed national data on 
the number of days that drug users spend in treatment, 
expenditure by the type of treatment, costs of social care 
per drug user and other important indicators of drug 
treatment expenditure are still lacking ( Švaljek and Budak, 
2014, p. 422).
The results of public expenditure studies can show whether 
the programmes afforded the highest priority receive the 
most money. Drug treatment accounts for a relatively small 
proportion of total drug-related public expenditure. The 
majority of public funds allocated to drug policy are spent 
on law enforcement. Prevention accounts for a much lower 
proportion of funding than law enforcement, even though it 
is deemed to be the first priority of drug policy.
This paper describes the main steps taken in Croatia to 
estimate labelled public expenditure, focusing on treatment 
programmes. The main aim of this study was to contribute 
to the development of a sound method to estimate drug-
related expenditure, depending on the type of drug policy 
programme. Then, in future studies it will be possible to 
analyse the cost-efficiency of alternative programmes 
and improve the allocation of resources for drug policy. 
It is hoped that this study provides a useful baseline for 
further work to improve the national system for reporting 
on public expenditure in the field of drugs, as well as policy 
evaluation and planning.
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I  The institutional framework of drug treatment
In the Czech Republic, drug abuse treatment is delivered 
through GPs, low-threshold programmes, inpatient and 
outpatient drug treatment centres, detoxification units, 
opioid substitution therapy (OST) units, therapeutic 
communities and aftercare programmes. Treatment is 
primarily delivered by public organisations and NGOs. It 
is also delivered, to a lesser extent, by private institutions, 
which provide three main treatment services: detoxification, 
outpatient care and institutional care. Inpatient services 
are divided into short-term (four to eight weeks), medium-
term (three to six months) and long-term (seven months 
or more) services. NGOs mainly provide outpatient care 
and OST, and some of these programmes are accredited 
as healthcare facilities. There are also 15 NGO-based 
therapeutic communities that provide long-term residential 
care for drug users. OST with methadone was introduced in 
the Czech Republic in 1998. OST is delivered in specialised 
psychiatric facilities and is also available in prisons. In 
addition, any medical doctor, regardless of his or her 
speciality, may initiate high-dosage buprenorphine as well 
as Suboxone (buprenorphine and naloxone) treatment. An 
independent agency is responsible for the accreditation of 
medical and inpatient drug treatment facilities.
In the Czech Republic, the Council of the Government for 
Drug Policy Coordination (CGDPC) is the main coordinating 
body for drug-related initiatives. Healthcare is funded 
from three sources, including health insurers (public 
health insurance), public budgets (the state budget, 
local budgets) and households. The ministries directly 
concerned with the financing of drug treatment include 
the CGDPC, the Ministry of Labour and Social Affairs, the 
Ministry of Health and the Ministry of Justice (for drug 
service in prison). Local budgets are managed at the 
regional and municipality levels. OST and outpatient and 
inpatient medical and pharmacological drug treatment 
are mainly financed through public health insurance, 
whereas outpatient and inpatient psychosocial treatment 
are primarily funded by the public budget at national and 
regional/local levels.
I  Identification of labelled drug treatment costs
Expenditure on drug treatment forms part of the 
total expenditure on drug policy. Drug-related public 
expenditure in the Czech Republic is divided into labelled 
and unlabelled expenditure (Vopravil and Běláčková, 
2013). Labelled drug-related expenditure is expenditure 
earmarked for drug policy (EMCDDA, 2008). It is accounted 
for in the state and/or regional and/or municipal budgets 
and divided into (1) sources of funding — from the state 
budget and local budgets (regional budgets and the 
budgets of municipalities); (2) geographical level of drug 
policy implementation; and (3) purpose (type of service) — 
using Reuter’s classification of drug policy (prevention, 
harm reduction, treatment and enforcement) (Reuter, 
2006).
Data are obtained from the final accounts of the national 
ministries whose budgets include drug policy programmes 
on treatment. Additional information is obtained directly 
from the representatives or contact persons of individual 
ministries and governmental institutions and from regional 
drug policy coordinators (Mravčík et al., 2012). Labelled 
expenditure on drug treatment from the state budget is 
partly transferred to the regional level and the remainder 
supports national programmes. Labelled expenditure on 
drug treatment from regional and municipal budgets is 
designed for regional drug treatment programmes. The 
finance for regional drug treatment programmes (from 
both state and local budgets) is geographically divided 
into 14 regions, in accordance with the EU classification 
(Nomenclature of Territorial Units for Statistics, NUTS) for 
EU regions (Eurostat, 2011) at the NUTS3 level.
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The main division of drug expenditure, in general, follows 
Reuter’s classification: prevention, harm reduction, 
treatment and law enforcement (Reuter, 2006). For the 
purposes of this chapter, harm reduction and treatment are 
relevant areas of expenditure.
In order to provide a useful analysis for policymakers, 
Reuter’s classification needs to be more detailed. Harm 
reduction is thus divided into drop-in centres and outreach 
programmes, and treatment is divided into healthcare 
(outpatient and inpatient alcohol/drug treatment, including 
substitution therapy, detoxification and social services 
provided as part of institutional healthcare), non-health 
outpatient care (outpatient and intensive outpatient non-
health programmes, crisis intervention, social counselling, 
social rehabilitation, and prison-based programmes 
delivered by NGOs) and therapeutic communities. It also 
includes a separate item for aftercare services and for the 
sobering-up stations (for alcohol and other drug users), 
which are treatment centres with harm-reduction services 
financed by local budgets.
Table 3.1 shows the detailed treatment expenditure by 
service category for 2013, and Table 3.2 shows expenditure 
between 2009 and 2013 by general service category, in 
nominal terms (no adjustment for inflation).
TABLE 3.1
Labelled drug-related expenditure on treatment provided from public budgets by service categories in the Czech 
Republic, 2013 (thousand EUR and nominal terms)
Service category GCDPC Ministry of 
Labour and 
Social Affairs
Ministry 
of Health
Ministry 
of Justice
Regions Municipalities Total
Harm reduction Outreach programmes 617 653 18 – 635 576 2 499
Drop-in centres 1 119 1 393 66 – 514 451 3 543
Integrated programmes 152 0 111 – 325 80 668
Total 1 888 2 046 195 – 1 474 1 107 6 710
Outpatient 
services
Health services 0 24 202 – 340 104 670
Social services 27 197 0 – 99 143 466
Others and unspecified 419 0 0 – 97 25 541
Total 446 222 202 0 536 272 1 678
Prison-based services 41 52 334 40 13 480
Residential 
services
Inpatient health services 0 33 148 – 7 84 272
Therapeutic communities 756 706 – – 518 151 2 131
Others and unspecified 0 – – – 0 2 2
Total 756 739 148 0 526 237 2 406
Aftercare services 255 627 – – 319 153 1 354
Sobering-up stations 0 – – – 3 070 1 3 071
Total 15 699
Source: Mravčík et al., 2014.
TABLE 3.2
Labelled drug-related expenditure on treatment provided from public budgets by service categories in the Czech 
Republic, 2009-2013 (thousand EUR and nominal terms)
Service category 2009 2010 2011 2012 2013
Harm reduction 6 616 6 572 6 209 6 410 6 710
Treatment 4 278 4 304 4 155 4 460 4 564
Sobering-up stations 2 421 3 449 2 807 3 175 3 071
Aftercare 1 201 1 238 1 200 1 349 1 354
Total 14 516 15 563 14 371 15 394 15 699
Source: Mravčík et al., 2014.
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I  Identification of unlabelled drug treatment costs
Unlabelled drug-related expenditure cannot be directly 
identified from public budgets or reports, and therefore 
an estimation exercise must be carried out. In the case of 
drug treatment, this includes all drug treatment expenses 
incurred by health insurers (Mravčík et al., 2014).
The estimation uses the SHA, developed by international 
organisations (OECD et al., 2011). The data from the health 
insurers are collected by the Czech Statistical Office.
The Ministry of Health (Institute for Health Information and 
Statistics) makes an estimation of unlabelled expenses 
incurred by health insurers on any treatment of substance 
use disorders on an annual basis, concerning drug 
treatment provided either by hospitals or by any doctor who 
initiates an outpatient drug treatment. It uses data from 
the International Shortlist for Hospital Morbidity Tabulation 
(ISHMT) on the expenses of public health insurers 
classified using the SHA (Mravčík et al., 2014), using the 
ICD-10 for the diagnosis categories (1).
Therefore, in this study we extracted from the data for the 
expenditure of public health insurance directly identifiable 
expenditure with the codes F11-F19. Then, we added 
unidentifiable costs, with no link to a diagnosis, in the 
proportion of what was spent in relation to F11-F19 
diagnoses compared with that spent on total diagnoses 
(Mravčík et al., 2011). These data are not duplicated in 
any reported labelled expenditure, because they refer 
only to public health insurance expenditure rather than all 
expenditure.
The National Monitoring Centre for Drugs and Drug 
Addiction, in collaboration with the Institute of Health 
Information and Statistics, processed data estimating 
expenditure on drug treatment from health insurance 
funds over the period 2007-2010 (Mravčík, et al., 2012). 
Data on health insurance were processed by the Czech 
Statistical Office for inclusion in the SHA. This system is 
(1) The diagnoses F11-F19 used were F11, Opioid-related disorders; F12, 
Cannabis-related disorders; F13, Sedative, hypnotic, or anxiolytic-related 
disorders; F14, Cocaine-related disorders; F15, Other stimulant-related 
disorders; F16, Hallucinogen-related disorders; F17, Nicotine dependence; 
F18, Inhalant-related disorders; and F19, Other psychoactive substance- 
related disorders.
used to give a comprehensive estimate of the total national 
healthcare spending. Expenditure is broken down by source 
of healthcare finance (such as social security, private 
health insurance, out-of-pocket payments). The largest 
share of the financing of healthcare in the Czech Republic 
is covered by the public system of health insurance, which 
includes approximately three quarters of all medical 
expenses. The costs from health insurance can be 
calculated from the ICD-10 diagnoses and their subgroups 
(F11-F19). Based on the data reported by insurers, 
treatment costs associated with the use of drugs and 
tobacco (alcohol not included) were estimated (F11-F19) 
as the sum of costs identified for each diagnosis, and as 
the sum of unidentifiable costs that were not allocated 
by diagnosis. The unidentifiable costs had to be adjusted 
before processing. The expenditure on different healthcare 
segments (inpatient care, outpatient care, capitation 
payments to medical practitioners, etc.) was estimated 
by multiplying the proportion of the primary F11-F19 
diagnosis costs by total costs for each of these segments 
(Table 3.3).
I Conclusions
Labelled expenditure on drug treatment in the Czech 
Republic is collected from the state and local budgets, 
where these items are identifiable. The difficulty in 
distinguishing between harm reduction and treatment 
remains, and therefore these two categories are combined 
under drug treatment.
Unlabelled expenditure on drug treatment in the Czech 
Republic are currently estimated with data extracted 
from national reporting according to the SHA. These data 
are produced in EU countries annually and reported to 
Eurostat. The model of estimation could be improved 
for implementation in other countries and used for 
international comparison. The Czech Republic already has 
time series of labelled and unlabelled expenditure on drug 
treatment.
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TABLE 3.3
Estimated costs incurred by health insurers in relation to the F11-F19 diagnoses (unlabelled drug-related expenditure) 
according to the type of care, 2007-2012 (thousand EUR)
Type of care
Cost of diagnoses F11-F19
2007 2008 2009 2010 2011 2012
Treatment services 7 826 9 127 10 766 11 283 12 546 13 741
Inpatient care 6 620 7 857 9 244 9 699 11 088 11 545
Intensive inpatient care 323 339 467 532 495 453
} inc: — psychiatry 122 111 129 117 126 82
Standard inpatient care 1 289 1 552 1 583 1 659 1 266 1 648
} inc: — psychiatry 870 1 031 901 915 910 997
— child psychiatry 1 1 9 1 2 5
Long-term inpatient care 5 002 5 955 7 182 7 492 9 316 9 444
} inc: — alcohol/drug treatment (addiction clinics) 1 686 1 591 2 198 2 242 2 460 2 352
— psychiatry 3 264 4 276 4 879 5 127 6 670 6 956
— child psychiatry 51 88 98 120 180 130
One-day care 7 11 11 17 11 34
Outpatient care 1 184 1 223 1 496 1 553 1 432 2 147
Primary care 24 15 25 28 28 37
Dental care 4 4 15 5 3 3
Specialised outpatient care 931 994 1 193 1 282 1 098 1 981
} inc: — alcohol/drug treatment (AT clinics) 150 128 163 144 187 196
— psychiatry 552 582 603 639 757 751
— child psychiatry 15 11 16 13 18 12
Other specialised outpatient care 90 117 114 108 132 126
} inc: — clinical psychology 75 82 98 92 116 125
— psychotherapy 0 0 1 0 0 0
Home care 15 35 14 14 14 15
Rehabilitation services 10 8 100 136 138 24
Long-term care 37 138 99 144 150 71
Supporting services 1 419 1 369 1 558 1 637 1 308 1 403
Laboratories 1 169 1 100 1 247 1 306 999 1 041
} inc: — toxicology 295 303 388 320 363 317
Imaging techniques 84 85 122 134 74 95
Transport and emergency medical services 166 184 189 198 235 267
Medication and medical equipment and supplies 2 561 2 753 3 306 3 233 3 792 3 488
Medication 2 395 2 579 3 066 3 011 3 560 3 443
Medical equipment and supplies 166 174 241 222 233 44
Prevention 76 738 154 114 56 26
Unidentified care 10 28 9 19 14 43
Total 11 931 14 150 15 981 16 551 18 035 18 796
Source: Mravčík et al., 2014.
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I Introduction
This paper gives an overview of the methods applied in 
a 2006 study to estimate drug abuse treatment-related 
expenditure incurred by the health insurance system 
and social care system in Hungary. The study was 
commissioned by the Hungarian national focal point and 
carried out between May and September 2006.
The project considered only significant expenditure borne 
by the sub-systems of the Hungarian public finances and 
indicated in the budget that arise directly from the misuse 
of illicit drugs. Only large-scale items were included in the 
estimation. According to Reuter (2006), drug-related public 
expenditure comprises four main categories. The goal of 
the project — which was the first of its kind in Hungary — 
was to give an estimation of drug-related expenditure 
for each of these categories — (1) law enforcement; (2) 
drug treatment; (3) prevention/research; and (4) harm 
reduction — and to contribute to a European study 
(EMCDDA, 2008).
The objective of this study was to provide an overview and 
discussion of the major methodological and conceptual 
issues that emerged in the course of estimating Hungary’s 
drug treatment expenditure. The institutional framework 
was — at the time of the study — quite complex. 
Furthermore, the study required the development of 
a methodology that would overcome existing data 
limitations. Therefore, this chapter aims to offer an insight 
into the assessment of drug treatment public expenditure 
that may be useful for other countries characterised by 
similar systems. Such an overview will also contribute to 
the ongoing discussion about the refinement of a plausible 
approach to estimating the drug budget in EU Member 
States (EMCDDA, 2003, 2004; Reuter, 2004).
I  Identification of drug-related health costs
A major conceptual choice in the estimation of drug 
treatment public expenditure was the question of whether 
or not, and to what extent, expenditure resulting from 
various indirect health consequences of drug abuse — 
such as treatment of injuries or of medical problems 
caused by drug abuse — should be included, in addition to 
direct drug treatment costs, in our concept of drug-related 
expenditure.
A decision was made to narrow down the focus to the 
estimation of drug treatment costs only. In other words, 
the estimation focused only on the costs of medical 
interventions. In operational terms, detoxification/
stabilisation and rehabilitation/continuing care formed 
part of our concept of drug treatment. The reasons for this 
restricted conceptualisation were twofold:
1) The complex causal structure of medical conditions — 
involving multiple and/or bi-directional causation and the 
overwhelmingly probabilistic, as opposed to deterministic, 
causal connections — make it very difficult to describe any 
non-arbitrary concept of drug treatment that is broader 
than the above.
2) From a practical perspective, the limited reliability and — 
even more often — the lack of data currently available in 
Hungary make it difficult to operationalise any broader 
concept of health expenditure.
In view of these considerations, it is no surprise that 
a similar narrowing down of the concept has been 
applied in other drug-related public expenditure research 
(Harwood et al., 1999; SAMHSA, 2003).
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I Institutional framework
During the period covered by this research, drug treatment 
institutions in Hungary were run and financed by two 
different sources: ambulatory and active inpatient (1) 
treatment institutions operated in the framework of the 
National Health Insurance Fund, while chronic inpatient, 
outpatient and residential treatment institutions were 
funded by the Ministry of Social and Labour Affairs. In 
both cases, supplementary funding was provided to the 
local or county self-governments, churches or non-profit 
organisations operating the service. All expenditure 
estimated using the following methods was public 
expenditure, borne by the state (either National Health 
Insurance Fund or Ministry of Social and Labour Affairs).
I Method of estimation
I  Bottom-up approach: estimating treatment costs funded by the health insurance system
One of the core features of the institutional segment 
funded by the health insurance system was the existence 
of a national-level, official, centralised database system, 
into which detailed, transaction-level data on each medical 
treatment and patient are recorded and stored for the entire 
period covered by the study. These data include, among 
others:
 the ICD-10 classification of medical diagnoses;
 the ICHI (International Classification of Health 
Interventions by WHO) classification of medical 
treatments/interventions applied;
 detailed, individualised data on the healthcare providers 
and the patients involved;
All sets of data given above were available for outpatient 
and both types of inpatient (active and chronic) treatment, 
as well as for medication and laboratory tests.
(1) In the Hungarian hospital system, there is a differentiation between what 
are known as ‘active inpatient’ and ‘chronic inpatient’ treatment. The 
former type is highly personalised and involves specialised examinations 
and individualised services; expenditures are reimbursed by the National 
Health Care Fund individually according to the particular treatment a per-
son received. The ‘chronic inpatient’ treatment, in turn, is focused rather 
on simply providing care to patients and involves fewer personnel and 
a lower level of treatment personalisation; the public financing scheme 
pays a flat rate per day of treatment and per capita.
An important element of the bottom-up estimation method 
was using interviews with key experts to reveal the content, 
location, format, limitations and biases of existing data. 
Subsequently, this information was used to build a particular 
method of estimation in each different organisational setting, 
tailored to the specific features of the given individual setting.
There was no pre-existing data collection on drug treatment 
that could be modelled in a straightforward way. Drug 
treatment service providers are deeply embedded in 
a broader institutional context in which many different 
types of care are provided, ranging from treatment for 
alcohol dependency and general mental health/psychiatric 
treatment to care for the elderly and the mentally or socially 
disadvantaged. Therefore, healthcare expenditure incurred 
by the National Health Insurance Fund was estimated on 
the basis of detailed activity data reported by health service 
providers to the Fund. These activity data cover every 
single treatment provided to patients; the data reported 
to the Health Insurance Fund include specific information 
concerning the patient, the healthcare provider, diagnosis 
and the treatment provided. These datasets are periodically 
sent to the Health Insurance Fund and form the basis of the 
funding received by the healthcare provider from the Fund.
In the system of healthcare provision related to drug use we 
can distinguish the following categories:
 Drug treatment provided by GPs: although it is not 
impossible that an individual using drugs visits a GP 
for a medical check-up or referral to some healthcare 
specialist, it is rather infrequent. Moreover, speaking in 
absolute terms, the vast majority of treatment services 
provided by GPs have minimal cost. Therefore, this 
expenditure category was not included in estimates.
 Specialised ambulatory care: includes mostly the 
‘drug ambulances’ — ambulatory treatment units 
dedicated specifically to providing drug treatment — 
and ambulatory services provided in the framework of 
general psychiatric ambulatory care.
 Acute inpatient care: concerns drug treatment provided 
in addiction clinics or, sometimes, general psychiatric, 
as well as detoxification procedures provided by other 
units, mostly physicians.
 Chronic inpatient care: provided by long-term addiction 
institutions.
 Medication used in drug treatment.
 Medical emergency services linked to hospital 
emergencies, drug-related accidents.
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A key feature of the health insurance system is the fact 
that the data reported by the healthcare providers are also 
used to calculate their own funding. As a consequence, 
the data reported suffered from generally poor quality 
and inconsistency. Furthermore, the funding system was 
organised in such a way that encouraged systematic bias in 
the data reported, in other words ‘reporting wrong data’ to 
increase funding. In order to improve the accuracy and the 
validity of the estimation, a layered method of estimation 
was used, involving the extensive use of expert judgement. 
More specifically, the estimation was made as the sum of 
the following components:
Component (1): total public funding provided to institutions 
that provide drug treatment only.
Component (2): total funding provided to treatments where 
a ‘drug diagnosis’ was reported (this set of diagnoses was 
identified by experts in the field) (2). Note that if these funds 
were already included in component 1, in order to avoid 
double counting, the database query was designed to omit 
them from this component.
Component (3): total funding provided for treatments 
provided to ‘drug users’ either (i) by institutions with 
a general psychiatric profile (3) or (ii) with a ‘drug diagnosis’. 
‘Drug users’ are persons who had received any treatment 
having fallen under component (1) or (2) during the 
preceding two years. ‘Drug diagnoses’ were determined, on 
the basis of the ICD-10, by selected experts. Likewise, the 
set of psychiatric institutions was identified by experts in 
the field. Note that funding already included in components 
1 and 2 is, in order to avoid double counting, not included in 
this component.
Component (4): total funding provided for medications 
reported on ‘drugs lists’ submitted over the years that the 
research covered.
(2) ICD-10 codes: F1100-F1290, F1400-F1690 and F1900-F1990.
(3) According to experts’ opinions, there is a set of diagnoses that doctors use 
instead of direct ’drug diagnoses’. Therefore, costs of treatment of patients 
with those particular diagnoses are included in the estimation as being 
actually drug treatment costs. Those include the following ICD-10 codes: 
F0100-F0130, F0180-F0190, F0240, F0700, F0720, F0780-F0790, 
F09H0, F2080-F2090, F21H0, F2200, F2280-F2290, FF2300-
FF2330, F2380-F2390, F28H0, F29H0, F3000-F3020, F3020-F3090, 
F3200-F3230, F3280-F3290, F4390, F3800-F3810, F3880, F39H0, 
F4000-FF4020, F4080-F4090, F4100-F4130, F4180-F4190, 
F4200-F4220, F4280-F4290, F4300-F4320, F4380-F4390, F4400-F44 
90, F4500-F4540, F4580-F4590, F4800-F4810, F4880-F4890, 
F5010, F5030-F5050, F5080-F5090, F5130-F5150, F5180-F5190, 
F5200-F5290, F5300, F54H0, F59H0, F6000-F6090, F61H0, 
F6280-F6290, F6390, F6800-F6810, F6880, F69H0, F88H0, F89H0, 
F9100-F9130, F9180-F9190, F9890, F99H0. 
Component (5): total funding provided for drug-related 
laboratory procedures over the years that the research 
covered (4).
In practice, three lists developed by experts on drug 
treatment were used in the database query producing 
the above five components. List 1 included institutions 
with a profile that was mostly or entirely drug related; list 
2 included all direct drug diagnoses; and list 3 included 
‘hidden’ diagnoses used by healthcare providers to ‘mask’ 
de facto drug-related treatments in order to achieve higher 
cost reimbursement from the National Health Insurance 
Fund (OEP) (5). The cost of such ‘hidden’ treatments was 
calculated on the basis of the assumption that treatments 
were based on such ‘hidden’ diagnoses — if provided to 
persons who within the preceding year either were a client 
of one of the institutions from list 1, or had a direct drug 
diagnosis in any other institution or were undergoing a de 
facto drug treatment (duplications in treatment data were 
eliminated in order to avoid double counting of the same 
expenditure).
I  Top-down approach: estimating treatment costs funded by social security
The estimation of costs for the system of social security 
covered all services provided to clients receiving drug 
treatment — inpatient, outpatient and residential care — 
that fall under the definition of ‘health treatment’.
In the face of poor quality of data, as a first step, relevant 
experts were identified using the snowball sampling 
method and invited to interview. This method was possible 
because the research was commissioned by Hungary’s 
top drug policy forums (and therefore may not be feasible 
for researchers who have little or no access to the ‘inner 
circles’). Among the stakeholders of this project were 
institutions such as the national focal point, the National 
Institute for Drug Prevention and the Committee on Drug 
Coordination. This gave us access to high-profile drug 
experts in various institutions, including the National Health 
Insurance Fund.
(4) ICHI codes: 21291, 21690-2695, 2169P, 22441, 25504, 25566-25568, 
26260-26261, 2627Q, 2627R, 2627S, 2627T, 2639A, 2639B, 2639E, 
2639L, 98410.
(5) Note that this type of masking — in practice, reporting false data — 
by healthcare providers to the OEP was and is a general practice in 
 Hungarian healthcare. There are commercial sofware products available 
which are used to ‘optimise’ treatment reports to increase the OEP 
funding, and the OEP’s capacity to control and limit this type of cheating is 
minimal or non-existent. The list of substitutive diagnoses was determined 
by healthcare experts with insider knowledge on institutional practices.
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Expert interviews with senior practitioners and researchers 
working in social and health administration, in the National 
Health Insurance Fund, in various addiction treatment 
facilities and in drug policy NGOs were conducted and 
used extensively in order to identify the data sources to 
be used for estimation; assess data quality; and improve 
estimations by incorporating correction methods for 
handling poor-quality data.
In total, 15 such expert interviews were prepared. On 
the basis of expert opinion, a list of service providers in 
each service category was compiled. The list included 50 
inpatient facilities (of which 17 had a drug-related profile) 
and 25 outpatient facilities (of which 12 had a drug-related 
profile, i.e. 30-100 % of clients using drugs). Total annual 
funding data for these service providers were available to 
a greater or lesser extent from ministry compilations.
However, many of the above organisations provided, in 
addition to drug treatment, various other services for 
non-drug-related clients. Therefore the proportion of 
drug treatment within the overall service output — and, 
thus, the proportion of drug-related expenditure in total 
expenditure — had to be estimated. This was done on 
the basis of telephone interviews with managers of the 
relevant institutions. The unit of measurement in this case 
was a unit cost for each drug treatment, based on the 
Hungarian Health Agency’s Classification of Procedures in 
Medicine categories (OEP, 2016) (6).
It is important to emphasise that estimating the drug-
related proportions within the overall budget of these 
institutions required original extensive data collection 
and use of expert and practitioner opinion. Specifically, 
a list of treatment institutions with at least some kind of 
drug treatment profile was created on the basis of expert 
opinion. Subsequently, each institution was contacted and 
queried regarding the proportion of its patients that were 
receiving some sort of drug treatment.
In 2007, a pilot project (Kelen-Consult BT, 2007) exploring 
the applicability of the EMCDDA guidelines (EMCDDA, 
2007) for estimating drug-related public expenditure 
was carried out. The suggested estimation method 
was similar to the one used to report data for the social 
security system, a top-down approach. However, the 
proposed starting point of the estimation was the Eurostat 
dataset, published by Eurostat and based on data on 
public expenditure categorised according to COFOG and 
provided by the Hungarian statistics agency. Analysis of 
the data showed that in the case of Hungary this procedure 
(6) Classification of Procedures in Medicine is an official list of procedures 
issued by the Hungarian Health Agency (OEP).
was not suitable for estimating drug-related public 
expenditure. The reason was that the level of aggregation 
in which expenditure data were available was too high 
to allow the estimation of drug treatment expenditure 
and the Hungarian research team was not able to design 
a model that produced the required estimates. Moreover, 
the method used to create the COFOG-based statistics 
was not clear enough and did not reflect the institutional 
and operational idiosyncrasies of healthcare providers 
in Hungary. Therefore, it should be emphasised that this 
method, suggested by the EMCDDA guidelines, was not 
used in the original expenditure assessment in Hungary.
I Discussion
Although health insurance activity data served as a basis 
for the estimates of the funding of drug health services, 
because of the lack of adequate control mechanisms the 
validity of these data is rather uncertain. In addition, the 
use of these data as a basis for the funding of services 
is an incentive to manipulate the data. However, the 
estimation method attempted to address this by using 
expert opinion and a number of different components. As 
activity reports containing activity data are stored in a large 
electronic database of the National Health Insurance Fund, 
resolving data queries was technically feasible. In the 
case of drug treatment financing by institutions funded 
from sources other than the Fund, budgetary estimates 
included the amounts directly transferred by the national 
government (known as normative financing), as well 
as additional funding from the public budget allocated 
to church-run centres and those provided by local and 
regional governments. In addition, the expenditure on 
social inclusion and diversion programmes, managed by 
the Ministry of Social Affairs and Labour, were also taken 
into account (7).
Hungary’s public services, unlike those in many northern 
European countries, cannot be considered ‘data rich’ by any 
standards. In other words, financial and activity data, and 
especially results-/products-related data (8) are, most of 
the time, very limited in scope and, sometimes, in reliability. 
This general feature is also a characteristic of the drugs 
field: none of the organisational (sub-)systems examined 
had data concerning the provision of drug-related health 
services. Nevertheless, the method used, particularly the 
(7) Namely social benefits, day care, care-providing institutions, rehabilitation 
centres, residential homes, organisations providing temporary accommo-
dation.
(8) By result/product we mean individual unit of activities and services, to 
which we can attach some particular value.
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inclusion of expert judgements, allowed the best possible 
estimations within the scope of the above limitations.
I Conclusions
The method of estimation reflected the significant 
differences in the data available between the two funding 
sources. The estimation of public expenditure on drug 
treatment in Hungary is hampered by poor-quality data, 
creating a challenging task. There are a number of reasons 
for this:
 Data are scattered or non-existent either because no 
systematic data collection exists or because existing 
policies and procedures for systematic data collection 
are not implemented.
 The validity of data may also be considered dubious, 
especially if reported data are used to establish funding 
or otherwise have significant material consequences for 
service providers.
 Finally, the reliability of data also suffers from the 
generally low level of administrative capacity and 
resources available for data collection and reporting.
The idiosyncrasies inherent in the Hungarian national 
healthcare system funded by the National Health Insurance 
Fund and, therefore, the drug treatment expenditure 
system at the time of conducting the study mean that the 
bottom-up method is unlikely to be widely adopted by many 
countries. The reason is that such detailed, transaction-
level data covering each and every medical intervention 
usually do not exist or are not available for the purpose 
of estimating expenditure. This method may, however, 
be a starting point for developing applicable methods, 
provided that such detailed activity reporting of healthcare 
interventions is collected in a centralised manner, and if 
the resulting — highly sensitive — personal health data are 
available for the purposes of the research.
In contrast, the top-down approach to estimates — backed 
by an achievable level of data collection and supported by 
expert judgement to estimate the drug-related proportions 
within providers’ operations — could be applied, provided 
that the resources and expertise for such field research 
are ensured. The top-down approach offers a flexible 
and feasible (possibly, the only feasible) method, even 
in relatively data-poor environments. What should be 
emphasised, however, is that in cases of highly aggregated 
data (e.g. COFOG classification), especially when 
combined with poor data collection methods, significant 
difficulties may arise. The institutional specifics of particular 
national healthcare systems might make it impossible to 
estimate specific costs of drug treatment. Therefore, the 
relatively limited accuracy of these estimations must be 
openly acknowledged and taken into account.
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I Overview
In Chapters 5-9, the authors focus, among other topics, on methods 
applied to estimate unlabelled public expenditure on drug abuse-
related health. In Chapter 5, Alain Origer describes the methods used in 
Luxembourg since 2002 to estimate annual public expenditure on hospital 
episodes, inpatient drug treatment episodes, OST, and the treatment of HIV 
infections and AIDS (acquired immune deficiency syndrome) associated 
with drug use. In Chapter 6, Charlotte Davies describes the method 
used to estimate public spending on drug treatment and on associated 
comorbidities in hospitals in the United Kingdom. Expenditure in hospitals 
accounts for inpatient stays, which covers emergency treatment for 
acute problems (overdoses and psychosis) and planned treatment for 
chronic associated infectious diseases. Davies shows that the adoption 
of a pragmatic approach allows estimates to be made based on routinely 
available data and allows estimates to be replicated in the future. In 
Chapter 7, Sabrina Molinaro and colleagues describe the development 
of a model to estimate public expenditure on drug treatment in Bergamo, 
Italy, taking into account drug-related pathologies and associated 
comorbidities. The authors include estimates for public spending on 
hospitalisation, outpatient specialist care, pharmaceutical prescriptions 
and services provided by drug abuse treatment services. Data were 
extracted from official healthcare administrative financial flows. In Chapter 
8, Bruno Genetti and colleagues describe a method to estimate public 
expenditure on OST in Italy, taking into account available datasets, with 
data for 2012 and 2013. The model uses a top-down approach to estimate 
spending on OST from annual public expenditure on addiction treatments 
(alcohol, drugs and gambling). The study disentangles spending on drug 
treatment from spending on the treatment of other dependencies, based 
on detailed budgets available for spending on personnel and medicines. 
Last but not least, in Chapter 9, Delfine Lievens and Freya Vander Laenen 
present a methodology to estimate public expenditure on drug treatment 
in hospitals, for most European countries. This method uses data drawn 
from Eurostat and applies a uniform methodology, allowing cross-country 
comparisons. The authors present a critical assessment of their method 
and database, which alerts readers to the limitations of estimates.
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I  Identification of drug-related health costs: methodological preliminaries
At their most holistic level, drug abuse-related public 
expenditure studies cover the entire spectrum of costs 
arising from drugs and to be borne in some way or another 
by a given community (e.g. the national population). 
The straightforward but relevant question to ask when 
determining whether or not an expense is eligible for the 
assessment of expenditure in the field of illicit drugs is 
the following: Would the expenditure have occurred if 
illicit drugs did not exist (1)? The purpose of this chapter is 
narrower, as it focuses on a selected type of expenditure in 
order to provide a methodological in-depth analysis.
This methodological inventory does not address global 
social costs, as it exclusively refers to unlabelled, direct 
public economic costs of selected drug demand reduction 
measures, thus excluding ‘external costs’ (e.g. loss of 
economic productivity) and ‘intangible costs’ (e.g. pain, 
suffering and loss of life quality), as well as expenditure 
related to the acquisition of illicit drugs by users, i.e. private 
spending on illicit drugs.
More specifically, we compiled an inventory of methods 
applied nationally to estimate public expenditure related to 
drug treatment hospital episodes, OST and the treatment 
(1) A sound example of the hypothetical causality between drugs and 
adverse, cost-generating outcomes might be seen in the acquisition 
of a liquid chromatography/mass spectrometry (LC-MS) system by 
a forensic laboratory. The latter may be used to analyse seized drugs and 
thus contribute to the fight against drug trafficking, for instance. However, 
the same analytical instrument may serve other purposes (e.g. forensic 
evidence for accidental poisoning) and might have been acquired anyway 
for overall service needs. The cost of the purchase may thus not entirely 
be attributable to illicit drugs-related outcomes, although the working time 
spent by the forensic experts, the chemical materials used and even the 
electrical power required to run LC-MS analysis on illicit drugs should be 
fully accounted for in a drug-related cost assessment.
of HIV infections and AIDS attributable to drug use. Applied 
methods and alternative models are discussed, as well as 
the eligibility of collateral costs and limitations in analysed 
data and final estimates.
Given that this paper is addressing the costs induced 
by the use of illicit psychoactive products and/or 
a series of licit products that have been diverted from 
their purely therapeutic use, it is essential to rely upon 
a classification that takes into account the nature and the 
origin of the substances involved. A substance such as 
heroin, for instance, is illicit under national law, whereas 
psychotropic prescription drugs are regulated but can be 
acquired illegally for a non-medical use, thus generating 
or maintaining an addictive condition. Polydrug use — 
combining illicit drugs and other substances such as 
benzodiazepines and alcohol — is the most frequently 
observed consumption pattern of problem drug users at the 
national level (Origer, 2015). For these reasons, and for the 
sake of editorial ease, we hereinafter refer to ‘illicit drugs’ 
as the entire range of illicit psychoactive substances and 
those diverted from their genuine therapeutic indication. 
‘Drug treatment’ thus refers exclusively to interventions 
targeting individuals who have problems related to the use 
of illicit drugs, possibly in combination with other drugs.
It is also relevant to set a ‘window of observation’ that 
applies to the estimation methods. The present analysis 
relies upon ‘prevalence-based calculations’, given that they 
reflect cost manifestations observable within a defined 
period of time (one year), whose origin or generating 
process may date back earlier. In contrast, in ‘incident-
based estimation’ only events (incidences) having occurred 
within the observation window are considered. An example 
that will be addressed in greater detail in the present 
inventory is the expenditure related to the treatment 
of HIV-positive clients and those living with AIDS who 
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were infected via (injecting) drug use. In a prevalence 
perspective, all referred clients in treatment during the 
observation window will be included in the estimation 
model, whereas, in an incidence-based estimation, only 
new HIV and AIDS cases caused by drug use-related 
transmission and having occurred during the observation 
period will be retained. 
The applied methodological approach is entirely based 
upon costs. The benefit, income or revenue aspects 
linked to illicit drug use or trafficking (e.g. selling income, 
confiscated assets) are not accounted for. Instead 
of referring to a cost-benefit analysis, the described 
approach builds upon the concept of the ‘cost of illness 
(COI)’ method (Hodgson and Meiners, 1982), abundantly 
developed in the English-language literature in the field of 
drug-related cost studies and applied notably by Rice et 
al. (1990), the National Institute on Drug Abuse research 
teams (NIDA, 1993) and Kopp and Fenoglio (2000). The 
COI method is closely linked to the concept of ‘cost of 
opportunity’, which assumes that resources allocated 
(to the fight against drugs in this case) might have been 
assigned to other needs — ideally in a more beneficial way.
The methods described herein have been applied 
nationally on the basis of available data or newly compiled 
or reformatted data, as well as multiplier and valuation 
techniques.
I Institutional framework 
According to the latest estimates, Luxembourg counts 5.68 
injecting drug users per 1 000 inhabitants aged 15-64 
(range 4.54-6.90) and 6.2 problem drug users per 1 000 
inhabitants aged 15-64 (range 4.60-7.83), figures that 
have been showing a decreasing trend since 2003 (Origer, 
2012).
Regarding demand reduction, specialised drug treatment 
services in Luxembourg rely on governmental support 
and control. Drug treatment is decentralised and is most 
commonly provided by state-accredited NGOs. Most of 
these specialised agencies have signed an agreement with 
the Ministry of Health that guarantees their annual funding. 
NGOs involved in drug treatment fall under the obligations 
of the so-called ASFT law (8/09/98) and the subsequent 
Grand-ducal Decree of 10 December 1998, both of which 
regulate the relationship (duties and rights) between the 
state and NGOs or organisations providing psychomedical, 
social and therapeutic care.
All specialised national treatment providers or agencies 
accept drug-using clients, irrespective of the type of 
substances that are involved. Detoxification treatment 
is provided by regional hospitals via their psychiatric 
units and related costs are generally covered by health 
insurance. Nationally, there are specialist outpatient 
treatment facilities, residential therapeutic communities 
and inpatient occupational centres. While outpatient 
treatment is provided free of charge (state financed), 
inpatient treatment is covered by health insurance. 
Special counselling and treatment offers for minors and 
young adults are available. In- and outpatient treatment 
opportunities for pregnant women, drug-using couples 
and mothers with children are also available. A dedicated 
psychosocial and medical care programme is operational in 
national prisons (Programme TOX).
OST is mainly delivered by office-based medical doctors. 
In addition, a multidisciplinary OST programme is run by 
a specialised NGO, which primarily provides liquid oral 
methadone and psychosocial care. The modified Grand-
Ducal Decree on substitution treatment of 30 January 2002 
regulates OST in general by means of substitution 
treatment licences granted to medical doctors and 
specialised agencies. This legal framework lists medicines 
allowed for substitution treatment, including methadone, 
buprenorphine and morphine-based medications, as well 
as substitution treatment modalities. It also sets the legal 
framework for the implementation of a pilot programme 
of heroin-assisted treatment at the national level. With 
regard to the cost of treatment, medical interventions and 
counselling are covered by health insurance, while the state 
covers pharmaceutical costs and pharmacy fees. In 2014 
around 1 300 clients received OST treatment nationally, 
which makes Luxembourg a country with one of the highest 
OST coverages per opioid user in the EU (EMCDDA, 2014).
A legal framework for a series of risk and harm reduction 
measures, such as supervised drug consumption rooms, 
was set in 2001 by amending the basic national drug law 
of 1973. The first supervised injection room at the national 
level opened in July 2005 and has been integrated into 
a low-threshold centre for drug users. By the end of 2014, 
some 1 500 clients had signed the facility’s user contract, 
and around 40 000 injections are annually supervised 
by trained staff. More than 1 800 overdose incidents 
had been managed in the consumption rooms by 2016 
and none ended fatally. In 2012, a first supervised blow 
(inhalation) room was opened within the same premises. 
According to the National Drugs Action Plan, a national 
feasibility assessment of heroin-assisted treatment was 
conducted and the first national heroin-assisted treatment 
was introduced as a complementary treatment option in 
Luxembourg in May 2017.
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The last national HIV and AIDS action plan was launched 
by the Ministry of Health in 2011. Its aims include the 
prevention of infectious diseases and harm reduction in 
drug-using populations. This plan has been elaborated to 
take into account the recommendations of the external 
evaluation of the previous plan. HIV prevention and 
counselling are provided by specialised agencies. A new 
national HIV/AIDS plan and a first national hepatitis action 
plan are expected to be launched in the course of 2018 
and 2017, respectively. Treatment of HIV-infected drug 
users is hospital based and the costs are covered by health 
insurance.
The national needle and syringe exchange programme, 
financed by the state, is decentralised and includes drug 
counselling centres, drop-in centres for sex workers and 
at-risk populations, low-threshold services and vending 
machines situated in the towns most affected by injecting 
drug use. Needle and syringe exchange is also provided at 
prison-based sites. In 2012, a mobile medical care unit was 
launched as an additional service, facilitating the provision 
of primary medical care at low-threshold agencies.
I Methods and required data
I  Annual costs of hospital-based inpatient drug treatment
Applied methodology
Expenditure generated by inpatient drug treatment 
episodes in hospitals (C HOSP ) is composed of infrastructural, 
nursing and pharmaceutical costs, also called hospital 
bed-day costs (C BED ) and the cost of in-house medical care 
(C MED ).
Hospital episodes are generally recorded according to the 
ICD-10, and the list of diagnostic criteria to be included in 
a given cost assessment should be compiled in the first 
place.
After consultation of national hospital staff and psychiatric 
units’ teams, the following ICD-10 criteria were included 
in national cost studies: mental and behavioural disorders 
due to use of opioids (F11), cannabinoids (F12), cocaine 
(F14), other stimulants (F15), hallucinogens (F16), 
volatile solvents (F18) and multiple drug use and use of 
other psychoactive substances (F19). Not included were 
episodes related to mental and behavioural disorders due 
to various licit and prescription drugs (i.e. alcohol (F10), 
sedatives or hypnotics (F13) and tobacco (F17)), unless 
they were associated with retained disorders. The selection 
of ICD codes should take into account coding routines 
and reflect the target population to which the estimation 
applies.
As a first step, national administrations of health insurance 
funds should be contacted to determine if they are in 
a position to provide a total annual cost breakdown 
according to relevant ICD-coded episodes. In the context 
of national cost studies, the principal ICD-10 diagnosis, 
as recorded at hospital discharge, is used. Otherwise, an 
alternative option is to use average multipliers provided by 
national administrations or experts. Required data for the 
latter approach and the respective calculation formulae are 
detailed in Table 5.1 and equation 5.1.
The quantification of costs related to medical consultations 
and care provided during inpatient hospital drug treatment 
requires a series of nationally specific data. Ideally, hospital 
administrations and/or central social security funds will be 
able to provide the sum of annual expenditures for medical 
care related to drug treatment as defined, as well as the 
specification of medical care interventions. In the event that 
these data are unavailable or inaccessible, the number of 
hospital drug treatment episodes (NEPITOTAL), the number of 
hospital bed-days (NDAYSHOSP) and the average number of 
medical consultations per day (AVRNMED/DAY) can be used as 
intermediate multipliers to calculate CMED.
Before running this type of cost equation, one must also 
take into account national medical consultation fees, social 
security intervention nomenclature and reimbursement 
schedules. Hospital fees and related medical interventions 
are commonly defined by social security codes. These fees 
might, however, be dependent on time factors such as 
length of hospital stay for instance. Medical fees due for 
the first hospital day might be higher than those due for the 
following days (as is the case in Luxembourg). This adds 
some complexity to the calculation, as one has to add up 
the costs of first hospital days and the following days based 
upon the number of consultations per day (NCONSMED1 
and NCONSMED1+) and daily medical care fees (FEEMED1 and 
FEEMED1+).
As only public expenditure is of interest here, it is necessary 
to deduce the proportion that is not reimbursed by social 
security schemes and thus to be borne by individual clients 
and not by the community.
INSIGHTS I Drug treatment expenditure: a methodological overview
66
I Information and data requirements
I Calculation formulae
The formulae to calculate CBED and CMED are the following:
  (5.1)
and
  (5.2)
The total public expenditures generated by hospital inpatient drug treatment episodes thus equal:
  (5.3)
TABLE 5.1
Information and data requirements for the determination of the annual cost of hospital-based inpatient treatment (CHOSP )
General preliminary 
information
Compilation of considered ICD codes
National selection F[11, 12, 14, 15, 16, 18, 19]
Inventory of eligible national hospitals (a)
National social security code (b)
Nomenclature of medical treatment (c)
Prescription medicines reimbursement schemes (d)
CBED data Number of episodes/ICD code (e) N/EPI
Average duration/episode (e) DUR/EPI
Average cost/episode (e) AVRC/EPIHOSP
% of hospital bed-days fees not reimbursed (e) SHAREPATHOSP
CMED data Total number of episodes (e) NEPITOTAL
Average number of medical consultations/day (e) AVRNMED/DAY
Total number of hospital bed-days (e) NDAYSHOSP
Number of first day medical consultations (e) NCONSMED1 = (NEPITOTAL × AVRNMED/DAY)
Number of after first day medical consultations (e) NCONSMED1+ = (NDAYSHOSP – NEPITOTAL)
Fee of first day medical consultations (c) FEEMED1
Daily fee of after first day medical consultations (c) FEEMED1+
% of medical care fees not reimbursed (c) SHAREPATMED
National data sources:
(a) Ministry of Health, National Health Map: http://www.sante.public.lu/fr/publications/c/carte-sanitaire-5e-ed-2012-doc-principal/carte-sanitaire-5e-ed-2012-
doc-principal.pdf
(b) Social security code: http://www.legilux.public.lu/leg/textescoordonnes/codes/code_securite_sociale/code_securite_sociale.pdf
(c) Ministry of Health, Ministry of Social Security, Caisse Nationale de Santé (CNS) (Mandatory Health Insurance — Social Security Fund): http://www.cns.lu/
employeurs/?p=121&lm=3-0-0&lp=125
(d) Ministry of Health, Ministry of Social Security, Caisse Nationale de Santé (Mandatory Health Insurance — Social Security Fund): http://cns.lu/files/li-
stepos/16.01_Liste_pos_assures.pdf
(e) CNS: specific data processing/breakdown upon request.
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I  Requirements, strengths, weaknesses and limitations of applied methodology
The described methodology implies sound knowledge of the 
national hospital offers, ICD coding routines, health insurance 
funds, social security codes and reimbursement schemes.
A crucial condition for the application of this methodology 
is that hospital episodes are coded in accordance with 
ICD standards and that the primary diagnosis codes refer 
to mental and behavioural disorders related to the use of 
psychoactive substances. If the ICD code attributed to 
a given client entering hospital treatment corresponds to 
the hospital discharge diagnosis, the sum of expenditure 
per client comprises all related medical interventions (e.g. 
treatment of wounds or injection site infections), included 
in the total cost of the episode.
Interventions at medical emergency units for drug-related 
problems, without an overnight hospital stay, are not 
included in the present methodology. However, according 
to medical hospital staff and specialised treatment 
agencies, these interventions generally lead to subsequent 
inpatient episodes in national hospitals. Thus, the costs not 
accounted for are deemed to be limited in Luxembourg, 
although the situation might be different in other countries 
or settings and should be assessed beforehand.
For the sake of completeness, it should be noted that 
recent research has also addressed public spending 
estimations of drug treatment based on information 
provided by international institutional-based databases as 
well as their inherent limitations (Lievens et al., 2014).
I  Annual costs of outpatient opioid substitution treatment (COST)
I Applied methodology
OST might be provided by different channels and services 
according to national policies and legislations. It is 
therefore important to draw up an inventory of national 
OST offers and determine their financing schemes before 
estimating costs. For instance, in Luxembourg a structured 
multidisciplinary OST programme exists, run by 
a specialised agency and financed by the Ministry of Health 
via a direct convention, and the reimbursement of costs is 
related to substitution drugs prescribed in the framework 
of the programme. The list of medicines that may be 
prescribed for OST at the national level is set by law.
A second channel is the provision of OST by specially 
accredited doctors in the framework of their medical 
practice. Occurring costs are, on the one hand, the medical 
consultation fees that may be partly or entirely reimbursed 
by national, public or private health insurance and, on the 
other hand, refer to prescribed OST drugs that might also 
be reimbursed to some extent.
Where other types of OST providers exist in the country of 
study (e.g. hospital-based OST), these programmes must 
also be included in the cost equation.
In order to determine annual costs of agency-run OST 
(CAGENCY ), operating costs and human resources expenses 
have to be accounted for. Where a formal contract 
between the state and the agency or NGO exists, the cost 
breakdown is recorded in the annual state budget lines 
or may be provided by the accounting department of the 
agency or any alternative financing source. This task is 
generally straightforward, in contrast to the assessment 
of annual public expenses on prescribed OST drugs. To 
this end, it is most relevant to be familiar with the national 
prescription routines and administrative rules.
Methodologically speaking, the best-case scenario is 
the prescription of OST medical products by means of 
specific prescription protocols (e.g. OST specific counterfoil 
carnet, multiple copy prescriptions programmes) and/
or prescription drug monitoring programmes. These 
routines allow not only the running of prescription control 
mechanisms, but also the competent administrations to 
break down OST-specific costs and distinguish the latter 
from the prescription of other opioids or for other purposes 
(e.g. pain treatment). As previously described for the 
costs of hospital-based inpatient drug treatment, social 
security reimbursement schemes might vary according to 
different types of OST prescription drugs and individual 
contributions have to be subtracted from the final costs.
Public expenditure generated by OST provided by 
accredited doctors in private practice (CMD) embrace medical 
consultation fees and related costs for prescribed OST drugs.
In the event that no hard data are available, expert opinions 
or OST prescribers’ and clients’ surveys might be used to 
compile representative average OST prescription figures. 
Alternative multipliers, estimators and calculations are 
presented in Table 5.2 and equation 5.6. 
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I Information and data requirements
I Calculation formulae
The formulae to calculate CAGENCY and CMD are the following:
  (5.4)
and
  (5.5)
or (alternative equation)
  (5.6)
TABLE 5.2
Information and data requirements for the determination of annual COST
General preliminary 
information
Types of national OST providers (a)
(e.g. OSTAGENCY, OSTMD)
List of doctors accredited for OST prescription (b)
National prescription rules and regulations (c)
Competent ministries and institutions (b)
National state budget (d)
National social security code (e)
Nomenclature of medical treatment (f)
Prescription medicines reimbursement schemes (g)
CAGENCY data Annual running and human resources costs (h) CAGENCYOP
Annual costs of agency-prescribed OST drugs (h) CAGENCYDRUG
% of medical consultation fees not reimbursed (f) SHAREPATOSTAGCO
% of prescription OST drugs costs not reimbursed (g) SHAREPATOSTAGDRUG
CMD data Annual OST medical consultation fees (i) CMDCO
Annual costs of OST prescription drugs (i) CMDDRUG
% of medical consultation fees not reimbursed (f) SHAREPATOSTMDCO
% of prescription OST drugs costs not reimbursed (g) SHAREPATOSTMDDRUG
Alternative CMD expert data Total number of OST clients in year x (b) NOSTPAT
Total number of OST prescribers in year x (a,b) NOSTMD
Average number of OST clients per prescriber (j) AVRNOSTPAT/MD
Average costs per OST client (j) AVRC/OSTPAT
Average frequency of medical OST consultations (j) AVRF/OSTMDCO
Fee for medical OST consultation (e) FEEOSTMDCO
Average annual doses (units/packages) of OST drugs prescribed per client (j) AVRF/OSTMDDRUG/PAT
Price of OST drugs per unit (a,g) POSTDRUG/UNIT
National data sources:
(a) Ministry of Health, National Surveillance Commission on Opioid Substitution Treatment.
(b) Ministry of Health, National Opioid Substitution Treatment Register.
(c) National legislative database: http://www.legilux.lu
(d) Ministry of Finance.
(e) Social security code: http://www.legilux.public.lu/leg/textescoordonnes/codes/code_securite_sociale/code_securite_sociale.pdf
(f) Ministry of Health, Ministry of Social Security, Caisse Nationale de Santé (CNS) (Mandatory Health Insurance — Social Security Fund): http://www.cns.lu/
employeurs/?p=121&lm=3-0-0&lp=125
(g) Ministry of Health, Ministry of Social Security, CNS (Mandatory Health Insurance — Social Security Fund): http://cns.lu/files/listepos/16.01_Liste_pos_as-
sures.pdf
(h) Accounting department of prescribing agency: e.g. annual cost breakdown.
(i) Ministry of Health, Ministry of Social Security, CNS.
(j) Expert opinions, prescribers’ and patients’ surveys.
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Optional estimators for NOSTPAT = NOSTMD × AVRNOSTPAT/MD
and for 
The total public expenditure generated by OST (COST) is the sum of CAGENCY and CMD:
  (5.7)
I  Requirements, strengths, weaknesses and limitations of applied methodology
The described method demands that researchers are 
familiar with the national OST prescription routines and 
administrative rules.
A clear distinction in recording and control routines between 
OST and other opioid-based treatments (e.g. pain treatment) 
is required in order to determine the exact number of clients 
and prescription parameters, regardless of the methodology 
that is used. If hard data are available and specific data 
breakdowns can be calculated — for instance by means of 
national OST surveillance registers or by other competent 
authorities — the accuracy of the cost estimation is higher.
The alternative method requires a large set of mostly 
aggregated data, based on average multipliers and 
provided by different data sources and tends to be less 
reliable. 
I  Annual treatment costs of HIV infections and AIDS caused by drug use (CHIV/AIDS) 
I Applied methodology
Expenditure generated by the treatment of persons 
living with HIV and AIDS (both referred to as PLWHIV) is 
relevant in the present analysis, as the transmission of the 
HIV infections might occur through drug use, mostly via 
injection. Since previous drug use and route of infection are 
generally not recorded in diagnostic coding or accessible 
treatment data, and as medical consultations for HIV 
are generally not recorded specifically, often an indirect 
method has to be designed in order to estimate the number 
of PLWHIV alive at time x (NPLWHIVALIVE), the proportion of 
PLWHIV who were infected via drug use (RHIVDU), the number 
of PLWHIV infected via drug use (NHIVDU), the number of 
the latter receiving HIV and AIDS treatment during the 
observation period (NHIVDUTREAT) and the cost of treatment per 
PLWHIV infected via drug use and in treatment (CHIVTREAT/DU).
According to national public health regulations and 
surveillance systems, data compilation might be facilitated 
insofar as HIV infections and AIDS are part of the medical 
conditions and diseases to be notified to public health 
authorities . Furthermore, specialised hospital departments, 
treatment units and retrovirology laboratories are important 
data sources to be addressed. These sources should 
allow the determination of the number of PLWHIV (cohort) 
recorded nationally. In addition, the route of infection 
is mostly assessed at some point of the diagnostic and 
treatment process. The rate (RHIVDU) to be used in the 
annual final cost CHIV/AIDS equation depends on available 
data. The rate observed within cases diagnosed during 
the observation year can be applied, whereas it might be 
more accurate, if longitudinal data are available, to use an 
average rate based upon longer periods (ideally covering 
the entire registration period), as these rates can be subject 
to important yearly variations.
Given that the window of observation is set to one year, 
one has to determine the number of PLWHIV infected 
via drug use and who have been receiving HIV and AIDS 
treatment during the referred period. If the referred number 
(NHIVDUTREAT) is available at the national level, this value can 
be used straightforwardly as a multiplier in equation 5.10.
If NHIVDUTREAT is unknown, the number of PLWHIV deceased 
since the beginning of HIV registration and surveillance 
(NPLWHIVDEAD) has to be subtracted from the total number of 
recorded PLWHIV (NPLWHIV) in order to obtain the estimated 
number of PLWHIV alive (and in need of treatment) 
(NPLWHIVALIVE). Once this figure is known, one can apply RHIVDU 
in order to obtain an estimation of the number of PLWHIV 
infected via drug use and alive (NHIVDUALIVE) during a given year.
HIV and AIDS treatment coverage comes into play at 
this point, as not all recorded persons with an HIV/AIDS 
diagnosis are necessarily in treatment. The number of 
PLWHIV alive in treatment and the rate of PLWHIV infected 
by drug use, alive and in treatment might be provided by 
a central national body (as is the case in Luxembourg). 
National data sources used are listed in the footnotes of 
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Table 5.3, stressing, however, that competent bodies and 
the availability of these data might be country specific. In 
the event that the in-treatment rates of recorded PLWHIV 
alive and of PLWHIV infected via drug use is 100 %, 
NPLWHIVALIVETREAT equals NPLWHIVALIVE and RHIVDUTREAT equals RHIVDU.
The present method requires a further variable: the annual cost 
of HIV treatment per client (CHIVTREAT/DU). As noted, these figures 
(per client or total) are often not readily available from central 
health insurance or social security authorities. Specialised 
hospital departments might be able to provide aggregated 
average figures on the basis of in-house data processing on 
a sample of patients or expert opinions might be asked for. It 
is worth mentioning that, according to national experts, the 
costs generated by treatment of HIV or AIDS are, to a large 
extent, similar, as they primarily reflect expenses related 
to antiretroviral treatment drugs. Slight variations may be 
observed in cases with specific combinations of prescription 
medications. Finally, according to national social security 
reimbursement schemes, potential financial contributions 
from clients have to be subtracted from the final costs.
I Information and data requirements
TABLE 5.3
Information and data requirements for the determination of annual CHIV/AIDS
General preliminary 
information
List of national HIV treatment providers (a)
National public health regulations as regards notification of infectious diseases (a)
National social security code (b)
Nomenclature of medical treatment (c)
Prescription medicines reimbursement schemes (d)
CHIV/AIDS data Total, cumulative number of PLWHIV recorded nationally (a) NPLWHIV
Number of PLWHIV deceased since HIV registration (a) NPLWHIVDEAD
Number of PLWHIV alive at time x NPLWHIVALIVE
Number of PLWHIV infected via drug use alive (a) NHIVDUALIVE
Rate of PLWHIV infected via drug use (a) RHIVDU
Rate of PLWHIV infected via drug use in treatment (a) RHIVDUTREAT
Number of PLWHIV infected via drug use and in treatment NHIVDUTREAT
Annual cost of treatment per PLWHIV infected via drug use and in treatment (e) CHIVTREAT/DU
% of HIV/AIDS treatment costs not reimbursed to clients (c) SHAREPATHIVTREAT
National data sources:
(a) Ministry of Health, National Surveillance Commission on HIV/AIDS, National Laboratory of Retrovirology. Luxembourg Institute of Health.
(b) Social security code: http://www.legilux.public.lu/leg/textescoordonnes/codes/code_securite_sociale/code_securite_sociale.pdf
(c) Ministry of Health, Ministry of Social Security, Caisse Nationale de Santé (CNS) (Mandatory Health Insurance — Social Security Fund): http://www.cns.lu/
employeurs/?p=121&lm=3-0-0&lp=125
(d) Ministry of Health, Ministry of Social Security, Caisse Nationale de Santé (Mandatory Health Insurance — Social Security Fund): http://cns.lu/files/li-
stepos/16.01_Liste_pos_assures.pdf
(e) Accounting department of hospital, expert opinions.
I Calculation formulae
The formulae to calculate NPLWHIVALIVE and NHIVDUTREAT are the following:
  (5.8)
  (5.9)
  (5.10)
The total public expenditure related to the treatment of PLWHIV infected via drug use (CHIV/AIDS) is calculated as follows:
  (5.11)
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I  Requirements, strengths, weaknesses and limitations of applied methodology
A first methodological limitation of this multiplier method, 
which applies equally to ‘hard data’ methods, is related 
to the issue of coverage. National records of PLWHIV in 
treatment do not necessarily represent the total number of 
current PLWHIV in a given country. That said, from a purely 
public expenditure perspective, the cost estimation is 
valid, as PLWHIV not in treatment do not generate direct 
treatment-related public expenses. That said, everything 
should be attempted to get PLWHIV into treatment as 
soon as possible, which may eventually also generate 
public expenditure (e.g. prevention and early detection 
campaigns). It should be added that even persons with 
a diagnosed HIV infection might not be involved in any 
treatment programme. HIV and AIDS treatment coverage 
of PLWHIV infected via drug use should thus be thoroughly 
assessed according to nationally available data when 
applying the present method.
Moreover, a fairly important number of variables are at 
play in the model and some values have to be estimated 
or are subject to important annual variability (e.g. RHIVDU), 
which makes the use of cross-sectional data for estimators 
questionable. Furthermore, the total cost of HIV and AIDS 
treatment is highly dependent on the price of retroviral 
drugs. These known important variations and the changes 
in therapeutic combinations of these drugs need to be 
accounted for within any longitudinal analysis and such 
analysis is, therefore, subject to caution.
This model exclusively addresses the medical treatment 
costs of PLWHIV infected via drug use. However, PLWHIV 
may also be in need of psychosocial care and housing. 
In Luxembourg, these offers are provided by specialised 
NGOs, financed by the state and, as such, the related costs 
are part of labelled public expenditure, easily retrievable 
and therefore not addressed here.
I Conclusions
It is of note that the sum of public expenditure in a given 
area, besides its value in terms of trend analysis, if serial 
comparable estimates are available, is genuinely an 
abstract figure. Indeed, absolute cost estimations do not 
reflect the magnitude of the financial burden to be borne by 
a given community (e.g. national population), nor do they 
reveal how much is spent for a given purpose.
In addition, they do not take into account the relevance of 
invested resources to the prevalence of the drugs problem 
dealt with, nor do they allow public expenditure to be 
situated in a supranational context. Therefore, comparable, 
proportional indicators are needed.
Costs can be presented in relative measures. First, in 
order to consider the size of the population at stake, 
the expenditures per inhabitant should be calculated. 
Second, irrespective of the size of the target population, 
the prevalence of drug use, and in particular problem 
and injecting drug use within the total, it is an important 
factor when it comes to comparing relative expenses 
per drug user at national and international levels. Third, 
since public expenditures have to be borne by the state, 
federal, regional or local government budget, a public 
expenditure breakdown might be of use. Finally, economic 
parameters and performances of countries are diverse and 
international country comparisons could be partially based 
upon indicators taking into account the expenses in relation 
to the country’s GDP.
Table 5.4 summarises distribution indicators and cost 
breakdowns that may be applied in the framework of 
drug-related expenditures studies in a serial and internal 
comparability perspective (Origer and Cloos, 2002). 
According to national definitions of drug demand reduction, 
categories may vary. It might be useful, for instance, to also 
include expenses related to risk and harm reduction in the 
analysis.
TABLE 5.4
Distribution and yearly breakdown indicators of public 
expenditures related to drug demand reduction
Distribution of expenses by domain of action
A. Expenses related to drug prevention
B. Expenses related to drug treatment and treatment of 
associated diseases
C. Expenses related to aftercare measures (e.g. rehabilitation and 
socioeconomic reintegration)
T. Total expenses dedicated to drug demand reduction
Expenses per person
Expenses A, B, C, T per inhabitant
Expenses A, B, C, T per problem illicit drug user (according to 
results of national prevalence studies)
Percentage of collective resources
Percentage of the GDP applied to expenses A, B, C, T
Percentage of the state budget applied to expenses A, B, C, T
Percentage of the social budget applied to expenses A, B, C, T
Source: Origer and Cloos, 2002.
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I Introduction
This chapter describes the methods used to estimate 
public expenditure on treating drug-related health 
problems in the United Kingdom as part of a wider 2012 
study estimating drug-related public expenditure. The study 
formed part of the 2012 national reporting to the EMCDDA 
(Davies, 2012) and built on methods first developed in 
a similar 2007 study (Davies, 2007). Although these two 
studies were stand-alone exercises, the framework within 
which they were carried out, forming part of reporting from 
national drug monitoring systems, means that the methods 
were developed with the aim of identifying data sources 
that could be used to monitor drug-related expenditure 
rather than as a research study. Thus a pragmatic approach 
to the choice of data and methods was taken. In addition, 
all elements of drug-related public expenditure were 
included, in order to ensure that expenditure data would 
be useful in ultimately assessing the cost-effectiveness of 
drug policy and funding decisions.
I  Background: institutional framework and drug treatment expenditure data
The National Health Service (NHS) in the United Kingdom 
is a publicly funded healthcare system free at the point of 
delivery. As healthcare is a devolved responsibility, each 
of the four UK countries runs its NHS independently and 
therefore has a separate drug treatment system and way 
of accounting for expenditure. While there are private 
hospitals and drug treatment centres, the vast majority of 
services for drug users are publicly provided.
Data on specialised drug treatment public expenditure 
were available for the United Kingdom in 2012 covering 
outpatient, inpatient, low-threshold and prison treatment 
(Davies, 2012). The level of detail and nature of the 
expenditure data, however, differed across the United 
Kingdom. In each country, expenditure data were available 
covering labelled, central government drug treatment 
allocations, although in Wales and Northern Ireland (where 
there are combined drug and alcohol strategies) this also 
included elements of alcohol expenditure. The expenditure 
data were recorded in administrative systems, and labelled 
expenditure reflects budget allocations rather than actual 
expenditure.
Expenditure estimates for drug treatment from local 
mainstream funding sources are unlabelled forms of 
expenditure and were calculated in different ways across 
the United Kingdom’s constituent countries. For England, 
aggregated expenditure from local mainstream budgets 
such as general healthcare and police was estimated using 
annual local treatment plans representing a bottom-up 
estimation exercise. In Scotland, a one-off study carried 
out by Audit Scotland (2009) estimated the expenditure 
on drug treatment services in 2007/08 by collecting 
expenditure data from each health board. This was used 
to create an attributable fraction to be applied to the 
total healthcare budget in subsequent years. In Wales, an 
internal exercise estimating expenditure on substance 
misuse services from NHS mainstream allocations 
was carried out and, based on the findings, the Welsh 
Government ring-fenced 0.4 % of local health boards’ 
future mainstream budgets for substance misuse services. 
The annual value of this is used to estimate additional 
mainstream expenditure, although local health boards may 
spend more. In Northern Ireland, no estimate was available 
for unlabelled mainstream expenditure.
The expenditure data on drug treatment were, therefore, 
generated through both a top-down and a bottom-up 
approach, and represented both labelled and unlabelled 
expenditure and a mixture of actual expenditure and 
budget allocations. The methods for estimating unlabelled 
expenditure differed, with each UK country adopting 
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a pragmatic approach based on the information it had 
available.
While the United Kingdom has been able to estimate 
expenditure on drug treatment services across all 
countries, it has focused on specific drug services rather 
than the wider healthcare costs related to drug use. This 
restricts the ability of public expenditure data to be used in 
a way that is relevant to policymakers, namely in assessing 
the full cost-effectiveness of policy and financial decisions. 
It does not allow an assessment of the impact of changes 
in healthcare spending in one area on other areas of 
healthcare. Being able to demonstrate how investment 
in one area will provide savings in others is vital in an era 
of tight healthcare budgets. One of the aims of the 2007 
and 2012 public expenditure studies was to identify 
relevant drug-related health costs and to explore methods 
of estimating these that could be replicated in order to 
monitor a wider range of drug-related healthcare treatment 
costs. This paper describes the methods used to do this for 
the health conditions set out in Table 6.1.
TABLE 6.1
Health conditions included in the 2012 UK estimate
Health condition Wholly 
attributable to 
drug use
Source of attributable 
fraction and year
Attributable 
fraction used
ICD-10 code
Infectious disease
HIV No
HPA data on transmission 
route of those diagnosed 
with HIV (2010)
0.018 B20-B24
Viral hepatitis B No HPA laboratory data (2003) 0.18 B16, B18.0, B18.1
Viral hepatitis C No
HPA risk information data 
from laboratory reports 
(1996-2010)
0.88 B17.1, B18.2
Neuropsychiatric conditions
Mental and behavioural disorders due to use of 
psychoactive substances
Yes N/A
F10-F12, F14-F17, 
F19
Cardiovascular diseases
Acute and subacute endocarditis No Single et al. (1996) 0.14 I33
Maternal drug use
Low birthweight and short gestation; neonatal 
conditions
No
Author calculation using 
data on births recording 
drug misuse and outcome 
in Scotland (2008/09) and 
prevalence of problem drug 
misuse (2009/10)
0.009-0.030 
depending on 
condition
P02.0-P02.2, P04.8, 
P05-P07
Fetus and newborn affected by maternal use of 
drugs
Yes N/A P04.4, P96.1
Pregnancy complications No Author calculation
0.009-0.030 
depending on 
condition
O35.5, O36.5, 
O44-O46, O67
Unintentional injuries
Motor vehicle accidents No
Adjusted odds ratio from 
DRUID study (Hels et al., 
2011) and 2010/11 last 
month drug use estimate 
(UK focal point, 2011)
0.063
Various V codes 
excluding non-traffic 
accidents; Y85
Accidental poisoning and exposure to illegal 
drugs
Yes N/A
T40.0-T40.5, T40.7, 
T43.6
Intentional injuries
Suicide No
Degenhardt et al. (2004), 
Australia
0.09 X60-X84
Assault No
Author re-analysis of 
Arrestee Survey data 
(2005/06)
0.022 X85-Y09
Note: HPA, Health Protection Agency.
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I  Identification of drug-related health costs
Estimating public expenditure on drug-related healthcare 
services ideally requires the following three elements: first, 
identification of relevant drug-related health conditions; 
second, a drug-related attributable fraction for those 
health conditions not wholly attributable to drug use; third, 
the health service expenditure by health condition. In 
reality, the last is rarely available; therefore, for a bottom-
up estimation exercise, a fourth element, health service 
utilisation data, is required along with compatible unit cost 
data. The identification of the relevant drug-related health 
conditions was the first step in the estimation exercise and 
was informed by research on the association between drug 
use and health.
While many studies have shown an association between 
drug use and health harms, causality is rarely demonstrated 
and it is recommended that studies that demonstrate 
only association are not used (Single et al., 2003). Causal 
inference implies that temporality should be established in 
a study, and some cost studies have used further criteria. In 
their Canadian cost of substance abuse study, for example, 
Rehm et al. (2006a) specify four conditions for inclusion: 
(1) consistency across several studies; (2) established 
experimental biological evidence of biological mechanisms; 
(3) strength of the association; and (4) temporality.
Given the complexities of determining causality, a decision 
was made to use only the conditions identified by Rehm 
et al. (2006b) based on the WHO’s 2000 Global Burden of 
Disease Study (Mathers et al., 2002). This list of conditions 
is used in existing substance misuse cost studies in 
Canada (Rehm et al., 2006a) and is almost identical to the 
conditions used in an Australian study (Collins and Lapsley, 
2008). Table 6.1 is partly adapted from these studies and 
uses the International Classification of Diseases (ICD-
10) (1) to identify relevant conditions.
I Methods
I Calculating drug-related attributable fractions
Many of the health conditions identified in Table 6.1, 
however, are not wholly attributable to drug use and, in 
order to estimate public expenditure on treating drug-
(1) See http://apps.who.int/classifications/icd10/browse/2016/en 
related health conditions, it is necessary to determine 
the proportion that are. The calculation of an attributable 
fraction is one method of achieving this. This can be 
calculated by using the relative risk, which approximates 
the causal relationship between exposure to the risk 
behaviour and the health condition, and the prevalence 
of the risk behaviour in the studied population (Chikritzhs 
et al., 2002). Relatively few case-control studies exist 
that estimate the relative risk of drug use and health 
conditions — where such studies do exist, they include 
a limited number of conditions and are predominantly from 
countries outside the United Kingdom such as Australia 
(English et al., 1995) and Canada (Single et al., 1996). 
Using relative risks derived from a population different from 
the one being studied can be problematic, as differences 
in the prevalence of drug use and the extent of the harm 
associated with use can affect the applicability of the 
relative risk and the validity of the attributable fraction 
derived from it (Riddell et al., 2008). Nevertheless, this is 
the approach that was taken when calculating alcohol-
attributable fractions in England (NWPHO, 2008).
The lack of population-specific drug-attributable fractions 
and research that could underpin the calculation of 
attributable fractions creates a barrier to estimating 
drug-related expenditure. In order to overcome this, in 
addition to published epidemiological research studies, 
various official data sources were interrogated to see 
whether or not they provided data that could be used to 
calculate drug-related attributable fractions. Data used 
in the study included published monitoring data from the 
Health Protection Agency on known transmission routes 
for HIV (Health Protection Agency, 2011a, 2011b) and the 
re-analysis of a large dataset from a government research 
study, the Arrestee Survey for England and Wales (National 
Centre for Social Research, 2011) to provide an attributable 
fraction for injuries due to assault (2). The preferred source 
for estimating drug-related attributable fractions was case-
control studies providing relative risks or an odds ratio from 
which relative risks could be approximated. Where such 
studies were available concerning non-UK populations, 
they were used where no other data were available. If 
other data were available on which to base calculations, 
a decision was made on which method was most 
appropriate. The reasons for the choices made were set 
out in an unpublished technical document (3). This flexible 
approach allowed as wide a range of health conditions 
as possible to be included in the estimate, based on the 
estimator’s judgement.
(2) This involved estimates based on self-reporting of the effect of drug use 
on individuals’ criminal behaviour.
(3) Available from the author on request.
INSIGHTS I Drug treatment expenditure: a methodological overview
78
Table 6.1 shows the source of the attributable fraction 
for various health conditions, the year of data for the 
underlying data and the value used. The use of regular 
monitoring data sources allows annual calculation of 
attributable fractions, but the majority were calculated 
from one-off studies that would require periodic updates. 
Assigning appropriate ICD-10 codes to each health 
condition allows calculation of the drug-attributable 
proportion using a common classification of disease 
system.
Example: Using administrative data to 
calculate an attributable fraction for 
maternal drug use
No UK research studies could be found that provided 
a drug-attributable fraction for birth problems or the 
relative risk of these occurring among drug users. 
Administrative data, however, were available on all births 
in Scotland, whether the infant was born prematurely 
or with a very low, low or normal birthweight and the 
number of these recording drug misuse (ISD Scotland, 
2012). This allowed the calculation of relative risks for 
the different birth outcomes recorded. The national 
estimate on the prevalence of drug misuse provided 
data on prevalence (ISD Scotland, 2011), from which a 
drug-attributable fraction was calculated. The relative 
risks and attributable fractions for each condition are 
shown below.
Outcome Relative risk
Attributable 
fraction
Very low birthweight 1.958 0.009
Low birthweight 4.042 0.030
Very low and low birthweight 3.669 0.026
Pre-term 2.076 0.011
Pre-term and low birthweight 2.743 0.017
I Data on health service utilisation
The next step to estimate the impact of drug use on health 
services required data on health service utilisation. While 
aggregated data were available for many levels of the 
health service — GP visits, accident and emergency (A&E) 
department visits, outpatient hospital attendance and 
inpatient stays — there were minimal data available at 
a disaggregated level by health condition. This means, for 
example, that there were no data available on the reason 
for a GP visit, although individual practices or areas may 
carry out audits. Consequently, for large parts of the health 
service, it was not possible to estimate public expenditure 
on treating drug-related health conditions. Hospital 
inpatient stays were the exception. Primary diagnosis data 
are available across the United Kingdom broken down by 
ICD-10 code, although the extent to which these data are 
made publicly available differs.
Annual Hospital Episode Statistics are published in detail 
for England, allowing access to data on individual ICD-10 
codes, which are matched to the health conditions in 
Table 6.1. Scotland, Wales and Northern Ireland publish 
data at various aggregated levels. It was not possible, 
therefore, to get activity data for some health conditions in 
all UK countries using routinely published data. The data 
for England include the number of episodes and number 
of bed-days and the percentage that were emergency 
cases. These activity data can then be combined with 
the drug-attributable fraction to estimate drug-related 
hospital activity associated with the treatment of drug-
related problems. Having detailed data on hospital activity 
provides greater opportunity to estimate expenditure, as 
there is a greater likelihood of a measure of activity being 
consistent with available cost data.
I Health service cost data
The main source of unit cost data for England was National 
Health System reference cost data. Published annually, 
they give unit costs of providing NHS treatment broken 
down by health resource group (HRG) (Department of 
Health, 2011a). This is a method of grouping together 
clinically similar treatments, which use common levels of 
healthcare resources. The data are also the reference unit 
costs on which the national tariff payment system is based. 
For inpatient stays, an HRG is derived based on diagnosis 
codes (ICD-10) and procedure codes (OPSC-4 (4)) for each 
spell of treatment. In order to gain consistency with the 
published activity data (based on ICD-10 codes), it was 
necessary to map the relevant conditions to the published 
HRGs. The corresponding cost per episode could then be 
used. If more than one HRG was mapped to the relevant 
condition, the weighted average cost was calculated as 
per the method set out in the NHS cost manual. One issue 
was the fact that HRG-4, unlike previous versions, moved 
to a spell rather than an episode basis. This may introduce 
an element of double counting when using episode-based 
activity data. However, given that the vast majority of 
spells have only one consultant episode (Monitor and 
NHS England, 2013) and the change was not mandated 
(4) The Office of Population, Censuses and Surveys Classification of Surgical 
Operations and Procedures (4th revision) is a classification system used 
in the UK to assign codes to surgical operations, interventions and pro-
cedures. The OPCS-4 classification is reviewed annually and updated to 
reflect changes in clinical care.
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in 2010/11 (Department of Health, 2010), this should not 
have affected the 2012 estimate.
The reference cost data are collected on a full absorption 
basis including costs relating directly to the delivery of 
client care (e.g. staffing costs), other costs related to the 
delivery of care, but not able to be identified at individual 
level (e.g. catering and linen), and overhead costs for the 
overall running of the service (e.g. payroll). They use a top-
down methodology where costs are apportioned to HRGs 
from pooled costs (5).
For some services, such as mental health inpatient 
services, cost data were available on a bed-day basis, 
drawn from the unit costs of health and social care 
publication (Curtis, 2011). Therefore, a different unit of 
activity, one compatible with this method of calculating 
cost data, was used, namely the number of bed-days.
I  Combining data to calculate drug-related expenditure
For most of the health conditions, the expenditure 
calculation consisted of the product between the number 
of hospital episodes and the attributable fraction for each 
disease considered multiplied by the unit cost for each 
condition.
In some instances, however, a more specific source of 
cost data was available and hospital inpatient data were 
not used. For example, in England HIV/AIDS treatment 
has its own budget line in programme budget reporting, 
which includes the costs of outpatient treatment as well 
as inpatient. Therefore using the overall expenditure data 
and applying the attributable fraction, it was possible to 
produce a more comprehensive estimate of expenditure.
In other instances, additional elements of expenditure 
were added to the calculation. For example, information on 
prescription costs was available (6) that allowed estimates 
of expenditure on hepatitis B and C medicines in addition 
to expenditure on inpatient stays.
(5) The definition of ‘direct’ costs and ‘indirect’ costs used in the NHS Costing 
Manual differs from that commonly used in economic terms. Full details 
on the definition can be found in the publication (Department of Health, 
2011b).
(6) See http://digital.nhs.uk/catalogue/PUB02274 and http://content.digital.
nhs.uk/pubs/hospre10
Example: Using research findings 
to underpin estimates — treating 
infection site wounds
A UK research study identified a further element of 
drug-related treatment expenditure that had not been 
included: the cost of treating infection site wounds. 
The research asked injecting drug users whether they 
had had an injection site wound, whether they had 
sought treatment for it and where they had sought 
treatment. By applying these findings to the latest 
estimate of injecting drug use in the UK (n = 133 112; 
Davies et al., 2012) an estimate of healthcare activity 
can be calculated. The unit cost of a GP visit including 
direct care staff and the national average unit cost of 
accident and emergency (A&E) attendance was used 
(Curtis, 2011), with the adjusted average unit cost for 
non-elective hospital stays related to intermediate and 
minor skin conditions used for hospital admissions 
(Department of Health, 2011a). 
Healthcare Number
Unit cost 
(GBP)
Total cost 
(GBP)
GP visit 16 791 30 503 730
A&E no admittance 3 276 106 347 256
A&E admitted 11 614 1 267 14 714 938
Total 31 681 – 15 565 924
I Limitations
There will always be limitations on how expenditure 
studies can be interpreted. Estimates can reflect only 
what is currently known about drug use and its impact 
on health. They are based on assumptions and on other 
estimates, so they rely on the accuracy of these. The 
quality and availability of the data and research for 
each of the four elements varies: (1) identification of 
relevant health conditions; (2) calculation of drug-related 
attributable fractions; (3) data on health service utilisation; 
and (4) available cost data. Research on which to base 
assumptions is mainly restricted to individual studies, and 
it may be old or from a different country. Administrative 
data also rely on accurate recording, but the accuracy of 
ICD-10 coding has been questioned (Monitor, 2012), as it 
is primarily carried out by dedicated coding staff using case 
notes rather than by health professionals. As coding affects 
financial reimbursement, there may also be an incentive 
to code the primary condition as the one that attracts the 
highest reimbursement rather than the most appropriate 
for the case.
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Furthermore a recent audit of costing in the NHS found 
that across NHS trusts ‘the accuracy of costs is variable, 
and only a small handful of trusts had good quality costing’ 
(Capita, 2014). The report also highlighted the importance 
of accurate underlying data for the calculation of unit costs, 
stating that ‘no matter how detailed and accurate costing 
methodologies are, if the activity data is incorrect, then so 
will be the unit costs.’
Owing to the absence of detailed data on health service 
utilisation for many levels of the health system, such as 
GP visits and non-admitted hospital care, estimates are 
unlikely to provide a true reflection of total expenditure on 
treating drug users. Given this fact, a decision was made to 
choose different data sources and methods of estimating 
based on what would provide the most comprehensive 
estimate. Therefore, it is not possible to compare healthcare 
costs between conditions, as they may include different 
elements. However, even if only inpatient hospital 
expenditure was calculated, it may not be possible to 
compare expenditure between conditions, as the setting in 
which treatment occurs could differ substantially between 
them, as well as their costs. For example, some conditions 
may be more likely to be treated in outpatient settings than 
inpatient settings.
I Conclusion
Given the limitations of public expenditure estimates 
and the immaturity of the subject area for drugs, global 
estimates of expenditure are unlikely to prove accurate and 
may have limited use. However, identifying data sources 
on which estimates of expenditure for various drug-related 
health conditions can be calculated may allow these 
relevant areas of expenditure to be factored into local 
funding decisions and allow a wider assessment of the 
benefits of treating drug users.
In England, the removal of the ring-fenced budget for drug 
treatment and the mainstreaming of funding into a wider 
public health grant has meant that there is a greater need 
to demonstrate return on investment. Identifying wider 
drug-related healthcare costs, and costs in other areas 
such as social care, allows a wider assessment of the 
impact of treating drug users. Using routinely collected 
data reduces the time and resources required to produce 
estimates and should enable changes over time to be 
monitored.
While the use of a pragmatic approach and wider definition 
of drug treatment allows for a more comprehensive 
identification of drug-related healthcare expenditure 
at a national level, it is not exactly replicable in other 
countries. There is no reason, however, that the underlying 
steps cannot be performed in each country. That is, 
a common set of drug-related health conditions are agreed 
upon, sources of data for the calculation of drug-related 
attributable fractions are identified for these, and sources 
of data for healthcare costs and healthcare activity are 
identified. While the absence of data for any of these 
components may mean that an estimate is not possible, 
mapping out what is available is a useful exercise in itself 
and can identify research gaps and new data sources and 
inform improvements to data collection and reporting.
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I Introduction
The burden and cost of substance use in market economies 
and public health systems are huge. In the World Health 
Report 2004, the WHO estimated the impact of risk 
factors on the burden of disease. The results showed that 
substance-attributable burden of disease across developed 
sub-regions was high, with tobacco accounting for 12.2 % 
of all disease burden in the year 2000 in market economies 
(highest burden of all 26 risk factors examined), alcohol 
accounting for 9.2 % (third most important risk factor) and 
illicit drugs accounting for 1.8 % (eighth most important 
risk factor). One of the differences between these three 
categories of substance is the fact that they inflict their 
disease burden on different age groups. The use of illicit 
drugs inflicts its mortality burden earliest in life and alcohol 
mainly before the age of 60, while tobacco-related deaths 
occur mostly after the age of 60 (WHO, 2004, 2013; Rehm 
et al., 2006a).
Notably, both total deaths and age-standardised death 
rates due to alcohol use disorders significantly dropped 
between 2005 and 2015, falling by 12.6 % (range from 7.0 
to 16.7) and 29.2 % (range from 24.7 to 32.4), respectively. 
However, drug use disorders accounted for an increasing 
number of deaths, resulting in a rise of 31.8 % (range 
from 20.4 to 39.4) since 2005. Deaths due to opioid use 
disorders accounted for 71.9 % (range from 69.5 to 73.3) 
of these drug-related deaths in 2015, increasing by 29.6 % 
(range from 18.2 to 37.2) (GBD 2015 Mortality and Causes 
of Death Collaborators, 2016).
Cohort studies show that, with respect to the general 
population, illicit drug users have a higher risk of morbidity 
and premature death caused by overdose, HIV and AIDS, 
suicide and trauma (World Health Organization, 2004; 
Degenhardt et al., 2006; Mathers et al., 2013; Kennedy et 
al., 2015). Unlike tobacco and alcohol use, other adverse 
health effects of illicit drug use have been less widely 
explored. Three factors may account for this knowledge 
gap: (1) the relatively recent undertaking of research on 
the effects of illicit drug use in many countries; (2) the low 
prevalence of use of drugs in the population compared 
with alcohol and tobacco; and (3) the fact that its illicit 
nature encourages users to conceal or deny their drug use, 
hence inhibiting research on the effects on morbidity and 
mortality.
At the European level, the EMCDDA estimated in 2013 
that at least 1.6 million individuals received some kind 
of treatment for illicit drug use (EMCDDA, 2015). Data 
also show that, in the same year, there were more than 
172 000 hospital discharges for mental and behavioural 
disorders due to the use of psychoactive substances, 
including nicotine (Eurostat, 2015). By just looking at the 
total number of people in treatment, it appears clear that 
drug abuse treatment has a significant cost for European 
healthcare systems.
Furthermore, drug use imposes a burden on wider 
healthcare services. A Canadian study found that, in 2002, 
‘hospital diagnoses attributable to use of illegal drugs 
were dominated by mental and behavioural disorders 
due to psychoactive substance use’, which accounted for 
63 % of all illicit drug-attributable diagnoses in acute care 
hospitals. Among mental and behavioural disorders due 
to psychoactive substance use, multiple drugs and other 
psychoactive substance use was the largest specific cause 
of hospital diagnoses (29 %), followed by cocaine (24 %), 
cannabinoids (24 %) and opioids (17 %). The second major 
contributor (17.7 %) was opiate and cocaine poisoning 
(non-fatal overdoses). The third and fourth largest 
categories of hospital diagnoses attributable to illicit drug 
use were HCV (7.6 %) and non-fatal suicide (6.7 %) (Rehm 
et al., 2006b, 2007).
Taking account of this complex scenario, the aim of this 
study was to estimate the direct and indirect healthcare 
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costs of hospitalisation, outpatient specialised treatment 
and prescription drugs incurred over the 2013-14 period by 
illicit drug users taken in charge in 2012 by the addiction 
treatment services (SERT) of the city of Bergamo (a 
province of northern Italy). This will also take into account 
the potential comorbidity profile of each client.
I The healthcare system in Italy
To understand the meaning of data and results, it is 
necessary to describe the structure and organisation of the 
healthcare provision system in Italy, as well as its funding 
and information processes.
Healthcare services are provided to all Italian citizens 
and residents in the framework of a mixed public-private 
system. The public part is provided by the National Health 
Service (Sistema Sanitario Nazionale, SSN), which is 
organised under the Ministry of Health and is administered 
at regional level through the local health authorities 
(Azienda di Sanità Locale, ASL). Until 1998, the SSN was 
funded directly by central government. The SSN provides 
hospital stay and treatment (including tests, surgery and 
medication during hospitalisation), territorial medical 
assistance (mental health, drug addiction, services for 
people with disabilities, and others) and coordinates GPs’ 
activities and the other territorial health structures (Health 
Ministry, 2012).
Prescribed drugs can be purchased only under 
practitioners’ prescription. If prescribed by the GP, they are 
generally subsidised, requiring only a co-payment (ticket) 
that depends on the type of medicine and the patient’s 
income. Visits to specialist doctors or diagnostic tests are 
provided by public hospitals and health structures or by 
private ones (under a specific agreement indicating costs 
co-financed by the public authorities), and, if prescribed by 
a GP, require only a co-payment. However, patients can opt 
for private healthcare services provided by both public and 
private hospitals, which are paid out of their own pockets 
and generally have much shorter waiting lists. Surgery and 
hospitalisation services provided by public hospitals or by 
private ones (under a specific agreement whereby costs 
are co-financed by public authorities) are completely free of 
charge for everyone, regardless of income level.
Some particular circumstances (disability, chronic diseases, 
drug addiction, incapacity of generating a minimum level of 
income that guarantees survival, low income or age-related 
reasons) entitle patients to co-payment exemptions.
Collection, processing and treatment of data relevant to the 
statutory healthcare system and to citizens’ health status 
fall within the mandate of the Ministry of Health, which 
in 1984 established the Health-care Information System 
(Sistema Informativo Sanitario, SIS) to this end. Regions 
collect data from the ASLs of their territory and transmit 
them to the Health Ministry.
Common and interoperable languages have been 
specifically developed for the SSN’s sub-components 
(hospitalisation; outpatient specialised treatment; 
monitoring of care networks; information system on 
mental health; national information system on addictions; 
traceability of pharmaceuticals; emergency; home 
care; residential and semi-residential care; others), 
allowing these different informatics systems to interact. 
Consequently, specific data flows with the information 
required were collected (individual characteristics, 
treatments/drugs, tariffs, co-pay fee exemption) generated 
by citizens’ contacts with the SSN.
Patients are identified by the same code across all data 
flows: only the data provider (ASL) can link the code to the 
real identity of patients.
I Methods 
The anonymised list of clients that attended the addiction 
treatment service (SERT) of Bergamo province in 2012 
was linked to all the administrative data flows, registering 
clients’ interaction with the national healthcare system 
(hospitalisations, outpatient visits and treatments excluding 
GPs, drug prescriptions, co-payment fee exemption). This 
information system has allowed the development of an 
individual electronic health record for each individual client 
concerning the period 2013-14.
Information about drug use was extracted from SERT 
registries, while information about healthcare treatments, 
comorbidities and costs came from administrative data flows.
Data flows were integrated in the data warehouse through 
a linkage procedure based on the anonymised numerical 
code originally assigned to each client by the data provider, 
in compliance with the requirements of Italian Legislative 
Decree 196/2003 on privacy.
This procedure was used to build a database, which 
includes the demographic characteristics of each client, 
the diagnosis of illicit substance use disorders (e.g. 
information concerning the use of heroin and opioids, 
cocaine, cannabis, hallucinogens, synthetic drugs such 
as amphetamines, and pharmaceutical drugs such as 
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benzodiazepines or barbiturates as primary drug) and the 
comorbidities.
Individual information was classified according to the 
diagnosis code ICD-9-CM (from the hospital discharges 
data flow), the outpatient specialised treatment code (from 
the outpatients data flow), the co-payment exemption and 
drug classes, using the anatomical therapeutic chemical 
(ATC) classification index and the defined daily dose (DDD, 
from the drug prescriptions data flow).
The DDD is the given average maintenance dose per day 
for a drug used for its main indication in adults. It should 
be emphasised that the DDD is a unit of measurement 
and does not necessarily reflect the recommended or 
prescribed daily dose. Doses for individual patients 
and patient groups often differ from the DDD and have 
necessarily to be based on individual characteristics 
(e.g. age and weight) and, for instance, pharmacokinetic 
considerations. Therefore, drug consumption data indicated 
in DDDs give only a rough estimate of consumption and 
not an exact estimate of actual use. Nevertheless, the 
DDD provides a fixed unit of measurement independent 
of price and dosage form (e.g. tablet strength and purity) 
and enables the researcher to assess trends in drug 
consumption and to perform comparisons between 
population groups.
Information collected in the data warehouse have been 
used to identify patients’ comorbidity profile (Franchini 
et al., 2015, 2016) by means of a classification method 
that defines the groups of conditions that the individual 
patient belongs to. This method, originally developed by 
the University of Pavia (Cerra and Lottaroli, 2004), defines 
17 classifications with different orders of severity. For 
instance, a patient is considered type 2 diabetic if (1) he or 
she has drug prescriptions of insulin or analogues (ATC 3 
group code A10A) with at least 10 % DDD and/or (2) he or 
she has drug prescriptions for oral hypoglycaemic agents 
(ATC 3 group code A10B) with at least 30 % DDD and/or 
(3) he or she has a diagnosis of diabetes mellitus type 2 at 
hospital discharge (ICD-9-CM code 250).
In the final version, each patient’s record contains 
information about gender, age class, substance of abuse 
and comorbidity macro-classifications (1). Furthermore, 
a number of specific conditions have been identified 
(1) Type of comorbidity classifications are severely disabled ‘Disability’, 
psychiatric disorders ‘Mental_dis’, chronic renal insufficiency ‘Renal_ins’, 
transplantation ‘Transplant’, neoplasms ‘Neoplasm’, cardiovascular 
diseases ‘Cardiovascular’, chronic obstructive pulmonary disease ‘COPD’, 
gastro-enteropathy ‘Gastro’, neuropathy ‘Neuro’, autoimmune ‘Auto-
imm_dis’, endocrine and metabolic diseases ‘Endometabol_dis’, diabetes 
‘Diabetes’, rare diseases ‘Rare_dis’, pregnancy ‘Pregnancy’, other health 
conditions that cannot be classified as chronic disease or pregnancy 
‘Residual’.
through a specific algorithm: illicit substance disorder 
‘Drug_addict’, alcohol use disorder ‘Alcohol_addict’, 
HIV/AIDS diagnoses ‘HIV_AIDS’ and, more specifically, 
HCV, non-fatal suicide and overdose. Then, individual 
comorbidity profiles were created by linking each patient to 
his or her specific conditions.
Healthcare costs were estimated using the tariff associated 
with each treatment (Health Ministry, 2012): in particular 
the DRG’s reimbursements for hospitalisation, the tariff 
rates for outpatient treatments and the reimbursement 
price for drug prescriptions. Healthcare costs were 
differentiated either as overall costs or by type of 
healthcare treatment provided (hospitalisation, outpatient 
specialised treatment and drug prescriptions), substance 
of abuse and comorbidity profile.
In some cases, costs were tabulated separately into two 
years of observation, to highlight possible changes in the 
patient’s health status. Furthermore, average per capita 
estimates were calculated by the staff of the territorial 
SERT on the basis of the costs borne for the inpatient 
treatments for drug addiction (residential and semi-
residential), outpatient treatments and laboratory tests 
directly provided by the territorial service itself referring to 
internal tariffs defined at local level.
I Results
I Treatment population
The cohort of clients treated for illicit substance use by 
SERT in 2012 amounts to 2 737 subjects. Of these, 2 372 
clients had at least one contact with the SSN (other than 
SERT) in 2013 and/or 2014 and were captured through 
the linkage procedure among data flows. Men accounted 
for 82.7 % of all clients and were slightly older than women 
(men 38.1 years on average, standard deviation (SD) ± 9.9 
years; women 36.7 years on average, SD ± 9.8 years) 
(Figure 7.1).
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FIGURE 7.1
Distribution of the cohort of 2 372 clients by age and 
gender, 2012
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Table 7.1 shows the distribution of the 2 372 clients by 
the primary drug used, as indicated by SERT. Heroin, 
morphine and other opioids were the most frequently used 
drugs among both men and women, followed by cocaine 
and crack, used by slightly younger clients. Cannabis and 
synthetic cannabinoid users were the youngest clients with 
respect to both genders. Furthermore, SERT indicated that 
methadone was the primary drug for 11 clients, probably as 
a consequence of their long history of drug addiction.
I  Healthcare costs of individuals receiving drug treatment
The overall cost of healthcare services provided in terms 
of hospitalisation, drug prescriptions and outpatient 
treatments amounted to EUR 10 million over two years, 
with the reimbursement price for drug prescriptions 
being the most expensive (48.2 % of the total costs). 
Women generated the highest cost per client for all items 
(Table 7.2).
In general, heroin, morphine and other opioid users 
generated the highest per capita cost across genders, 
and women generated higher costs than men. The second 
group of clients in terms of healthcare consumption 
costs was the one using neuroleptics, hypnotics, 
benzodiazepines and barbiturates. These clients in 
particular had the highest costs of hospitalisation 
(Table 7.2).
Among drug users, the distribution of costs by age did not 
follow a clear trend, contrary to what generally happens 
in the general population, where, the older clients are, the 
higher the costs (Alemayehu and Warner, 2004).
TABLE 7.1
Distribution of clients by primary drug and gender, 2012
No of clients % Mean age SD
Men 1 961 100 38.1 9.9
Other drugs 3 0.20 34.0 13.7
Cannabis, synthetic cannabinoids 184 9.40 24.4 8.8
Cocaine, crack 468 23.90 36.1 8.2
Heroine, morphine, other opioids 1 296 66.10 40.8 8.8
Methadone 6 0.30 40.8 13.6
Neuroleptics, hypnotics, benzodiazepines, barbiturates 4 0.20 41.8 9.5
Women 411 100 36.7 9.9
Other drugs 3 0.70 40.0 12.8
Cannabis, synthetic cannabinoids 19 4.60 24.6 8.9
Cocaine, crack 82 20.00 34.1 9.4
Heroine, morphine, other opioids 289 70.30 37.7 9.1
Methadone 5 1.20 39.6 10.7
Neuroleptic, hypnotics, benzodiazepines, barbiturates 13 3.20 47.1 11.3
Total 2 372 37.9 9.9
Source: SERT.
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TABLE 7.2
Distribution of healthcare cost (per capita) by type of item, year of observation, gender and substance of abuse
Average cost, per capita (EUR)
Other 
substances
Cannabis,
synthetic 
cannabis
Cocaine,
crack
Heroin,
morphine,
other 
opioids
Methadone Neuroleptics,
hypnotics,
barbiturates,
benzodiazepines
All 
substances
Men
Number of clients 3 184 468 1 296 6 4 1 961
Hospitalisation costs (2013) 623 733.9 654.2 663.3 0 1 311.3 667
Drug prescription costs (2013) 31.7 156.6 282.3 1 306.80 302 518.8 947.7
Outpatient specialised 
treatment costs (2013)
117.7 334.8 251.5 329.8 300.5 22.3 310.6
Total average cost, per capita 
(2013)
772.3 1 225.3 1 188.0 2 299.9 602.5 1 852.3 1 925.3
Hospitalisation costs (2014) 0 556.8 597.1 678.6 229.3 783.8 645.6
Drug prescription costs (2014) 2 185.7 391.7 1 379.80 1 305.8 431.8 1 027.70
Outpatient specialised 
treatment costs (2014)
56.3 383.5 218.1 427.1 589.2 7.3 372.2
Total average cost, per capita 
(2014)
58.3 1 126.0 1 206.9 2 485.5 2 124.3 1 222.8 2 045.4
Annual average costs, per 
capita (2013-14)
415.3 1 175.6 1 197.4 2 392.7 1 363.4 1 537.5 1 985.3
Women
Number of clients 3 19 82 289 5 13 411
Hospitalisation costs (2013) 480.7 290.6 922.9 1 377.20 300.2 806.8 1 198.60
Drug prescription costs (2013) 232 112.6 592.4 1 440.80 871 472.6 1 163.80
Outpatient specialised 
treatment costs (2013)
406.7 151.8 331 518.7 587.4 231.8 455.2
Total average cost, per capita 
(2013)
1 119.3 555.1 1 846.3 3 336.8 1 758.6 1 511.2 2 817.7
Hospitalisation costs (2014) 734 244 694.2 1 062.40 630.8 1 660.80 962.3
Drug prescription costs (2014) 301.3 195.1 677 1 523.00 296.6 1 026.30 1 253.30
Outpatient specialised 
treatment costs (2014)
217.3 94.6 385.2 662.7 323 636.7 572.9
Total average cost, per capita 
(2014)
1 252.7 533.7 1 756.3 3 248.1 1 250.4 3 323.8 2 788.5
Annual average costs, per 
capita (2013-14)
1 186.0 544.4 1 801.3 3 292.4 1 504.5 2 417.5 2 803.1
Men + Women
Number of clients 6 203 550 1 585 11 17 2 372
Hospitalisation costs (2013) 551.8 692.4 694.2 793.5 136.5 925.5 759.1
Drug prescription costs (2013) 131.8 152.4 328.6 1 331.20 560.6 483.5 985.2
Outpatient specialised 
treatment costs (2013)
262.2 317.7 263.3 364.3 430.9 182.5 335.6
Total cost, per capita (2013) 945.8 1 162.5 1 286.1 2 489.0 1 128.0 1 591.5 2 079.9
Hospitalisation costs (2014) 367 527.5 611.6 748.6 411.8 1 454.50 700.4
Drug prescription costs (2014) 151.7 186.6 434.3 1 405.90 847.1 886.4 1 066.80
Outpatient specialised 
treatment costs (2014)
136.8 356.4 243 470 468.2 488.6 406.9
Total cost, per capita (2014) 655.5 1 070.5 1 288.8 2 624.5 1 727.1 2 829.5 2 174.1
Annual average cost, per 
capita (2013-14)
800.7 1 116.5 1 287.5 2 556.7 1 427.5 2 210.5 2 127.0
Source: administrative data flows.
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I Comorbidity profiles
Each client’s comorbidity profile was created by chaining all 
the conditions to which he or she belongs.
Those conditions were identified according to the diagnosis 
code ICD-9-CM (from the hospital discharges data flow), 
the outpatient specialised treatment code (from the 
outpatients data flow), the co-payment fee exemption 
and the drug classes, by making use of either the ATC 
classification index or the DDD (from the drug prescriptions 
data flow) of the WHO.
As shown in the Methods section, this algorithm defines 
17 classifications with different orders of severity that 
were combined to define the comorbidity profile of 
each client. In particular, out of the 2 372 clients in drug 
treatment, only 1 373 clients were identified as drug 
addicted (‘Drug addiction’ label, alone or combined with 
other classifications) on the basis of their contacts with the 
SSN in 2013 and/or 2014. The remaining clients in drug 
treatment were identified as belonging to one or more of 
the other comorbidity classifications.
We hypothesise that the distribution of clients by 
comorbidity profile could be a possible explanation for the 
variability of costs in the same age class among men and 
women and within the same class of illicit drug used.
As shown in Table 7.3 (2), the most frequent profiles in both 
men and women were the ‘Residual’ (health conditions 
non-classified as chronic disease or pregnancy (3)), the 
‘Drug addiction (4)’ (as identified by some specific ICD-9-CM 
codes or DRGs, drug prescriptions and the co-payment 
(2) In Table 7.3 each subject is counted only once.
(3) Among the comorbidity profiles listed in Table 7.3, the only profiles that do 
not indicate chronic conditions are ‘Residual’ and ‘Pregnancy-Residual’. In 
the first case, patients were suffering from health conditions not classified 
as chronic disease, while, in the second, they had some contact with SSN 
because of pregnancy and other non-chronic health conditions.
(4) In Table 7.3, where a patient is classified as ‘Drug_addict’, it means that 
the algorithm of classification applied to administrative data flows identi-
fied the patient as drug addicted.
TABLE 7.3
Distribution of clients by comorbidity profiles
Co-morbidity profile (a) Men % Rank men Women % Rank women
Residual 605 30.9 1 106 25.8 1
Drug_addict- 361 18.4 2 58 14.1 3
Drug_addict-Residual 299 15.2 3 73 17.8 2
Drug_addict-HIV_AIDS-Residual 45 2.3 4 15 3.6 4
Drug_addict-Cardiovascular-Residual 42 2.1 5 6 1.5 9
Neuro-Residual 35 1.8 6 12 2.9 5
COPD-Residual 30 1.5 7 10 2.4 6
Gastro-Residual 30 1.5 8 7 1.7 7
Drug_addict-Gastro-Residual 25 1.3 9 5 1.2 11
Drug_addict-Neuro-Residual 24 1.2 10 7 1.7 8
Cardiovascular-Residual 20 1.0 11
Drug_addict-Cardiovascular-Gastro-Residual 17 0.9 12
Drug_addict-COPD-Residual 14 0.7 13
Drug_addict-Alcohol_addict-Residual 12 0.6 14 3 0.7 15
Cardiovascular-Gastro-Residual 11 0.6 15 3 0.7 16
Neuro 11 0.6 16
COPD 10 0.5 17
Drug_addict-HIV_AIDS-Gastro-Residual 6 1.5 10
Pregnancy-Residual 5 1.2 12
Drug_addict-Endometabol_dis-Residual 4 1.0 13
HIV_AIDS-Residual 4 1.0 14
Total 1 591 81.1 324 78.8
Other profiles 370 18.9 87 21.2
(a) See note 1 on page 85 for the definition of each category that co-occurs within each comorbidity profile.
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fee’s exemption code for drug addiction) and a combination 
of both. This indicated that the majority of clients with 
substance use disorders did not have other chronic 
conditions.
From the fourth position onwards, clients had comorbidity 
profiles that included HIV and AIDS, cardiovascular disease, 
neurological disorders and others.
I Effect of comorbidity on healthcare costs
The distribution of costs by comorbidity profile followed 
a different order. The first 10 profiles, sorted on the basis 
of per capita costs (Table 7.4), included 0.7 % of men who 
generated 7.8 % of costs (per capita value up to EUR 23 000/
year) and 2.9 % of women who generated 27 % of costs 
(per capita value about EUR 26 000/year). The ranking of 
comorbidity profiles differed between men and women.
To verify if the ‘Drug_addict’ label generated by the 
algorithm of classification could be efficient in identifying 
the real costs related to drug addiction condition, we 
focused on the drivers of costs among clients with and 
without the ‘Drug_addict’ label in their comorbidity profile.
Among men, the highest costs were associated with 
a single client aged 25, identified by SERT as a cannabis 
TABLE 7.4
Distribution of per capita costs (2013-14) by comorbidity profiles (first 10 sorted profiles) and gender
Rank Comorbidity profile No of 
clients
Total costs 
2013 + 2014
Average annual 
costs per 
capita (a)
M
en
1 Renal_insuf-Cardiovascular-Gastro-Residual 1 87 900 43 950.0
2
Drug_addict-Alcohol_addict-Cardiovascular-Gastro-Neuro-
Endometabol_dis-Residual
2 11 341 28 585.3
3
Drug_addict-HIV_AIDS-Neoplasm-Cardiovascular-COPD-Gastro-
Residual
1 50 877 25 438.5
4
Mental_dis-Drug_addict-HIV_AIDS-Cardiovascular-Gastro-Neuro-
Residual
1 49 203 24 601.5
5 Drug_addict-HIV_AIDS-COPD-Gastro-Neuro-Residual 1 45 714 22 857.0
6 Alcohol_addict-Cardiovascular-Gastro-Neuro-Endometabol_dis-Residual 1 41 446 20 723.0
7 Drug_addict-HIV_AIDS-COPD-Gastro-Residual 1 41 067 20 533.5
8 HIV_AIDS-COPD-Gastro-Neuro-Residual 1 36 235 18 117.5
9 HIV_AIDS-Neuro-Endometabol_dis-Residual 2 70 353 17 588.3
10 Drug_addict-HIV_AIDS-Diabetes-Residual 2 66 705 16 676.3
Profiles 1-10 13 (0.7 %) 603 8410 (7.8 %) 23 224.7
Other profiles 1 948 7 182 591 1 843.6
All profiles (2013 + 2014) 1 961 7 786 432 1 985.3
W
om
en
1
Transplant-HIV_AIDS-Diyabetes-Cardiovascular-Gastro-Endometabol_
disResidual
1 124 967 62 483.5
2
Drug_addict- Renal_insuf-HIV_AIDS-Cardiovascular-Gastro-Neuro-
Endometabol_disResidual
1 116 096 58 048.0
3 Drug_addict-HIV_AIDS-Cardiovascular-COPD-Residual 1 96 740 48 370.0
4 Drug_addict-HIV_AIDS-Neoplasm-Gastro-Neuro-Residual 1 48 401 24 200.5
5 Drug_addict-HIV_AIDS-COPD-Residual 1 37 127 18 563.5
6 Drug_addict-Alcohol_addict-Cardiovascular-Gastro-Residual 1 36 114 18 057.0
7 Mental_dis-Neuro-Residual 2 61 370 15 342.5
8 Drug_addict-HIV_AIDS-Cardiovascular-COPD-Gastro-Neuro-Residual 1 25 914 12 957.0
9 Drug_addict-HIV_AIDS-Cardiovascular-Gastro-Residual 2 51 338 12 834.5
10 HIV_AIDS-Cardiovascular-COPD-Neuro-Residual 1 24 495 12 247.5
Profiles 1-10 12 (2.9 %) 622 562 (27 %) 25 940.1
Other profiles 399 1 681 585 2 107.2
All profiles (2013 + 2014) 411 2 304 147 2 803.1
(a) Costs per capita are expressed as ‘average annual costs’ and were estimated by summing costs generated across two years (2013, 2014). This is possible 
because in Italy tariffs are fixed by law and did not change between 2013 and 2014.
INSIGHTS I Drug treatment expenditure: a methodological overview
90
user, who belonged to the ‘Renal_insuf-Cardiovascular-
Gastro-Residual’ profile. His profile did not include the 
‘Drug addiction’ classification.
Table 7.5 shows the specific drivers of cost by year 
for this client. In this case, hospitalisation costs, drug 
prescriptions and outpatient specialised treatments were 
clearly generated by the client’s comorbidities (other 
than cannabis disorders). This is in line with the absence 
of indications in data flows regarding his drug addiction 
status.
In contrast, the two clients in second position with the 
‘Drug_addict-Alcohol_addict-Cardiovascular-Gastro-Neuro-
Endometabol_dis-Residual’ profile showed drivers of costs 
more strictly related to their toxicological history (Table 
7.6a,b). Moreover, those clients, although sharing the same 
comorbidity profile, had very different per capita costs, due 
to the declining health status of the younger client.
TABLE 7.5
Focus on the client with the highest per capita cost among men: one client, male, 25 years old, cannabis
Type of costs Cost DRG code and description
Hospitalisation costs (2013) 2 548 089_ Simple pneumonia & pleurisy age > 17 with CC
233 145_ Other circulatory system diagnoses with CC
2 781
Drug prescription costs (2013) 782
Outpatient specialised treatment costs (2013) 37 639
Changed health status None
Hospitalisation costs (2014) 165 317_ Admit for renal dialysis
2 761 479_ Other vascular procedure without CC
2 761 479_ Other vascular procedure without CC
500 187_Dental extractions and repairs
3 208 315_ Other interventions on kidney & urinary tract
9 395
Drug prescription costs (2014) 32
Outpatient specialised treatment costs (2014) 37 271
Overall costs 2013 + 2014 87 900
TABLE 7.6a
Focus on the clients with the second highest per capita cost among men: one client, male, 42 years old, heroin
Type of costs Cost DRG code and description
Hospitalisation costs (2013) 3 977 202_ Cirrhosis and alcoholic hepatitis
3 310 089_ Simple pneumonia & pleurisy age > 17 with CC
3 977 202_ Cirrhosis and alcoholic hepatitis
11 264
Drug prescription costs (2013) 7 146
Outpatient specialised treatment costs (2013) 459
Changed health status + Transplant-Diabetes-
Hospitalisation costs (2014) 73 756 480_ Liver and/or intestine transplantation
73 756
Drug prescription costs (2014) 11 485
Outpatient specialised treatment costs (2014) 5 526
Overall costs 2013 + 2014 109 636
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I Substance use-related comorbidity healthcare costs
As a consequence of the possible overestimation of costs 
due to a limited correlation between addiction status and 
the healthcare demand generating the costs in Table 7.2, 
we decided to focus our analysis on those clients with 
a profile, from data flows, that included the ‘Drug addiction’ 
label (n = 1 424) alone or combined with other diagnoses 
such as alcohol disorders and/or HIV and AIDS and/or HCV 
or non-fatal suicide and/or overdose.
This choice derives from the assumption that, if clinicians 
put an indication of drug addiction status in the client’s 
medical record (‘Drug addiction’ label), which consequently 
appears in the data flows, the morbidity profile of that client 
will be highly related to the illicit drug use.
Table 7.7 shows the comparison of the costs associated 
with all clients in drug treatment (n = 2 372) and the costs 
related to those clients with a profile, from data flows, that 
include the ‘Drug addiction’ label. This last group of clients 
amounts to 60 % of total clients (59.4 % of men and 63 % 
of women) and their costs amount to 82 % of the overall 
cost of all clients under treatment.
Furthermore, per capita costs of clients with drug addiction 
as a diagnosis were 36.5 % higher than the average per 
capita costs of all clients. The distribution of costs by 
comorbidity profile is characterised by a high variability 
(mean per capita value: EUR 2 493 men, EUR 2 762 
women; range: EUR 26-28 585 men, EUR 66-62 483 
women).
I Substance use-related direct costs
As mentioned above, the costs attributable to substance 
use disorders also include the direct cost incurred by the 
territorial service, SERT. As shown in Table 7.8, these costs 
concern inpatient treatments for drug addiction (residential 
and semi-residential), outpatient treatments and laboratory 
tests directly provided by SERT.
Based on the analysis of medical records directly 
collected and managed by SERT, it is estimated that 
average per capita costs amounted to approximately 
EUR 660 for outpatient treatments, EUR 99 for laboratory 
tests and up to EUR 22 000 for inpatient treatments 
(Table 7.8).
TABLE 7.6b
Focus on clients with the second highest per capita cost among men: one client, male, 55 years old, cocaine
Type of costs Cost DRG code and description
Hospitalisation costs (2013)
2 838
523_ Abuse or dependence on alcohol/drugs without rehabilitation 
therapy, without CC
2 838
Drug prescription costs (2013) 255
Outpatient specialised treatment costs (2013) 872
Changed health status None
Drug prescription costs (2014)) 320
Outpatient specialised treatment costs (2014) 420
Overall costs 2013 + 2014 4 705
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TABLE 7.7
Comparison between the overall costs and those related to patients with a profile, from data flows, including ‘Drug 
addiction’ classification
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As shown in Table 7.8, the estimated per capita costs 
include a number of healthcare services. The total per 
capita cost depends on the combination of healthcare 
services provided, the individual addiction treatment of 
each client, and his or her pathological profile. As general 
values, the per capita costs (direct and indirect costs) 
ranged from EUR 3 544 to EUR 3 800 for those clients who 
did not benefit from inpatient treatments, while it ranged 
from EUR 25 827 to EUR 26 160 for those clients who 
entered an inpatient addiction treatment programme.
I Conclusions
Public expenditure on treatment for illicit drug disorders 
is an emerging field of investigation. In Italy, an estimation 
of the total amount of public resources spent on this 
specific field has become crucial, particularly in the light 
of the spending review imposed by the current economic 
situation. If, on the one hand, most of the national 
(Dipartimento Politiche Antidroga, 2014) and EU (Lievens 
et al., 2014) estimates produced in this area concern 
the costs borne for the treatment of individuals affected 
by drug use disorders, on the other hand, the analysis of 
the costs associated with the diagnostic profile of these 
subjects has not been examined in depth. Regional 
addiction treatment services (as well as central services) 
usually have a clear picture of costs directly related to their 
clients (staff costs, laboratory tests and others), while they 
have limited information about the total expenditure that 
their clients generate within the healthcare system for 
pathologies related to substance use disorders.
This study aimed to identify a method for estimating the 
healthcare costs of hospitalisation, outpatient specialised 
treatment and prescription drugs, attributable to 
a population of illicit substance users, taking into account 
the comorbidity profile of each client. The study provides 
interesting results on various levels.
First, as highlighted in previous studies (Lievens et al., 
2014), in order to be able to monitor public spending 
on treatment for substance use, it is essential to have 
a systematic and consistent registration of inpatient 
and outpatient data. In fact, the availability of high-
quality administrative data of a complementary nature 
and collected in a standardised manner improves the 
completeness of information.
Second, this study establishes criteria for identifying clients 
with substance use disorders, providing a method for 
isolating the comorbidity profiles that are best correlated 
with illicit drug use.
Applying these criteria showed that, although clients with 
evidence of drug addiction amount to 60 % of the total 
clients seen by addiction services, their costs add up to 
82 % of the costs of all clients in treatment. By inference, 
this amount could be considered the added financial 
burden on the healthcare system of comorbidities related 
to drug use.
TABLE 7.8
Estimated overall and per capita costs (EUR) including the item directly incurred by the territorial service, SERT
2013 2014
Costs directly 
incurred by the 
territorial service
Inpatient treatments for 
drug addiction (residential 
and semi-residential)
Number of clients 258 269
Overall costs 5 834 951.0 5 931 206.0
Per capita costs 22 616.0 22 049.0
Outpatient treatments 
directly provided by the 
territorial service
Number of clients 2 372
Overall costs 1 709 126.4 1 898 051.6
Per capita costs 720.5 800.2
Laboratory tests Number of clients 2 372
Overall costs 264 063.7 270 114.6
Per capita costs 111.3 113.9
Health administrative data estimate Number of clients 1 424
Hospitalisation costs (per capita) 936.6 945.3
Drug prescription costs (per capita) 1 506.4 1 543.5
Outpatient specialised treatment costs (per capita) 379.8 497.2
Subtotal 2 822.8 2 986.0
Total per capita costs excluding inpatient treatment 3 654.6 3 900.0
Total per capita costs including inpatient treatment 26 270.6 25 949.0
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Third, the translation of data and algorithms into 
meaningful information in the present study is inspired by 
the principle of efficiency (use of available data sources 
and semiautomatic querying activity).
A global analysis of the healthcare costs associated with 
treatments provided to illicit drug users, which includes 
client characteristics (age, gender and substance 
used) and their comorbidity profiles, is essential for 
a comprehensive evaluation and identification of more 
efficient pathways of care, which goes beyond only 
addiction treatment services activity. In particular, the 
inclusion of comorbidity in the analysis needs to be 
considered as a key element to better identify public 
expenditure attributable to substance use. By addressing 
an information gap still existing today, this could lead 
to a more comprehensive evaluation of treatment for 
substance abuse, thus allowing better planning and 
implementation of evidence-based policies, at both 
national and European levels.
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I Introduction
This study aims to estimate the costs of opioid substitution 
treatment (OST) in Italy, in 2012 and 2013, and to suggest 
a method that could be used to design macro-studies on 
the costs of these treatments, in order to provide input to 
cost-benefit and cost-effectiveness analyses. The study 
provides an example of a method to estimate public 
expenditure on OST, which may be used by researchers in 
other countries to provide a better understanding of the 
cost structure of OST in Europe, to improve the allocation of 
resources to more cost-effective therapies and, in the long 
term, to facilitate the evaluation of public policy in Europe. 
Last but not least, the costs of OST are a component of the 
social costs of opioid use.
I Background and context
In Italy, in 2013, 77.4 % of the total health spending was 
paid by the public sector (1). The public sector provides 
healthcare to people who use illicit substances free of 
charge. In 2013, drug-related healthcare was provided 
by a network of 645 public outpatient services, spread all 
over the national territory, and by 960 social rehabilitative 
public facilities accredited to provide semi-residential and 
residential care.
The reasons for focusing on OST in this analysis are four-
fold. First, opioid use is responsible for a disproportionate 
amount of morbidity and mortality related to drug use, 
in Italy and in Europe (EMCDDA, 2013). The literature 
confirms that opioids (mainly heroin) were the primary 
drug taken by more than 170 000 individuals accessing 
drug treatment in Europe in 2013: this represents 41 % of 
all reported treatment entrants (EMCDDA, 2015). Second, 
OST is the most commonly used and effective therapy for 
(1) https://data.oecd.org/healthres/health-spending.htm
treating opioid dependence, as flagged by the EMCDDA’s 
Best practice portal (2). Third, costs are a crucial component 
of treatment. Fourth, currently, there is still neither an 
updated estimate for these costs nor an agreement on 
a consistent method to estimate them either in Italy or in 
other European countries.
Medication for opioid dependence is an important part of 
chronic and comprehensive care. Substitution therapy in 
the management of opioid dependence is defined as ‘the 
administration under medical supervision of a prescribed 
psychoactive substance — pharmacologically related to the 
one producing dependence — to people with substance 
dependence, for achieving defined treatment aims (usually 
improved health and well-being)’ (WHO, 2004).
According to the EMCDDA’s best practice portal (3) and 
to the US Food and Drug Administration (FDA) (Chalk et 
al., 2013), methadone and buprenorphine are the most 
common medications used to treat opioid dependence, 
being used both as detoxification medications, which 
can suppress symptoms and curb cravings, and as 
maintenance medications, whereby the suppression of 
withdrawal and craving helps to reduce non-medical opioid 
use.
Since 1991, the most frequently prescribed OST 
medication in Italy was methadone — a full synthetic opioid 
agonist that acts on the same receptors as opiate drugs 
and therefore blocks the effects of heroin (Colombo et al., 
2003; Ministry of Health, 2008). Methadone maintenance 
treatment is safe and very effective in helping people 
to stop taking heroin, especially when combined with 
behavioural therapies or counselling and other supportive 
services (Colombo et al., 2003; World Health Organization, 
2004; Serpelloni et al., 2013). Buprenorphine was also 
introduced in Italy in 2000 — a partial agonist at μ-opioid 
receptors. Buprenorphine stops the compulsive need 
(2) http://www.emcdda.europa.eu/best-practice/treatment/opioid-users
(3) http://www.emcdda.europa.eu/best-practice/
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to use opioids and has a longer duration of action than 
methadone but without the side effects of the full agonists, 
i.e. the risk of respiratory depression, which is the primary 
cause of overdose (Colombo et al., 2003; WHO, 2004; 
Serpelloni et al., 2013).
At the European level, the economic evaluation of OST 
programmes has received increased attention recently. 
Understanding costs is important to policymakers 
because decisions about the provision of treatment, and 
its design, are best taken with a good understanding of 
the range of costs that public services may incur. Since 
the 2008 economic recession and the public austerity 
that followed, public expenditure on health has been 
substantially reduced in many European countries and 
there are concerns about the capacity to reduce costs 
further (EMCDDA, 2014). Addressing this information gap 
will have benefits for both decision-makers and treatment 
providers: the latter need accurate information on the costs 
of treatment provision in order to plan the allocation of 
resources, while decision-makers can use such information 
as a means of cost control (EMCDDA, 2011).
Over the period 2012-13, around 70 % of drug users in 
treatment in Italy (approximately 85 000 per year) were 
outpatients being treated for opioid abuse (as the primary 
drug) (4). Of these, over 90 % (approximately 80 000 
per year) were receiving pharmacological treatment, 
which accounts for a large proportion of the total cost of 
outpatient care. To date, the literature has focused mainly 
on the clinical aspects of these treatments, investigating 
their effectiveness and adverse drug reactions and 
interactions with other prescribed drug therapies (anti-HIV, 
anti-HCV) (Colombo et al., 2003).
A brief review of the literature summarises previous 
attempts to estimate these costs. In 1997, a study 
estimated the social costs of drug abuse, based upon 
a French population of drug users (Fenoglio et al., 2003). 
The authors used the ‘cost of illness’ method to estimate 
the economic cost of alcohol, tobacco and illicit drugs. 
Between 1995 and 2000, the National Treatment Outcome 
Research Study (NTORS) investigated treatment outcomes 
among drug users in the United Kingdom. It estimated 
costs and revealed detailed information on the pre-
treatment behaviours, problems and social circumstances 
of the cohort, and the operational characteristics of 
the treatment programmes and the interventions and, 
in particular, provided information about outcomes of 
treatment across a range of measures (Godfrey et al., 
(4) DAP, 2014. Note that there are significant differences between the num-
ber of clients who entered treatment for the first time and the number of 
clients who were already in treatment at the beginning of the year (40 % 
entered treatment for the first time, while 80 % were already in treatment 
at the beginning of the year).
2004). More recently, a study evaluated OST provided in 
Greece (Geitona et al., 2012), using the Greek Organization 
Against Drugs’ (OKANA’s) data for 2008. In Lithuania, an 
economic analysis of methadone substitution treatment 
was performed in the first six months of 2004, and the 
costs of providing outpatient methadone maintenance to 
opioid-dependent persons were estimated for the first time 
(Vanagas et al., 2010). In Spain, another study evaluated 
the economic impact of combined buprenorphine and 
naloxone, as an agonist opioid treatment for opiate 
dependence, on clients in different opioid treatment 
programmes (OTPs) (Martínez-Raga et al., 2010). These 
studies used different methodological approaches, data 
sources, cost definitions and inclusion criteria, which limits 
their comparability.
I Method
This study aims to present a method and to estimate 
the total annual health costs of OST for clients receiving 
methadone and buprenorphine during opioid treatment in 
Italy, paid by the general government. It neither estimates 
the ‘cost of illness’, because it does not estimate total costs 
incurred by society (the social costs), nor is it a cost-benefit 
analysis, because it does not estimate the benefits of OST 
or compare it with alternative interventions.
Estimates for the healthcare costs of OST can take two 
approaches: the ‘bottom-up’ or the ‘top-down’ approach. 
The top-down approach disentangles from the total costs 
of a broad treatment programme the costs of a particular 
component of this programme (e.g. it isolates the costs of 
the OST from the total costs of treating alcohol, drugs and 
gambling). An advantage of using the top-down method is 
that it guarantees that all known costs attributable to the 
service are considered (EMCDDA, 2011). However, using 
this method may often make it difficult to differentiate 
some specific components of costs for similar types of 
treatment.
The bottom-up approach, conversely, is based on the 
unit cost of services provided. It starts by estimating the 
cost of each unit of service provided and then estimates 
these costs applied to the whole population treated. The 
bottom-up method usually allows a detailed analysis of 
the specific components of costs, but it also requires 
extensive information systems that are not always available 
(EMCDDA, 2011).
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FIGURE 8.1
Italian regions and autonomous provinces included in 
the study
Covered
Not covered
In this study, the authors applied a top-down approach. 
This option was based on a pragmatic analysis of the 
available data. Data on both total public expenditure 
on health addiction services and treatment provision 
(allowing disaggregation of expenditure on different types 
of treatments) were available for the majority of the Italian 
territory. As remarked by Vander Laenen et al. (2009), 
a repartition key is commonly used to isolate a specific 
component of costs. Therefore, the authors disentangled 
public expenditure on OST from public expenditure on 
broad addiction services (drugs, alcohol and gambling) 
using a repartition key based on data for expenditure on 
different types of treatments (pharmacological, integrated, 
psychosocial).
I Data sources and information flows
In order to define the ‘repartition key system’, out of the 
21 Italian regions, data referring to 15 Italian regions and 
autonomous provinces were used over the period 2012-13 
(Figure 8.1). Data were available for the total number of 
clients of the Italian addiction services (5) and public health 
expenditure on addiction treatments.
Data on the number of clients treated by the 
addiction services
In Italy, outpatient addiction services treat drug and alcohol 
users, as well as clients with problem gambling. There 
(5) In 2012 and 2013, these regions treated close to 85 % of the total number 
of clients of the Italian addiction services.
are different types of treatment available for drug users: 
pharmacological treatment (substitution treatment with 
methadone or buprenorphine), psychosocial treatment and 
integrated treatment (pharmacological and psychosocial). 
For alcohol users and clients with gambling problems, 
psychosocial or integrated treatments are usually provided.
Over the period 2012-13, all clients of the addiction 
services (217 493 clients in 2012 and 216 130 clients 
in 2013) were classified by type of treatment received 
(pharmacological, integrated or psychosocial). Data 
and the classification of clients treated for drug misuse 
were provided by the National Information System for 
Drug Dependencies, Sistema Informativo Nazionale per 
le Dipendenze (SIND, 2010; Department for Anti-Drug 
Policies, 2011). The classification of clients treated for 
alcohol misuse was provided by the Ministry of Health, 
and data were available for the period 2010-12 (Ministry 
of Health, 2012). There were no data available for alcohol 
users in 2013, so the number of treated alcohol users 
was estimated based on the data from the previous three 
years (2010, 2011 and 2012). Finally, data on gamblers 
undergoing treatment (representing fewer than 5 % of all 
clients of the addiction services) were not available by 
treatment typology, and the results of a national pilot study 
conducted in 2007 were used (Rascazzo and Reynaudo, 
2007).
Data for public expenditure on addiction treatment 
In Italy, public healthcare expenditure is reported in 
accordance with national legislation (6) and, therefore, 
data on public expenditure are collected according 
to the criteria defined by local health authorities and 
hospitals (7). The data include six main macro-categories of 
annual costs: (1) consumption of goods and services; (2) 
personnel; (3) depreciation; (4) other operating expenses; 
(5) extraordinary expenses; and (6) other costs. Data 
for public health expenditure on outpatient treatment of 
addictions were provided by the authorities of the regional 
and autonomous provinces to the Department for Anti-drug 
Policies (2013, 2014). The strengths of these data are that, 
first, they apply a uniform classification of costs (standard 
criteria) and, second, datasets are complete. The main 
weakness is that the data are not disaggregated by type of 
addiction. Furthermore, in Italy not all addiction services 
supply information to the Department for Anti-drug Policies. 
In two regions, such services report to the Departments 
of Psychiatry. In these cases, the drug-related healthcare 
expenditure was extracted from the public healthcare 
(6) Ministry of Health, 2007. See D.lgs. 502/92 and the ‘Intesa Stato Regioni’ 
of 23/03/2005, article 3, subsection 7.
(7) http://www.salute.gov.it
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accounts of psychiatric centres, based on the personnel 
employed, for psychiatric patients and pathological 
addiction patients.
Modelling repartition keys
The data available are total public health expenditure 
on the treatment of addictions (drug use, alcohol and 
gambling) (8). Therefore, the authors modelled a repartition 
key to isolate spending on OST from public expenditure 
on health. The approach used had four main steps. The 
first step aimed to estimate public expenditure on OST 
by person a year (per person-year), namely the average 
number of days spent by the public health system 
treating each type of addiction client. The average time 
estimated took into account both the different types of OST 
provided — pharmacological, integrated or psychosocial — 
and the type of medicine — methadone or buprenorphine. 
Second, the authors computed the average cost of 
personnel and purchase costs of drugs administered, in 
person-years, by type of client (drug user, alcohol user, 
gambler), by type of treatment and by medicine. The third 
step estimated the repartition keys that were applied to 
each Italian region to extrapolate the public expenditure on 
OST from the total expenditure on addictions. Finally, the 
authors estimated the average costs of treating drug users 
(in person-years) by type of client (drug user, alcohol user, 
gambler), type of treatment (pharmacological, integrated 
or psychosocial) and type of medicine (methadone or 
buprenorphine). These four steps are detailed in the 
following sections.
The model
The four steps applied to estimate the costs of OST are 
depicted here.
Step 1 — Average length of treatment per client per year
The study estimated the average annual public 
expenditure on OST (methadone and buprenorphine 
in either pharmacological or integrated treatment) per 
outpatient client, over the period 2012-13. To compute 
these averages, clients were defined by a standard unit 
(treatment per year and per person).
(8) Information on public expenditure on the treatment of addictions was pro-
vided by the Italian regional governments (from local health authorities’ 
accounts).
For each type of client (addicted to drugs, alcohol 
or gambling) and for each treatment typology 
(pharmacological, integrated, psychosocial), the number 
of clients was converted into person-years by applying the 
following formula:
  (8.1)
where:
t = person-year by client and by treatment;
i  = type of client (drug user, alcohol user, gambler);
j = type of treatment (pharmacological, integrated, 
psychosocial);
v = type of pharmacological treatment (methadone or 
buprenorphine), only if j is equal to pharmacological or 
integrated;
d = duration of the treatment, in days;
s = client (1, …, nij).
nijv = number of client by type of client (i) type of treatment 
(j) and type of pharmacological treatment (v).
Data for the duration of drug and alcohol treatment come 
from the SIND (109 427 drug clients in 2012 and 118 443 
in 2013; 4 524 alcohol clients in 2012 and 5 525 in 2013). 
The data show that the average length of treatment 
(integrated and psychosocial) of alcohol users does not 
differ much from that of drug users (integrated 25.0 days 
versus 26.4 days, respectively; psychosocial 38.4 days 
versus 37.2 days, respectively). Concerning pathological 
gamblers, specific information on the average duration 
of treatment is not available. Therefore, coefficients were 
estimated as the arithmetic mean of the average length of 
alcohol and drug treatment. Given the small percentage 
that gamblers represented of the total number of clients 
treated (close to 5 %), the uncertainty introduced into 
estimates by this assumption is acceptable.
Table 8.1 presents data for the average time and unit 
‘partial costs’ of different types of services (medical, 
nursing, psychological, etc.) provided to drug users. The 
SIND (2010) provided data for the number of consultations 
that drug and alcohol clients received in the period 2012-
13, for each type of drug treatment and client.
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Step 2 — Average costs, per client per year
Based on these data, the product of the average cost of 
each type of service and the length of service provided 
gives the average ‘partial cost’ of different types of 
consultation. By adding the ‘partial costs’ of services, the 
authors obtain the average ‘partial cost’ of drug treatment:
  (8.2)
where:
c = average cost of personnel, in person-years, by treatment 
typology;
p = number of consultations provided;
e = average duration of consultations provided, in minutes;
f = average cost (per minute) of personnel by type of 
consultation provided;
t = person-year by treatment typology;
j = type of treatment (pharmacological, integrated, 
psychosocial);
k = type of consultation provided (1, …, n);
s = drug, alcohol user (1, …, nj);
d = drug user;
a = alcohol user
nj = number of clients by type of treatment (j)
m = total number of consultations.
The costs of treating gamblers were extrapolated. The 
costs of drugs (methadone and buprenorphine for drug 
users and disulfiram for alcohol users) administered in the 
pharmacological treatment and the integrated treatment 
were added, as shown in Table 8.1. The average cost per 
millligram of drugs administered (Colombo et al., 2003; 
Williams, 2005; Hunter and Ochoa, 2006; Serpelloni and 
Gomma, 2006) was multiplied by the average number 
of doses for each administration and by the number of 
administrations, in the reference period:
TABLE 8.1
Types of drug treatment: services, length of service provision and ‘partial costs’ (2012-13)
Pharmacological treatment Integrated treatment Psychosocial treatment
Services provided Average 
time 
(minutes) 
(a)
Average 
unit cost 
(EUR per 
minute) 
(b)
Services provided Average 
time 
(minutes) (a)
Average 
unit cost 
(EUR per 
minute) 
(b)
Services provided Average 
time 
(minutes) (a)
Average 
unit cost 
(EUR per 
minute)
(b)
Clinical clients’ 
reports
40 0.55
Clinical clients’ 
reports
40 0.55
Clinical clients’ 
reports
40 0.55
Visits 45 0.55 Visits 45 0.55 Visits 45 0.55
Examinations and 
clinical procedures
10 0.40
Prevention
meetings
30 0.55
Prevention
meetings
30 0.55
Drug administration 7 0.40
Assistance
meetings
60 0.55
Assistance
meetings
60 0.55
Prevention 
interventions
30 0.40
Prevention 
interventions
30 0.40
Examinations 
and clinical 
procedures
10 0.40
Examinations and 
clinical procedures
10 0.40
Drug 
administration
7 0.40
Psychotherapeutic 
intervention
60 0.55
Psychotherapeutic 
intervention
60 0.55
Socio-educational 
intervention
60 0.40
Socio-educational 
intervention
60 0.40
Psychological 
examination
90 0.55
Psychological 
examination
90 0.55 Transferring clients 120 0.40
Transferring 
clients
120 0.40
Preparation of 
the therapeutic 
programme
45 0.55
Preparation of 
the therapeutic 
programme
45 0.55
Sources: (a) Ministry of Health and Ministry of Welfare, Regions and Autonomous Provinces, 2004; (b) Ministry for Employment, 2013.
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  (8.3)
where:
γ = average cost of drugs administered in person-years, by 
treatment typology;
u = number of administrations by type of drug;
y = mean dose of drug administered, by type of drug;
z = average cost (per mg) of drug administered, by type of 
drug;
t = person-years by treatment typology;
j = type of treatment (pharmacological, integrated);
v = type of drug administered (methadone, buprenorphine);
s = drug, alcohol user (1, …, nj);
d = drug user;
a = alcohol user.
njv = number of client by type of treatment (j) and type of 
drug administered (v).
This method was not applied to the costs of treating 
pathological gamblers, because the data available were 
aggregated. Therefore, the average cost of personnel and 
purchase costs of drugs administered, in person-years, by 
type of client and treatment typology, was defined as:
  (8.4)
where:
w = weight for costs (by type of client, treatment typology, 
type of pharmacological treatment);
c = average personnel cost in person-years by type of client, 
treatment typology, type of pharmacological treatment;
γ = average drug administration cost in person-years by 
type of client, treatment typology, type of pharmacological 
treatment;
i = type of client (drug user, alcohol user, gambler);
j = type of treatment (pharmacological, integrated, 
psychosocial);
v = type of pharmacological treatment (methadone or 
buprenorphine), only if j is equal to pharmacological or 
integrated treatment.
Step 3 — The repartition key
The repartition key applied to each Italian region, to 
disentangle public expenditure on OST from total public 
expenditure on addictions, is obtained by applying the 
weights for each type of addiction treatment (equation 8.4) 
to the clients in treatment in each region (in person-years) 
using the following formula:
  (8.5)
and v≠0 if j equal to pharmacological or integrated
where:
δ = percentage of the cost relative to the client’s treatment, 
i, for the treatment, j, and the pharmacological treatment, v;
w = weight of the cost of treatment;
t = person-years by type of client and treatment typology;
i = type of client (drug user, alcohol user, gambler);
j = type of treatment (pharmacological, integrated, 
psychosocial);
v = type of pharmacological treatment (methadone or 
buprenorphine), only if j is equal to pharmacological or 
integrated treatment;
R = region (1, …, 15).
Step 4 — The top-down methodology
Based on the repartition key, it is possible then to estimate 
total costs of treating drug users (in person-years), 
separately for methadone and buprenorphine, using the 
following formula:
  (8.6)
and v ≠ 0 if j is equal to pharmacological or integrated 
treatment
where:
c = average treatment cost in person-years, by type of 
client and type of pharmacological treatment, if j is equal to 
pharmacological or integrated treatment;
C = total cost of the addiction services by region and 
reference year (2012 and 2013);
δ = percentage of the cost relative to the client’s treatment, 
i, for the treatment, j, and the pharmacological treatment, v;
i = type of client (drug user, alcohol user, gambler);
j = type of treatment (pharmacological, integrated, 
psychosocial);
v = type of pharmacological treatment (methadone or 
buprenorphine), only if j is equal to pharmacological or 
integrated treatment;
R = region (1, …, 15).
CHAPTER 8 I Public expenditure on opioid substitution treatment in Italy
103
I Results 
In this section, the repartition key parameters are applied to 
the total public expenditure on addiction treatment, based 
on data on the total costs of treating addiction provided by 
the Italian regional and local governments. In this way, the 
authors estimate the average annual cost of the OST in 
Italy in 2012 and 2013.
Tables 8.2 and 8.3 present the data for the total number 
of outpatients by region, type of addiction (drugs, alcohol 
or gambling) and type of treatment (pharmacological, 
psychosocial or integrated treatment) in 2012 and 2013. 
The data concern 15 Italian regions (out of 21), covering 
92.5 % of drug users in treatment, 67.5 % of alcohol users 
in treatment and 87.7 % of gamblers in treatment. The 
last columns of Tables 8.2 and 8.3 show the ‘partial public 
expenditure’ on addiction services in 2012 and 2013 (these 
values include only public expenditure on personnel and 
medicines).
On average, the majority of addiction services’ clients 
were receiving treatment for drug use (about 70 % of the 
total). However, there was considerable variability between 
regions (for instance, only 43.4 % of the total were drug 
users in Friuli-Venezia Giulia, while they represented 
95.4 % of the total in Puglia). Large variability is observed 
also in the type of treatment provided to drug users: in six 
regions (Lombardy, Marche, Piedmont, Puglia, Sicily and 
Tuscany) drug users were treated mainly with psychosocial 
treatment, while in seven other regions (Abruzzo, Basilicata, 
Emilia Romagna, Lazio, Liguria, Umbria and Veneto) 
drug users were mainly in integrated treatment. Only 
in Campania were most drug users in pharmacological 
treatment.
TABLE 8.2
Number of clients and costs in 15 Italian regions, 2012
Region Drug users Alcohol users Pathological gamblers Total
users
Partial costs
(EUR)
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Abruzzo 519 1 911 1 564 3 994 215 883 1 098 63 44 107 5 199 11 000 000
Basilicata 260 734 410 1 404 122 397 519 12 8 20 1 943 6 259 000
Campania 10 640 2 991 2 306 15 937 870 1 874 2 744 273 189 462 19 143 49 026 089
Emilia 
Romagna
432 7 636 4 967 13 035 2 634 2 887 5 521 526 309 834 19 390 74 392 333
Friuli-Venezia 
Giulia
230 1 475 1 468 3 173 533 3 386 3 919 132 92 224 7 316 19 061 617
Lazio 1 249 7 837 6 067 15 153 534 1 438 1 972 140 97 237 17 362 55 000 000
Liguria 653 3 496 2 961 7 110 776 1 121 1 897 109 75 184 9 191 24 395 423
Lombardy 935 4 327 12 926 18 188 2 538 8 895 11 433 871 606 1 477 31 098 67 505 000
Marche 355 1 315 3 323 4 993 354 1 075 1 429 70 49 119 6 541 16 352 000
Piedmont 518 1 350 7 879 9 747 2 069 5 455 7 524 700 486 1 186 18 457 70 000 000
Puglia 3 872 4 682 6 631 15 185 75 320 395 197 137 334 15 914 55 178 000
Sicily 772 4 624 5 545 10 941 816 2 027 2 843 352 244 596 14 380 60 000 000
Tuscany 1 252 6 391 10 305 17 948 1 885 3 441 5 326 124 177 301 23 575 58 544 000
Umbria 890 1 492 701 3 083 418 2 145 2 563 31 11 42 5 688 17 237 690
Veneto 1 808 5 598 4 453 11 859 2 512 7 264 9 776 389 271 660 22 295 50 892 861
Total 24 385 55 859 71 506 151 750 16 351 42 608 58 959 3 989 2 795 6 784 217 493 634 844 013
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I  Average cost by type of addiction and treatment (costs of personnel and medicines only)
Taking ‘partial costs’ per client into account, Table 8.4 shows 
that integrated pharmacological treatment is always more 
expensive (comparing dependence on drugs, alcohol or 
gambling), while pharmacological treatment is the cheapest. 
In 2012 and 2013, within pharmacological treatment, the 
average costs of methadone treatment ranged between 
EUR 360 and EUR 1 384 per client per year compared with 
an average of EUR 482 to EUR 1 432 for treatment with 
buprenorphine, as shown in Figure 8.2. Indeed, comparing 
the average cost of pharmacological treatments shows that 
the costs of administering methadone are, most of the time, 
lower than those of administering buprenorphine, although 
this is not statistically significant. This corroborates the 
results of previous studies (Colombo et al., 2003; Serpelloni 
and Gomma, 2006).
However, within integrated treatment, methadone 
therapy has higher average ‘partial costs’ that are more 
variable than those for buprenorphine therapy (Table 
8.4). The higher average ‘partial cost’ is attributable to the 
greater number of methadone administrations and the 
greater number of medical and psychological services 
(psychotherapeutic interventions and psychological 
examinations) provided to clients treated with methadone. 
On the contrary, clients treated with buprenorphine 
received a greater number of prevention services and 
socio-educational interventions. These facts, first, reveal the 
more clinical complexity of clients treated with methadone 
resulting in a greater variability in the average ‘partial 
costs’ estimated in person-years and, second, reflect the 
propensity to administer buprenorphine to the youngest 
clients (Serpelloni et al., 2013), who are better engaged in 
re-employment assistance programmes.
Table 8.4 shows also that expenditure on treating alcohol-
related problems is higher than that on treating drug-
related problems — on average, per client, taking only 
the costs of medicines and personnel into account. This 
difference is more marked in integrated therapy. This is due 
to the higher costs of the medicines used to treat alcohol 
users than those used to treat drug users, as the costs of 
the other services provided as part of integrated treatment 
are almost identical.
TABLE 8.3
Number of clients and costs in 15 Italian regions, 2013
Region Drug users Alcoholics Pathological gamblers Total
users
Partial costs
(EUR)
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Abruzzo 59 2 601 1 233 3 893 204 948 1 152 103 71 174 5 219 11 084 766
Basilicata 309 726 330 1 365 107 411 518 42 30 72 1 955 7 421 566
Campania 8 746 3 757 2 756 15 259 1 038 2 274 3 312 354 246 600 19 171 48 381 061
Emilia 
Romagna
501 7 493 5 041 13 035 1 572 1 804 3 376 1 101 718 1 819 18 230 70 401 810
Friuli-
Venezia 
Giulia
314 1 788 1 170 3 272 280 1 989 2 269 188 131 319 5 860 16 336 033
Lazio 1 764 8 011 8 524 18 299 631 1 701 2 332 182 126 308 20 939 59 245 699
Liguria 327 3 050 2 669 6 046 811 1 064 1 875 130 90 220 8 141 21 667 527
Lombardy 2 296 4 087 13 436 19 819 2 208 8 084 10 292 1 115 774 1 889 32 000 71 248 014
Marche 243 903 2 282 3 428 262 837 1 099 142 99 241 4 768 13 202 546
Piedmont 649 1 693 9 367 11 709 2 076 5 728 7 804 888 618 1 506 21 019 82 556 513
Puglia 3 305 4 615 7 412 15 332 70 320 390 316 219 535 16 257 54 524 230
Sicily 570 3 643 3 413 7 626 732 1 800 2 532 619 430 1 049 11 207 49 788 495
Tuscany 1 281 6 580 10 552 18 413 2 330 5 033 7 363 194 163 357 26 133 65 988 601
Umbria 918 1 440 686 3 044 465 2 439 2 904 46 10 56 6 004 18 425 388
Veneto 2 329 5 369 4 043 11 741 1 464 4 687 6 151 788 547 1 335 19 227 44 989 402
Total 23 611 55 756 72 914 152 281 14 250 39 119 53 369 6 208 4 272 10 480 216 130 635 261 651
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I Total costs
In 2013, in the 15 Italian regions considered, public 
expenditure on OST represented about half of the spending 
on addiction services (55.8 % in 2012 and 55.1 % in 2013 – 
Table 8.5). The high proportion of spending on OST is due 
to the greater number of drug users in treatment and, in 
particular, to the greater number of drug users receiving 
pharmacological integrated treatment than alcohol users.
In order to estimate public spending on OST for the whole 
Italian territory, it was assumed that the clients from the 
six regions (excluded from the available database) had an 
average total cost per person-year that was not significantly 
different from the average cost for the 15 Italian regions 
with data. Table 8.6 presents estimates for public 
expenditure in Italy in 2012 and 2013.
FIGURE 8.2
‘Partial costs’ per person-year, type of addiction and treatment typology (euros), 2012-13
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TABLE 8.4
‘Partial costs’ per client, by type of client and treatment typology (euros), 2012 and 2013
Drug users Alcohol users Pathological gamblers
Pharmacological treatment Integrated treatment Psychosocial 
treatment
Integrated 
treatment
Psychosocial 
treatment
Integrated 
treatment
Psychosocial 
treatmentMethadone Buprenorphine Methadone Buprenorphine
Total 822 853 1 973 1 721 1 092 2 359 1 035 2 004 1 092
Minimum 360 482 1 206 1 343 632 1 421 354 1 252 632
Maximum 1 384 1 432 3 443 2 502 1 697 4 000 2 001 3 477 1 697
SD 277 302 553 343 280 792 421 557 280
TABLE 8.5
Total costs by type of client (percentage of total and cost in euros), 2012-13
OST (drug users) Other treatments 
(drug users)
Alcohol users Gamblers Total
Costs (% of the total cost of addiction treatment)
Total 15 regions (2012) 55.8 15.0 25.1 4.1 100
Total 15 regions (2013) 55.1 16.0 22.5 6.4 100
Costs (EUR)
Total 15 regions (2012) 354 495 749 95 438 545 159 086 976 25 822 743 634 844 013
Total 15 regions (2013) 349 843 517 101 996 094 143 058 050 40 363 991 635 261 651
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In Italy, public expenditure on outpatient care for clients 
with addiction problems was EUR 683.8 million and 
EUR 688.5 million in 2012 and 2013, respectively. These 
costs represented 0.044 % of the Italian GDP in both 
years. Estimated public expenditure on OST amounted to 
EUR 371.8 million in 2012 and EUR 368.1 million in 2013 
(0.024 % of GDP in 2012 and 2013). These estimates 
may be compared with a set of totally different estimates, 
namely those for public expenditure on drug law offenders 
in Italian prisons. Although they are not comparable, 
they may provide a benchmark for the proportion of the 
GDP that different drug-related interventions represent. 
For instance, the EMCDDA (2014) estimates that public 
expenditure on drug law offenders in prison represented 
between 0.041 % and 0.082 % of GDP over the period 
2000-10. As shown in Table 8.6, the 2009-10 data related 
to the public expenditure on drug law offenders in prison 
increased (0.041 % of GDP in 2009; 0.047 % of GDP in 
2010), whereas, over the period 2011-12, drug-related 
public expenditure fell (0.105 % of GDP in 2011; 0.099 % of 
GDP in 2012).
I Conclusions
Efforts to quantify expenditure on drug treatment in 
Europe are still at an early stage (EMCDDA, 2011). This 
study constitutes the first detailed analysis that aimed to 
disaggregate public expenditure on OST in Italy from total 
expenditure on addiction services. In Italy, the majority of 
the addiction services treat different types of users (drug 
users, alcohol users, gamblers). It is not always possible 
to calculate costs for each client type, because of the 
absence of analytical accounting systems. In this study 
the authors present a methodology for extracting the costs 
of OST, applying a common method to isolate a specific 
component of the costs: the repartition key (Vander Laenen 
et al., 2009). Therefore, the authors disentangled public 
expenditure on OST from public expenditure on broad 
addiction services (drugs, alcohol and gambling), using 
a repartition key based on data for the expenditure on 
different types of treatments (pharmacological, integrated, 
psychosocial).
The availability of reliable data, compiled with a well-
defined methodology across most of the country, and the 
use of a consolidated and transparent methodology are 
essential tools to estimate public spending. However, until 
now, in Europe, there have been relatively few attempts to 
provide this type of estimate. Consequently, comparing our 
results with other European studies is not possible. The 
few other studies available used a different methodology 
and type of data and their definitions of expenditure and 
inclusion criteria were too different to allow a meaningful 
comparison.
This study estimated Italy’s public expenditure on OST. To 
achieve this, first, the study estimated public expenditure 
on OST per client per year, taking into account the ‘partial 
costs’ accounting for spending on medicines and personnel 
(because there are detailed cost data only for these items). 
Second, the study took into account other available studies 
on the costs of treating alcohol dependence. Third, the 
study assumed average parameters to estimate the costs 
of treating clients dependent on gambling. Based on these, 
the proportions of total public spending on addiction 
treatment that was spent on drug, alcohol and gambling 
treatment was estimated for each of the 15 Italian regions 
for which data were available. These proportions were 
then applied as key coefficients to total public spending 
on the treatment of addictions by region to the 15 regions 
with data — representing 85 % of clients being treated for 
addiction. Taking into account the annual average cost per 
client from these 15 regions and the number of clients in 
the other six regions (with no data on costs), the authors 
estimated public spending for the whole country.
Estimates suggest that public spending on OST amounted 
to EUR 371.8 million and EUR 368.1 million, in 2012 and 
2013, respectively, in Italy. Public expenditure on OST 
represented 0.024 % of the Italian GDP and close to 50 % 
of the total spending on addiction in Italy, in those years.
TABLE 8.6
Public expenditure in Italy (euros and percentage of GDP)
Year GDP (a) ADD
Addiction 
treatment
OST Addiction 
treatment
OST Drug law 
offenders in 
prison (b)
Drug-related 
public 
expenditure (c)
EUR (million) (% GDP)
2012 1 566 911.6 683.8 371.8 0.044 0.024 0.041 0.105
2013 1 560 023.8 688.5 368.1 0.044 0.024 0.047 0.099
Sources: (a) Eurostat; (b) EMCDDA (2014), data concern 2009 and 2010; (c) Relazione al Parlamento sullo stato delle tossicodipendenze in Italia — Presidency of 
the Council of Ministers (data 2011-12).
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A more detailed analysis of the results shows that different 
types of OST implied different costs. Estimates suggest 
that, per client, public spending on integrated OST (using 
either methadone or buprenorphine) is, on average, higher 
than public spending on pharmacological treatment for 
any of the three addictions analysed. The average public 
spending on pharmacological treatment (per person per 
year) is about half of the spending on integrated OST (for 
both methadone and buprenorphine).
These results are in line with those obtained for Spain by 
Martínez-Raga et al. (2010). Those authors concluded 
that integrated psychosocial and pharmacological 
treatment (combined buprenorphine and naloxone) 
treatment was significantly more expensive than agonist 
opioid treatments. There are not many other studies in 
Europe comparable to the current one because most of 
the economic evaluations of OST focused on economic 
benefits, related to the reduction of either criminal 
behaviours or social harms inflicted on the victims of drug-
related crime (Godfrey et al., 2004; Vanagas et al., 2010; 
Geitona et al., 2012).
This study also concluded that the costs of 
pharmacological OST, using either methadone or 
buprenorphine, do not significantly differ. An economic 
evaluation of methadone versus buprenorphine in OST in 
the United Kingdom (Maas et al., 2013) also found that 
the covariate-adjusted mean of total costs did not differ 
significantly in a pharmacological treatment with either 
methadone or buprenorphine.
Finally, this study also estimated the percentage of 
Italy’s GDP that the total costs of addiction treatments 
(drugs, alcohol and gambling) represented in the period 
2012-13. These costs represented 0.04 % of Italy’s 
GDP in both years. Postma (2006) found that, in some 
European countries (Belgium, Spain, France and Austria), 
the total costs of drug treatment represented between 
0.07 % (in Spain) and 0.09 % (in Belgium) of the GDP. 
Notwithstanding the fact that these European studies used 
different methods to estimate costs and concern different 
years, our findings seem to be in line with them.
The main strengths of this study are its wide data coverage 
and the availability of national standards for data collection. 
The annual availability of data on types of treatment and 
services provided, as well as socio-demographic data, 
the primary drug used, and other information for 175 000 
clients, for two consecutive years allowed a detailed 
analysis of the structure of the costs of providing addiction 
treatment. Furthermore, the large size of the samples 
allowed the calculation of reliable and robust estimates 
for the average costs of treatment by type of treatment. 
Another strength is the availability of detailed data on 
public expenditure on healthcare for the addiction services.
The main limitations of this study are also related to data. 
The first concerns some recently introduced restrictions 
on the use of clients’ information by the Italian addiction 
services. This limitation has reduced the degree of data 
coverage and therefore of data completeness. Another 
limitation is the absence of an identical information 
system for alcohol users and gamblers, which requires 
estimation of parameters and may reduce the accuracy of 
estimates. The third limitation concerns the fact that not all 
of the Italian addiction services are organised in separate 
departments; in some regions these services are part of 
the Departments of Psychiatry. In these cases, healthcare 
expenditure on clients receiving addiction treatment was 
estimated with data from expenditure on psychiatric 
patients.
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I Introduction
Drug policy interventions can be studied within a single 
country (e.g. prevention interventions in different secondary 
school classrooms) and many important dimensions of 
policy operate at the national level. Nevertheless, making 
cross-national comparisons of policies and problem 
severity is important and there is a growing body of 
literature on cross-country comparisons of health policy 
(Cacace et al., 2013). Undertaking a cross-country 
comparison in health policy serves three purposes: learning 
about national policies; learning why they take the forms 
they do; and learning lessons from these policy analyses 
(for application in other countries) (Marmor et al., 2005). 
These comparative studies have also gained attention 
from drug policy analysts. Nevertheless, public expenditure 
studies on drug policy are confronted with a set of generic 
problems such as lack of available data, differences 
in methodology and comparability problems between 
countries (EMCDDA, 2014a; Lievens et al., 2012; Reuter, 
2006; Ritter, 2007).
In order to move the study of public expenditure on drug 
policy forward, this chapter investigates the possibility 
of conducting an EU cross-country comparison of 
government spending on drug treatment using a uniform 
methodology. Given the paradigm of drug policy as 
a resource allocation problem (Caulkins, 2004), the focus 
lies on public expenditure. For McDonald (2011), this 
resource allocation is the most powerful instrument of 
government policy. Moreover, public expenditure analysis 
has been acknowledged as an important step for the 
economic evaluation of drug policy (EMCDDA, 2008; 
Vander Laenen et al., 2008). A cross-country comparison 
makes it possible to view the different options in drug 
policy and explore the correlation between different drug 
policies and public expenditure on the various options. 
Furthermore, a comparison could stimulate individual 
countries to measure the cost-efficiency of public policy, 
for example, if the treatment expenditure per problem drug 
user is much higher in one country than other countries 
(Reuter, 2006).
Since the beginning of the 21st century, public expenditure 
studies on drug policy (including drug treatment) have 
been conducted in Australia, Belgium, France, Germany, 
Luxembourg, the Netherlands, and Sweden, among other 
countries (De Ruyver et al., 2004, 2007; Kopp and Fenoglio, 
2003, 2006; Moore, 2008; Mostardt et al., 2010; Origer, 
2002; Postma, 2004; Ramstedt, 2006; Rigter, 2006; Ritter 
et al., 2015). These single-country studies used different 
concepts and definitions to define the term ‘public 
expenditure’, and the conceptual framework influences 
what counts as public expenditure for drug policy (Vander 
Laenen et al., 2008). The main objective of drug-related 
public expenditure is to finance drug policy interventions 
directly. Some public expenditure studies (e.g. Mostardt et 
al., 2010; Postma, 2004; Ramstedt, 2006; Rigter, 2006), 
however, include a certain degree of expenditures related 
to the consequences of drug use. For example, Mostardt 
et al. (2010) includes spending on treatment of infections 
contracted through the use of contaminated needles. 
Moreover, methodological differences, for example using 
a top-down or bottom-up approach (EMCDDA, 2011), and 
differences in the healthcare systems in the countries 
might also influence the estimation of public expenditure. 
Consequently, a cross-country comparison with single-
country public expenditure studies can be of only limited 
value for decision-makers because of conceptual and 
methodological differences. It seems that a common 
conceptual and methodological framework is indispensable 
for a valid cross-national comparison on drug-related public 
expenditure. The current study developed a methodology 
that can be applied across all the EU Member States, 
which allows a valid cross-country comparison. In order 
to suggest a method, first, this paper is based upon 
a systematic review previously published by the authors 
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(Lievens and Vander Laenen, 2013) (1). In that paper, the 
authors reviewed the methods used in public expenditure 
studies and assessed the best possible method to use 
for a European estimate, taking into account datasets 
published by international organisations (WHO, Eurostat, 
EMCDDA, OECD, etc.). Datasets published by international 
organisations were analysed to identify a feasible method 
to estimate healthcare expenditure on drug treatment. 
The current paper presents a method to estimate public 
expenditure on treatment for illicit drug misuse in hospitals 
in European countries. Moreover, the factors that influence 
the interpretation of the public expenditure and drug 
treatment policies are discussed.
I Methods
I  Calculation methods for the estimation of public expenditure
Lievens and Vander Laenen (2013) distinguished three 
main methodologies to estimate public expenditure 
on drug treatment: drug-specific budgets; a proration 
technique; and unit expenditure (Lievens et al., 2012). For 
the drug-specific methodology, no further calculations 
are necessary. The proration technique and unit 
expenditure methods are used to estimate spending on 
drug programmes that are embedded within broader 
budget categories. This means that a process must be 
followed to ascribe the portion of that broader budget 
category to the drug programme (Van Malderen et al., 
2009). The proration technique requires a repartition key 
to isolate public expenditure on illicit drugs from the global 
budget. For instance, a possible criterion could be the 
proportion of treatment visits for illicit drugs in the total 
number of treatment visits. The unit expenditure starts by 
estimating the cost of a unit of service provided, which 
is then multiplied by the total number of similar services 
provided. An example of how this approach can be applied 
is by estimating the cost of each drug treatment during 
a hospitalisation, per day, which is then multiplied by the 
number of days a drug user is hospitalised.
The methodology to measure public expenditure or costs 
of drug treatment (outpatient or inpatient) varies between 
studies. Each method has advantages and disadvantages. 
However, the choice of a calculation method is mainly 
(1) This study was conducted for the EMCDDA. The objective of the study 
was to carry out a systematic literature review on the methods and data 
sources used to estimate public expenditure on treatment for users of 
illicit drugs, in Europe and beyond. 
driven by the availability and quality of data (2). The 
literature review revealed that many studies use the unit 
expenditure technique to measure hospital expenditure. 
These studies multiplied the number of hospitalisation days 
attributable to illicit drugs or substances (depending on the 
scope of the study) by the unit cost of a hospitalisation day. 
This formula takes into account the time (i.e. hospital days) 
spent on drug treatment.
I  International data sources for estimating public expenditure
An international database analysis was conducted to 
assess the possibility of applying these data sources 
for estimating public expenditure on drug treatment in 
Europe. The databases of eight international organisations 
or networks (OECD, WHO, Eurostat, EMCDDA, United 
Nations, EMA—European Medicines Agency, ECDC — 
European Centre for Disease Prevention and Control, 
and World Bank) were investigated to identify sources of 
reliable, timely, comparable, uniform and comprehensive 
data on government expenditure, taking the objective of 
expenditure on health as the main criterion, with data 
available for EU countries. These international databases 
should allow for a uniform cross-country comparison, since 
the data collection is based upon common concepts.
The main conclusion of the database survey was that the 
international databases provide limited data for estimating 
drug-related expenditure. It was only possible to estimate 
the drug-related public expenditure for inpatient hospital 
treatment based on the data available in one database, 
namely the Eurostat database. Eurostat provides hospital 
data for multiple European countries. Eurostat publishes 
data for the number of hospital days by diagnostic 
category, whereas one category corresponds to those 
hospital days for which the primary diagnosis was ‘mental 
and behavioural disorders due to psychoactive substance 
use’ (with the corresponding ICD-10 codes being 
F11-F19, e.g. acute intoxication, harmful use, dependence 
syndrome and withdrawal state) (3). Furthermore, Eurostat 
(together with OECD and WHO) reports financial data 
(2) The proration technique is used if the government communicates in 
terms of global budgets, and the unit expenditure is used if unit costs are 
provided. 
(3) Hospital days for inpatients available at the Eurostat website: http://ec.eu-
ropa.eu/eurostat/web/products-datasets/-/hlth_co_hosday. 
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with the SHA (4). These data are used to calculate the 
average cost per hospital day, by dividing the public health 
expenditure of hospitals by the total hospital days for 
treating all causes of diseases. Ideally, the international 
databases should provide hospital day prices according to 
DRG. DRG might be useful for cross-country comparisons, 
since the DRGs and the DRG-based hospital payment 
system have been adopted in many European countries. 
However, no cross-country comparison is possible at this 
moment because of significant variations in the design of 
the DRG systems across the EU countries (Busse et al., 
2011) (5).
To sum up, a valid cross-national comparison with 
a uniform methodology across EU Member States is 
possible only for drug-related public expenditure on 
hospital treatment. Based on the data in the Eurostat 
database, government spending on illicit drug treatment in 
hospitals was identified using the following formula:
average cost per hospital day × hospital  
days for treating illicit drug disorders
 (9.1)
It should be noted that the hospital days are taken into 
account for mental and behavioural disorders due to 
psychoactive substance use. Other health problems related 
to illicit drugs, such as HIV or hepatitis, have been excluded 
in the current study.
I Limitations of the Eurostat data(base)
The current cross-country comparison is restricted to 
inpatient hospital treatment (see Figure 9.1), as there 
were no Eurostat data for clients who were not admitted 
to hospitals (e.g. those treated in the Accident and 
Emergency Department without admission). Moreover, the 
number of inpatient treatment episodes in a community-
residential setting (i.e. residential treatment facilities, such 
as therapeutic communities and crisis centres, within the 
community of clients with drug use problems), outpatient 
(4) The ‘health expenditure and financing’ of SHA (Eurostat, 2015) sets 
the guidelines for health accounts, i.e. defines a classification system 
that allows the systematic reporting of financial flows associated with 
the provision of healthcare. These guidelines serve as the basis for the 
production of annual data in each country. The SHA adopts a tri-axial ap-
proach to healthcare expenditure: by healthcare function, by provider, and 
by financing scheme. The SHA is a collaborative activity by OECD, Eurostat 
and WHO (OECD/Eurostat/WHO, 2011).
 Data for healthcare expenditure by financing agent are available for 
hospitals (HP1) at the Eurostat website: http://ec.europa.eu/eurostat/data/
database (see metadata on healthcare expenditure at the Eurostat website: 
http://ec.europa.eu/eurostat/cache/metadata/en/hlth_sha11_esms.htm).
(5) The EuroDRG project focused on comparative analyses of the building 
blocks of DRG systems across 12 European countries, which are embed-
ded in various types of health systems (Germany, Estonia, Ireland, Spain, 
France, Austria, Netherlands, Poland, Portugal, Finland, Sweden and 
England (United Kingdom)) (Busse, 2012).
FIGURE 9.1
Registration of (drug) treatment in the Eurostat database
Included Non-included
 – Inpatient treatment in 
hospital setting
 – Outpatient treatment: in 
and outside hospitals (e.g. 
emergency services, GP, 
day care centres)
 – Inpatient treatment in 
community setting (e.g. 
crisis centres, therapeutic 
communities, etc.)
 – Drug treatment in prison
treatment episodes (e.g. substitution treatment by a GP (6) 
or treatment in a day care centre) and drug treatment 
services in prison were unavailable. As a result, hospital 
expenditure covers only part of treatment costs.
In the current study, a formula based on hospital days 
was applied because it was assumed that hospital days 
capture the prevalence of recorded substance misuse 
and they take into account the time spent on treatment. 
Even so, this method has some data limitations (Lievens 
et al., 2014). The first is that the average cost per hospital 
day is calculated by dividing the public health expenditure 
of hospitals by the total hospital days for treating all 
causes of diseases. This methodology assumes that all 
diagnoses have the same unit cost of treatment, despite 
the common-sense notion that the cost per hospital day 
varies across diagnoses. Second, the hospital expenditure 
data used to calculate the average cost per hospital day 
includes inpatient, emergency and outpatient hospital 
services. The Eurostat (healthcare expenditure) database 
makes no distinction between these three types of hospital 
services. Consequently, the expenditure for outpatient and 
emergency services is attributed to inpatient activities and 
that leads to an overestimation of the average cost per 
hospital day. The third limitation is that Eurostat reports the 
hospital days for ICD-10 codes F11-F19 in one category, 
‘Mental and behavioural disorders due to psychoactive 
substance use’. Opioid-, cannabis- and cocaine-related 
disorders are included in this category. However, nicotine 
dependence and sedative-, hypnotic- or anxiolytic-related 
disorders are also reported in this category. Thus, the 
number of hospital days and public expenditure are 
overestimated because of this classification. Moreover, 
the Eurostat database reports the healthcare activities 
for the main condition diagnosed at the end of the 
(6) Eurostat reports the consultations of medical doctors (in private practice 
or as outpatient) per inhabitant; however, the number of consultations by 
diagnosis/treatment is not available. 
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hospitalisation (7). In the current study, hospital days with 
a primary diagnosis of mental and behavioural disorders 
due to psychoactive substance use are included. In 
the case of multiple diagnoses, the most severe and 
resource intensive of these diagnoses is recorded as the 
primary diagnosis. Consequently, public spending on 
substance misuse is underestimated because patients 
with a non-substance misuse-related primary diagnosis 
and a substance misuse disorder as a secondary diagnosis 
cannot be included in the calculation of expenditure.
I Results
A cross-country comparison was conducted for 15 of the 
27 EU Member States in 2012. The public health budgets 
(7) See metadata on the healthcare activities at the Eurostat website: http://
ec.europa.eu/eurostat/cache/metadata/en/hlth_act_esms.htm. Eurostat 
reports the hospital days for general hospitals (HP.1.1), mental health 
hospitals (HP.1.2), and other specialised hospitals (HP.1.3). This ICHA-HP 
classification of the 2011 SHA does not distinguish between public and 
private hospitals (OECD et al., 2011).
for five EU Member States (Greece, Ireland, Italy, Malta and 
the United Kingdom) were not available and another eight 
EU Member States (Belgium, Denmark, Estonia, Greece, 
Spain, France, Cyprus and the Netherlands) reported 
incomplete data on the number of hospital days (8). Table 
9.1 presents the countries that did register illicit drug 
treatment hospital days and expenditure for all types of 
hospital (general, mental health and specialty hospitals). 
The average hospital expenditure for illicit drug treatment 
in the EU-15 was EUR 5 per capita, and 0.013 % of GDP, in 
2012.
Table 9.1 shows a large variation in public spending 
on illicit drug treatment in hospitals across the EU-15. 
Luxembourg invests the most in hospital-based illicit 
drug treatment (EUR 39.5 per capita and 0.056 % of 
GDP), primarily because the number of hospital days for 
illicit drug treatment (30 per 1 000 capita) appears to 
(8) Belgium, Spain, Cyprus, France and the Netherlands did not report 
hospital days for all hospital types (general, mental health and specialty 
hospitals). Estonia did not report data for the number of days patients 
spent in hospital because of mental and behavioural disorders associated 
with psychoactive substance use, and Denmark had this type of data 
published only for the year 2009. Greece did not report any hospital days.
TABLE 9.1
Hospital days and expenditure for illicit drug treatment (general, mental health and specialty hospitals), for  
15 EU countries, 2012
Country Public 
expenditure 
per hospital 
day (EUR)
Hospital days 
for illicit drug 
treatment per 
1 000 capita
Proportion of 
hospital days 
attributable to illicit 
drug treatment (%)
Illicit drug 
treatment 
expenditure by 
hospitals (EUR 
million)
Illicit drug 
treatment 
expenditure by 
hospitals, per 
capita (EUR)
Illicit drug treatment 
expenditure by 
hospitals, as 
percentage of GDP (a)
Luxembourg (b) 1 328 30 2.38 21 39.5 0.056
Austria (b) 634 16 0.75 86 10.2 0.030
Germany 416 17 0.74 577 7.2 0.022
Czech Republic 238 19 0.97 46 4.4 0.020
Slovenia 433 (c) 8 0.64 7 3.5 0.016
Finland 518 6 0.33 18 3.4 0.011
Sweden 1 884 2 (d) 0.24 41 4.3 0.013
Slovakia 164 (c) 12 0.83 11 2.0 0.010
Poland 181 6 0.50 40 1.1 0.006
Hungary 110 8 0.43 9 0.9 0.005
Portugal 812 (c) 0.7 (d) 0.11 6 0.6 0.003
Latvia (b) 112 (c) 3 0.21 0.6 0.3 0.002
Bulgaria 76 (c) 2 0.12 1 0.1 0.001
Lithuania 126 0.7 0.04 0.3 0.1 0.000
Romania 83 0.5 0.03 0.8 0.04 0.000
Mean 474 9 0.55 58 5 0.013
(a) Illicit drug treatment expenditure is divided by the GDP at current prices — million purchasing power standards.
(b) In contrast to the other countries, the live-born infants (Z38) of Latvia, Luxembourg and Austria are not included in total hospital days, and this could lead to an 
overestimation of hospital expenditure.
(c) Bulgaria, Latvia, Portugal, Slovenia and Slovakia have no healthcare expenditure for the year 2012; therefore, the hospital expenditure for 2011 is used.
(d) Sweden and Portugal have only data for hospitals days available for 2013. The Swedish hospital data for mental and behavioural disorders due to psychoac-
tive substance use might be incomplete for the year 2013, because the hospital days for this diagnosis decreased from approximately 80 000 hospital days 
(2007-10) to 21 524 hospital days in 2013. This change cannot be explained by Swedish drug treatment policy, because no changes in treatment demand or 
responses have been reported (EMCDDA, 2015).
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be high. Moreover, the expenditure could be explained 
by its relatively high public expenditure for hospital care 
(EUR 1 328 per hospital day). Austria (EUR 10 per capita 
and 0.030 % of GDP) and Germany (EUR 7 per capita 
and 0.022 % of GDP) complete the top three because of 
a high number of hospital-based treatments for illicit drugs 
(16 and 17 per 1 000 capita respectively). A number of 
eastern European countries (Bulgaria, Latvia, Lithuania and 
Romania) reported low hospital expenditure per capita and 
in proportion to their GDPs. The cost per hospital day of 
these countries is less than one third of the average in the 
EU-15, and this is combined with rates of hospital-based 
treatment per 1 000 capita that are less than three.
As already indicated above, the main limitation of our 
study is that the cross-country comparison is restricted 
to hospitals, as data were unavailable for other types of 
treatment providers. It is not clear which proportion of the 
clients receive hospital treatment in a given country, let 
alone throughout the EU. The TDI (9) used in the EU cannot 
determine the proportion of clients treated in hospitals 
for substance use, as it only distinguishes between 
the proportion of illicit drug clients entering inpatient 
treatment (10) and outpatient centres, and no further detail is 
provided on the type of inpatient services (e.g. in hospital or 
in a therapeutic community). TDI data are not comparable 
to the data used in this study because, first, they are flow 
variables, i.e. they report data on clients entering treatment 
instead of showing the total number of clients attending 
treatment; second, because they report data on clients in 
inpatient treatment (which includes hospital treatment 
but also other residential treatment such as therapeutic 
communities and crisis centres). Nevertheless, it is useful 
to provide an idea of how variable the weight of hospital 
treatment costs can be in different countries. What we 
can tell from the TDI is that the proportion of reported 
clients entering inpatient centres for drug-related problems 
is around 11 % in Europe, and this proportion varies to 
a large extent by country: from 2 % in France to 79 % in 
Luxembourg. Furthermore, 2 500 residential treatment 
facilities are identified, of which 170 are hospital-based 
facilities (EMCDDA, 2014b). However, these data should 
be interpreted with caution because of variations in data 
coverage (11). In any case, no information is available on 
the size of these residential facilities. It is worth presenting 
and discussing hospital data, as many public expenditure 
(9) The TDI is a monitoring tool developed by the EMCDDA to gain insight into 
the characteristics, risk behaviours and drug use patterns of people with 
illicit drug-related health problems. To this end, data are collected on the 
number and profile of clients entering drug treatment during each calen-
dar year. This tool is used by 30 countries (the 28 EU Member States, plus 
Norway and Turkey), which send national data to the EMCDDA (EMCDDA, 
2012).
(10) The inpatient centres include therapeutic communities, private clinics, 
units in hospitals and centres that offer residential facilities.
(11) In 2011, the data coverage of clients entering specialist outpatient and 
inpatient treatment ranged from 14 % to 100 % (EMCDDA, 2014b).
studies (e.g. De Ruyver et al., 2004, 2007; Origer, 2002; 
Vander Laenen et al., 2011) have shown that hospital 
expenditure on illicit drug treatment is an important part of 
treatment expenditure, at least in some countries.
I Discussion
Multiple approaches can be taken to comparative 
drug policy analysis. During this study, the focus lay on 
public expenditure in view of the growing demands for 
accountability and evidence-based policy, and concerns 
about the unsustainability of rising healthcare costs (Ritter 
et al., 2015). A cross-national comparison makes it possible 
to view the different options in drug treatment policy and 
may enable the monitoring of drug policy interventions 
with benchmarking information on public spending. For 
a valid cross-national comparison on public expenditure, 
a common conceptual and methodological framework 
is indispensable. The previous literature review (Lievens 
and Vander Laenen, 2013) showed that the calculation 
methods for drug treatment expenditure vary between 
countries, treatment setting and type of treatment. 
More problematic is that the only international database 
providing detailed data on hospital expenditure is Eurostat. 
Moreover, data for other types of treatment (outpatient 
services, inpatient treatment services, treatment in prisons, 
harm reduction and social reintegration) are registered 
neither in Eurostat nor in any other international database.
The cross-national comparison we executed on hospital 
expenditure shows that a uniform method based on 
the costs per day of treating a drug user in hospital (the 
unit expenditure method) can be applied with data from 
international databases. However, we were confronted with 
the significant limitations of these databases. For instance, 
no hospital charges according to DRGs are available. 
Furthermore, in the Eurostat database, hospital days are 
limited to primary diagnosis, and hospital expenditure is 
not subdivided into inpatient, emergency or outpatient 
service. Next, the Eurostat data are sometimes incomplete: 
seven EU Member States (Belgium, Denmark, Greece, 
Spain, France, Cyprus and the Netherlands) did not provide 
data for all types of hospitals (general, mental health and 
specialty hospitals), and five EU Member States (Ireland, 
Greece, Italy, Malta and the United Kingdom) could not 
report health expenditure.
Databases should also be expanded to allow a cross-
national comparison of public spending on other types 
of treatment such as nursing and specialised residential 
care facilities and providers of ambulatory healthcare. 
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This would require countries to systematically monitor 
and register this type of data. To this end, two options are 
possible: an expansion of either the EMCDDA’s TDI or the 
Eurostat database. First, TDI, a database with information 
on the total number of treatment demand clients by type 
of treatment, could be used (12). This would, however, 
require an expansion of the current variables in order to 
determine the fraction of clients receiving drug treatment. 
For instance, the total number of clients (including non-
drug-related clients) for each treatment service should be 
collected. Furthermore, this would require data on the total 
budget of the treatment services. Ideally, more detailed 
information should also be available for the cost calculation 
of drug treatment, namely the number of activities and 
the related unit cost per activity (13). Second, the Eurostat 
database could also be expanded to allow calculation of 
the drug treatment expenditure. Therefore, systematic data 
registration for in- and outpatient activities (e.g. inpatient 
or outpatient curative care, rehabilitative care, long-term 
care) by diagnosis should be included. This would allow 
estimation of the proportion of treatment for illicit drug 
disorders, and this could be multiplied by healthcare 
expenditure (by function, reported on the Eurostat website). 
Overall, even if the Eurostat database were not expanded, 
its data coverage could be improved to obtain more reliable 
results for each of the EU Member States (our analysis 
showed that only 15 of the 28 EU Member States provided 
sufficient data for the Eurostat database), as consistency of 
reporting is indispensable for international benchmarking 
of budget expenditure across countries.
All of these suggestions will improve the quality of 
cross-country comparisons and will allow analysis of the 
distribution of expenditure between types of treatment, 
as well as analysis of trends over time (EMCDDA, 2011). 
Based upon these estimates of public expenditure on 
drug treatment, one could develop country profiles 
compiling information on treatment organisation and 
budgetary impact. A comparison of funding for treatment 
of substance misuse in different countries provides 
important information for a full economic evaluation. By 
doing so, these country profiles might help policymakers 
reallocate drug budgets. Ideally, these efforts would lead 
to an evidence-based policy in which financial resources 
are assigned to cost-effective substance misuse treatment 
(Wood et al., 2010). However, the results of estimates of 
public expenditure must be used with caution in a cross-
national comparison (even if national and international 
(12) The following types of treatment centres are defined in the TDI out-
patient treatment centres/programmes; inpatient treatment centres/pro-
grammes; treatment units in prison/programmes; general practitioners; 
low-threshold agencies/programmes; other types of treatment centres/
programmes (with a specification of the type of treatment).
(13) The average cost per day for inpatient centres and the average cost per 
treatment episode/contact for outpatient centres. The EMCDDA could 
retrieve these financial data from the national focal points.
data registration is improved and a uniform methodology 
is systematically applied to measure expenditure). In 
particular, caution must be exercised when using the 
results of a free-standing public expenditure study for 
policy (decision-making) purposes. Indeed, other factors 
should be taken into account to contextualise the results 
of public expenditure studies, as countries differ in terms 
of their social security systems, institutional structures, 
cultural traditions, etc.
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I Overview
The focus of this section is to move from the methods available to estimate 
spending on drug treatment and provide examples of other types of 
methods applicable when the goals of the analysis change. Chapter 10 
presents a tool that allows drug treatment providers to assess their own 
costs. Chapter 11 describes a method to estimate the changes in costs 
caused by changes in the level of service provision, according to the 
different types of drug treatment services available.
In Chapter 10, Virginia Musto describes a tool — a calculator — developed 
by Public Health England to support local authorities in their appraisal 
of their spending on drug-related specific interventions. The results are 
expected to allow estimates of the cost-effectiveness of interventions 
and the social return on public investment. Furthermore, national health 
authorities expect that this calculator will improve the annual report of 
drug-related expenditure to central government and national projections 
of unitary costs. This study provides an example of a tool that can be made 
available to treatment providers to support their own estimates of costs 
and to build on drug treatment providers’ capacity to evaluate costs and 
analyse cost-effectiveness.
Ricardo Gonçalves and colleagues go a step further in Chapter 11, 
presenting a method to assess the cost sensitivity of activities carried 
out by substance abuse treatment networks deployed in Portugal. In 
this country, small drug treatment teams provide drug prevention, harm 
reduction, social reintegration and treatment. Therefore, the authors 
estimate the costs of providing these different services and how much 
costs would increase if each of these services increased its activity.
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I Introduction
Since 1 April 2013, public service delivery and 
commissioning in England has undergone significant 
change. Spending on drug treatment is no longer ring-
fenced by central government and is instead determined 
by a local assessment of local need. Previous drug-related 
spending estimates assumed that funding allocations 
equated to expenditure. However, with the removal of the 
ring-fence, actual expenditure reports are required from 
every local authority (LA) to estimate public expenditure on 
drug treatment in England.
In conjunction with an advisory group comprising cross-
government economists, policy leads and local alcohol 
and drug treatment commissioners, Public Health England 
(PHE) developed a cost calculator to help local authorities 
break down their global substance misuse spending on 
specific interventions. The calculator is a first step to 
supporting local authorities to advance their understanding 
of local drug-related spending, as well as local cost-
effectiveness and social return on investment. It is hoped 
that the calculator will help improve the validity of annual 
drug-related financial expenditure reports to government, 
as well as national estimates of unit costs generally.
This paper explains the methodology used in the calculator 
to disaggregate spend, the required local authority input in 
the context of the new commissioning environment, and 
the calculator’s wider application and utility.
I  Institutional framework of expenditure on drug treatment 
Specialised drug treatment in England comprises a range 
of services including OST and psychosocial interventions, 
which take place in community, inpatient and/or residential 
settings. Treatment is tailored following a comprehensive 
assessment of need, which is regularly reviewed with 
the client. As well as structured treatment programmes, 
drug users in England may access less formalised 
interventions — information, advice and other services 
related to substance misuse — provided in general and 
open-access services. Non-structured interventions 
(also known as low-threshold services) can be delivered 
alongside structured treatment, although they can also act 
as a gateway to structured treatment. Examples include 
needle and syringe programmes, street outreach, drop-
ins, identification and brief advice, and recovery support 
interventions (such as help with employment and housing).
To provide a robust estimate of public expenditure 
on drug treatment in England, it is important to know 
the configuration of local treatment systems and the 
amount that local authorities are taking from centrally 
provided funding to spend on drug dependency. Since 
implementation of the Health and Social Care Act 2012 in 
April 2013, local authorities have received an annual ring-
fenced public health grant; however, funding for specific 
services within the grant, such as drug treatment, is not 
ring-fenced. Previous UK focal point studies assumed that 
drug treatment expenditure equated to drug treatment 
planned budget; however, this is no longer a viable option, 
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as local health and well-being boards (1) determine 
expenditure allocation across a range of public health 
services following an assessment of local need.
Local authorities report their annual forecast and 
actual public health expenditure to the Department for 
Communities and Local Government (DCLG). In 2014/15, 
the national estimated expenditure on adult drug misuse 
services was GBP 541.3 million, with a further GBP 66.7 
million being spent on drug and alcohol services for young 
people. However, as adult substance misuse services 
are mostly integrated, with providers typically treating 
both drug and alcohol clients, and drug users often 
presenting with both drug and alcohol problems, isolating 
the specific spend on drug treatment can be challenging. 
Not surprisingly, there have been issues with the financial 
returns to DCLG. For example, some areas reported their 
combined alcohol and drug treatment budgets rather than 
disaggregated spending, while others merely split their 
substance misuse budgets and allocated half to drugs and 
half to alcohol treatment.
While disaggregating integrated substance misuse budgets 
by drugs and alcohol is difficult, disaggregating drug 
treatment spending by structured and non-structured types 
of intervention and/or setting is harder still. The DCLG 
does not require local authorities to report spending at this 
more detailed level, so we do not know how much local 
authorities spend on different types of services. This means 
that there are no up-to-date national or local unit costs.
(1) There is a minimum membership required for a health and well-being 
board: the local director of public health, a representative from each local 
clinical commissioning group, the local director of adult social services, 
the local director of children’s social services, a representative nominated 
by NHS England, a local elected representative, and a representative from 
the local Healthwatch. Beyond this mandatory membership other interest-
ed local stakeholders may also be invited. These may include representa-
tives of third-sector or voluntary organisations, other public services such 
as police and crime commissioners, or the NHS.
I The cost calculator 
PHE, in conjunction with an advisory group comprising 
cross-government economists, policy leads and local 
alcohol and drug treatment commissioners, developed 
a cost calculator to help local authorities break down 
their integrated substance misuse spending into that 
on specific structured and non-structured services and 
interventions. The cost calculator is solely intended for 
alcohol and drugs commissioners in local authorities who 
want to understand their expenditure and improve the 
value for money achieved by the services they commission. 
The tool is based on Microsoft Excel and uses a mixture of 
already input local authority-level data from the National 
Drug Treatment Monitoring System (NDTMS) (2), publicly 
available unit costs data (3) and user-input spending 
data to calculate estimates of how much is spent locally 
on adult drug and alcohol interventions. The treatment 
data provided to the EMCDDA through the TDI are drawn 
from the NDTMS and is therefore compatible with the 
information provided on drug treatment utilisation services.
The pharmacological and psychosocial interventions 
outlined below occur in outpatient settings. Inpatient 
settings are disaggregated into detoxification in an 
inpatient unit and residential care. Non-structured (also 
known as low-threshold) services can occur in a variety of 
settings (see Figure 10.1).
(2) NDTMS is the English database of activity in the drug and alcohol treat-
ment sector.
(3) http://www.pssru.ac.uk/project-pages/unit-costs/2016/index.php
FIGURE 10.1
Substance misuse treatment structure/categorisation
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Drugs
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I Steps to estimating expenditure
1. Drug and alcohol commissioners input their integrated 
substance misuse expenditure in a given financial 
year (4). This should include social care services and 
GP incentives, on all interventions aimed at addressing 
alcohol and drug use among adults. As a default, the 
cost calculator tool is prefilled with the DCLG revenue 
information: analysis and anecdotal evidence suggests 
that the sum of the drugs and alcohol components of 
the DCLG is more accurate than the disaggregated data 
(see Figure 10.2). Users of the tool are able to input 
more robust data into the tool if relevant.
2. Commissioners are then required to either input 
a monetary value or estimate the proportion of the 
integrated money spent on non-structured (low-
threshold) alcohol and drug interventions.
3. Once the above values have been input into the Excel 
file, the calculator automatically updates and apportions 
the remaining spending into that on drug and alcohol 
structured treatment separately. This estimate is based 
on the number of drug and alcohol clients receiving 
treatment in a local authority in the specific year of 
interest and for how many days they receive treatment, 
as recorded on the NDTMS. The resulting estimate 
is fairly crude in that it does not account for different 
intensities of treatment for various clients and assumes 
the hourly cost of all interventions to be identical.
(4) The current version is based on 2014/15; a 2015/16 and 2016/17 version 
will be available in autumn 2017.
Public expenditure on structured drug treatment  is 
estimated as a proportion of public expenditure on total 
structured treatment – alcohol and drugs – ( ), 
reflecting the total number of people and days spent in 
treatment ( ), and the amount spent on non-structured 
(lower threshold) care ( ).
  (10.1)
 
  (10.2)
  (10.3)
where
Exp = expenditure;
D = drug;
A = alcohol;
S = structured;
NS = non-structured;
d = days
FIGURE 10.2
Disaggregating integrated substance misuse spending
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data available.
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I  Steps to estimating unit costs (spending per day) 
For structured drug treatment, four types of mutually 
exclusive unit costs are estimated in the cost calculator (5):
1. community pharmacological treatment (outpatient 
intervention);
2. community psychosocial treatment (outpatient 
intervention);
3. inpatient treatment (inpatient aggregated setting);
4. residential rehabilitation (inpatient aggregated setting).
The groups are high-level interventions or settings 
recorded on the NDTMS. Inpatient and residential 
rehabilitation are settings in which pharmacological and/
or psychosocial interventions could take place, but they 
have been aggregated to better reflect the way services are 
commissioned and therefore the type of expenditure that 
information commissioners are more likely to have at their 
disposal.
National estimates of daily expenditure derived from 
previous studies are presented in Table 10.1. These are 
publicly available data on national unit cost averages 
adjusted to today’s prices using the GDP deflator to 
account for how much more or less expensive one 
intervention is than another (6). These unit costs are based 
on a 2007/08 data collection exercise (7) and so predate 
the current Drugs Strategy (2010) and the Health and 
Social Care Act 2012.
There are two approaches to estimating spending per 
day (8): top-down and bottom-up (9). The top-down 
(5) The non-structured treatment component is very similar and so will not be 
discussed in detail here. 
(6) We apply the Department of Health market forces factor to national 
averages when estimating local costs to account for differential staff and 
premises costs across the country.
(7) See the 2010 UK focal point report for more information: http://www.nta.
nhs.uk/uploads/2010.pdf 
(8) A unit cost captures the total cost of providing one unit of a service, such 
as residential rehabilitation. Unit costs should include all service provision 
costs — direct costs, indirect costs (e.g. heating and lighting, time and 
travel costs) and overheads (e.g. human resources and finance); include 
‘intention to treat’ costs — such as triage assessment costs for people 
who choose not to engage with a treatment provider, drop out of treat-
ment, or are referred elsewhere; and add up to the total cost of service 
provision.
(9) The bottom-up approach requires greater detail than the top-down 
method: all resources used to provide a service, such as staff, prescribed 
drugs and premises, need to be identified and a value assigned to each. 
To calculate the unit cost, the values are then summed and multiplied 
by the unit of activity. Breaking down costs in this way establishes 
transparent and more robust estimates and allows commissioners to 
explore drivers of variation, such as whether some service users account 
for a disproportionate share of the costs. This method is more reliable for 
forecasting how costs can change as a result of a reduction in service 
usage or demand. For more information, see A Guide to Social Return on 
Investment for Alcohol and Drug Treatment Commissioners: www.nta.nhs.
uk/uploads/a-guide-to-social-return-on-investment-for-alcohol-and-drug-
treatment-commissioners.pdf 
TABLE 10.1
Unit costs (2015/16 prices)
Intervention/setting Cost per day (GBP)
Pharmacological intervention 7.96
Psychosocial intervention 9.92
Inpatient treatment 160.42
Residential treatment 100.86
approach is relatively straightforward: divide total 
expenditure by total units of activity. For example, the 
top-down calculation for the average cost of residential 
rehabilitation per day would be:
Total spend on residential rehabilitation services/ 
Total days in residential rehabilitation services
Commissioners are asked to enter expenditure on an 
intervention or setting; then, using local NDTMS data on 
people and days in treatment, the calculator automatically 
estimates the unit cost using the calculation above. If 
a local authority does not know its total spending on 
an intervention or setting, to ensure that the resulting 
estimates are as meaningful as they can be, the default 
calculations account for known relative differences in 
spending per day (see Table 10.1). Therefore, the calculator 
automatically assumes when disaggregating spend by 
interventions/settings that, all things being equal, the local 
authority spending per day associated with residential 
rehabilitation is 13 times as much as a pharmacological 
intervention in the community (GBP 100.86 versus 
GBP 7.96 respectively), for example.
If known, the expenditure on any of the interventions 
or settings can be overwritten. For example, some 
commissioners informed us that they would find it easier 
to report spending on residential rehabilitation and 
inpatient detoxification settings but not on individual 
pharmacological and psychosocial interventions, because 
the contract arrangements for residential and inpatient 
services, e.g. block contracts and spot purchases, facilitate 
this. This means that it is possible for the calculator to 
include a mixture of known and assumed costs based on 
user input and the parameters set; every time a new data 
item is included, the calculator adjusts the overall spending 
accordingly.
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I Conclusion
Commissioners have welcomed PHE’s support in 
disaggregating spending and using the data to estimate the 
social return on investment in drug treatment and explore 
the cost-effectiveness of different types of interventions. 
Some commissioners have submitted their completed 
calculators in the hope that enough local authorities 
follow suit, as that would allow PHE to include financial 
benchmarked information in future economic tools, thereby 
allowing local authorities to compare their spending 
and value for money with other similar authorities. In 
addition, the calculator can help to improve the accuracy 
of the revenue outturn submitted to the DCLG, as well as 
improving understanding of investment and estimates of 
national and local expenditure.
The cost calculator is still relatively new and, as use 
becomes more frequent, suggestions for improvement 
will inevitably come, which will result in changes to the 
approach over time. The current version is deliberately 
simple so as to introduce the technique and thinking to 
commissioners; over time as areas become experienced in 
disaggregating expenditure, it is expected that a bottom-up 
approach to estimating unit costs will be included, which 
will improve accuracy and be more conducive to identifying 
what actually drives costs, other than the number of clients 
and time spent in treatment.
In the meantime, while the assumptions and expenditure 
calculations may seem fairly crude, their effectiveness 
for economic analysis is sufficient. After all, the monetary 
values assigned to the social and economic benefits of 
drug treatment in economic modelling, e.g. improved health 
and reduced criminal activity, are proxies, not exact savings 
that a local authority can expect to receive should it invest 
in treatment. What is needed, therefore, are whole cost 
estimates that are generally comparable in accuracy with 
the benefit estimates. The cost calculator provides this.
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I Introduction
Illicit drugs have a significant impact on users and society, 
and the burden of health-related problems resulting from 
their use is enormous. The approach to drug policy varies 
widely across countries and enforcement still consumes 
the bulk of public resources, even in countries with an 
element of decriminalisation such as the Netherlands 
(Rigter, 2006) (1). However, it is now apparent that drug 
abuse and addiction treatment is much less expensive than 
its alternatives (such as imprisonment), and it substantially 
reduces the associated health and social costs. For 
instance, in the United Kingdom, Gossop et al. (2001) 
estimated a return of GBP 3 for every additional GBP 1 
spent on treatment, as a result of cost savings associated 
with lower direct and indirect crime-related costs.
Health and social policy programmes have a medical-
response component (dealing with a medical need) and 
a policy-response component (measures aiming to change 
individual behaviour) (Pacula et al., 2009). It is estimated 
that around 25 % of Europe’s adult population have ever 
used an illicit drug and that, in 2011, at least 1.2 million 
people received some kind of treatment for illicit drug use in 
the EU and its candidate countries (EMCDDA, 2013).
Health expenditure, which includes drug abuse and 
dependence treatment, is largely public in nature in 
the majority of OECD countries (OECD, 2015, p. 170). 
Providing good-quality services for drug users is therefore 
a significant challenge, particularly in a difficult economic 
climate, and governments face increasing pressure to 
monitor their costs.
Research is under way to estimate expenditure — and, in 
particular, public expenditure — on illicit drug treatment 
in several countries. However, most researchers are 
(1) EMCDDA (2014, p. 70) shows that a larger share of drug-related public 
expenditure is allocated to drug supply reduction activities (as opposed 
to demand reduction) in most of the 16 European countries that have 
detailed public expenditure breakdowns.
hampered by a lack of detailed data, as often data — when 
available — do not make a distinction between expenditure 
on drugs and on alcohol or mental disorders (Ramstedt, 
2006; Rigter, 2006). There have also been attempts to make 
cross-country comparisons (Lievens et al., 2014), which are 
even more difficult, as data are often not available.
Portugal is an example of a country in which substance 
abuse and dependence are mostly treated with public 
funds. The National Strategy for the Fight Against Drugs, 
approved by the Portuguese government in 1999, is 
based on a health-oriented rationale and encompasses 
various policy measures, including, from 2000 onwards, 
the decriminalisation of illicit drug possession and 
consumption. In particular, it also includes an extension 
of the healthcare services network, a syringe exchange 
programme, an increase in scientific research funding 
and specialist training, and a significant financial budget 
increase for drug-related problems. It led to the setting up 
of the Portuguese Institute for Drugs and Drug Addictions 
(IPDT), a public organisation with several responsibilities. 
In particular, from 2005 onwards and after the merger 
of the IPDT with the SPTT (2), the Portuguese Institute 
for Drugs and Drug Addictions (Instituto da Droga e da 
Toxicodependência, known as IDT) became responsible for 
the drug-related healthcare treatment network and for the 
elaboration and implementation of the National Action Plan 
Against Drugs and Drug Addiction (3).
In order to pursue these objectives, an innovative 
organisational model was introduced. Small treatment 
teams, belonging to integrated response centres, provide 
services associated with prevention, harm reduction, social 
reintegration and treatment. Some of these services are 
outsourced (e.g. harm reduction, a significant percentage 
(2) Serviço de Prevenção e Tratamento da Toxicodependência. 
(3) The 2005-12 national plan detailed policy objectives for specific periods 
in the following areas: prevention; harm reduction and risk minimisation; 
treatment; social reintegration; combating illicit drug trafficking and money 
laundering; research, statistical and epidemiological information; evalu-
ation; international collaboration; legal regulation; and decriminalisation 
consumption. 
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of prevention- and treatment-related services), but those 
costs are allocated to the relevant treatment team (e.g. in 
the case of treatment services, the treatment team that has 
referred the patient) (4). In addition, some of these services 
are provided at the individual level (e.g. treatment), but 
others may be provided to larger groups (e.g. prevention 
activities targeting specific groups or communities) and, 
naturally, the associated costs may be very different. 
A major advantage of this organisational model, from 
a research perspective, is that it keeps track of costs at the 
treatment team level, thus generating a rich and useful 
database of treatment team costs and outputs or activities 
carried out.
Relying on this IDT cost and output data for its treatment 
network, during the years 2011 and 2012, we estimated 
a cost function that allowed us to calculate the costs 
associated with the various types of dependence-related 
activities carried out by the various treatment teams across 
different geographical areas within Portugal. We uncovered 
some interesting results: for example, the average cost 
of each prevention event (all substances) is EUR 2 330, 
while for treatment it is EUR 134 (5). Drug-related activities 
(including prevention, harm reduction, social rehabilitation 
and treatment) have an average event cost of EUR 128.
These estimates are quite relevant from a policy point of 
view. First, they provide an indication of how costly are the 
various types of activity carried out by treatment teams. 
Second, they allow for more informed decisions if some 
of these activities were to be further outsourced (e.g. 
to non-profit or private healthcare organisations) (6). In 
addition, although we did not pursue this line of research in 
this chapter, it also allows for an analysis of the (possible) 
existence of economies of scale or scope. This is relevant 
in terms of understanding the adequacy of the treatment 
network currently in place. More broadly, in the drug 
dependence field, this methodology can be used by other 
countries that have geographically decentralised treatment 
teams to carry out an estimation of their treatment costs. 
Naturally, depending on what costs are borne by each 
treatment team, the estimates may vary from country 
to country, reflecting not only cost differences, but also 
differences in each country’s organisational structure for 
the treatment of addictive behaviour.
(4) In the case of social reintegration, treatment teams are responsible for 
only some activities (and their underlying costs), e.g. social service ap-
pointments (social situation diagnosis and referral), targeted interventions, 
e.g. to increase social or other competences. Other concrete measures 
for social reintegration (e.g, housing, employment, etc.) are carried out by 
social security services and their costs are not included in the analysis. 
(5) As we will later clarify, the unit used for each type of activity is an ‘event’ or 
‘episode’ registered in the treatment network database.
(6) Law no 7/97 allows this outsourcing to occur and, indeed, as mentioned 
above, this possibility is already used for some activities (e.g. prevention, 
harm reduction or treatment). 
The chapter is organised in the following way: a brief 
overview of cost functions, a description of the data used, 
a results section and a conclusion. Annex A provides 
a detailed, technical description of the methodology used.
I Cost functions: a brief overview
In a nutshell, an organisation or a firm produces (possibly 
multiple) outputs (e.g. products or services) making use 
of inputs (for instance, staff or raw materials). For a given 
choice of output levels, the organisation or firm is typically 
expected to be economically efficient, that is, to choose the 
combination of inputs that minimises its costs. The concept 
of a cost function embodies this notion. In particular, the 
cost function allows the identification of the minimum 
possible costs that an organisation or firm must incur to 
produce a given level of outputs.
Estimating a cost function allows a researcher to 
understand how changes in output levels may change 
production costs. Therefore, it is a particularly important 
concept when organisations or firms wish to depart 
from their current production levels, as it allows the cost 
implications of such decisions to be calculated. Such 
functions can be estimated using data on total costs, 
output levels and input prices.
I Data
Treatment teams report their costs on an annual 
basis to IDT, broken down into several cost categories, 
namely staff costs (including all relevant subsidies or 
additional remuneration on top of salary costs) and 
acquisition of services and supplies (clinical material — 
including methadone, for substitution therapies — food, 
communications, transport, insurance, security, etc.), 
which also includes patient referral costs within the drug 
treatment network, that is, the cost associated with treating 
a particular treatment team’s client at another drug-related 
healthcare provider (e.g. inpatient treatment in therapeutic 
communities) (7). Therefore, once a client is admitted by 
a treatment team, the costs of all services provided to that 
client (either within the treatment team or, through referral, 
(7) Although a broader referral concept is legally possible — through which 
users under treatment could be referred to other health providers, e.g. for 
diagnostic examinations or other procedures — it was never adopted by 
IDT insofar as it would be questionable whether such referrals would be 
related to the addiction problem. 
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by other drug-related healthcare providers) are typically 
allocated to that treatment team.
Output levels were extracted from SIM (8), activity 
management software used by all treatment teams when 
registering their activity. This software registers a wide 
variety of information for each ‘event’, which is associated 
with a particular client, namely specific information on each 
service area (medical, psychological, nursing services) or 
the main substance to which it refers (alcohol, illicit drugs, 
tobacco, etc.) (9). In addition, event-specific information is 
also registered, namely whether or not it was scheduled, 
whether or not the event actually took place (e.g. not all 
scheduled events actually take place) and the type of 
activity to which it refers (e.g. prevention, harm reduction).
(8) Sistema de Informação Multidisciplinar. 
(9) An ‘event’ is the broad term we use to define an activity registered in SIM. 
For example, a treatment event is usually associated with face-to-face 
contact for a specific purpose (e.g, an appointment, a blood test, a psy-
chological evaluation). Therefore, on a specific day when interacting with 
the treatment network, a client may trigger more than one event in SIM.
We collected this data for the years 2011 and 2012, as 
during that period the data collection procedure was 
broadly consistent. From 2013 onwards, IDT became 
SICAD (10) and its responsibilities changed significantly, 
which ultimately translated into significant differences 
in the functioning of treatment teams and particularly in 
the way costs were registered. An important implication 
of this change is that extending the analysis we carried 
out to subsequent years (2013 onwards) would not be 
straightforward and would (almost certainly) involve 
a lengthier and more intensive data collection exercise. 
Summary statistics for each of the main variables are 
presented in Table 11.1.
(10) Serviço de Intervenção nos Comportamentos Aditivos e nas 
Dependências. 
TABLE 11.1
Descriptive statistics of the main variables used in the regressions
Variable No of 
observations
Mean SD Minimum Maximum
Total costs (EUR) 83 1 170 063 912 894 22 594 4 649 957
Number of staff 73 15 9 1 42
Number of events 83 10 879 6 338 1 273 31 983
Number of treated individuals 83 799 455 166 2 611
Average event duration (minutes) 83 29 5 15 46
Model 1 outputs (number of events)
Prevention 83 117 154 0 811
Harm reduction 83 124 672 0 6 070
Social rehabilitation 83 1 452 1 324 45 7 137
Treatment 83 9 157 5 765 143 30 786
Other 83 29 92 0 611
Model 2 outputs (number of events)
Alcohol 83 1 098 908 69 4 382
Drugs 83 9 548 5 967 1 200 29 334
Tobacco 83 34 75 0 467
Other 83 200 226 0 1 273
Model 3 outputs (number of events)
Alcohol 83 1 098 908 69 4 382
Opiates 83 6 478 3 699 848 17 910
Stimulants 83 454 410 0 1 786
Hallucinogens 83 5 10 0 45
Cannabis 83 302 231 12 1 081
Other drugs 83 2 309 2 706 65 15 372
Tobacco 83 34 75 0 467
Other 83 200 226 0 1 273
Note: ‘Number of observations’ refers to the number of treatment teams for which data were available; ‘Mean’ refers to the mean of a given variable across 
treatment teams; number of staff was not available for all 83 treatment teams.
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I Results
We present the results of the cost function estimation 
(Annex A — equation A11.2) in Table 11.2 (11) (12). The 
cost elasticity of a given output (see Annex A) represents 
the percentage change in costs when that output level 
(11) All models exhibit a high r2 and many individually insignificant t-ratios, 
a typical result when estimating flexible cost functions because of multi-
collinearity (see, for example, Gonçalves and Barros, 2013). In this type of 
estimation, multicollinearity is normally associated both with non-linear 
explanatory variables (squared output levels and input prices) as well as 
the interaction variables. Although multicollinearity does not violate OLS 
assumptions (estimated coefficients remain unbiased), standard errors 
are typically larger, which leads to statistical insignificance of estimated 
coefficients. 
(12) We estimated equation A11.2 using other controls, such as geographical 
location or the integrated response centre to which each treatment team 
belonged. However, these were typically statistically insignificant and we 
chose not to include them. 
varies by 1 %. In other words, the cost elasticity shows how 
sensitive total costs are when a given output level changes 
by 1 %. Calculating the cost elasticities (at the sample 
means) using the results presented in Table 11.2 leads to 
the following conclusions:
TABLE 11.2
Estimation results
Model (1)
[5 outputs]
Model (2)
[4 outputs]
Model (3)
[8 outputs]
Model (1)
[5 outputs]
Model (2)
[4 outputs]
Model (3)
[8 outputs]
Parameter Variable Coefficient 
(significance 
level)
Coefficient 
(significance 
level)
Coefficient 
(significance 
level)
Parameter Variable Coefficient 
(significance 
level)
Coefficient 
(significance 
level)
Coefficient 
(significance 
level)
β
1
Y
1
0.12 (*) 0.04 0.01 1/2.β
44
Y
4
.Y
4
–0.17 0.02 0.01
β
2
Y
2
–0.13 (***) 0.73 (***) –0.60 (**) β
45
Y
4
.Y
5
0.09 (***) 0.00
β
3
Y
3
0.12 0.03 0.71 (**) β
46
Y
4
.Y
6
0.00
β
4
Y
4
1.22 (***) 0.09 (*) 0.14 β
47
Y
4
.Y
7
0.00
β
5
Y
5
–0.05 0.19 β
48
Y
4
.Y
8
–0.02
β
6
Y
6
–0.20 1/2.β
55
Y
5
.Y
5
0.00 –0.13
β
7
Y
7
–0.03 β
56
Y
5
.Y
6
0.20
β
8
Y
8
0.03 β
57
Y
5
.Y
7
0.13 (**)
1/2.β
11
Y
1
.Y
1
0.01 0.05 0.42 (***) β
58
Y
5
.Y
8
0.28 (*)
β
12
Y
1
.Y
2
–0.02 0.03 0.06 1/2.β
66
Y
6
.Y
6
0.21 (**)
β
13
Y
1
.Y
3
–0.04 0.00 –0.22 β
67
Y
6
.Y
7
–0.08 (***)
β
14
Y
1
.Y
4
0.18 (**) –0.03 –0.03 β
68
Y
6
.Y
8
0.00
β
15
Y
1
.Y
5
–0.01 –0.02 1/2.β
77
Y
7
.Y
7
0.00
β
16
Y
1
.Y
6
0.43 (***) β
78
Y
7
.Y
8
–0.05 (*)
β
17
Y
1
.Y
7
–0.06 (**) 1/2.β
88
Y
8
.Y
8
0.06
β
18
Y
1
.Y
8
0.16 γ
1
ln(w
1
) 0.60 (***) 0.61 (***) 0.62 (***)
1/2.β
22
Y
2
.Y
2
–0.01 (*) 0.00 0.99 (**) γ
2
ln(w
2
) 0.40 (***) 0.39 (***) 0.38 (***)
β
23
Y
2
.Y
3
0.03 0.00 0.45 1/2.γ
11
(ln(w
1
))2 0.07 (***) 0.07 (***) 0.06 (***)
β
24
Y
2
.Y
4
0.05 0.02 –0.12 (***) 1/2.γ
22
(ln(w
2
))2 0.07 (***) 0.07 (***) 0.06 (***)
β
25
Y
2
.Y
5
–0.01 (***) –2.04 (***) γ
12
ln(w
1
).ln(w
2
) –0.14 (***) –0.13 (***) –0.12 (***)
β
26
Y
2
.Y
6
–0.55
D – Year 
2012
–0.56 (**) –0.25 (***) –0.53 (***)
β
27
Y
2
.Y
7
–0.08 α Constant 14.02 (***) 14.02 (***) 14.02 (***)
β
28
Y
2
.Y
8
–0.16
1/2.β
33
Y
3.
Y
3
0.05 0.00 0.02
β
34
Y
3
.Y
4
–0.07 –0.01 0.10 (***)
β
35
Y
3
.Y
5
–0.03 (**) –0.07
β
36
Y
3
.Y
6
–0.04 Number of observations 75 75 75
β
37
Y
3
.Y
7
0.03 r2 (cost function) 0.69 0.51 0.83
β
38
Y
3
.Y
8
–0.21
r2 (labour share 
equation)
0.06 0.06 0.07
***Significant at the 1 % level; **significant at the 5 % level; *significant at the 10 % level.
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 In model 1 (five outputs), as the number of prevention 
events increases by 1 %, cost increases by 0.12 %; for 
treatment events, the corresponding cost increase is 
1.22 % — therefore, costs are rather sensitive to the 
number of treatment events.
 In model 2, only two outputs (out of four) have 
statistically significant cost elasticities. For example, the 
cost elasticity of illicit drug events is 0.73, while that of 
other substances is 0.09; therefore, costs are (in relative 
terms) more sensitive to illicit drug-related events;
 Results from model 3 are more difficult to interpret (13).
Two cost measures can be calculated using the estimates 
presented in Table 11.2 (see Annex A). First, we can 
calculate average incremental costs. These are equivalent, 
in this type of multi-output setting, to an average cost, that 
is, on average, how much it costs to produce each unit 
of a given output. This cost measure is a simple indicator 
of how much, on average, each unit of output costs to 
produce. Second, the marginal cost of an output tells us 
how much total costs change when (assuming all else is 
constant) an additional unit of a given output is produced. 
This is likely to be different from the average incremental 
cost, because in order to produce an additional unit it may 
be that the total cost increases by less than the average 
incremental cost. For example, it may be that this additional 
unit requires not a significant increase in fixed or quasi-
fixed costs (e.g. number of staff) and only an increase in 
variable costs. Therefore, evaluating all variables at their 
sample means, we find that:
 In model 1, the average incremental cost of prevention 
events is EUR 2 330, while the marginal cost is 
EUR 1 206; for treatment events, the respective figures 
are EUR 134 and EUR 164.
 In model 2, the average incremental cost of drug-related 
events is EUR 128 while the marginal cost is EUR 93.
 In model 3, the average incremental cost of stimulant-
related events is EUR 2 687 while the marginal cost is 
EUR 1 913.
(13) Because of the significantly larger number of variables included in the 
regression, the results of model 3 are more difficult to interpret. For 
example, only two cost elasticities are statistically significant — opiates 
and stimulants — but only the latter is positive. In addition, the cost elas-
ticities of alcohol or tobacco-related events are quite different from those 
obtained in model 2. 
TABLE 11.3
Marginal cost estimates of models 1 and 2
Output Marginal cost
(EUR)
Model 1
Prevention 1 206
Harm reduction –1 274
Social rehabilitation 98
Treatment 164
Other –2 076
Model 2
Alcohol 40
Drugs 93
Tobacco 941
Other 563
Although these are most plausible results, we present all 
the marginal cost estimates for models 1 and 2 in Table 
11.3 (14).
I Conclusion
This paper has addressed a little-explored topic: the costs 
associated with the treatment of substance abuse. Owing 
to its particular characteristics — namely the fact that 
a geographically spread treatment network reports costs 
and output levels to a single public organisation, IDT — we 
carried out a cost function estimation that allowed us to 
empirically estimate the costs (average incremental costs 
and marginal costs) associated with the treatment of 
substance abuse. We found that prevention and especially 
treatment appear to be the most cost-sensitive activities 
(measured by their cost elasticities) carried out by the 
treatment network. Looking in particular at the treatment 
cost elasticity, we found that a 1 % increase in the number 
of treatment events would result in an overall cost increase 
of 1.22 %. In addition, illicit drugs have a relevant and 
significant cost elasticity — more so than other substances.
These estimates have (at least) three immediate practical 
uses. First, within each treatment team, they may be used 
as a tool for budgeting — that is, predicting yearly costs on 
the basis of expected output levels. Second, they may be 
used as benchmarks to identify inefficiency — for instance, 
if the observed average cost of an activity is much larger 
than that predicted, it may be because of inefficiencies 
in service provision, which may then be corrected 
immediately. Third, these estimates may also be used as 
benchmarks if some of these activities were to be further 
(14) Average incremental costs rely on evaluating the cost function far away 
from the approximation point (when one output level is evaluated at zero) 
and are thus more sensitive to estimation problems than marginal costs. 
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outsourced — they provide an indicator of how costly it is 
to provide a given service within the treatment network and, 
therefore, may be used as a cap or reference value when 
contemplating the possibility of outsourcing such services 
to not-for-profit or private sector providers.
Further research in this area is warranted. This 
methodology allows the analysis of economies of scale 
or scope within the treatment network, although we did 
not pursue it in this chapter. These data also allow a more 
detailed efficiency analysis, in which comparisons could 
be made of the outputs produced by each treatment team 
with the available inputs (e.g. staff). In addition, data for 
more years or additional variables that can explain the 
costs of the treatment teams would certainly improve the 
results of the estimation and thus provide a more accurate 
calculation of average incremental costs as well as 
marginal costs. These are likely to be the next steps in our 
research.
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I  Annex A Methodology: cost function estimation
A firm’s long-run cost function indicates the minimum cost at which a firm produces a given 
quantity of its various outputs (yi) for given input prices (wi). Under the assumption of n 
outputs and m inputs, a firm’s long-run cost function is typically given by:
  (A11.1)
We assume that treatment teams operate in the long run, that is, we explicitly assume that 
they can change the quantity they use of all the production inputs in response to changes in 
input price or output level. This strikes us as a plausible assumption because (1) treatment 
teams are typically small and appear to make limited use of inputs that might be considered 
fixed in the short run (and hence whose quantity would not change in response to input 
price or output level changes), and because (2) treatment teams can refer clients to other 
drug treatment providers with relative ease, thus effectively allowing possible short-run 
input constraints to be easily bypassed.
We use the generalised translog cost function to represent the long-run cost function. 
This cost function is particularly suited when a significant number of observations contain 
zero values for some output categories. The main difference with respect to the translog 
cost function is that all output levels are subjected to a Box-Cox transformation instead of 
the log-transformation commonly used under the translog cost function, that is, all output 
levels yi are transformed into (
15). In addition, prior to the Box-Cox transformation of 
the output data (yi), we mean-scale all our variables (
16).
The generalised translog cost function is a second-order Taylor approximation to the true 
(but unknown) functional form and it is given by:
 
 (A11.2)
In line with the literature, we assume a symmetry constraint βij=βji , and γij=γji ,as well as linear 
homogeneity in input prices (i.e. doubling the price of all inputs leads to a doubling of costs):
 
 (A11.3)
(15) We assume that λ=0.1.
(16) For each output (yi (i=1,…,n)) and for each input price (wj (j=1,…,m)), we divide each observation by the respective 
mean. Therefore, the mean of the mean-scaled variables is equal to 1. 
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The cost proportion equations are obtained through the logarithmic differentiation of the 
cost function (Shephard’s lemma):
  (A11.4)
where  is the cost share of input i (xi represents the quantity used of input i).
A key question in our estimation is the definition of outputs for the treatment teams. Indeed, 
treatment teams have various functions and their work covers a wide variety of areas. As 
such, it is not easy to define what their outputs are. Therefore, we have estimated three 
different models, each of which considers a different type of output for treatment teams:
 Model 1: outputs are considered to be activity based, namely we assume that treatment 
teams provide services in the areas of prevention, harm reduction, social rehabilitation, 
treatment or other areas.
 Model 2: outputs are considered to be substance based (in broad categories), that is, 
treatment teams are assumed to provide services associated with alcohol, illicit drugs, 
tobacco or addiction to other substances.
 Model 3: as in model 2, outputs are considered to be substance based, but illicit drugs 
are further broken down into opiates, stimulants, hallucinogens, cannabis or other 
drugs (alcohol, tobacco and other substances are considered, as in model 2, as broad 
categories).
It strikes us as plausible to assume that all treatment teams rely essentially on two inputs: 
staff and other costs (which include services and acquisition of supplies). Staff costs were 
calculated in the following way: for each treatment team, we know how many people in 
each staff category there are (doctor, nurse, administrative staff). Using the annual salary 
of each staff category for that year, we can compute an average salary per treatment 
team (17) (18). This is clearly an imperfect measure of staff unit costs. Ideally we would use 
total staff costs divided by the number of staff, but it appears as if several treatment teams 
have significant discrepancies in their overall staff costs when compared with the number 
of staff they report, possibly because of cost allocation errors. In the face of this problem, 
our proposed method appears more reliable.
Our second input — other costs — is essentially a composite of various input categories. As 
such, we assume that the price of this input is the result of the division of its total costs by 
the number of effective events registered by each treatment team (see below). Therefore, as 
in Garcia and Thomas (2001), this unit price is expressed as a cost per unit of output.
Equations A11.2 and A11.4 were estimated with the homogeneity restrictions of equation 
A11.3 using Zellner’s seemingly unrelated regression (SUR) technique. Because the cost 
proportions add up to unity, only one of them is independent, and we have thus dropped 
the second cost proportion equation (associated with other inputs) from the regression. It 
is immaterial which cost proportion equation is dropped, but input prices are not readily 
available for the second input. In addition, given the relatively low degrees of freedom in 
some models (namely model 3), we have estimated all models under the assumption of 
homotheticity, that is, we assume that the cost-minimising mix of inputs is not affected by 
(17) Treatment teams’ staff are public servants and, as such, their salaries are defined according to a payscale. 
(18) For a small number of teams, we did not have the staff mix. In this case, we have assumed these units to have the 
average staff mix in the sample. 
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the volume or mix of outputs, which implies that changes in input prices affect costs only 
by a scale factor (Smet, 2002). This implies that, in equation A11.2, input prices are not 
interacting with output levels.
In order to eliminate potential outliers, we excluded from the analysis observations whose 
event unit cost (total costs divided by the total number of effective events) was in the top or 
bottom 5 % (eight observations in total).
Define ηi as the cost elasticity of output:
  (A11.5)
That is, ηi  represents the percentage change in costs when output i varies by 1 %. Following 
Vita (1990), the cost elasticity of output when we use the generalised translog cost function 
is given by:
  (A11. 6)
where yi are the untransformed outputs and λ is the Box-Cox transformation parameter. 
Because all variables are mean-scaled, at the sample mean the cost elasticity of output is 
simply given by ηi=βi.
The average incremental cost of output i is equivalent, in a multi-output setting, to an 
average cost. It provides an indication of how much, on average, each unit of output i 
costs to produce and it is calculated in the following way (see Grannemann et al., 1986, for 
example):
  (A11.7)
It is based on the incremental cost of output i, that is, the difference in overall costs 
between producing all n outputs and producing all the outputs except i.
The marginal cost of output is the variation in total costs when (assuming all else is 
constant) an additional unit of output is produced and is given by:
  (A11.8)
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SECTION V
Contextualising costs
CHAPTER 12
Estimating the costs of substitution therapy for 
heroin and opioid addiction in the United States: 
insights and challenges
CHAPTER 13
A cross-national comparison of public expenditures 
on drug treatment: context is key
CHAPTER 14
Social cost of illicit drugs in France: what’s new in 
estimating the value for lives lost and illness?
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I Overview
Section V shows that public spending on drug treatment is only part 
of the picture that explains costs and, therefore, should be set in the 
right context. Do methods to estimate spending on drug treatment 
vary if the private sector pays a significant part of the bill? What are the 
socioeconomic factors to analyse if one wants to contextualise the size 
and meaning of public spending on drug treatment? What other costs 
does society bear, besides the drug treatment bill?
In Chapter 12, Ervant Maksabedian and colleagues show how the 
costs of addiction treatment vary in the United States, according to the 
payer (public versus private payers), type of treatment (inpatient versus 
outpatient providers) and type of pharmacological treatment adopted 
(pharmacological versus behavioural therapy). Treatment options for 
any given client vary based on a whole host of factors, including the 
setting in which treatment is offered, the credentials or certification of the 
provider, geographic variation in access to therapies, and differences in 
what is covered by health insurers; these complicating factors, coupled 
with the lack of price transparency for most services, make calculation 
of the average cost of treatment a challenging task. In this context, this 
study provides an example of how bottom-up estimates for the costs of 
treatment for opioid addiction in outpatient settings in the United States 
may vary, for instance, because of the costs of pharmaceuticals.
In Chapter 13, Freya Vander Laenen and Delfine Lievens suggest 
a methodological framework for understanding and contextualising 
the size of drug treatment spending. The authors discuss the main 
factors contributing to this expenditure. In their view, three classes of 
factors explain public spending: (1) the type of healthcare policy; (2) the 
type of drug treatment policy; and (3) the socioeconomic context. To 
operationalise this model, taking a pragmatic approach, the authors base 
their analysis on data available in international databases. By focusing 
on these factors, the chapter moves the discussion forward from a pure 
analysis of public expenditure studies to a broader context that is more 
valid for a drug policy.
Completing the section, in Chapter 14, Pierre Kopp and Marysia Ogrodnik 
present a general methodology for computing the social costs of drugs. 
The authors show that drug-related public expenditure is only part of 
the costs associated with illicit drugs and borne by society. This chapter 
frames public expenditure in the context of other costs, borne by private 
entities, public entities or the members of society. To make this study 
more applicable to practice, the authors apply this method to France and 
estimate the social costs of illicit drugs in France for the year 2010.
12
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I Introduction
The enormous rise in the non-medical use of prescription 
opioids and heroin in the United States has concerned 
policymakers, researchers and the general public for 
several years. According to the National Survey on Drug 
Use and Health, in 2012, an estimated 2.3 million people 
suffered from opioid abuse or dependence in the previous 
year, with the vast majority not receiving any treatment 
(US Department of Health and Human Services, 2015). 
The number of fatal poisonings due to prescription pain 
medications quadrupled between 1999 and 2010, a rate 
of growth that was parallelled by the distribution of 
prescription pain medications during the same period 
(Centers for Disease Control and Prevention, 2011a). 
Opioid-related Accident and Emergency Department 
visits more than doubled, from 21.6 per 100 000 in 2004 
to 54.9 per 100 000 in 2011, for a total of 1.24 million 
Emergency Department visits involving non-medical use 
of pharmaceuticals and pain relievers in 2011 (SAMHSA, 
2013a). Opioid-related treatment admissions grew at an 
even faster rate, increasing nearly six-fold between 1999 
and 2009 (Centers for Disease Control and Prevention, 
2011b). Even today, despite modest declines in the total 
amount of opioids prescribed (Guy et al., 2017), more 
than 33 000 lives are lost annually to opioids (Rudd et al., 
2016a). The decline in prescription opioid deaths between 
2010 and 2012 would be more reassuring if heroin 
overdose deaths had not more than doubled during the 
same period (Rudd et al., 2016b), suggesting that some 
individuals may have shifted from prescription opioids to 
heroin. The magnitude of the ‘opioid problem’ (heroin and 
prescription opioids together) remains substantial, with 
opioid-related mortality now representing the leading cause 
of injury deaths in the United States, exceeding deaths 
from suicide, gunshot wounds and motor vehicle accidents 
(Kochanek et al., 2016).
The Obama Administration, acting through the Office 
of National Drug Control Policy (ONDCP) and the US 
Department of Health and Human Services (DHHS), viewed 
increasing access to treatment as one of the key strategies 
to address the prescription opioid epidemic in the United 
States. This included expanding private and public health 
insurance coverage for addiction services through a variety 
of policy levers. Historically, substance abuse treatment 
services were commonly separated both physically and 
financially from other healthcare services in the United 
States. Addiction treatment services were generally 
delivered in separate speciality facilities, with regulations 
frequently limiting the amount of information that could 
be shared with non-addiction (i.e. regular healthcare) 
providers. Many private health insurance carriers have 
traditionally provided little or no coverage for addiction 
treatment services, despite evidence that effective 
treatment reduces subsequent healthcare utilisation and 
patient costs (SAMHSA, 2009; Wickizer et al., 2012). This 
led to a situation in which for decades the largest payer 
for addiction services was the US government, through its 
block grants and then through health insurance coverage 
for the poor (Medicaid) and military veterans (the Veterans 
Health Administration) (Bohnert et al., 2014; Mark et al., 
2011).
The 2008 Mental Health Parity and Addiction Equity Act 
and the Patient Protection and Affordable Care Act of 2010 
changed the landscape for addiction treatment services 
by mandating that substance use disorder treatment be 
covered by insurance at a level similar to comparable 
medical treatments if it was offered and requiring that 
plans offered to private individuals on health exchanges 
include it as an essential covered benefit. A growing 
understanding and acceptance of opioid addiction 
as a treatable medical disorder by both the medical 
community and the American public made these insurance 
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expansions legislatively possible (McLellan et al., 2000; 
Humphreys and McLellan, 2011). The lack of accepted 
clinical guidelines for treatment pertaining to opioid 
addiction therapies among the broader medical community 
make it uncertain exactly what expanding coverage will 
mean in terms of treatments that are covered by insurers.
While both behavioural therapies and pharmacological 
treatments have been available in the United States, 
methadone was by far the primary replacement therapy 
for opioid use disorders until the mid- to late 2000s. 
Methadone, another form of pharmacotherapy, can 
be dispensed only through certified Opioid Treatment 
Programmes (OTPs), which in the majority of instances 
are based in stand-alone treatment centres separate from 
the healthcare system. Treatment protocols require that 
a client take the medication at an OTP clinic daily under 
supervision; take-home dosages from OTPs are available 
to patients only after they have been in a maintenance 
treatment programme for an extended period of time 
(SAMHSA, 2013a) (1). Given the separation of these 
programmes from medical services, the lack of geographic 
access in many regions (Dick et al., 2015), and the lack 
of prior coverage of these benefits among many insurers 
(Volkow et al., 2014; Burns et al., 2016), the majority of 
individuals with opioid use disorders do not receive this 
therapy, despite its demonstrated effectiveness and cost-
effectiveness.
The 2002 FDA approval of buprenorphine for the treatment 
of opioid use disorders was an event welcomed by 
addiction providers because of the increase in access to 
treatment that was expected with this new drug therapy 
(Ducharme and Abraham, 2008; O’Brien, 2008). Unlike 
methadone, buprenorphine can be dispensed by both 
an OTP and a physician (either in their office or through 
a regular retail pharmacy with a prescription) if the 
physician has received a waiver from the Drug Enforcement 
Agency (2). Naltrexone is the only other current medication 
that can be prescribed by any US medical provider in the 
United States today. And, although it can be prescribed 
by any medical provider, even those without a waiver, it 
is primarily recommended for patients who have already 
undergone detoxification and have a relatively short or less 
(1) While federal regulations passed in 1999 endorsed office-based meth-
adone therapy, they required that physicians interested in doing so have 
addiction medicine training, be affiliated with a methadone clinic or be 
monitored by the medical director of a methadone clinic (CFR, 1999). 
Hence, delivery has remained largely in OTP settings.
(2) To get a buprenorphine waiver, a physician must (1) be board certified in 
addiction medicine, (2) be board certified in addiction psychiatry or (3) 
have completed 8 hours of specialised training on addiction. Under the 
Drug Addiction Treatment Act of 2000 (DATA 2000), DEA-waivered physi-
cians can prescribe buprenorphine in various settings, including commu-
nity hospitals, health departments and even correctional facilities, which 
makes buprenorphine far more accessible in areas where physicians have 
waivers.
severe history of addiction or who are also being treated 
for a co-occurring alcohol use disorder (SAMHSA, 2015a). 
In the light of these recommendations, few commercial 
insurance providers provide benefit coverage for those 
who wish to use this form of pharmacotherapy (Volkow et 
al., 2014).
While all of these medication-assisted therapies have 
been shown to be both cost-effective and safe, they 
remain underutilised in the United States (Chalk et al., 
2013). Even today, fewer than 30 % of individuals with 
opioid use disorders have received opioid agonist therapy 
(Oliva et al., 2013; Gordon et al., 2015). Given the more 
recent availability of medication-assisted therapy (MAT) in 
traditional medical settings (i.e. physicians’ offices), more 
attention is being paid to other barriers to access, including 
the cost of these treatments (Barry and Sindelar, 2007). 
Many of these medications and therapies have not been 
covered by public or private insurance carriers until fairly 
recently (Chalk et al., 2013; Stein et al., 2015). Even when 
the medications are covered by insurance, some public 
and private insurers often limit the coverage to a particular 
phase of treatment (e.g. detox, not maintenance). 
Because MATs are not consistently covered for all phases 
of treatment and because discounted prices through 
insurance companies apply only during the benefit-covered 
period, the financial cost of prolonged OST can become 
a real burden to the individual who must cover the cost 
when treatment exceeds the specified benefit period.
In this chapter we discuss the variation in the cost of 
treatment for opioid addiction in outpatient settings in 
the United States. To do this we must first provide a brief 
description of the US healthcare financing system, as the 
complex environment of private and public payers means 
that patients with different health insurance plans often 
face different prices for the same drug treatment, even 
within the same treatment setting. With this information 
as background, we then review the US literature identifying 
studies that have attempted to estimate the cost per 
daily dose of the three pharmacotherapies approved by 
the FDA for use in the regular settings in which they are 
administered. From the identification of our small set of 
studies we demonstrate the difficulty in trying to describe 
the cost of OST, because different definitions of ‘treatment 
episodes’ are used in addition to different standardised 
doses. We then show, through our own original analysis 
of multi-payer pharmacy data, how, even if we focus on 
a particular pharmacotherapy that is becoming more widely 
used in the United States (buprenorphine), a particular 
stage of treatment (maintenance), and a particular setting 
(outpatient), there are still big differences in the average 
cost per dose of this drug because of the different costs 
negotiated by different US health insurance payers.
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I  Background on the US health insurance system and its role in determining access to pharmacotherapies 
In the United States, healthcare is financed through 
a mixed payer system. Potential payers for services include 
individuals (uninsured), private companies (e.g. employers 
and/or commercial health plans) and public entities (federal 
government, state government and other local government 
agencies). According to recent statistics reported by the 
Kaiser Family Foundation, the majority of Americans 
(56 %) in 2015 were covered by private insurance, mostly 
obtained through (and brokered by) employers (Henry J. 
Kaiser Family Foundation, 2015). Another 20 % in 2015 
were covered by Medicaid, a shared federal-state public 
insurance programme covering individuals on low incomes 
and with disabilities. Medicare, the federal public health 
insurance system for the elderly and people with disabilities, 
provides insurance coverage to another 14 %, while other 
public insurance, including the Federal Children Health 
Insurance Plan (CHIP), TRICARE (which provides care 
for those active in the military and their families) and the 
Department of Veterans Affairs, which provides care for 
retired military personnel, provides insurance for another 
2 % of the population. In 2015, approximately 9 % of the 
total population was without any healthcare insurance 
(Henry J. Kaiser Family Foundation, 2015).
Although the majority of the American population is 
covered by private insurance, it pays for less than 13 % of 
all national substance use disorder treatment expenditures 
(SAMHSA, 2016). State block grants and other local 
spending have covered the largest share of funding (69 %) 
historically (SAMHSA, 2016), although such funding is likely 
to diminish in importance in the era of healthcare reforms. 
State Medicaid, however, which had grown by 2014 to 
cover about 25 % of total national spending, is expected 
to rise substantially due to the expansion in eligibility for 
Medicaid that occurred under the Affordable Care Act 
(Buck, 2011; Mark et al., 2011). Therefore, state agencies 
remain an important payer of substance abuse services.
In the United States, it is health insurance carriers that 
commonly negotiate prices with pharmaceutical companies 
as part of the process of negotiating the inclusion of 
specific pharmaceuticals in the health insurance plan’s 
drug formularies, using the size of their enrollee population 
as a negotiating tool in their bargaining. While insurance 
companies cannot withhold any particular medicine 
recommended by a provider from the patient, they do 
determine whether the insurance company covers some, 
half, most or all of the cost of a given medication by placing 
specific drugs in different ‘tiers’ in their drug formulary. 
Therefore, a drug that is being covered entirely by the health 
insurance company (e.g. vaccines such as flu vaccines), 
would be placed in the lowest tier (implying lowest cost 
to the patient). Generic versions of widely used branded 
prescriptions are also often available at much lower cost 
to the patient than the branded drug and generally placed 
in a low tier. Expensive drugs, particularly those still under 
patent, are often placed in higher tiers, requiring the patient 
to share more of the cost. Some medications, particularly 
new drugs that apply to only small patient groups, often do 
not get included on the insurance plan’s drug formulary, in 
which case the patient is left to cover the full cost of the 
drug at the price listed by the pharmaceutical company.
The US government negotiates pharmaceutical prices 
only for patients covered by federal health insurance 
plans (i.e. Medicare, TRICARE, Veterans Affairs and the 
Federal Employees Health Benefit group). Separate state 
agencies negotiate prices for the patients they cover 
under state insurance plans, including Medicaid and state 
employee health programmes. Private insurance plans 
or large employers who self-insure negotiate directly 
with pharmaceutical companies to obtain prices for the 
prescription drugs that are most frequently used by their 
insured populations.
Given the substantial reforms that are taking place in the 
US healthcare system because of the Mental Health Parity 
and Addiction Equity Act and the Patient Protection and 
Affordable Care Act, access to MATs is expected to change 
dramatically in the United States, with public (Medicaid) 
and private insurance playing an even larger role in terms of 
its paying for MAT (Barry and Huskamp, 2011; Buck, 2011). 
This is due, for instance, to federal subsidies encouraging 
the expansion of eligibility criteria for the state Medicaid 
population, rules increasing the age at which parents can 
cover their adult children on their own health insurance 
(now includes adult dependent children up to age 25), and 
the required integration of medical and behavioural health 
services. Hence, regulations that state Medicaid agencies 
have passed related to access to MAT and the shared cost 
of the drugs are going to be important factors, and they are 
far from homogeneous (Burns et al., 2016). By 2013, most 
state Medicaid programmes covered methadone and/or 
buprenorphine (although some states still do not cover 
both for all Medicaid-enrollees more than a decade after 
buprenorphine’s approval), and most listed buprenorphine 
on their preferred drug lists. However, other Medicaid 
regulations — related to prior authorisation, co-payments 
and counselling requirements — differ considerably across 
states and could potentially limit physicians’ and clients’ 
use of both these MATs (Mark et al., 2011; Stein et al., 
2015; Burns et al., 2016).
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I  Government estimates of the cost of opioid substitution therapies
In 2004, the Substance Abuse and Mental Health Services 
Administration’s (SAMHSA’s) Center for Substance 
Abuse Treatment developed a range of cost estimates 
considered ‘reasonable’ for the delivery of substance 
abuse treatment delivered in different treatment modalities 
to inform policymakers’ funding decisions (SAMHSA, 
2004b). However, these ranges were generated when 
buprenorphine and naltrexone were not widely available 
to clients and the range of cost estimates was so wide 
that little could be inferred from them, as French and 
colleagues (2008) pointed out in their update to SAMHSA’s 
work. However, even French and colleagues’ update 
does not provide a breakdown of the costs by type of 
pharmacotherapy treatment, nor does it clearly distinguish 
between treatments that are administered through 
a programme with supporting behavioural therapies and 
those that are delivered just as pharmacotherapies on 
an outpatient basis. While pharmacotherapies during 
induction and stabilisation are frequently provided as 
inpatient services in hospitals, OTPs or other residential 
locations, maintenance medications, particularly 
buprenorphine and naltrexone, may be administered as 
outpatient therapies, meaning that a doctor can simply 
prescribe the drug for clients to take at home as needed 
with no additional services. Thus, the cost per modality is 
not a good indication of the total cost per treatment, as 
a course of treatment commonly involves detoxification, 
induction and maintenance and different settings. Current 
estimates of the cost of treatment for substance abuse are 
not adequate to properly assess the cost of MAT or even 
the marginal cost of adding pharmacotherapy to an existing 
treatment regimen.
Nonetheless, SAMHSA does produce very reliable 
estimates of the total national spending on treatment of 
substance abuse disorders. SAMHSA’s latest estimate on 
spending for all substance abuse treatment prescription 
drugs (including medications for the treatment of 
alcohol use disorders) was USD 887 million in 2009, 
or approximately 0.006 % of US GDP in 2009 dollars 
(SAMHSA, 2013b). Of this amount, almost USD 754 
million, or 85 % of total expenditure on prescription 
drugs for treatment of substance abuse, was spent on 
combination buprenorphine/naloxone, and USD 62 million, 
or 7 %, on buprenorphine alone (3). Estimates for spending 
on methadone for drug addiction are captured as part of 
spending for specialty substance abuse centres where 
(3) Prescription costs reflect only the cost of the medication, not any over-
head or indirect services associated with dispensing the drug given that 
they can be dispensed in a retail pharmacy. 
methadone is dispensed, rather than with substance 
abuse prescription drug spending, so it is not possible to 
identify how much the government spends on methadone 
vis-à-vis buprenorphine formulations for opioid addiction. 
So, while total expenditure in substance abuse specialty 
centres in 2009 was substantially greater than spending 
on prescription drugs, USD 8 397 million, SAMHSA’s data 
do not permit disaggregation of methadone drug spending 
from other spending that occurs in these settings.
Despite all types of public and private payers being 
included in SAMHSA’s report, such as Medicaid, Medicare, 
private insurance, out-of-pocket-spending, and state 
and local spending, it is not possible to construct an 
average costs per dose by payer in these data. However, 
we found that costs per dose estimates are available for 
some, though not all, types of payers in the United States. 
For example, per a 2007 study of the Veterans Health 
Administration (VHA), the average daily cost of methadone 
(60 to 80 mg/day) in the VHA was USD 0.36 to USD 0.48 
(Goodman et al., 2007). Methadone, however, must be 
administered in an OTP, which is not necessarily available 
in all locations where buprenorphine is offered. Therefore, 
once buprenorphine started being offered in 2003, the 
VHA started providing typical daily doses (12 to 16 mg) — 
based on established national non-formulary guidelines for 
buprenorphine use in office-based practices — at a cost 
between USD 9.48 and USD 10.10 within the VHA system 
(Goodman et al., 2007). Consistent with this estimate, one 
study from 2006, when the VHA approved buprenorphine 
for formulary status and published criteria for its use, found 
that a day’s supply of buprenorphine, defined as a mean 
daily dose of 14 mg, would cost USD 9.82 (Barnett, 2009).
I  Literature review of the cost of medication-assisted opioid addiction treatments in healthcare settings in the United States
Given the regulatory complexities regarding the distribution 
of different pharmacotherapies (i.e. where they can be 
distributed), and the variation in the willingness of payers 
to cover such medications, we were interested in seeing 
the extent to which the literature provides information on 
the average cost of treatment for each of the FDA-approved 
therapies in certain healthcare settings. There have been 
other reviews of the cost-effectiveness and/or cost-benefit 
of these pharmacotherapies, with a recent review by 
Chalk et al. (2013) concluding that methadone was the 
least expensive (USD 30-50 per month of treatment). Oral 
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naltrexone was also fairly inexpensive (about USD 60 per 
monthly dose). Buprenorphine/naloxone combinations 
were a bit more expensive at USD 140-160 per month 
of treatment. Injectable extended-release naltrexone, 
which had only recently become available at that time, 
was the most expensive (at about USD 700 per month of 
treatment). A limitation of this review, however, is that it 
included studies conducted all over the world, and hence 
the estimate of the average cost of treatment incorporated 
availability and cost in different healthcare systems, with 
different levels of cost sharing transferred to the patient. It 
does not necessarily reflect the cost of this treatment in the 
United States, which is what we hope to provide here.
We used the following specific criteria for our systematic 
review. To be included, studies had to be published 
in English and consider care delivered within the US 
healthcare system; the population had to be 18 years 
or older; the study had to be conducted in or after 2002 
(when buprenorphine received FDA approval, as that also 
had an impact on the delivery of methadone); studies 
had to include estimations of average dose, estimate 
cost per dose or cost of treatment and specify the stage 
of treatment (induction, stabilisation or maintenance); 
and studies had to be a randomised controlled trial 
(RCT) or observational or simulation study on cost or 
cost-effectiveness. Studies could include any type of 
insurance or payer, provided the care was received in the 
US healthcare system. The studies could be about MATs 
that included buprenorphine in any of the following trade 
names in any formulation used to treat opioid use disorder: 
Suboxone, Buprenex, Butrans, Subsolve, Bunavail, and 
generic buprenorphine or buprenorphine HCl. Finally, 
the search terms used for this systematic analysis were 
‘medication assisted opioid treatment’, ‘medication 
assisted opioid therapy’, ‘medication assisted opioid detox’, 
‘opioid treatment’ and ‘opioid therapy’.
Our inclusion criteria yielded a selection of 38 studies, the 
vast majority of which were studies presenting findings 
from an RCT. A more careful assessment of these 38 
studies revealed that many did not in fact explicitly include 
acquisition costs for the pharmacotherapies employed. We 
also excluded studies that used price data prior to 2002 
(before buprenorphine was available on the market) or 
used price data from outside the United States. Studies 
that did not provide costs per dose or treatment or that 
did not state the phase of treatment — induction or 
maintenance — were also excluded from the final sample. 
Imposing these criteria reduced our discussion to only five 
papers that presented findings relying on observational 
or administrative data. While several relevant cost-
effectiveness studies that assessed the cost-effectiveness 
between MAT and MAT plus behavioural therapy might 
appear to be excluded (e.g. Sindelar et al., 2007), the 
problem with these studies is that they did not report 
the price of the pharmacotherapy, as it was being held 
constant between the treatment and control conditions. 
However, it is the price of the pharmacotherapy that we are 
focused on in this study.
This exercise demonstrated to us that, in the past 13 
years, very few rigorous real-world analyses of the cost 
of buprenorphine, methadone or naloxone have been 
carried out, as indicated by the relatively small number 
of included studies. Policymakers looking at these data 
would have a difficult time understanding exactly what 
the cost of a daily (or monthly) dose of any of these 
pharmacotherapies would be for a typical US patient. Table 
A12.1 in Annex B provides a snapshot of the key features 
of each of the five included studies. A quick glance at the 
results in the table reveals that the dosages of methadone, 
buprenorphine and naltrexone administered vary quite 
a bit across studies and for individuals over time, and 
they depend on each individual’s stage of treatment. 
Importantly, the perspective of cost also changes from 
study to study, sometimes reflecting the cost to a state 
agency, sometimes the client and sometimes the 
commercial payer. The studies we identified had more or 
less arbitrary lengths of study period for assessing the 
maintenance stage of treatment. As a consequence, each 
study would generate a different cost of treatment, because 
dosages can and do change over the maintenance period.
An important takeaway from this systematic review is 
that, while any given study might be able to provide an 
estimate of the cost of pharmacotherapy, it is important to 
pay attention to the phase of therapy for which the drug 
is being used (which is directly tied to the amount being 
prescribed), the setting of that therapy (inpatient, OTP or 
other outpatient) and the differential prices negotiated 
by payers. To date, most presume that the biggest source 
of variation in cost is associated with the setting in which 
therapy is given. However, the duration of therapies covered 
by insurance in each of these settings varies considerably 
across payers, which suggests that it is important to pay 
attention to the cost per phase of treatment in a manner 
that considers the client’s costs as well as the agency’s 
cost. The cost (and presumably cost-effectiveness) of what 
appears to be the same pharmacotherapy might differ 
significantly if focused on ‘treatment’, which may include 
behavioural therapies in addition to pharmacotherapies for 
some payers or programmes but only pharmacotherapies 
for others. All of these factors make it very difficult to 
construct an overall estimate of the cost of opioid abuse 
disorder treatment for the US healthcare system.
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I  Original analysis of cost of a standardised dose of buprenorphine by payer in 2012
In the light of the findings from the published literature, 
and because of our desire to understand the extent to 
which costs per standardised dose of a pharmacotherapy 
can differ across payers being treated in the same phase 
of treatment (e.g. maintenance), we decided to conduct 
some original analysis of the cost of pharmacotherapy 
received on an outpatient basis. Given the complexities of 
settings and the like, and the fact that there are no publicly 
available data sources containing information on the cost 
of drugs distributed through OTPs, we focus only on the 
drug buprenorphine and its distribution through retail 
pharmacies. This focus provides a clearer cost of just the 
drug itself rather than the additional cost of wrap-around 
services that may be administered during detox (done 
on an inpatient basis) or with behavioural therapies (if 
delivered in an OTP). By looking at buprenorphine alone, 
and standardised doses given during a maintenance 
phase, we can reduce the noise and complexity caused by 
considering other therapies, and focus only on the variation 
created by different payers negotiating prices for the drug.
Information on buprenorphine obtained through a retail 
pharmacy comes from the Symphony Health Solutions’ 
Integrated Dataverse and relates to a standardised dose 
(16 mg). The Symphony Health Solutions’ Integrated 
Dataverse includes transactions from approximately 55 000 
pharmacies, accounting for over 90 % of US prescription 
volume. This commercial database obtains and consolidates 
paid pharmacy transactions, physicians’ claims and hospital 
claims from all payers to create a multi-payer claims 
database. As we rely in our analysis on information reported 
solely in retail pharmacies’ claims, the cost we are examining 
represents only the cost of the medication, not the cost of 
dispensing it, which is absorbed by the retail pharmacy in 
the United States. We examine prices for the year 2012. We 
chose 2012 because this was the most recent calendar year 
before significant expansions in public health insurance 
took place under the Affordable Care Act (US Department of 
Health and Human Services, undated).
Our original dataset included 185 835 410 prescriptions 
administered throughout the year (2012). Of these, 
approximately 0.13 % (245 678 prescriptions) were for 
buprenorphine HCl (8 mg buprenorphine sublingual tablets) 
and Suboxone (oral strips, 8 mg buprenorphine/2 mg 
naloxone and 4 mg buprenorphine/1 mg naloxone 
dosages). We collapsed the data by uniquely identified 
client so that we could identify what the average cost of 
treatment was per client. For about 9.7 % of these clients, 
information on the cost of the prescriptions received was 
missing and could not be explained by rejected claims. 
Therefore, we dropped these observations. The final dataset 
contained 41 093 clients for whom we could construct an 
average cost of buprenorphine per day and month by plan 
type and buprenorphine formulation during the year.
Table 12.1 presents frequency and percentage of clients by 
type of payer and for the different forms of buprenorphine 
products available in the United States. Half (49.87 %) of 
our sample were individuals who paid for buprenorphine 
with commercial health insurance, while about one quarter 
of payers (25.67 %) obtained their medications by paying 
for them entirely with cash (out-of-pocket expenses). Public 
programmes, such as Medicare and Medicaid, represent 
almost 14 % of our sample. The remaining 11 % of clients 
purchased buprenorphine through savings clubs or 
assistance programmes (referred to here as ‘mixed’, as the 
payer can be mixed in these).
There are two plausible explanations for the relatively large 
proportion of commercially insured patients in our sample 
(vis-à-vis public insurance). First, as stated previously, 
the Symphony Health data contain only information on 
prescriptions picked up from retail pharmacies. To the 
extent that Medicaid- and other publicly insured clients pick 
up their buprenorphine from community health centres 
and/or prisons, these prescriptions would not be captured 
in the data (and hence would not be reflected in the primary 
payer). Second, by 2012 key elements of the Federal Mental 
Health Parity Addiction Equity Act and the Affordable Care 
Act had already come into effect, presumably extending 
substance abuse treatment coverage to more individuals 
(Nosyk et al., 2013).
TABLE 12.1
Clients by type of payer in the United States in the year 2012
Type of payer Buprenorphine HCl 
(sublingual) 8 mg
Suboxone (oral strip) 
4 mg/1 mg
Suboxone (oral strip) 
8 mg/2 mg
Total (%)
Cash — no insurance 9 913 0 637 10 550 (25.67)
Private insurer 17 361 4 3 130 20 495 (49.87)
Public entity 4 863 1 777 5 641 (13.73)
Mixed 3 414 0 993 4 407 (10.72)
Total 35 551 5 5 537 41 093 (100)
Source: Symphony Health Solutions’ Integrated Dataverse
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Table 12.1 also provides a frequency count of the types of 
buprenorphine products and formulations that were obtained 
from retail pharmacies by type of plan. Buprenorphine HCl 
(the generic formulation) is by far the most common form 
of buprenorphine distributed by pharmacies (over 86.5 % of 
all prescriptions), with Suboxone (8 mg/2 mg) formulations 
coming in second (13.5 %). The rest of our analysis will, 
therefore, focus on these two products.
As different insurance companies have different rules 
regarding length of treatment covered and clients used 
varying quantities of buprenorphine by type of product, we 
created a ‘standard daily dose’ for maintenance in order to 
calculate cost to individual patients and types of insurance. 
We set this daily dose at 16 mg to be consistent with 
FDA guidelines (US Food and Drug Administration, 2014) 
and because it was within the usual range of dosage for 
patients on maintenance treatment (SAMHSA, 2004).
Next, we constructed an average total cost per standard 
dose of buprenorphine. This was the sum of average cost 
to clients (shared payments they made or full amounts, 
depending on whether or not they had any insurance) and 
plans per client identifier (4). Table 12.2 shows the overall 
costs to clients and plans and total cost of a standard 
dose of buprenorphine in the United States in 2012. When 
average costs are considered for all forms together, it would 
appear that the patient and plan equally share the average 
cost per daily dose. However, the story changes when 
(4) Our sample included observations in which there were negative payments 
for payers. These could have been reimbursed by pharmacies or paid by 
the patient. Because we wanted not to show negative costs but still reflect 
the dynamics of payments in the data, we decided to offset these nega-
tives costs through the client payments, thus lowering the client payment 
and total cost for these observations. Therefore, no information was lost 
and the visual representation makes more sense.
the sample is broken down into its generic formulations 
versus one of its branded formulations (Suboxone oral strip 
8 mg/2 mg). In the case of generic buprenorphine, clients 
pay a larger share of the total cost per daily dose than 
health plans and the total cost per daily dose is less than 
USD 10. In the case of branded buprenorphine (Suboxone 
oral strip 8 mg/2 mg), it is the plans that pay about two 
thirds of the cost per daily dose, and the total average daily 
cost overall is close to twice that of the generic formulation.
While the difference in total average cost per daily 
dose between generic formulation and Suboxone is not 
unexpected, the extent to which there is variation in the 
average plan cost per daily dose is surprising, particularly 
in the case of generic buprenorphine, where competition 
should drive the price down to the cost of production, and 
hence payers should face relatively stable and similar 
costs. However, Table 12.2 shows that both the standard 
deviation and interquartile range for a standard dose of 
generic buprenorphine paid for by the insurer (‘plan’) vary 
substantially, exceeding the mean. Interesting, the standard 
deviation of the plan cost per daily dose of Suboxone is 
similar in magnitude, although the interquartile range (75th 
percentile value to 25th percentile value) is much larger. 
Because pharmaceutical drugs are not bought and purchased 
in normal markets — prices are negotiated on the clients’ 
behalf by insurance companies in private — variation remains.
TABLE 12.2
Average costs of a standard daily dose of buprenorphine, United States, 2012
Standard dose of buprenorphine 
(16 mg)
Mean 
(USD)
Standard
deviation 
(USD)
Minimum 
(USD)
Maximum 
(USD)
Interquartile range
All formulations Patient cost per daily dose 5.4 5.0 0.0 44.6 9.3
(n = 41 093) Plan cost per daily dose 5.6 5.5 0.0 46.4 9.7
Total cost per daily dose 11.0 6.5 0.0 60.2 9.5
Generic 
buprenorphine HCl
Patient cost per daily dose 5.3 4.6 0.0 44.6 9.2
(n = 35 551) Plan cost per daily dose 4.5 4.8 0.0 46.4 7.3
Total cost per daily dose 9.8 5.6 0.0 48.0 9.1
Suboxone oral strip 
8 mg/2 mg
Patient cost per daily dose 6.2 7.2 0.0 27.0 13.3
(n = 5 537) Plan cost per daily dose 12.5 4.8 0.0 28.7 1.2
Total cost per daily dose 18.7 6.6 0.0 54.0 6.9
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In Table 12.3 we take a closer look at the average cost per 
dose for generic buprenorphine by type of payer (private 
insurance, public insurance and so on) to make this point 
even clearer. Because small differences in daily dose prices 
can translate into large differences in monthly drug costs, we 
show the average cost per monthly dose of buprenorphine, 
rather than the cost per daily dose, which was shown in 
Table 12.2. To generate these monthly costs, we multiplied 
the daily cost by 30.
Several important insights can be gained from the simple 
descriptive statistics in Table 12.3. First, private insurers 
have a higher average total cost per monthly dose of generic 
buprenorphine than either public insurers (Medicaid/
Medicare) or individuals who pay their drug costs without 
insurance. However, most of those costs are passed on to 
the patient, because the average plan cost per monthly dose 
is significantly lower on average for the private insurers than 
for the public insurers. Second, substantial variation remains, 
as indicated by the standard deviation, even within plan type 
for the same generic medication. Interestingly, however, the 
standard deviation is similar between public and private 
insurers from the plan perspective (what the insurer pays). 
That is not the case in terms of the variation in the client’s 
share of these costs for people with these types of insurance. 
The variability in average cost to the client among the 
privately insured is even greater than that for the plan. Finally, 
mixed programmes appear to have the highest average total 
costs, with clients paying the biggest share of these higher 
costs. However, the variability in client costs is substantially 
lower for clients in these mixed programmes than if they 
were paying out of pocket, which suggests that there is 
indeed some negotiating power associated with receiving the 
medication through this source instead of paying cash.
Figure 12.1 illustrates the findings from Table 12.3 in graphic 
form in terms of client components and plan components 
by primary type of payer (public or private insurance, no 
insurance and other mixed options), but adds to the graph 
similar information on the average monthly cost of Suboxone. 
Here it is easy to see that, regardless of the type of plan or 
insurance, generic buprenorphine is less expensive than 
Suboxone in terms of plan costs across the board. The cost 
to the plan is higher but less variable for Suboxone than 
for the generic formulations, as is indicated by the smaller 
interquartile range shown in the box and whisker plots. That 
stands in contrast to the costs paid by the client in each plan, 
which have greater variability in the case of Suboxone even 
when median average costs (indicated by the line inside the 
rectangular boxes) are lower. The higher variability in the 
client’s share of the costs may reflect different total prices of 
the drugs (so a function of just passing through the higher 
costs), or the variability may be generated by different private 
insurance companies placing the branded pharmaceutical in 
different tiers (requiring different levels of client cost sharing). 
From this graph alone we cannot tell.
Figure 12.2 combines the total health plan and patient costs 
by insurance type for each drug and plots the total monthly 
costs for a standard dose of buprenorphine. Coloured 
asterisks indicate statistically significant differences in mean 
values in the monthly cost paid between formulations of 
buprenorphine for the same plan type. Thus, we can see 
statistically significant differences between the costs for 
TABLE 12.3
Average monthly costs of a standard dose of generic buprenorphine by type of payer in the United States in 2012
Type of payer Variable Mean (USD) Standard 
deviation (USD)
Minimum 
(USD)
Maximum 
(USD)
Interquartile 
range
Private insurer
(n = 17 361)
Average client cost per monthly dose 129.6 121.6 0.0 1 339.5 202.8
Average plan cost per monthly dose 175.0 140.3 0.0 1 130.7 226.6
Average total cost per monthly dose 304.6 179.5 0.0 1 438.8 305.4
Public entity
(n = 4 863)
Average patient cost per monthly dose 30.0 75.1 0.0 1 110.7 9.3
Average plan cost per monthly dose 231.6 143.8 0.0 1 393.2 155.8
Average total cost per monthly dose 261.7 141.9 0.0 1 429.2 184.1
Cash — out of 
pocket (OOP)
(n = 9 913)
Average patient cost per monthly 
dose
233.4 135.3 0.0 959.4 138.2
Average plan cost per monthly dose 0.0 0.0 0.0 0.0 0.0
Average total cost per monthly dose 233.4 135.3 0.0 959.4 138.2
Mixed
(n = 3 414)
Average patient cost per monthly 
dose
263.1 80.0 0.0 1 021.3 64.6
Average plan cost per monthly dose 184.8 98.4 0.0 1 058.6 68.4
Average total cost per monthly dose 447.9 89.3 33.2 1 266.5 0.0
Note: Average plan and total costs were capped at zero. Some observations had negative values.
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Suboxone and generic buprenorphine for all of the payer 
types. That is, total monthly costs for a dose of generic 
buprenorphine are consistently lower than the total costs 
for Suboxone for public entity payers, as well as for private 
insurers, out-of-pocket payers and mixed programmes.
What is particularly interesting about Figure 12.2 is that it is 
possible to see the extent to which total costs per monthly 
dose (which combines plan and client costs) varies by type 
of payer in comparison with the variation in pass through 
to plan or client. While we saw in Figure 12.1 that mixed 
payers had variability in the plan and client costs for generic 
buprenorphine separately, we see in Figure 12.2 that there 
is no variability in the total cost for generic buprenorphine 
within the mixed insurer category. There is only one value for 
the total cost per monthly dose (a set price), and what varies 
is just how that one cost is distributed between the client and 
the payer that is subsidising those costs (possibly associated 
with different cost sharing associated with different coupon 
or group deals). That is fairly different from total monthly 
prices faced by clients who pay entirely out of pocket (i.e. 
without insurance or with other coupons or subsidies). 
Clients who pay out of pocket entirely for the average monthly 
dose still see variability in the price paid whether paying for 
generic buprenorphine or Suboxone. The variation in price 
is less than that observed when the drug is being paid for 
primarily through private insurance. Negotiated prices by 
private insurers clearly vary quite a bit both in the total cost 
(shown in Figure 12.2) and in the distribution of who pays 
those costs (as shown in Figure 12.1). And, similarly, we see 
quite a bit of variation in the average monthly cost of generic 
buprenorphine paid for by clients with publicly provided 
insurance. While the average total monthly cost of Suboxone 
is still higher than that of generic buprenorphine for those 
purchasing it with public insurance, the variation in monthly 
cost per dose for the branded version is quite a bit less than 
that for the generic among the publicly insured.
The main point illustrated by these figures is that, despite 
there being a single cost for a pharmaceutical firm to 
produce these pharmaceuticals, the prices paid for them 
vary quite a bit depending on who is negotiating the price, 
and then the share of that cost that is borne by the insurer 
versus the client is also highly variable in most instances 
(with the exception of public insurance). Some of the 
variability between plan and client within the private insurer 
category may be due to differential placement of these 
drugs in their drug formularies (with different tiers requiring 
different levels of co-payment), or the generic version being 
excluded entirely from the drug formulary (causing the client 
to pay the full price). We cannot say from these data alone 
which factors are driving the bulk variation; we can only 
speculate on potential factors that may be causing some of 
the variation.
I Discussion and conclusions
Despite modest declines in prescription opioid overdose 
deaths since 2010, more than 33 000 lives are lost annually 
to opioids (Rudd et al., 2016b). Thus the prescription drug 
problem remains significant in the United States. Increasing 
access to effective treatment is a major strategy proposed 
for dealing with the opioid epidemic in the United States, 
but the US treatment system is not well situated to deal 
with this problem because the primary payers — not 
private insurers — are not well informed about the real 
cost of treatment. Efforts to calculate the average cost of 
treatment for substance abuse (of any type) within this 
system are influenced by a variety of cost drivers that 
include (1) where substance use is delivered (inpatient, 
outpatient or partial outpatient settings), (2) the type of 
FIGURE 12.1
Monthly costs using a standard daily dose of generic 
buprenorphine and Suboxone by type of payer in the 
United States in 2012
Note: OOP, out-of-pocket expense
FIGURE 12.2
Total monthly costs for a standard daily dose of 
generic buprenorphine and Suboxone by type of payer 
in the United States in 2012
*P-value < 0.05
**P-value < 0.01
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facility in which it is delivered (inpatient hospital settings 
are different from inpatient OTPs) and (3) the additional 
services that frequently get delivered with the therapy. 
This chapter highlights yet another important source of 
variation in the cost of treatment, particularly relevant for 
pharmacotherapies, and that is the variation in negotiated 
input prices. While some attention has been given to the first 
three sources of variation listed, far less attention has been 
paid to differences in negotiated input prices for the exact 
same therapy, which by definition influences average cost.
Even when we focus on just the pharmaceutical cost of 
providing OST, we find that a variety of factors can influence 
the negotiated price paid, including the particular type of 
drug offered, the dose required (which varies depending on 
the stage of treatment) and the payer. We demonstrate in 
the last section of this chapter that, even when comparing 
standardised dosages and comparing the same stage of 
treatment, the expected payer matters when considering 
the average cost of the treatment. Looking at the data 
collected, we can see clearly that individuals with different 
types of insurance are paying different amounts for their 
daily and monthly doses of buprenorphine. While there 
are some general trends (branded pharmaceuticals are 
more expensive than generic ones), considerable variability 
remains in the prices paid within these categories, some of 
which are completely absorbed by the plans (in the case of 
public insurance) and some of which are more likely to be 
absorbed by the patient (in the case of private insurance).
The study has several limitations that need to be 
considered when drawing conclusions from it. First, we 
have focused here only on the cost of the pharmacotherapy 
portion of treatment, not any additional services that may 
make pharmacotherapy more or less effective. Second, 
we have been able to examine variation in the cost of 
only one pharmacotherapy (buprenorphine) that is 
prescribed and administered through retail pharmacies. 
This study cannot say anything about the variation in 
the cost of buprenorphine or other pharmacotherapies 
offered in other healthcare settings (community health 
clinics, hospitals, OTPs). Third, we have looked only at 
the cost of a standardised dose of a drug offered in the 
maintenance stage, which may not be the most important 
or expensive aspect of a full treatment episode (particularly 
if detoxification or induction into treatment is largely 
done in inpatient settings). Fourth, we could only provide 
information on the cost of this pharmaceutical only for 
clients who continued taking the drug. If clients were less 
likely to stay on a particular formulation because the costs 
were prohibitive, then our sample may be biased by people 
who had lower average costs in the first place (and hence 
were willing to stay on it for longer periods of time).
Even with these limitations, this study provides some 
useful insights and cautions for policymakers interested 
in drawing comparisons regarding the relative cost or 
cost-effectiveness of pharmacotherapies received in the 
United States to those countries that operate healthcare 
at a national level. The unique healthcare environment in 
which these services are currently being delivered may 
heavily influence the relative cost of the care received, but 
so too might the payer of the services (for instance, when 
purchasing power by large entities, such as government or 
large private networks, can affect the final price of these 
medications and their cost-effectiveness). Thus, it will be 
important for researchers to think of ways to standardise 
information across countries in a meaningful way so that 
relevant direct comparisons of costs across countries can 
be made. To the extent that international comparisons of 
the cost of treatment are made including countries with 
a single public payer, it would be wise to use information on 
the cost of treatment paid by our public insurers (Medicaid/
Medicare) rather than private insurers, as the cost paid for 
the exact same therapies in the United States clearly differs 
depending on the bargaining power of the payer.
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I  Annex B  US regulations and clinical guidelines regarding the delivery of opioid agonist therapy in the United States
Prior to 2002, methadone and levo-alpha-acetyl methadol (or LAAM) were the only federally 
approved and supported OSTs available in the United States and both had to be distributed 
in certified OTPs. Methadone was first introduced on a national scale in the early 1970s, 
whereas LAAM, manufactured by Roxane Laboratories, received FDA approval in July 1993 
(Center for Substance Abuse Treatment, 1995) but was taken off the market in 2004, when 
Roxane Laboratories stopped producing LAAM because of an increased risk of cardiac 
complications (Center for Substance Abuse Treatment, 2005).
Methadone treatment dosage, like that of the other pharmacotherapies, is expected to vary 
based on the stage of treatment. Regulation 42 CFR § 8.12 (h)(3)(ii)) states that, in the case 
of methadone, initial doses should not exceed 30 mg and the total dose for the first day 
should not exceed 40 mg unless the client’s opioid withdrawal symptoms do not dissipate 
(SAMHSA, 2015b). For clients in the maintenance stage stage, there is no agreement 
on optimal dosages for patients. However, a common conclusion from several studies is 
that patients receiving higher methadone doses report better outcomes than those on 
lower maintenance doses (Leavitt, 2003). Only oral forms of methadone are allowed to be 
dispensed for opioid addiction treatment; non-oral forms are strictly prohibited. Currently, 
only oral forms of methadone can be dispensed for opioid use disorders, where non-oral 
forms are strictly prohibited. In the past, only liquid formulations could be dispensed, but 
current SAMHSA regulations permit solid forms of the medication (SAMHSA, 2015b).
A major limitation of methadone (and LAAM) is that it can be administered only within an 
OTP. Thus patients who would not or could not routinely attend OTPs for geographical, 
ideological or practical considerations are not well served by it (Fiellin and O’Connor, 2002; 
Oliva et al., 2011). It was not until the Drug Addiction Treatment Act of 2000 that the FDA 
allowed Schedule III-V medications, such as buprenorphine, to be prescribed for opioid use 
disorder treatment in non-OTP settings. Buprenorphine was approved by the FDA as a drug 
for the treatment of opioid addiction in 2002 (Kleber, 2007), and was expected to have 
an immediate impact on the utilisation of MAT (Ducharme and Abraham, 2008; O’Brien, 
2008). Under the Drug Addiction Treatment Act (Civic Impulse, 2017) waivered physicians 
were permitted to prescribe or dispense buprenorphine to no more than 30 patients for 
the treatment of opioid use disorder at any one time. The Office of National Drug Control 
Policy Reauthorization Act of 2006 modified restrictions to grant approval for treating up to 
100 patients at a time to physicians who had been waivered for at least a year, who were 
currently treating patients with buprenorphine and who opted to apply for the higher patient 
limit (Office of National Drug Control Policy Reauthorization Act, 2006).
In the case of buprenorphine as treatment for opioid use disorder, the optimal dosage 
for individuals also varies based on the stage of treatment (induction — also known 
as detoxification — stabilisation or maintenance). When approved, the recommended 
initial (i.e. first day) dose for someone in the induction phase is between 2 and 8 mg, and 
the usual stabilisation dosage is 12-24 mg per day (US Food and Drug Administration, 
2014). As clinical experience with buprenorphine has increased, there has been greater 
appreciation of the nuances of prescribing buprenorphine reflected in more recent 
guidelines (Farmer et al., 2015; Kampman and Jarvis, 2015), but there remains a consensus 
that the recommended daily dose for most individuals receiving maintenance treatment lies 
between 12 and 16 mg per day (US Food and Drug Administration, 2014), with little clinical 
support for doses above 32 mg.
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Naltrexone, approved by the FDA in tablet form in 1984 for treatment of opioid dependence, 
was not frequently administered to patients in pill form because of patient compliance 
problems as well as noteworthy side effects, now prominently featured on medication 
labels (Tai et al., 2001; SAMHSA, 2009; Rinaldo and Rinaldo, 2013). That changed in 
October 2010 when the FDA approved Vivitrol, a long-lasting injectable slow-release 
formulation that lasts for approximately 30 days. Naltrexone implants, which also provide 
sustained doses to a patient over several months, are available in other countries, but have 
not yet been approved by the FDA for use in the United States.
Patients using naltrexone pills may receive an initial dose of 25 mg during the detoxification 
(or induction) stage and then transition to 50 mg pills (one each day) during maintenance 
phase. However, those patients at risk of adverse events (young people, women, those with 
a shorter period of abstinence) may need lower daily doses, from 12 to 25 mg, building 
up to 50 mg per day (SAMHSA, 2009). The recommended dose of Vivitrol, the extended-
release injectable formulation of naltrexone, is 380 mg, to be delivered intramuscularly once 
a month.
Our systematic review of studies examining the average cost of various substitution therapy 
pharmaceuticals identified only five studies in which information on the average dose of the 
pharmacotherapy was available (in real-world settings where these drugs were being paid 
for entirely through the usual market system). These studies, and the key characteristics of 
each, which are described in detail in the main chapter, are shown in Table A12.1.
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TABLE A12.1
Previous cost estimates of substitution therapy using buprenorphine, combined buprenorphine/naloxone and 
methadone in the United States
Study Year RCT, 
observational 
or simulation?
Purpose: 
maintenance 
or induction 
(detox)
Insurance 
(payers)
Average dose Average cost per dose (in 
constant 2015 USD)
Jackson 
et al.
2015 Simulation 
using cost 
data from 11 
state Medicaid 
programmes 
and single-state 
agencies
Maintenance (six 
months total)
State addiction 
treatment payers
Flexible doses 
for methadone, 
buprenorphine 
and extended-
release naltrexone 
(simulation)
N/A. Only costs per day of 
treatment are available: 13.31 
for methadone, 21.16 for 
buprenorphine and 48.36 for 
extended-release naltrexone
Schackman 
et al.
2012 Simulation 
using cost 
data from an 
observational 
study
Maintenance 
(excluding first 
six months of 
treatment)
N/A 8 mg 
buprenorphine/2 mg 
naloxone
8.33 for four tablets of 2 mg 
buprenorphine/0.5 mg naloxone 
and 0.93/mg for an 8 mg 
buprenorphine/2 mg naloxone 
tablet. Authors adjusted for 
discounts frequently available to 
large public and private insurers 
using the published local discount 
for all Medicaid drugs (14 % 
discount plus 3.15 dispensing fee 
per 30-day prescription). Original 
data in 2010 dollars (7.62 for four 
tablets of buprenorphine/naloxone 
and 0.85 per 8 mg tablet)
Polsky et al. 2010 RCT Induction and 
maintenance (12 
weeks total)
Six community
out patient 
treatment 
programmes in 
New Mexico, North 
Carolina, Maryland, 
Maine and 
Pennsylvania
No average dose was 
provided
Adjusted average acquisition cost 
of buprenorphine/naloxone. No 
costs per dose were provided 
although substance abuse 
costs were 87.48 and 26.01 for 
buprenorphine administration 
during the induction and 
maintenance phases (74 and 22 in 
2006 dollars from original data)
Jones et al. 2009 RCT Maintenance 
after one year 
of stabilisation 
period (six 
months total)
Clinical trial 
(analysis assumed 
patients did not 
incur costs for 
medications)
17 mg per day of 
buprenorphine (range: 
6-24 mg);
69 mg per day 
(range: 20-100 mg) 
for clinic-based 
(MC) methadone; 
and 70 mg per day 
(range:25-100 mg) 
for office-based (MO) 
methadone.
Buprenorphine: 10.02 per daily 
dose (original data in 2006 dollars: 
8.48 using 0.53 per mg as base)
Clinic methadone: 3.56 per daily 
dose (original data in 2006 dollars: 
3.01 using 0.05 per mg as base)
Office methadone: 3.39 per daily 
dose (original data in 2006 dollars: 
2.87 using USD 0.05 per mg as 
base)
Kaur et al. 2008 Observational 
(using 
administrative 
data)
Initiation (fixed 
observations 
for six calendar 
months) and 
maintenance 
(fixed 
observations 
for 12 calendar 
months)
Commercial health 
maintenance
organisation, 
point-of-service, 
preferred provider 
organisation, direct 
access, medical 
savings account, 
and traditional 
indemnity plans 
in a New Jersey 
managed care 
organisation
Between 4 and 24 mg 
of buprenorphine 
with a range from < 4 
to 48 mg (authors 
calculated per 
individual prescription 
per day
using the following 
formula: number 
of tablets divided 
by days’ supply 
multiplied by 
the strength of 
buprenorphine 
naloxone
filled
19.4 per patient per day during 
six-month initiation period and 
3.44 per patient per day during 
12-month follow-up (15.9 for 
six-month initiation and 2.82 for 
12-month follow-up in original price 
data. Note: authors did not specify 
dollar years, assumed 2005 dollars
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I Introduction
From the papers in this report it has become clear that 
public expenditure research is a complex matter. Four 
methodological elements contribute to this complexity: 
(1) the lack of good-quality data; (2) the complexity of 
the estimation methods as such; (3) the difficulty in 
disentangling data for different addictive substances and 
behaviours (illicit drugs (and different types of illicit drugs), 
alcohol, tobacco and gambling); and (4) the difficulties 
in developing a uniform methodology across different 
countries that allows country comparisons.
With regard to the last point, it is quite clear that when 
comparisons are made across countries it is important 
that the same measures are used (Ásgeirsdóttir and 
Ragnarsdóttir, 2013). A common conceptual and 
methodological framework is indispensable for a valid 
cross-national comparison (as advocated in 2000 by 
Collins and colleagues). A cross-national comparison 
of public expenditure is important, in particular for the 
countries in the EU. It allows countries to compare 
their specific, national results with expenditure in other 
countries.
Even if national and international data registration is 
improved and a uniform methodology is systematically 
applied to measure expenditure, the results of such an 
analysis must be used with caution in a cross-country 
comparison. In particular, caution is required when using 
the results of a free-standing public expenditure study for 
policy (decision-making) purposes. In fact, other factors 
should be taken into account to contextualise the results 
from public expenditure studies. Countries differ in terms of 
drug policy, in healthcare and treatment organisation and 
financing, in the provision of types of drug treatment and 
in the socioeconomic context (Mathers et al., 2010; Metz 
et al., 2014; OECD, 2014; Eurostat, 2016). The challenge 
is how to make meaningful comparisons across countries 
with different characteristics.
In order to take into account that cross-national 
comparisons are affected by the characteristics of 
national treatment policies and systems, we present 
a multidimensional model to improve the analysis of public 
expenditure studies.
I  A multidimensional model for improving the analysis of public expenditure studies
Figure 13.1 presents a multidimensional model for the 
interpretation of expenditure on treatment of illicit drug 
users. Government policy is the starting point of the model, 
given its overall influence on different policy domains and 
competence levels. Furthermore, this contextualisation 
model takes into account that drug treatment expenditure 
is determined by the drug policy, drug treatment policy, 
healthcare policy and the socioeconomic context. We 
elaborate on each of these domains, and investigate 
whether or not EU data are available on these topics.
FIGURE 13.1
Model for the contextualisation of drug treatment 
public expenditure
Socioeconomic context
1. Economic growth (GDP)
2. Size of the population
Healthcare policy
Government policy
General context Drug-related context
1. Healthcare organisation
2. Source of nancing
Drug policy
Drug policy mix
Drug treatment policy
1. Prevalence
2. Treatment organisation 
     and provision
3. Treatment access
CHAPTER 13
A cross-national comparison of public 
expenditures on drug treatment: 
context is key
Freya Vander Laenen and Delfine Lievens
INSIGHTS I Drug treatment expenditure: a methodological overview
160
I Drug policy
The drug policy is likely to influence drug treatment 
expenditure. Overall, in European countries, drug policy 
has a balanced and integrated approach with a focus on 
alternatives to punishment for drug users and on (drug) 
treatment (Reuter, 2009; Council of the European Union, 
2012), although these measures are available to varying 
degrees in the different countries (EMCDDA, 2015a). As 
a consequence, for instance, should the policy change 
to an approach that is more focused on punishment, this 
is likely to influence the drug budget of governments. 
Public expenditure studies on drug policy provide insight 
into how drug expenditures are composed or what the 
public authorities’ ‘policy mix’ is. Consequently, the 
prevailing balance between the various sectors of drug 
policy (prevention, treatment, harm reduction and law 
enforcement) becomes visible (Moore, 2008; Vander 
Laenen et al., 2008; EMCDDA, 2014a).
I Drug treatment policy
In addition to this relationship between drug policy 
and drug treatment policy, there is interaction between 
drug treatment policy and drug treatment expenditure. 
However, the government might have less impact on 
expenditure related to the consequences of illicit drugs, 
such as hospital and other inpatient treatment, since this 
expenditure is influenced more by clients’ clinical and 
behavioural characteristics (Metz et al., 2014) and by the 
drug treatment organisation than by deliberate drug policy 
options (Moore, 2008).
This relationship between drug treatment policy and 
public expenditure is determined by a couple of factors. 
A country’s drug treatment policy is, among other things, 
influenced by the prevalence of different types of illicit 
drug misuse and different profiles of illicit drug users, the 
organisation and provision of drug treatment, and the 
number of treated persons (of the target group).
Public expenditure in a given country will be influenced 
by the prevalence of different types of problem drug use 
and the profiles of drug users. Substantial variation can 
be found between the EU countries in the levels, types 
and sequences of substance use (EMCDDA, 2015b; 
Degenhardt et al., 2016). However, differences in public 
expenditure cannot be solely explained by the country’s 
prevalence rates of problem drug use. For instance, an 
EU cross-country comparison on hospital drug treatment 
found no positive correlation between the number of 
substance abusers and a higher rate of hospital occupation 
for these problems (Lievens et al., 2014). The EMCDDA 
summarises the (last year) prevalence of high-risk drug 
use of the EU Member States; however, data are missing 
for most countries (1). The registration of prevalence 
estimations should be increased so that policymakers can 
monitor the key targets and the allocation of resource to 
drug policy (Hickman et al., 2002).
Next to the prevalence rates of problem drug use and drug 
users, the organisation of drug treatment influences the 
policy and subsequently the public expenditure, as the 
choice of inpatient or outpatient drug treatment affects the 
drug treatment budget. In fact, the unit cost for inpatient 
care is much higher than that for outpatient care. For 
example, Gossop and Strang (2000) estimated a cost of 
EUR 168 (per patient per day) for opioid detoxification in 
the inpatient setting compared with EUR 7 in the outpatient 
settings (year 1999/2000). From this point of view, it is 
interesting to separate inpatient treatment expenditure 
from those for outpatient treatment. However, we should 
add that, taking the concept of economies of scale into 
account (Glied and Smith, 2011), the size of a treatment 
service will have an impact on the costs of the treatment as 
well: bigger treatment services will result in lower average 
costs (2).
In Europe, a wide range of treatment interventions 
is available, from detoxification, pharmacological 
maintenance, psychosocial care and long-term 
rehabilitation to community-based interventions or 
harm reduction. However, there are important disparities 
regarding the provision of types of drug treatment across 
the EU Member States (Metz et al., 2014). In general, the 
(dominant type of) treatment provision depends on the 
sociocultural context of the country (Reissner et al., 2012; 
Metz et al., 2014). Mathers et al. (2010), for example, 
reported that opioid maintenance treatment is more 
provided in the western European countries than the 
eastern European countries. The treatment offer can also 
differ with regard to the provision of treatment for different 
domains linked to problem drug use, such as interpersonal 
relations, personal development and social inclusion, and 
to what extent treatment is illness focused or wellness 
oriented (Neale et al., 2011). This applies for instance to 
the provision of additional psychosocial support and the 
provision of OST (Vanderplasschen et al., 2015). For EU 
countries, the TDI provides useful data on the number of 
new clients entering outpatient and inpatient treatment 
centres in EU Member States, making it possible to monitor 
(1) Since 2012, problem drug use has been known by the broader term 
‘high-risk drug use’. High-risk drug use is defined as the use of psycho-
active substances (excluding alcohol, tobacco and caffeine) in a high-risk 
pattern (e.g. intensively) and/or by high-risk routes of administration in the 
last 12 months.
(2) Although Kristensen et al. (2008) do warn that services may become so 
large that the cost of treatment will be higher because of diseconomies of 
scale. 
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(differences in the use of) the types of drug treatment 
(Mounteney et al., 2016).
Next to the prevalence and the profile of problem drug 
use and the types of treatment interventions, access 
to treatment will have an impact on drug treatment 
expenditure. In mental healthcare, a treatment gap — i.e. 
the gap between the number of people who need and the 
number of people who actually receive treatment — has 
been frequently reported (Woodward et al., 1996; Alonso 
et al., 2004; Kohn et al., 2004; McLellan and Meyers, 2004; 
Wittchen et al., 2011; Rehm et al., 2013) (3). There is no 
international database providing data on the treatment 
gap; nevertheless, the prevalence rates of problem drug 
users (given that recent data are available on the EMCDDA 
website) and the number of clients in treatment can be 
provided by the EMCDDA Statistical Bulletin, as part of 
the data published in the ‘treatment demand’ database (4). 
The EMCDDA provides only estimates of the treatment 
gap for clients covered by estimates of problem drug use 
(predominantly opiate-using clients).
I Healthcare policy
Drug treatment expenditure is influenced by the general 
healthcare policy. The healthcare system and the 
organisation of healthcare might affect this expenditure. In 
fact, as is the case for drug treatment, the organisation of 
(mental) healthcare in the EU differs by country. Whether 
drug treatment is (partly) integrated within the (mental) 
healthcare system in a given country or operates largely 
independently from that system, many studies (e.g. Priebe 
et al., 2008; Samele et al., 2013; Haro et al., 2014) have 
reported considerable variation in mental healthcare 
provision across Europe. Yet we are unable to make good 
systematic comparisons of these differences across 
countries.
Furthermore, the structure of healthcare systems also 
determines public spending on drug treatment. Drug 
treatment expenditure is influenced by the source of 
finance, i.e. general taxation or insurance-based systems. 
Countries with predominantly insurance-based systems 
(e.g. Belgium, Germany, France, Luxembourg and the 
Netherlands) have higher healthcare expenditure, 
because the insurance-based system is characterised 
by a lower degree of control over expenditure (Pestieau, 
2006). Moreover, the mix of public and private health 
financing differs in EU countries, leading to differences in 
(3) Kohn et al. (2004) reported a 92.4 % median treatment gap for alcohol 
misuse and dependence in Europe. This study did not report the treat-
ment gap for illicit drug disorders. 
(4) See http://www.emcdda.europa.eu/data/stats2016
reimbursement and coverage of costs (Metz et al., 2014). 
The eastern European countries are characterised by 
a lower proportion of public financing of healthcare (e.g. 
54 % in Bulgaria and 62 % in Hungary) than the western 
European countries (e.g. 83 % in Luxembourg and 77 % 
in Germany) (Eurostat, 2016). Health expenditure by 
type of financing (general government, social security, 
private out-of-pocket and private insurance) and by type 
of function (inpatient care, outpatient care, long-term care, 
medical goods and prevention) is an essential component 
of the SHA (5). The SHA provides a systematic description 
of the annual financial flows related to the consumption 
of healthcare goods and services in European countries. 
Its intention is to describe a health system from an 
expenditure perspective. Furthermore, it aims to provide an 
integrated system of comprehensive, internally consistent 
and internationally comparable accounts, which should 
as far as possible be compatible with other aggregated 
economic and social statistical systems and can be 
retrieved from the Eurostat or OECD database.
I Socioeconomic context
Public expenditure should also be framed within the 
socioeconomic context of a country. Socioeconomic 
variables that are known to be associated with the 
likelihood of substance misuse, such as employment 
status, education and income, should be reported (Henkel, 
2011). For EU Member States, the EU Statistics on Income 
and Living Conditions (SILC) instrument is used to collect 
data on income, poverty, social exclusion and living 
conditions (available on the Eurostat website) (6). Next, 
changes in the economic situation may affect expenditure 
on healthcare and drug (treatment) policy. For example, an 
EMCDDA study (2014b) on the 2008 economic recession 
showed the impact of austerity on public expenditure 
regarding drug policy, and even on the mix of public and 
private health financing. The same study noted that public 
austerity has led governments to move from inpatient 
to outpatient treatment because of the cost savings 
(EMCDDA, 2014b). In this context, the economic situation 
and the wealth of a country, as well as its population, are 
part of our model.
First, public expenditure analysis can be contextualised 
in terms of the proportion of the GDP. Drug-related 
expenditure as a proportion of GDP is relevant, because 
it takes into account that a richer country might invest 
more in drug (treatment) policy for a given size of problem 
(5) Eurostat (2016, 2017).
(6) Data on income and living conditions can be extracted from the EU 
SILC instrument, see http://ec.europa.eu/eurostat/web/income-and-liv-
ing-conditions/data/database
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(Reuter, 2006). Healthcare expenditure in eastern Europe 
is much lower than in the other EU countries, linked to the 
lower GDP per capita. Moreover, the proportion of GDP 
spent on illicit drug treatment should be compared with 
the proportion spent on other health problems (e.g. mental 
illness, obesity, cancer) (Knapp, 2003; Moore and Caulkins, 
2005). This economic impact analysis allows decision-
makers to monitor resource allocation in accordance with 
the economic burden imposed by the different health 
problems (McDonald, 2011).
Second, public expenditure on illicit drug treatment 
should be reported per capita. The population size has an 
impact on the demand for public goods and related public 
expenditure.
These economic and demographic data of the EU Member 
States, such as the GDP and the population, are reported 
by the Eurostat and OECD databases. These databases 
also provide extensive data on healthcare expenditure (by 
provider, by function and by financing agent). Unfortunately, 
expenditure by type of health problem is not available, 
which prevents comparisons of the proportion of GDP 
spent on illicit drug treatment with the proportion spent on 
other health problems.
To sum up, with this model we want to provide a framework 
to contextualise drug treatment expenditure. By developing 
this model, we are trying to incorporate the critique 
that public expenditure studies are overall limited to 
cross-national descriptive comparisons rather than 
comparative policy analysis (Ritter et al., 2015). Our 
model helps to explain differences between countries in 
their drug treatment expenditure with the help of three 
indicators (healthcare policy, drug treatment policy and 
the socioeconomic context). We are aware that some 
external factors have not been included in the model. For 
example, this is the case for community values (e.g. the 
marginalisation and stigma attached to substance use; see 
Wittchen et al., 2011), and the cultural context in a country 
will influence the differences in treatment approaches 
as well as the clients’ characteristics (Valentine, 2009; 
Matheson et al., 2014; Metz et al., 2014). Another example 
is the quality of evidence in a given country that is available 
to guide policy decisions and the value that is attached 
to scientific evidence in the policy debate. However, in 
our model, we focused on factors for which EU data are 
available in international databases. By focusing on these 
factors, we want to move the discussion forward on public 
expenditure studies in drug policy.
I Concluding thoughts
This multidimensional model can provide a valuable basis 
for an assessment of public spending on drug treatment 
policy, and this kind of model could be applied to other 
health problems. Adapting this framework for different 
diseases would allow us to make comparisons between 
different health problems across EU countries. Providing 
information on social security systems, institutional 
structures, cultural traditions, etc. becomes even more 
important if studies from high-income countries are 
compared with studies from low-income countries (Lievens 
and Vander Laenen, 2016). To give but one example, 
with respect to the healthcare system, Dickson-Gómez 
(2012) stated that the treatment of substance misuse 
disorders in some developing countries is not adequate 
to meet demand, is not evidence based and is of poor 
quality. Conversely, the eventual shortage of treatment 
provision is caused by the fact that in low-income countries 
the proportion of public expenditure allocated to drug 
treatment is lower than in high-income countries.
However, it should be clearly stated that our model does 
not pursue an (economic) evaluation of drug treatment 
policy. An evaluation model would require an investigation 
of outcome measures such as the quality of care or the 
cost-effectiveness of the treatment. A public expenditure 
study cannot detect a lack of performance without other 
types of research such as a cost-effectiveness analysis 
(Lievens et al., 2012; Ritter et al., 2015). Therefore, public 
expenditure studies should be conducted and, in particular, 
the results reported with caution. They run the risk of 
being misused for policy means because money is the 
common metric for putting expenditure on a common 
footing (Dominguez Rivera and Raphael, 2015; Lievens 
et al., 2016). In fact, money cannot be the only metric for 
evaluating policy, let alone be the only basis for policy 
decisions. Health, human rights and development are 
essential factors to be considered in policymaking and in 
developing a balanced drug policy, as was clearly stated by 
the Lancet Commission on Drug Policy and Health on the 
eve of the 2016 United Nations General Assembly Special 
Session on Drugs (Csete et al., 2016).
To conclude, governments and health systems are 
confronted with a number of problems such as increasing 
costs while available financial resources are under pressure 
(Bhattacharya, 2016). As a consequence, they are faced 
with difficult decisions in allocating available resources 
(Hoang et al., 2016). In view of the increasing importance 
of accountability and the requirement for an (economic) 
evaluation of drug policy, it is clear that economic methods 
of policy evaluation are here to stay.
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Despite the lack, so far, of a uniform methodology to 
measure public spending in different countries, it is still 
possible, even when comparability is low, to contextualise 
the results of public expenditure studies. Overall, to 
increase comparability, we recommend at least presenting 
public expenditure per capita and as a proportion of GDP 
(Lievens and Vander Laenen, 2016).
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I Introduction
Social cost studies are a useful tool for public authorities. 
They allow the ranking and prioritising of public policies. 
In the present case, the social cost of drugs measures the 
monetary resources expended by the various social agents 
as a consequence of the consumption, production and 
trafficking of illicit drugs.
The objective of this chapter is to describe the general 
methodology used to compute the social cost of drugs. It 
falls into three parts. Part one defines what a social cost 
study is, its usefulness and its composition, depending 
on the available methodologies. Part two explains how 
to compute the social cost of drugs according to the 
methodology chosen. The third part shows how the 
methodology was applied to French data for 2010 and the 
data sources used.
I What is a social cost study?
I Definition and objectives
In economics, consumption of goods generates a private 
cost, intentionally borne by the consumers, which they 
agree to pay in order to enjoy the benefits of the goods. 
However, sometimes, it can also produce a social cost, 
which includes all the costs unintentionally borne by 
society that the consumers did not take into account in 
their initial consumption decision.
From the perspective of policymakers, social cost is 
a synthetic indicator of the extent and importance of 
a social problem that is useful to compare and rank 
different social issues. Expressed in a monetary unit that 
will be meaningful to everyone, it represents the value 
of the losses to society resulting from the phenomenon. 
Consequently, it helps policymakers to adopt an 
appropriate policy, especially when it involves significant 
public expenditure that is a burden on the national 
public budget. Furthermore, when a policy evaluation is 
sufficiently precise, it also permits better evaluation of 
the benefits of a given public policy such as prevention or 
repression. It also acts as a guide to changing taxation rates 
or reviewing related legislation.
The social cost of drugs evaluates the overall 
consequences of drugs in terms of their monetised costs 
to society. The trade in and consumption of these drugs 
have negative consequences, as they lead to illnesses, 
loss of quality of life for individuals, premature deaths, loss 
of production for businesses and public expenditure. The 
state has to prevent and treat those consequences. On 
the other hand, drug users dying prematurely may ‘save’ 
some public funds (in terms of foreseeable but prevented 
spending on health, social care or pensions), and these 
consequences must also be taken into account. A complete 
social cost study estimates the net social costs, i.e. 
estimates total costs and deducts social benefits of illicit 
drugs.
I Composition of social cost
Social cost is composed of an external cost and of the 
effect of net public expenditure on social welfare, as 
detailed in Table 14.1.
Some harms including pain, fatigue and suffering in 
relation to disease, referred to as ‘intangible costs’, are 
difficult to measure and to put a value on. Those intangible 
costs concern the victims and their relatives (who may stop 
working to care for the victim). They are usually entered in 
cost-benefit analyses as a theoretical, if unmeasurable, 
construct that should be forgotten in decision-making. 
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Given the difficulty of estimating intangible costs, these are 
excluded from social cost calculations.
External cost 
External cost is made up of the costs that do not directly 
affect the consumer but directly negatively affect a group 
of other citizens who do not receive any monetary 
compensation for that cost. In the case of drugs, those 
classic externalities comprise accidents provoked by drug 
use and affecting third parties, as well as production losses 
for firms and administrations when drug users have to stop 
working. The components of this external cost have to be 
converted into a monetary unit.
In addition, external cost includes all the secondary 
effects that are unintentionally borne by consumers, i.e. 
intrapersonal externalities. In the case of drug use, the 
inclusion of costs borne by consumers in this category or 
private costs (the latter are not included in the external cost) 
depends on the methodology chosen. One the one hand, 
some authors consider those intrapersonal externalities to 
be a private cost, as they assume that consumers are fully 
responsible for the consequences of their choices, because 
they should be aware of the risks associated with drug 
consumption. This position is advocated by the defenders 
of Becker and Murphy’s (1988) theory of rational addiction, 
such as Walker and Kelly (2011). On the other hand, it 
can be considered that drug users’ addiction impairs their 
capacity to take in information and make rational decisions. 
That is to say that the part that looks for pleasure is resistant 
to the part that understands the negative consequences of 
drugs (Collins and Lapsley, 1995). Thus, in this second case, 
the harms that individuals cause themselves by consuming 
drugs (loss of quality of life, premature death) are included 
in the external cost.
As described above, private costs refer to drug-related 
expenses that are considered to be intentionally borne 
only by the drug consumer and are therefore excluded 
from the scope of external cost. There are three sources of 
private costs. First, private costs concern drug purchases 
that are fully assumed by the consumer. This can be 
explained by the assumption that the utility derived from 
drug consumption is at least equal to their price. As for 
the consequences, it is supposed that the private benefits 
arising from drug use and the monetary amounts spent 
on drugs compensate each other. This explains why the 
benefits directly retrieved from drug consumption are 
absent from the analysis and why the components of the 
social cost seem to be quite one-sided. Second, the fines 
imposed on drug consumption and on driving under the 
influence of drugs are included in the category of private 
costs. Finally, health expenditure that is not reimbursed by 
public health insurance, but is either paid by drug users 
themselves or reimbursed by private insurance, is also 
considered to be private costs. It can also be noted that 
private costs can also include intrapersonal externalities 
depending on the theoretical framework chosen.
Effect of public net expenditure on general welfare
There are two main sources of drug-related public 
expenditure: (1) the part of treatment paid by public health 
insurance for every disease caused by drugs and (2) public 
expenditure on prevention, treatment and reduction of 
supply funded by the government. They all have a negative 
impact on public finance. However, when drug users die, 
they no longer receive pensions and other benefits, so it has 
a positive impact on the public finance budget. Moreover, 
some countries that chose to legalise the supply of certain 
drugs, e.g. cannabis in some of the US states or Uruguay, 
receive tax revenues, which also has a positive impact. The 
difference between the two first elements and the last two 
provides the net public expenditure related to drugs.
As public expenditure has to be financed by additional 
taxes, it has an impact on general welfare. The marginal 
cost of public funds refers to this impact — when 
government raises one additional unit of revenue to finance 
expenditure. Therefore, the effect of public expenditure 
on general welfare is obtained by multiplying the net 
public drug-related expenditure by the marginal cost of 
public funds. There are many published estimations of 
this parameter. For instance, the European Commission 
provides the calculation for European countries (Barrios et 
al., 2013), but there are also national estimations, such as 
the Quinet report (Quinet, 2013) in France.
I Calculation methods
I Preliminary calculations
Calculating the components of the social cost requires first 
an assessment of mortality and morbidity caused by drugs, 
as well as the age of death for the former.
Morbidity and mortality
Data on morbidity and mortality are used to compute the 
value of deterioration in life quality and the values of lives 
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lost, production loss, treatment cost and pensions not paid 
due to premature deaths.
Collection of these data necessitates first listing the drug-
related diseases. In the case of illicit drugs, most studies 
identify overdose, HIV and AIDS, HCV, HBV and accidents 
(EMCDDA, 2011; Institut de Veille Sanitaire, 2011). Then, 
it is necessary to compute the associated morbidity and 
mortality for each disease.
Sometimes national data are detailed and provide the 
morbidity and mortality induced by drugs for each disease, 
but in many cases there are only global data per whatever 
the cause of it. In the latter case, it is necessary to use tools 
to estimate drug-induced morbidity and mortality. For that 
purpose, the population attributable fraction (PAF) used 
by the WHO (2016) are applied. Population attributable 
fraction refers to the chance of developing or dying from 
a disease, D, due to the presence of one risk factor (here 
it is the use of a given type of drug). It is computed by the 
formula:
  (14.1)
where P(D) is the probability of developing or dying from 
the disease, E an exposed subject, E is a non-exposed 
subject and P(D ⁄ E) is the probability of developing or dying 
from the disease if the risk factor did not exist. Here, for one 
drug type, one population attributable fraction is computed 
for each drug-related disease. Note that PAF ∈ [0,1], and 
that a different population attributable fraction linked to 
the same risk factor cannot be added. Indeed, there could 
be multiple causes of a death, and this comorbidity is not 
taken into account in the population attributable fraction 
calculation. For each disease, morbidity and mortality 
are multiplied by the associated population attributable 
fraction, in order to obtain the number of ill people and 
deaths attributable to drugs.
Age at death
The age at death from a drug-related disease is also 
necessary to estimate the number of years lost in order 
to compute the values for lives lost, lost production and 
civil servants’ unpaid pensions. There are two methods 
of estimating the number of years lost. If the average 
age at death for a given disease is known, it is possible 
to compute the difference between the life expectancy 
of the whole population and the average age at death. 
This difference is then multiplied by the mortality. It is an 
imprecise methodology, as the average age at death is 
not an accurate parameter. The second method consists 
of multiplying, for each age group, the number of deaths 
by the number of years lost, and then adding the results 
found for each age group. This method is more reliable 
but more complicated to interpret, and it requires more 
detailed data. This study adopts the first method. In both 
cases, such estimations are potentially biased by the fact 
that most drug users come from deprived areas where 
life expectancy is lower than in the overall population (1). 
However, in the absence of data on the socio-economic 
status of drug users, life expectancy of a whole country 
is used. It potentially leads to an overestimation of the 
costs. Nevertheless, this overestimation concerns only 
the last years of life, which are the most discounted in the 
calculations.
I External cost
Unlike public expenditure, which is directly valued in 
monetary units, external cost is more complex to estimate. 
The value attributed to those costs directly depends on the 
methodology chosen. When interpersonal externalities are 
included, it corresponds to the sum of the values of losses 
of quality of life, lives lost and lost production.
Value of loss of quality of life 
For a given drug-related disease, d, the value of loss in life 
quality (LLQ) is calculated by the formula:
  (14.2)
where M b represents the morbidity for the drug-related 
disease d, VLY the value for one year lived, and ωd the 
coefficient of deterioration in life quality.
The calculation of the value of loss in life quality requires 
choosing a value for one year lived. Various methodologies 
exist. Some studies differentiate according to the age and 
the individual’s position. Other researchers refuse to make 
such a differentiation because studies have shown few 
conclusive results of making such a differentiation and, 
above all, they do so for ethical reasons. Consequently, they 
propose a fixed value for one year lived for every individual. 
For instance, Quinet (2013) set it at EUR 115 000 per year 
saved for the French population. His calculations are based 
(1) In France for instance, there is a gap of six years in life expectancy be-
tween executives and workers among men, and three years among wom-
en. See http://www.insee.fr/fr/themes/document.asp?ref_id=ip1372#en-
cadre1 (accessed 25 April 2016).
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on the recommendation of the OECD report (OECD, 2010), 
which computes a ‘value of a statistical life’ derived from 
surveys in which people were asked their willingness to 
pay for a small reduction in their mortality risk. This value 
lies between EUR 1.5 million and 4.5 million in OECD 
countries. Desaigues et al. (2011) use another method 
(the contingent valuation) and recommend a valuation of 
EUR 40 000 for the European population and do not take 
into account the specificities of the different countries. 
The choice of a value will impact markedly on estimates 
of the social costs. Addicted individuals suffering from 
a disease experience a loss in life quality during the period 
of treatment or remission. The WHO (2004) provides 
coefficients of deterioration in life quality for each disease 
that can be used. For each disease, this coefficient is 
multiplied by the value of one year lived. The result gives 
the annual cost of loss in life quality per person for one 
disease.
Value of lives lost
Unlike morbidity, which is a stock variable, mortality is 
a flow variable, for which values are based on present 
and future periods, i.e., when one individual dies during 
a given period, the consequences are spread over time. For 
each drug-related disease,the value of lives lost (VLL) is 
computed according to the following formula:
  (14.3)
where VLY represents the value of one year lived, M t the 
number of deaths caused by the drug-related disease d, Td 
the number of years lost and α the discount rate.
Such calculation requires choosing the value for one year 
lived used in the calculation of the value of the deterioration 
in life quality and a discount rate from the literature. 
For instance, the Australian Government recommends 
a discount rate of 7 % (Office of Best Practice Regulation, 
2007), whereas the United States recommends a discount 
rate of 3 % (Interagency Working Group on Social Cost of 
Carbon, 2010) and Quinet a discount rate of 4 % for France 
(Quinet, 2013).
Production loss
The loss to society caused by a death is also valued in 
terms of production lost when the subject stops working 
partially or completely. The values for production losses 
are calculated by disease type in two ways (INCa, 2007). 
The first is the ‘flow of discounted revenues’ approach. 
It considers that one individual is like a machine from 
society’s point of view: a departure from the market 
represents a loss in potential production, and this loss is 
calculated via a discounted flow. This method is consistent 
with the hypothesis of full employment of resources (2). 
It is important to note that, under that hypothesis, the 
effects of drug production, supply and use on creating 
employment are not taken into account. The second 
method of computation is the ‘frictional cost’ approach. It 
consists of an examination of the production losses caused 
by a disease from the organisation’s point of view. These 
losses depend on the duration of the organisation’s internal 
reorganisation to recover the previous production level. 
For extended absences, it is assumed that the work of the 
absent employee is accounted for by an increase in internal 
productivity or by the recruitment of a new employee. Thus, 
after a given period, the production level always returns to 
its previous level. This second calculation method is very 
complex and is not compatible with the hypothesis of full 
employment of resources.
When data provide an annual value for production lost per 
disease that is already discounted, this value is multiplied 
by the number of years lost to give the production loss 
caused by a disease. Then, for each disease (d), this 
production loss per individual (APL) has to be multiplied by 
mortality (M t) to obtain production loss (PL):
  (14.4)
I Public net expenditure
Every country has its own social system and its own rules 
for recording public expenditure. Despite the work that has 
been done by Eurostat, the OECD and the WHO on public 
expenditure on health programmes to estimate national 
public expenditure on mental health and substance abuse, 
there are no specific estimates of public expenditure on 
drug-related interventions.
Public net expenditures are obtained by adding treatment 
costs to spending on research, prevention and repression, 
and by deducting from this civil servants’ unpaid pensions 
and — when applicable — tax revenues.
(2) All available resources are used in the most efficient way. There is no 
unemployment (or only frictional unemployment).
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Treatment costs
Treatment costs borne by public health insurance are 
calculated by multiplying each drug-related disease by the 
annual cost of the treatment of one patient by the number 
of individuals concerned. Operating costs for the structures 
caring for drug users are added to those treatment costs. 
When annual treatment cost per disease is available (TC
d 
), 
total treatment cost (TTC) for a drug-related disease (d) is 
obtained by multiplying it by morbidity (MBd):
  (14.5)
Spending on research, prevention and repression
It is difficult to estimate the resources allocated to policing 
illicit drugs, as this is only a part of the police’s activity 
and the funding of drug-related initiatives is embedded in 
the wider budgets of public entities. In France, Kopp and 
Fenoglio (2006) estimated drug-related public expenditure 
by estimating drug offences as a proportion of the total 
number of offences and by assigning that proportion of the 
police budget to supply reduction initiatives. However, such 
estimates only provide an order of magnitude for costs.
Concerning the cost of health prevention initiatives, it is 
necessary to define the area of prevention (for instance, if 
the funds are allocated to drug prevention or to other health 
risk prevention). Moreover, in addition to accounting for the 
budget for prevention initiatives, it is necessary to include 
all support provided to the organisations involved.
Unpaid civil servants’ pensions
The death of a civil servant puts an end to the payment 
of his or her pension, thereby generating savings for the 
government. The amount of pensions (UP) that are not 
paid by the state is estimated through a discounted sum of 
annual unpaid pensions (AP). Here it is required to take into 
account only retirement years. Assuming that the average 
years of retirement is average life expectancy minus 
average age of retirement, the formula is:
  (14.6)
Here we use the number of years lost instead of the 
number of retirement years lost, because, if an individual 
dies before the age of retirement, there will be ϑ years of 
pension unpaid in both cases, but the discounted value of 
those unpaid pensions will depend on the years remaining 
before retirement.
There are also biases in this calculation because the 
proportion of public servants among drug users is 
unknown. Considering the proportion of public servants 
in the general population will lead to a possible over-
estimation of the benefits.
Tax revenue
Data for tax revenue are generally provided by the national 
statistical service. When applicable, the measure is 
accurate for sales, but data concerning the taxation of firms 
producing drugs are not always available. In addition, when 
individuals die, they no longer pay taxes. The last factor is 
very complex to measure and is often omitted from social 
cost studies.
I The social cost calculation
Social cost is the sum of the external cost, and the effect of 
public expenditure on general well-being. In order to obtain 
the effect of net public expenditure on general welfare, drug-
related net public expenditure is multiplied by the marginal 
cost of public funds. Many studies provide a value for this 
marginal cost (Dahlby, 2008), and the value chosen affects 
the results. Finally, social cost is calculated by the formula:
  (14.7)
I  Estimating the social cost of illicit drugs in France in 2010
I Methodology and parameters chosen
Most of parameters used are based on Quinet’s (2013) 
recommendations: the value for one year lived is fixed at 
EUR 115 000, the discount rate at 4 % and the marginal 
cost of public funding at EUR 1.2. Quinet’s report, which 
relies on the OECD’s recommendations (2010), is the most 
relevant recent study for France. Moreover, the estimation 
we have chosen to use is annual production loss based on 
flow discounted revenues, and thereby we assume that there 
is a full employment of resources. Average life expectancy 
is fixed at 80, and average age of retirement at 60. Data 
sources used for the calculation are detailed below.
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I Data collection
Mortality and morbidity
The data for illicit drugs come from multiple sources. 
Morbidity and mortality data for AIDS and for overdoses 
were obtained from the French observatory for drugs and 
substance abuse (OFDT, 2013). For overdoses, the average 
number of deaths in the period 2000-10 was used. We 
also used Laumon et al.’s (2011) data for the number of 
fatal traffic accidents due to cannabis. For HIV morbidity, 
Morlat (2013) indicates that 150 000 individuals were living 
with HIV in France in 2013, 74 % of whom were covered by 
the health insurance system. Moreover, 89 % of illicit drug 
users who are infected with HIV are following a course of 
treatment and 10.9 % of the individuals infected with HIV 
are drug users (Jauffret-Roustide et al., 2013). Thus, the 
morbidity associated with HIV is 150 000 × 0.74 × 0.109 
÷ 0.89 = 13 600. The French national statistical service, 
INSEE (3), indicates that non-fatal serious traffic accidents 
that generate hospitalisations are 10 times as frequent 
as fatal serious traffic accidents. Thus, accident morbidity 
is 230 × 10 = 2 300. As the data of interest are provided 
directly, there is no reason to use the population attributable 
fraction here. HCV morbidity is derived from Dhumeaux’s 
(2014) estimation, which concluded that 40 % of HCV 
cases reported were associated with drug use and, by his 
estimate, 8 % of people with HCV have a chronic disease.
Average age at death
In order to make the results easier to interpret, the choice 
was made to use the average age at death for the whole 
population instead of making calculations for each age 
group. Average age at death due to an illicit drug overdose 
was based on an estimation by Janssen and Palle (2010). 
For AIDS, we used data for 2009 from the Institut de Veille 
Sanitaire (2009). For accidents, Laumon et al. (2011) 
estimated that the majority of deaths in traffic accidents 
caused by cannabis are in individuals under the age of 
25, so we took that as our estimation. To compute the 
number of years lost, average age of death per disease was 
deduced from the average life expectancy of 80.
Annual production loss
Here we use the estimates of the French national cancer 
institute (INCa, 2007), based on the human capital 
method, which follows the hypothesis of full employment 
(3) http://www.insee.fr/fr/themes/document.asp?reg_id=24&ref_id=18715
of resources. Even if unemployment is important in our 
society, and even if individuals are replaced after their 
departure, we considered here that one death corresponds 
to one work position lost. The logic for this is that there is 
a loss of welfare when a resource is wasted (4). Therefore, it 
is more pertinent to suppose that each working hour lost by 
a drug user is not replaced. The estimation of EUR 12 349 
per year is already discounted and takes into account 
the lost production before retirement and the unpaid 
production after retirement.
Treatment costs
For illicit drugs, HIV data come from a French health 
insurance provider’s statistics (Medic’AM, 2014). The last 
available study on the cost of care for HCV (Ducret et al., 
1998) is for the year 1998, but the unitary cost of care has 
been multiplied by two since the introduction of interferon-
alpha and ribavirine (Medic’AM, 2014). Therefore, we also 
multiplied Ducret’s estimation of the annual cost of care 
by two. Finally, data from Vallier et al. (2006) are used for 
chronic complications. For substitution treatments, thei 
cost is also estimated on the basis of Medic’AM (2014) 
data and by making additional assumptions. Medic’AM 
data indicate that substitution treatment spending 
stands at EUR 93.5 million. We supposed that 50 % of the 
endowment for illicit drugs made by the French centres 
for the treatment and prevention of addiction (CSAPA) 
(EUR 60 million) was devoted to substitution treatments. 
Spending on substitution prescriptions by addiction liaison 
and care teams (ELSA) was presumed to be the same. 
Finally, the cost of ambulatory medical prescriptions 
was estimated by considering that patients who receive 
buprenoprphine (103 000 in 2010) need a monthly 
prescription, whereas those who receive methadone 
(41 000) need two prescriptions per month. A visit to 
a doctor cost EUR 22 in 2010, and consultations for 
substitution treatment prescriptions cost EUR 93 million. 
Consequently, the cost of substitution treatments stands at 
EUR 262 million.
Research, prevention and repression costs
To estimate public spending related to drugs, we use the 
French observatory on drugs and drug addiction’s report 
(OFDT, 2013), which relies on a French drug-related report 
(4) A doctor who cures a patient who has lung cancer caused by cigarettes 
cannot simultaneously cure another patient who has developed cancer 
that is not related to consumption of any type of drug. Therefore, one 
patient is not cured because of diseases caused by drugs. This is why 
treating drug users generates a cost. If the hypothesis of fully employed 
resources were dropped, the doctor would be always available to cure 
a new patient.
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(Document de politique transversale, 2011) describing 
different public policies. According to this document, 
it appears that the proportion of public spending on 
law enforcement and prevention is 66 % for illicit drugs 
(EUR 913 million).
Unpaid civil servants pensions
The death of a civil servant puts an end to the pension 
payments, thereby generating savings for the government. 
In France, the average year of retirement is assumed 
to be 60. According to the National Bureau of Statistics 
(INSEE (5)), the average annual pension was EUR 15 072 in 
2011. The sum of the unpaid pensions was then actualised, 
as previously, using a discounting rate equal to 4 % (Quinet, 
2013) over the future years of unpaid pension. The total 
unpaid pension was multiplied by 21 %, which corresponds 
to the proportion of public employees in the workforce. 
I Results
We found that the annual social cost of illicit drugs is 
EUR 8.7 billion. Expressed as a ratio per inhabitant, 
it represents a cost of EUR 133 in 2010. This cost 
represented 0.44 % of French GDP in 2010. In comparison, 
the social costs of tobacco and alcohol are EUR 122 billion 
and EUR 118 billion, respectively.
External costs represent a large proportion of the social 
costs (67.9 %) of illicit drugs. This can be explained by 
the number of lives lost (1 605) and by the value chosen 
for a year saved (EUR 115 000), which result in a value of 
lives lost of EUR 2.7 billion. The loss of quality of life also 
represents a sizeable cost (EUR 2.6 billion).
Drugs lead to an increase in the net public expenditure. 
Although civil servants’ unpaid pensions lead to cost 
saving (EUR 45 million), this does not compensate for the 
expenditure on reducing supply and prevention (EUR 913 
million) and treatment (EUR 1.4 billion). Consequently, 
the net difference in public expenditure equalled EUR 2.3 
billion for illicit drugs in 2010. In comparison, it was 
EUR 13.8 billion for tobacco and EUR 3.0 billion for alcohol.
(5) http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NAT-
TEF04571.
I Conclusion
The aim of this study was to explain how to estimate 
the social costs of illicit drugs. Although there is a more 
commonly accepted methodology, several specific 
adjustments can be made when making estimates, which 
have an impact on the results (6). Therefore, the results 
obtained from a social cost study will depend on the choice 
of methodology, which is influenced by national specifics. 
Here, the parameters chosen to compute the social cost of 
drugs in France in 2010 were based on a report (Quinet, 
2013) that makes official recommendations for France that 
are based on OECD (2010, p. 33) recommendations, using 
a value for one year lived of EUR 115 000, a discounting rate 
of 4 % and a marginal cost for public funding of EUR 1.2.
Owing to the variety of methods available, cross-country 
comparisons of estimates of social costs are also 
difficult. The fact is that the value of a human life and the 
discounting rate, the importance of which we have shown 
for the cost estimates, are not the same from one country to 
another. Furthermore, existing studies do not use the same 
definition of social costs. While, for instance, some take 
into account intangible costs, others do not (Reuter, 1999). 
Finally, the provision of public services also differs greatly 
from one country to another. In particular, the portions 
of spending on care that come from public and private 
expenditure depend on how the system of healthcare 
funding is organised (individual insurance versus social 
charges). The rules of public accounting can vary widely in 
different countries, even within the EU. However, social cost 
studies remain a powerful tool for governments to assess 
the scale of a social problem and rank the different issues 
by priority. Moreover, even if the value of one year lived can 
be the subject of debate, mortality and morbidity, as well 
as the net expenditure arising from drugs, are a reality and 
the French government needs to look at new strategies to 
reduce them.
(6) For instance, in the case of France, intrapersonal externalities were taken 
into account, intangible costs were omitted, the value for one year lived 
was fixed for the whole population whatever the age and the social status, 
and WHO data were used to evaluate loss of quality of life. 
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TABLE 14.1
The social cost of illicit drugs in France in 2010
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This EMCDDA Insights report has gathered together studies 
from a wide range of experts, providing a unique overview 
of the methodologies used for estimating expenditure 
on drug treatment. The very existence of these studies 
is testament to the growing importance of this field of 
enquiry within the current economic climate, where cost-
effectiveness of interventions, evaluation of policies and 
ensuring value for money in public investment are high up 
on the political agenda. Nevertheless, the topic remains 
in its infancy and, despite an increase in the number of 
studies over the past decade, there is still much to be 
done in terms of methodological development. Issues 
such as the absence of commonly agreed definitions and 
approaches, the lack of harmonised or complete datasets 
on drug-related public spending or costs and/or on the 
activity of drug-related health providers, and uncertainty 
about the most appropriate economic models to use all act 
as barriers to rapid development of this field of analysis.
In the absence of systematic discussion of these issues, 
there has been little opportunity for policymakers, 
practitioners and researchers to take advantage of existing 
knowledge and experience. As a first step in addressing 
this gap, this report has brought together a set of diverse 
studies, encompassing much of the recent work on drug 
treatment expenditure in different parts of the world. It 
therefore represents the current state of the art in this 
field and, by focusing on methods, it has allowed the 
main methodological commonalities and considerations 
that arise from these types of estimates to be identified. 
A discussion of these commonalities and considerations 
forms the basis of this chapter.
I Scope and objective of estimates
Some of the studies presented are diverse in terms of their 
aims and objectives. It is clear that the different aims and 
potential uses of a study have a significant impact on the 
methodology, definitions used, choices of data sources and 
results of estimates.
For example, studies such as those by Davies (Chapter 6) 
and Molinaro and colleagues (Chapter 7) seek to explore 
the impact of drug use on drug-related health expenditure 
and may be a first step for cost-benefit analysis. Other 
studies aim to estimate spending on certain types of 
treatment or in certain specific settings, such as Gennetti 
and colleagues (Chapter 8), who estimate spending on 
OST, and Lievens and Vander Laenen (Chapter 9), who 
estimate spending on inpatient drug treatment in hospitals. 
If expanded, these types of study allow a comparison of 
the costs of treatment with the benefits these treatments 
provide. Furthermore, if the costs and benefits are 
compared with the costs and benefits of alternative types 
of treatment, it is possible to conduct a cost-effectiveness 
analysis. When the costs of certain types of treatment are 
added to the costs of all other drug treatments provided, 
the full amount of drug treatment expenditure can be 
calculated.
In this vein, the studies described by Hajnal and Kender-
Jeziorska (Chapter 4), Ritter and colleagues (Chapter 
1), Mikulić (Chapter 2), Origer (Chapter 5) and Vopravil 
(Chapter 3) all aim to estimate total public expenditure 
on drug treatment and may provide a good basis for the 
economic evaluation of drug treatment and public policies 
at a macro level. Kopp and Ogrodnik (Chapter 14) go a step 
further and exemplify a method to evaluate drug policy 
and estimate social costs, i.e. the costs borne not only by 
the public sector but by the whole of society, showing how 
public expenditure is only one part of the picture when 
assessing costs from a societal perspective.
Other types of study such as the one by Gonçalves and 
colleagues (Chapter 11), which aimed to see how changes 
in the provision of different health services impact on the 
costs of the drug treatment network, may be relevant for 
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cost-sensitivity analysis. This type of analysis explores, for 
instance, how changes in treatment activity, changes in 
the costs of inputs or uncertainty in the cost allocation can 
impact on treatment costs.
The geographical focus will also have an impact on the 
study design. While most of the papers focus on national 
estimates, Lievens and Vander Laenen (Chapter 9) 
aimed to find a method for cross-national comparison 
of expenditure, and their primary focus was, therefore, 
the identification of harmonised international datasets 
that could be used for this purpose. In contrast, Molinaro 
and colleagues (Chapter 7) carried out their analysis 
at a regional level and were able to link regional health 
datasets to achieve their study aims.
It is important that policymakers and those commissioning 
studies are clear about the aims, objectives and specific 
policy question they are seeking to answer in order to guide 
the design of an appropriate methodology. The papers 
contained in this publication may provide a useful starting 
point and trigger discussion on the types of models that 
are suitable to answer different policy questions and 
stimulate the future development of guidelines on the most 
appropriate methods.
I Defining drug treatment
The definition of drug treatment adopted will impact on 
the design and on the results of any study on expenditure. 
Since definitions provided by international organisations 
such as the WHO (1988, p. 3) or the EMCDDA (2012) 
are rather broad, they allow a wide range of differences 
in the operational use of the term ‘drug treatment’. These 
differences are apparent in the studies presented in 
this publication. Within the broad parameters set by the 
international definitions, the authors of the studies have 
chosen to operationalise the term in a way that allows 
estimates of costs to be made in practice. The scope 
and objective of the study will influence this, but data 
considerations are also important.
A major consideration is how expansive the chosen 
definition of treatment should be. The operational definition 
developed for the monitoring of drug treatment activity data 
(EMCDDA, 2012) is the most straightforward. This restricts 
the focus to structured interventions that aim to address 
a person’s drug use. This is the option taken by Ritter et al. 
in Chapter 1 and may be a sensible approach for studies 
looking at drug budgets in order to describe governments’ 
policies and their allocation of resources (Reuter, 2006). 
Studies looking at labelled expenditure as part of a wider 
study of public expenditure are most likely to use this 
definition, although Hajnal and Kender-Jeziorska (Chapter 
4) highlight the fact that choice can be limited by practical 
issues and the lack of data on causality.
Some authors add, to the costs of interventions 
addressing drug use, the costs of treating associated 
comorbidities. Their rationale may be to consider the 
more complete costs of treating drug users and/or to 
support an assessment of how public investment in one 
area of health (drug treatment, for instance) may provide 
savings in other areas of health (HIV or HCV treatment). 
This kind of cost-benefit analysis may be appropriate in 
situations where governments are trying to rein in public 
spending (Bhattacharya, 2016). The costs of associated 
comorbidities are taken into account by Molinaro and 
colleagues (Chapter 7), and Davies (Chapter 6) uses an 
expansive definition of drug treatment that includes most 
treated health conditions that are associated with drug 
use. The difficulty in determining causality between drug 
use and health conditions is highlighted, however, by the 
author choosing to restrict the definition to the conditions 
associated and considered in the WHO Global Burden of 
Disease study (Mathers et al., 2002).
Between these two operational definitions, other definitions 
have been used by authors. Origer’s definition (Chapter 5) 
‘refers exclusively to interventions targeting persons who 
show problems related to the use of illicit drugs’ and 
includes drug-related infectious disease. The inclusion 
of drug-related infectious disease is perhaps the least 
controversial of the related health conditions, given the 
well-documented and often quantified link between drug 
injecting and the prevalence of infectious disease and 
the role of OST and needle and syringe programmes in 
controlling the spread of drug-related infectious disease. 
Beyond this, there remains a lack of evidence and research 
on the proportion of illness and disease that is drug related 
from which to identify the relevant attributable fraction. This 
is likely to limit the use of a more expansive definition.
The decision to adopt a more expansive definition of 
treatment leads to the inclusion of different types of drug 
treatment services and, therefore, has a considerable 
impact on cost estimates and the methods and data 
required to carry them out. As Ritter and colleagues 
suggest (Chapter 1), a clear identification of the services 
accounted for is necessary when estimates of costs of 
treatment are made.
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I  Drug treatment, harm reduction and prevention
The unclear boundaries between the conventional 
categorisation of drug-related interventions — treatment, 
harm reduction and prevention — can make it difficult to 
adhere to a narrow definition of drug treatment. These 
essentially artificial constructs (Caulkins, 2006) may be 
easier to define on paper than in practice, particularly 
when attempting to separate the costs of various activities 
where interventions are delivered together as an integrated 
service (OECD et al., 2011, p. 73) and may be funded by 
the same source. Many local drug treatment providers 
deliver a suite of interventions across the prevention/
harm reduction/treatment spectrum. Ritter and colleagues 
(Chapter 1) state that, despite a clear definition of 
treatment in their Australian study, data provided by state 
governments included some elements of expenditure on 
prevention and harm reduction. In some cases this was 
identifiable (such as needle and syringe programmes), 
while in other cases the prevention and harm reduction 
activities could not be identified or, therefore, excluded. 
Vopravil (Chapter 3) included both treatment and harm 
reduction together, as it was not possible to distinguish 
spending between the two.
Some authors describe expenditure or cost studies 
that separate these services. For example, the tool 
described by Musto (Chapter 10) to estimate expenditure 
on ‘drug treatment’ by local authorities disaggregates 
expenditure on low-threshold services from expenditure 
on structured drug treatment services. Gonçalves and 
colleagues (Chapter 11) looked at all the costs incurred 
by drug dependence treatment teams and attempted to 
disentangle expenditure in order to estimate the marginal 
costs of different types of dependence-related activities. 
Methods to do this, however, are reliant on detailed activity 
and expenditure data.
In an ideal world, the definition of drug treatment would 
emanate from the scope and objective of the study and be 
supported by robust data that allow this definition to be 
operationalised in a linear-type fashion. Experience has 
shown, however, that compilation can be limited by the 
nature of national health systems and statistical systems. 
Studies are likely to require an element of pragmatism in 
decision-making, and it is important to clearly describe 
the options adopted and understand how these affect 
estimates.
I  Mapping service provision, funding sources and assessing coverage of estimates 
As Ritter and colleagues (Chapter 1) suggest, it may be 
helpful for studies to begin with the mapping of treatment 
types and funding flows. Such an exercise can shed light 
on the complexity of the latter, the many actors and the 
funding sources involved in the financing and delivery of 
drug treatment services (Chalmers et al., 2016). It can 
also provide a valuable resource for checking the coverage 
of estimates, controlling double counting and identifying 
areas for data improvement.
The System of Health Accounts (SHA) suggests 
a comprehensive conceptual accounting framework for the 
financing of health (OECD et al., 2011), and the structure 
can be used to support drug-related estimates. Respecting 
this structure assists the mapping process and helps to 
ensure completeness of estimates and comparability of 
results.
Even in countries where it is not possible to provide 
expenditure estimates, the mapping of treatment services, 
funding sources and flows will provide a foundation for 
future work, aid transparency and accountability, and it will 
help to assess how changes in funding may affect different 
parts of the treatment system (Chalmers et al., 2016).
When estimates of expenditure are provided, treatment 
maps can act as a useful tool for assessing the coverage of 
estimates. Few studies are able, at present, to provide full 
estimates of drug treatment across the entire healthcare 
system. Studies, for example, often do not include 
expenditure on treatment delivered by general practitioners. 
The missing areas of expenditure should be identified 
and, if possible, some assessment of the impact of this on 
the overall estimate should be made. Many of the studies 
estimate expenditure for inpatient hospital stays. However, 
hospitals represent only one setting for drug treatment and 
may account for a confined proportion of drug treatment 
activity, which also takes place in outpatient settings (1). 
Despite inpatient treatment costing significantly more 
per day than outpatient treatment (EMCDDA, 2014), 
using inpatient hospital data alone is likely to result in an 
(1) According to data available for inpatient hospital-based residential centres, 
in the 16 reporting countries with data available (out of 28 EU countries 
plus Norway and Turkey), these clients represented 6 % of the total 
number of clients receiving inpatient and outpatient treatment, in 2014. 
Taking into consideration that data for the number of clients in hospitals 
in outpatient-based treatment are not available (which may lead to an 
underestimation of the total number of clients treated in hospitals), we can 
conclude that hospital-based treatment represents a confined proportion 
of the total clients treated in Europe, on average. However, the data also 
show that the relative importance of outpatient and inpatient provision 
varies greatly within national treatment systems (EMCDDA, 2016).
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underestimation of drug treatment expenditure. However, 
the relative importance of the number of clients in inpatient 
hospital-based treatment varies greatly between countries, 
so country-specific information is vital and, as Vander Laenen 
and Lievens (Chapter 13) state, considering the differences 
in treatment structures and coverage of estimates is 
important when interpreting cross-national studies.
I  Isolating drug-related expenditure from addictions expenditure
A common challenge when estimating drug treatment 
expenditure or costs is how to isolate drug-specific data 
from broader datasets, particularly those integrating 
alcohol-related information. Some countries have an 
integrated strategy that includes other substances such 
as alcohol (EMCDDA, 2016) and it may be desirable to 
conduct evaluations of both policies together. Ritter and 
colleagues (Chapter 1) found that it was impossible to 
disaggregate drug and alcohol expenditure, and their 
estimate includes both. Some international data sources 
such as the SHA do not disaggregate the costs of drug 
treatment from the costs of alcohol treatment. Therefore, 
at this stage, it may require additional modelling if the data 
from international sources such as the SHA are going to be 
used to estimate drug-specific expenditure.
National accountancy and reporting systems may record 
and report public expenditure data on drug treatment 
alongside expenditure data on mental health problems 
or dependencies such as alcohol dependency. Some of 
the studies aim to disaggregate this expenditure, often 
using treatment activity data. For instance, Genetti and 
colleagues (Chapter 8) extracted data on the costs 
of illicit drugs from an aggregate budget containing 
expenditure data on drugs, alcohol and gambling. 
Gonçalves and colleagues (Chapter 14) also isolated 
costs of drug treatment from a wider addiction budget 
that included alcohol and tobacco. Their analysis allowed 
the identification of marginal costs for different types of 
addiction. Musto (Chapter 10) states that adult substance 
misuse services in England are mostly integrated, with 
providers typically treating both drug and alcohol clients, 
and drug users often presenting with both drug and alcohol 
problems, which means that isolating specific spending on 
drug treatment can be challenging. Local authorities deal 
with this issue pragmatically within their financial returns, 
with some reporting combined alcohol and drug treatment 
budgets, rather than disaggregated spending, and 
others merely splitting their substance misuse budget by 
allocating half to drug and half to alcohol treatment. Within 
the cost calculator that the author describes, separate 
costs for alcohol and drug treatment are estimated using 
treatment activity data on the number of days in treatment.
These examples show that it is possible to disaggregate 
expenditure in some instances, particularly where detailed 
activity data exist. Nevertheless, it may not always be 
desirable to do so and again this will be partly dictated by 
the scope and objective of a study. Regardless, in every 
estimate it is useful to list the different types of substances 
and dependencies covered for each type of intervention 
that is included.
I  Identifying labelled drug treatment expenditure
The government budget is one of the most important 
policy documents produced by governments, as it contains 
details of the financial resources committed towards 
the implementation of policy objectives. A review of 
budget and/or fiscal year-end accountancy reports and 
other budget and policy documents for implemented or 
executed budgets can help identify expenditure on drug 
treatment. In public accountancy, data can be published 
both for planned budgets and for executed expenditure. 
Data may differ between the two because of, for instance, 
unexpected changes in the drug situation (the reactive 
nature of some drug-related expenditure means that these 
costs depend upon the number of clients presenting for 
treatment, which cannot be known at the beginning of the 
financial year) or changes in the prices of inputs used in 
treatment (for instance, a change in the price of medicines). 
Differences may also be due to the regular overall revision 
and increased accuracy of public accountancy data after 
some years of a spending exercise. The latest data available 
should be considered the most accurate.
The studies in Sections II and III of this publication show 
that, in practice, expenditure on drug treatment may 
not always be easily identifiable in public accountancy 
documents, as they may not contain the level of 
disaggregation required to identify drug treatment 
expenditure.
Drug treatment funding is often embedded in programmes 
found at many different government levels (central, regional 
and local government). The examples provided by Mikulić 
(Chapter 2) and Vopravil (Chapter 3) for Croatia and the 
Czech Republic respectively show the importance and 
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challenges posed by the consolidation of drug-related public 
expenditure, when spending is realised by different levels 
of the general government. Ritter and colleagues (Chapter 
1) give the example of Australia, where different schemes 
financing drug treatment and their grant amounts are 
frequently labelled and can be found in a number of different 
sources, notably published public records, and extractable 
directly from the federal government budgets. Where 
possible, it is helpful to use two or more different sources 
as a check on the reliability of the figures. These authors 
found that sometimes data from different sources did not 
match perfectly. When this happened, they took the middle 
point for estimates. Furthermore, both Musto (Chapter 10) 
and Davies (Chapter 6) refer to the mainstreaming of the 
drug treatment budget into a wider public health budget in 
England. Along with a shift in responsibility for the allocation 
of drug treatment funding from central government to local 
government, this has had an impact on the availability of 
labelled drug treatment expenditure.
In order to overcome these difficulties, besides using the 
conventional approach of analysing public accountancy 
documents, some studies also rely on the contribution 
of key experts. The use of key experts is an established 
method often used to guide data collection and assist 
in the interpretation of data, as is the case of Hajnal 
and Kender-Jeziorska (Chapter 4). In some studies, 
for example those by Mikulić (Chapter 2), Vopravil 
(Chapter 3) and Musto (Chapter 10), key experts were 
asked to provide expenditure data themselves. Key experts 
used in the various studies included those responsible for 
consolidating health accounts, representatives from the 
relevant ministries, central and local government units 
and institutions responsible for the implementation of the 
national drug strategic documents, and treatment providers 
and commissioners. Experts should be selected based on 
their knowledge, position and a thorough assessment of 
bias and they can provide a valuable input into a project 
when appropriately selected. The choice of experts and 
the method of engaging them are important and will be 
influenced by the kind of information required and the 
resources available. Questionnaires may be appropriate 
for the collection of standardised expenditure data, while 
interviews may be more appropriate for gaining a better 
understanding of funding streams and data sources.
I Unlabelled drug treatment expenditure 
Public expenditure on drug treatment, however, is often not 
identifiable in accountancy documents and is embedded 
in broader budgets. This may include budgets of planned 
programmes that have elements of drug treatment 
alongside other elements such as criminal justice diversion 
schemes; wider budgets for the provision of healthcare 
services delivered on the basis of need, such as mental 
health and dependencies, or on the basis of the settings 
where treatment is provided, as is the case for hospital 
services. Budget lines that incorporate other addiction 
services such as alcohol or tobacco will also require 
disentangling to isolate drug-specific expenditure. These 
unlabelled expenditure items require identification before 
they can be measured and valued. Treatment system and 
funding maps can provide a useful tool for identifying 
relevant areas of unlabelled expenditure and for assessing 
the overlap with existing labelled expenditure data if 
relevant.
A key decision in the measurement and valuation of 
unlabelled expenditure is which modelling approach to 
apply. Two broad modelling approaches are commonly 
used: the top-down approach and the bottom-up approach. 
When data available on drug-related expenditure are 
embedded in broader programmes, the top-down 
modelling approach has been chosen. Models estimate 
the fraction that is attributable to drugs, based on objective 
criteria involving activity data. Bottom-up modelling 
requires knowing how much a unit of treatment costs, 
taking into account all possible productive factors involved 
in health provision and multiplying by the volume of the 
service utilisation.
There is no gold standard method and the decision on 
which costing method to use will depend on the scope 
and objective of the research and the availability of data 
and financial resources (Geue et al., 2012). As Hajnal 
and Kender-Jeziorska (Chapter 4) suggest, the top-down 
approach may be the only one feasible in countries with 
a lack of client-level data. It can also be cheaper and easier 
to implement than the bottom-up approach, although it 
may be less accurate (Mogyorosy and Smith, 2005). This 
is particularly so when services are not homogeneous, as 
it may assume that all services have an equal unit cost 
(Negrini et al., 2004).
The bottom-up approach, in contrast, is often more detailed 
than the top-down method, as it requires either data on 
the average unit cost of the different types of treatment 
provided or detailed information about the amount and 
price/wages/rents/tariffs of all types of resources used 
to provide a health service (such as staff, premises, 
equipment, energy, technology, prescribed medicines). 
As the Maksabedian and colleagues (Chapter 12) study 
shows, input costs as elementary as the price of medicines 
can vary significantly depending on the healthcare 
financing scheme paying for drug treatment, the setting 
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or the treatment provider. Therefore, a detailed inventory 
of costs related to a service is essential. This means 
that bottom-up estimates are often more complex and 
expensive to implement and may not fully take into account 
the costs that are not specific to that service (Negrini et 
al., 2004). Musto (Chapter 10) suggests, however, that this 
detailed method can be more robust and transparent and 
may allow exploration of the drivers of change.
All in all, there is a clear understanding that a mixed 
approach, using both top-down and bottom-up estimation 
methods, may be advantageous (Chapko et al., 2009).
The studies described in this Insights report used different 
approaches: bottom-up only, top-down only and a mixed 
approach. The bottom-up approach was used by Davies 
(Chapter 6), Origer (Chapter 5), Molinaro and colleagues 
(Chapter 7), Ritter and colleagues (Chapter 1) and 
Lievens and Vander Laenen (Chapter 9), and seems to be 
a common method for estimating hospital expenditure. 
This may be due to the availability of unitary costs and 
service utilisation data for hospitals and/or concerns about 
the high level of aggregation at the hospital level and the 
heterogeneity of services that the data cover. Indeed, the 
top-down approach was used in studies predominantly 
when the level of aggregation was low, for example when 
the starting point was addictions treatment expenditure, as 
in the papers by Gennetti and colleagues (Chapter 8) and 
Musto (Chapter 10).
One way to address uncertainties in the estimates and 
enable verification of the data is to conduct a comparison 
between a top-down and a bottom-up approach (Van 
Malderen et al., 2009). While Ritter and colleagues 
(Chapter 1) used a bottom-up methodology to estimate 
hospital expenditure, they carried out a top-down 
estimation as well and compared the results. They found 
a 15 % difference in estimated expenditure between the 
two approaches. This is of a similar magnitude to the 
differences between the two approaches found in other 
studies (Chapko et al., 2009). In Ritter and colleagues’ 
analysis and in Chapko et al.’s (2009) study, estimated 
expenditure on hospital drug treatment tended to be higher 
using the bottom-up approach. If such sensitivity analyses 
could be carried out in other studies, it would assist 
researchers to assess both the most appropriate method to 
use and the potential impact of choice of method on their 
results.
I  Top-down approach and expenditure data
The top-down approach estimates the proportion that drug-
related expenditure represents of the total broader budget, 
frequently with the help of activity data.
This requires the identification of both expenditure data 
sources and data sources on which to base the division. 
International databases include COFOG, published by 
Eurostat, and the SHA, published by Eurostat, the OECD 
and WHO. COFOG publishes data on expenditure by 
purpose and for the public sector in detail on health, by 
country. The SHA publishes data on total health and by 
sub-functions by purposes (18 sub-categories), by provider 
and financing schemes. These datasets benefit from the 
use of internationally accepted definitions, harmonisation 
of concepts and availability of annual data. Until 2012, 
differences were captured for expenditure data, with 
COFOG focused on government-funded healthcare and 
the SHA recording all expenditure on health. This led to 
large differences between the two databases in reported 
expenditure on similar items such as hospital services 
(Lievens et al., 2014). With the development of the SHA 
data system (2), this database has been improving, and 
it can be anticipated that the SHA will develop data for 
different financing schemes and, therefore, that data 
will be available for public sector expenditure on health, 
including for the 18 different functions. A European 
Commission Regulation adopted in 2015 requests that all 
EU countries report expenditure data annually using the 
SHA methodology for the reference year 2014 onwards (3). 
The high level of aggregation in the SHA dataset, in which 
drug-related expenditure is included within the category 
‘Mental health and substance abuse’, may not allow drug 
treatment expenditure to be fully isolated. In their study, 
Lievens and Vander Laenen (Chapter 9) reviewed the 
international literature and databases to see if they could 
be used for estimating drug treatment expenditure.
The studies contained in this publication mainly used a top-
down approach in cases where the expenditure data were 
more disaggregated. Musto (Chapter 10) and Gennetti and 
colleagues (Chapter 8) both sought to identify expenditure 
on an element of drug treatment and used expenditure on 
substance misuse services to do so. The tool described 
by Musto divides expenditure by days of treatment for 
the different types of treatment and can be described as 
a gross-costing method. Gennetti and colleagues used 
more of a micro-costing method to devise a ‘repartition key’ 
(2) See http://ec.europa.eu/eurostat/web/health/health-care/data/database
(3) See http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX-
:32015R0359&qid=1427698121193&from=EN 
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to apply to the expenditure data, which may reduce some 
of the inaccuracies in top-down methods, particularly in 
relation to resource use (Tan et al., 2009).
Ritter and colleagues used results from a survey of 
sampled GPs to find out what proportion of all prescriptions 
were for drug treatment and then applied that proportion 
to the overall expenditure on prescriptions. Other sources 
of data for separating out drug treatment expenditure may 
be administrative system data, activity data, annual reports 
and key expert opinion.
I  Bottom-up approach: measurement and valuation
In order to estimate expenditure on drug treatment using 
a bottom-up approach, it is necessary to have a measure of 
service utilisation and a value to attach to it. Data on service 
utilisation are more common for hospital inpatient services 
than for other levels of the healthcare system, so it is no 
surprise that the majority of authors estimating unlabelled 
expenditure used this data source to some extent. Activity 
data in hospitals and in many other healthcare settings 
are usually recorded using ICD-10 codes (from F11 to 
F19) referring to a diagnosis of mental and behavioural 
disorders due to psychoactive substance use (4). As Ritter 
and colleagues (Chapter 1) point out, however, the main 
ICD-10 classification does not correspond with a narrow 
treatment definition, given that it includes those seeking 
treatment for acute intoxication, psychotic disorders and 
other conditions related to their drug use rather than drug 
use itself. Using these data results in a wider estimate of 
expenditure. It is possible, however, to break down the 
diagnosis data further (5). For example, Davies (Chapter 
6) used a more detailed breakdown of the ICD-10 code in 
England, which allowed identification of the clinical states 
(using an additional level of coding). This means that cases 
that do not fit with the treatment type being studied can be 
excluded. Data, however, are commonly reported only at the 
substance level and in few sources.
In addition to the consistency between the coding system 
and the definition of drug treatment used in the study, 
researchers need to take into account of the impact of 
the coding process and the context in which it is carried 
(4) See: http://apps.who.int/classifications/icd10/browse/2010/en 
(5) While the F10-F19 coding system indicates the substance involved, 
the system used by Davies also specifies the clinical states. However, 
it should be noted that not all four-character codes are applicable to all 
substances; see http://www.who.int/substance_abuse/terminology/ICD-
10ClinicalDiagnosis.pdf 
out on the accuracy of the activity data. The adoption of 
healthcare payment systems based on DRGs for hospitals 
across Europe means that patient diagnosis is directly 
linked to financial reimbursement (6). The DRG system is 
an inpatient classification system that differentiates the 
amount of hospital resources required to provide care. The 
basic set-up of DRG-based hospital payment systems is: 
(1) a patient classification system (PCS) is used to group 
patients with similar clinical characteristics and relatively 
homogeneous resource consumption into DRGs; (2) some 
kind of hospital cost information is used to determine DRG 
weight levels, usually at (about) the average treatment 
costs of patients falling within a specific DRG; (3) DRG 
weights are converted into monetary values and the 
payment rate may be adjusted for structural (teaching 
status, region) and further resource consumption variables 
(length of stay, utilisation of high-cost drugs or services); 
before (4) hospitals are paid on the basis of the number 
and type of DRGs that they produce.
This system may lead to ‘upcoding’, whereby patients are 
classified into codes that attract higher reimbursement, 
and is a problem that has also been identified within 
healthcare data drawn from health insurance databases. 
This practice was identified in the United States, but it has 
also been documented in European countries (Busse et 
al., 2013). It is suggested that, following frequent updating 
of DRGs and payment rates and the use of meaningful 
classifications, upcoding can be minimised (Steinbusch 
et al., 2007). Many countries also audit a sample of cases 
per year to check on coding practice. Where ‘upcoding’ 
is deemed to be a potential problem for measuring drug 
treatment activity, there are steps that can be taken to 
minimise the impact. For example, in Hungary, where 
this practice is deemed to be standard and where there 
are commercially available software packages that help 
coders allocate cases to higher reimbursement categories, 
Hajnal and Kender-Jeziorska (Chapter 4) used expert 
knowledge to identify what they call ‘hidden’ diagnoses 
and cross-checked the client against other indications 
of drug use such as attendance at treatment services. 
Using a methodology like the one used by Molinaro 
and colleagues (Chapter 7), which links the healthcare 
records of individuals attending treatment services to 
create an electronic health record from which treatment 
costs of conditions thought to be linked to drug misuse 
can be included or excluded, may reduce its impact. This 
method would allow researchers to determine the relevant 
conditions for an episode of treatment to be included in an 
expenditure estimate, depending on the study definition. 
(6) DRGs are a way of grouping patients together into classifications based 
on both diagnosis and resource use. First implemented in the United 
States in 1983, the system was adopted by Portugal in 1988 and its use 
spread across Europe in the 1990s. 
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However, data linkage is not common and may not be 
possible in countries with strict data protection laws.
To cost the identified treatment activities, it is necessary to 
have a method of valuing the activities. The widespread use 
of activity based funding (ABF) means that there is often 
a source of cost data that is linked to activity data. Davies 
(Chapter 6), Molinaro and colleagues (Chapter 7) and Ritter 
and colleagues (Chapter 1) estimated unlabelled inpatient 
treatment costs from hospitals using unit cost data for the 
relevant patient group derived from the national tariff for 
reimbursement. These data are more accurately described 
as price rather than cost data, as they reflect the price 
paid within a certain country for the treatment delivered 
and may not reflect actual resource utilisation (Mogyorosy 
and Smith, 2005). The basis of the price calculation 
differs across countries and, although drawn from some 
kind of costing exercise, the final price may be adjusted 
for a number of factors, for example to encourage the 
adoption of best practice. Using insurance databases to 
attach monetary value to resources could be misleading 
in comparative studies because the reimbursement rate 
(cost-sharing rate) could differ significantly between 
countries (Boonen et al., 2003).
Often, however, the activity data are not recorded or 
reported using the same categories as the cost data. ICD-10 
codes, which form the basis of healthcare diagnosis, need 
to be mapped to the relevant DRG. This is carried out 
using a computerised algorithm for the purpose of DRG 
allocation, but researchers may need to map the categories 
themselves. For countries with an identifiable drug misuse 
DRG category such as Australia, this is not an issue. Despite 
the widespread use of DRGs, they have been developed 
separately by countries and there are large differences in 
the number of groups and the grouping logic that underlies 
them (Busse et al., 2011, 2013). However, the SHA has 
been working on this topic and international organisations 
are aware of the need to harmonise definitions in order to 
facilitate international comparisons (OECD et al., 2011), for 
example in the estimation of drug treatment costs.
Furthermore, the proportion of hospitals covered by the 
DRG payment system differs across countries, and some 
types of hospitals, such as psychiatric hospitals, may 
be excluded from the DRG system (Busse et al., 2011). 
DRG costs may also be expressed in a different unit; for 
example, in England, inpatient hospital activity is reported 
using number of episodes or bed-days, but the cost data 
refer to a spell of treatment from admission to discharge, 
which can comprise multiple episodes. Where this is the 
case, the impact of the differences may be explored, as 
in England, where it was found that the majority of spells 
contained only one episode. Alternatively, another, more 
compatible, method of measuring unit cost data can be 
found. In Lievens and Vander Laenen’s paper (Chapter 9), 
total expenditure on delivering inpatient hospital services 
in a country was divided by the total number of bed-days 
to calculate a unit price per bed-day. This is the same 
approach that was taken by Origer in Chapter 5.
I Categorisation
The method of data categorisation is not fully harmonised 
across studies, although there are some common 
categorisation options used. Normally categorisation 
responds to the structure of service provision or to the 
structure by which expenditure data are organised. In wider 
public expenditure studies, categorisation has tended 
either to follow Reuter’s classification of prevention, harm 
reduction, treatment and enforcement (Reuter, 2006) or to 
use the categories from COFOG, which has a category for 
health and sub-categories for medical products, appliances 
and equipment; outpatient services; hospital services; public 
health services; and R&D (OECD et al., 2011). However, 
these categories may not be sufficient for a detailed drug 
treatment expenditure study. Vopravil (Chapter 3), for 
example, although using Reuter’s classification, created 
a number of sub-categories in order to allow meaningful 
analysis for Czech policymakers. The creation of nationally 
relevant and sufficiently detailed categories of expenditure 
should ideally be carried out within a framework of 
internationally recognised categories of expenditure. Mikulić 
(Chapter 2) provides an example of drug treatment spending 
classified according to both Reuter’s and the COFOG 
classifications. Both classifications are possible but require 
additional work during the data collection exercise.
Within the healthcare field, the SHA is the main international 
system for categorising health expenditure. It was developed 
to allow an internationally harmonised way of recording 
health expenditure and to provide a tool for the monitoring 
and analysis of health systems (OECD et al., 2011). The SHA 
identifies three axes for categorisation: type of care function, 
care provider or funding scheme. As a guiding principle in 
their analysis, Ritter and colleagues (Chapter 1) sought 
to use the SHA categorisation. They found that they were 
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unable to accurately reflect drug treatment expenditure in 
Australia using just one of the axes and so took a pragmatic 
approach that blended mutually exclusive categories across 
the different axes.
I Concluding remarks and next steps
Across the diverse studies in this Insights report there is 
one overarching similarity: the adoption of a pragmatic 
approach to the methodological choices. The scope and 
objectives of each study, as well as its potential users, 
provide the framework within which decisions on the 
way that the treatment definition is operationalised, 
on the perspective taken, and on the data sources and 
methods to be used are made. Yet these decisions will 
also be influenced by data availability and the resources 
available for carrying it out. A study will involve a series 
of compromises, and researchers need to choose what 
works best for them, while respecting the good practices 
applicable to the field.
The heterogeneity of studies presented in this report 
provides a rich source of information for assessing the 
impact of methodology on study results and building 
up a knowledge base on which methods and data are 
appropriate in different circumstances. It is therefore 
essential that studies provide detailed methodological 
information either within the study report or in a separate 
technical document. This also aids transparency and allows 
study replication. The methodological considerations 
identified here may provide a good starting point, but 
the reporting of methodological information should 
be as detailed as possible, including, for example, the 
documentation of all decisions, however trivial.
Mapping drug treatment systems, funding sources and 
the data available for a study provides a tool that helps 
guide estimates, assess the coverage of estimates and 
encourage the improvement of data systems. The SHA may 
provide a good framework for the mapping exercise. This 
should be seen as the first step in carrying out estimates 
and can be a valuable exercise in itself, even for countries 
where actual expenditure estimates are not possible at 
this time. A mapping exercise can also provide contextual 
information for the interpretation of study results. While 
the diversity of studies makes the comparison of results 
difficult, the reporting of methodological information and 
descriptions of the treatment systems and funding sources 
will aid interpretation of results.
Contextualisation of the values obtained by estimates 
of public expenditure on drug treatment is important, 
particularly if the results are to be used in the context 
of policy evaluation or to compare regions or countries. 
Factors such as the type of drug policy in place, the 
prevalence of drug use, the prevalence of problem drug 
use, the proportion of clients who have access to drug 
treatment, the type of treatment favoured (for instance, 
inpatient versus outpatient) or the socioeconomic context 
of the treatment provision (for instance, the GDP or the 
wealth of a region/country considered) should all be taken 
into consideration.
Additional challenges remain to be addressed. There are 
a number of issues that still merit in-depth assessment 
because of the lack of agreement on the best solutions 
and their potentially major impact on results. This includes, 
for instance, which associated comorbidities should be 
included in the cost estimates of drug treatment and how 
to deal with the fluid boundaries between the conventional 
categorisation of drug-related interventions for treatment 
and other interventions, harm reduction, prevention and 
social reintegration. Similarly, disentangling the costs of 
drug treatment from the costs of other types of treatment, 
such as alcohol, tobacco and wider mental health service 
costs, remains a challenge and good practice in this area 
still needs to be identified.
Developing methods to estimate public expenditure on 
treatment requires effective working partnerships between 
drug policymakers, specialists in health accountancy, 
drug treatment activity and those in charge of economic 
modelling. Continuous improvements require the extension 
and maintenance of such partnerships, with the goal of 
developing good practices, standards and guidelines in the 
field. While aiming to develop commonly accepted models 
for estimates, with procedures for regular updates, should 
be a target in the field, such projects clearly carry a cost 
that needs to be assessed and minimised.
While recognising the limitations imposed by currently 
available models and datasets, it is important to promote 
consensus-based improvements in estimation methods 
and work towards agreement on best practices. This 
publication has shed some light on current practice and, 
in doing so, it highlights a number of areas for future 
development, as outlined in the box below.
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Towards improved methods for estimating expenditure on drug treatment
It is possible to identify certain good practices that can be used to improve and harmonise estimates of public 
expenditure on drug treatment. To fulfil this goal, it may be beneficial to:
 Ensure that clearly defined aims and objectives are developed for each exercise, and note that these may differ 
from case to case.
 Develop a clear definition of drug treatment for the study, including the operational definition applied in estimates. 
This should help to clarify the scope and objective of estimates.
 Adopt a clear operational definition of drug treatment that is consistent with the general definition of drug treatment 
and takes into account data availability and modelling approaches available.
 Develop a map of treatment provision and funding flows. This exercise will help identify missing data, minimise the 
risk of double counting and facilitate assessment of the coverage of estimates.
 Use, where possible, international recognised classification systems, such as the SHA, as a guide for identifying 
and classifying both healthcare service providers and financing sources. This ensures the use of a comprehensive 
conceptual accounting framework, supporting complete estimates and allowing cross-country and cross-sector 
comparability with other fields of health provision.
 Analyse all levels of government activity, budgets and/or fiscal-end accountancy reports to identify labelled 
expenditure on drug treatment, as responsibility for financing drug treatment can lie with multiple actors.
 Estimate unlabelled expenditure using both top-down and bottom-up modelling approaches where possible. 
Modelling decisions should be based on a pragmatic analysis of data and resources available, as well as the 
reliability and accuracy of estimates.
 Assess the overlap between labelled and unlabelled expenditure and take steps to prevent double counting of 
expenditure.
 Report detailed information about the estimation exercise, including the definitions, methods and data used.
 Contextualise the results of estimates. As the results of estimates will very much depend upon contextual factors, 
such as the extension of the use and the degree of risk taken by drug users and the social and economic framework 
or other social integration policies, setting results in context is key for insightful analysis.
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I Abbreviations
ABF activity-based funding
AIDS acquired immune deficiency syndrome
ATC anatomical therapeutic chemical
COFOG Classification of the Functions of Government
COI cost of illness (method)
DCLG Department for Communities and Local Government (England)
DDD defined daily dose
DRG diagnostic-related group
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EU European Union
FDA Food and Drug Administration (United States)
GDP gross domestic product
GP general practitioner
HBV hepatitis B virus
HCV hepatitis C virus
HIV human immunodeficiency virus
ICD-10 International Statistical Classification of Diseases and Related Health 
Problems, 10th revision
IDT Instituto da Droga e da Toxicodependência (Institute for Drugs and Drug 
Addictions, Portugal)
LAAM levo-alpha-acetyl methadol
MAT medication-assisted therapy
MBS Medicare Benefits Schedule (Australia)
NDTMS National Drug Treatment Monitoring System (England)
NGO non-governmental organisation
NHS National Health Service (United Kingdom)
NIDA National Institute on Drug Abuse (United States)
OECD Organisation for Economic Co-operation and Development
OST opioid substitution therapy
OTP opioid treatment programme
PHE Public Health England
R&D research and development
RCT randomised controlled trial
SAMHSA Substance Abuse and Mental Health Services Administration (United States)
SD standard deviation
SHA System of Health Accounts
SIND Sistema Informativo Nazionale per le Dipendenze (Italy)
SSN Sistema Sanitario Nazionale (National Health System, Italy)
TDI Treatment Demand Indicator
VHA Veterans Health Administration (United States)
WHO World Health Organization
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